

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number  
**WO 01/18250 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68,**  
**C07K 14/47**

(21) International Application Number: **PCT/US00/24503**

(22) International Filing Date:  
7 September 2000 (07.09.2000)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
60/153,357 10 September 1999 (10.09.1999) **US**  
60/220,947 26 July 2000 (26.07.2000) **US**  
60/225,724 16 August 2000 (16.08.2000) **US**

(71) Applicants: **WHITEHEAD INSTITUTE FOR  
BIOMEDICAL RESEARCH [US/US];** Nine Cambridge  
Center, Cambridge, MA 02142 (US). **MILLENNIUM  
PHARMACEUTICALS, INC. [US/US];** 75 Sidney  
Street, Cambridge, MA 02139 (US).

(72) Inventors: **LANDER, Eric, S.;** 151 Bishop Allen Drive,  
Cambridge, MA 02139 (US). **GARGILL, Michele;** 1 War-  
wick Park #3, Cambridge, MA 02140 (US). **IRELAND,**

**James, S.;** 1 Warwick Park #3, Cambridge, MA 02140  
(US). **BOLK, Stacey;** 202 Baker Street #1, West Rox-  
bury, MA 02132 (US). **DALEY, George, Q.;** 50 Young  
Road, Weston, MA 02193 (US). **MCCARTHY, Jeanette,**  
**J.;** 3625 Dupont Street, San Diego, CA 92106 (US).

(74) Agents: **HOGLE, Doreen, M. et al.;** Hamilton, Brook,  
Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA  
02421 (US).

(81) Designated States (*national*): **AU, CA, JP, MX.**

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

**Published:**

— *Without international search report and to be republished  
upon receipt of that report.*

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES**

(57) Abstract: The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from a gene, including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis. A role for the thrombospondin gene(s) in vascular disease is also disclosed. Use of single nucleotide polymorphisms in the thrombospondin gene(s) for diagnosis, prediction of clinical course and treatment response, development of therapeutics and development of cell-culture-based and animal models for research and treatment are disclosed.

WO 01/18250 A2

## SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES

## BACKGROUND OF THE INVENTION

The genomes of all organisms undergo spontaneous mutation in the course of their continuing evolution, generating variant forms of progenitor nucleic acid sequences (Gusella, *Ann. Rev. Biochem.* 55, 831-854 (1986)). The variant form may confer an evolutionary advantage or disadvantage relative to a progenitor form, or may be neutral. In some instances, a variant form confers a lethal disadvantage and is not transmitted to subsequent generations of the organism. In other instances, a variant form confers an evolutionary advantage to the species and is eventually incorporated into the DNA of many or most members of the species and effectively becomes the progenitor form. In many instances, both progenitor and variant form(s) survive and co-exist in a species population. The coexistence of multiple forms of a sequence gives rise to polymorphisms.

Several different types of polymorphism have been reported. A restriction fragment length polymorphism (RFLP) is a variation in DNA sequence that alters the length of a restriction fragment (Botstein *et al.*, *Am. J. Hum. Genet.* 32, 314-331 (1980)). The restriction fragment length polymorphism may create or delete a restriction site, thus changing the length of the restriction fragment. RFLPs have been widely used in human and animal genetic analyses (see WO 90/13668; W090/11369; Donis-Keller, *Cell* 51, 319-337 (1987); Lander *et al.*, *Genetics* 121, 85-99 (1989)). When a heritable trait can be linked to a particular RFLP, the presence of the RFLP in an individual can be used to predict the likelihood that the animal will also exhibit the trait.

Other polymorphisms take the form of short tandem repeats (STRs) that include tandem di-, tri- and tetra-nucleotide repeated motifs. These tandem repeats are also referred to as variable number tandem repeat (VNTR) polymorphisms.

-2-

VNTRs have been used in identity and paternity analysis (US 5,075,217; Armour *et al.*, *FEBS Lett.* 307, 113-115 (1992); Horn *et al.*, WO 91/14003; Jeffreys, EP 370,719), and in a large number of genetic mapping studies.

Other polymorphisms take the form of single nucleotide variations between  
5 individuals of the same species. Such polymorphisms are far more frequent than  
RFLPs, STRs and VNTRs. Some single nucleotide polymorphisms (SNP) occur in  
protein-coding nucleic acid sequences (coding sequence SNP (cSNP)), in which  
case, one of the polymorphic forms may give rise to the expression of a defective or  
otherwise variant protein and, potentially, a genetic disease. Examples of genes in  
10 which polymorphisms within coding sequences give rise to genetic disease include  
 $\beta$ -globin (sickle cell anemia), apoE4 (Alzheimer's Disease), Factor V Leiden  
(thrombosis), and CFTR (cystic fibrosis). cSNPs can alter the codon sequence of the  
gene and therefore specify an alternative amino acid. Such changes are called  
"missense" when another amino acid is substituted, and "nonsense" when the  
15 alternative codon specifies a stop signal in protein translation. When the cSNP does  
not alter the amino acid specified the cSNP is called "silent".

Other single nucleotide polymorphisms occur in noncoding regions. Some of  
these polymorphisms may also result in defective protein expression (e.g., as a result  
of defective splicing). Other single nucleotide polymorphisms have no phenotypic  
20 effects. Single nucleotide polymorphisms can be used in the same manner as  
RFLPs and VNTRs, but offer several advantages. Single nucleotide polymorphisms  
occur with greater frequency and are spaced more uniformly throughout the genome  
than other forms of polymorphism. The greater frequency and uniformity of single  
nucleotide polymorphisms means that there is a greater probability that such a  
25 polymorphism will be found in close proximity to a genetic locus of interest than  
would be the case for other polymorphisms. The different forms of characterized  
single nucleotide polymorphisms are often easier to distinguish than other types of  
polymorphism (e.g., by use of assays employing allele-specific hybridization probes  
or primers).

30 Only a small percentage of the total repository of polymorphisms in humans  
and other organisms has been identified. The limited number of polymorphisms  
identified to date is due to the large amount of work required for their detection by

-3-

conventional methods. For example, a conventional approach to identifying polymorphisms might be to sequence the same stretch of DNA in a population of individuals by dideoxy sequencing. In this type of approach, the amount of work increases in proportion to both the length of sequence and the number of individuals in a population and becomes impractical for large stretches of DNA or large numbers of persons.

#### SUMMARY OF THE INVENTION

Work described herein pertains to the identification of polymorphisms which can predispose individuals to disease, by resequencing large numbers of genes in a large number of individuals. Various genes from a number of individuals have been resequenced as described herein, and SNPs in these genes have been discovered (see the Table and Fig. 3). Some of these SNPs are cSNPs which specify a different amino acid sequence, some of the SNPs are silent cSNPs and some of these cSNPs specify a stop signal in protein translation. Some of the identified SNPs were located in non-coding regions.

The invention relates to a gene which comprises a single nucleotide polymorphism at a specific location. In a particular embodiment the invention relates to the variant allele of a gene having a single nucleotide polymorphism, which variant allele differs from a reference allele by one nucleotide at the site(s) identified in the Table and Fig. 3. Complements of these nucleic acid sequences are also included. The nucleic acid molecules can be DNA or RNA, and can be double- or single-stranded. Nucleic acid molecules can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30, 10-50 or 10-100 bases long.

The invention further provides allele-specific oligonucleotides that hybridize to the reference or variant allele of a gene comprising a single nucleotide polymorphism or to the complement thereof. These oligonucleotides can be probes or primers.

The invention further provides a method of analyzing a nucleic acid from an individual. The method determines which base is present at any one of the polymorphic sites shown in the Table and/or Fig. 3. Optionally, a set of bases occupying a set of the polymorphic sites shown in the Table and /or Fig. 3 is



-4-

determined. This type of analysis can be performed on a number of individuals, who are tested for the presence of a disease phenotype. The presence or absence of disease phenotype is then correlated with a base or set of bases present at the polymorphic site or sites in the individuals tested.

5        Thus, the invention further relates to a method of predicting the presence, absence, likelihood of the presence or absence, or severity of a particular phenotype or disorder associated with a particular genotype. The method comprises obtaining a nucleic acid sample from an individual and determining the identity of one or more bases (nucleotides) at polymorphic sites of genes described herein, wherein the  
10       presence of a particular base is correlated with a specified phenotype or disorder, thereby predicting the presence, absence, likelihood of the presence or absence, or severity of the phenotype or disorder in the individual.

          The thrombospondins are a family of extracellular matrix (ECM) glycoproteins that modulate many cell behaviors including adhesion, migration, and  
15       proliferation. Thrombospondins (also known as thrombin sensitive proteins or TSPs) are large molecular weight glycoproteins composed of three identical disulfide-linked polypeptide chains. The results described herein also reveal an important association between alterations, particularly SNPs, in TSP genes, particularly TSP-1 and TSP-4, and vascular disease. In particular, SNPs in these  
20       genes which are associated with premature coronary artery disease (CAD)(or coronary heart disease) and myocardial infarction (MI) have been identified and represent a potentially vital marker of upstream biology influencing the complex process of atherosclerotic plaque generation and vulnerability.

          Thus, the invention relates to the TSP gene SNPs identified as described  
25       herein, both singly and in combination, as well as to the use of these SNPs, and others in TSP genes, particularly those nearby in linkage disequilibrium with these SNPs, for diagnosis, prediction of clinical course and treatment response for vascular disease, development of new treatments for vascular disease based upon comparison of the variant and normal versions of the gene or gene product, and  
30       development of cell-culture based and animal models for research and treatment of vascular disease. The invention further relates to novel compounds and

pharmaceutical compositions for use in the diagnosis and treatment of such disorders. In preferred embodiments, the vascular disease is CAD or MI.

The invention relates to isolated nucleic acid molecules comprising all or a portion of the variant allele of TSP-1 (e.g., as exemplified by SEQ ID NO: 1), and to  
5 isolated nucleic acid molecules comprising all or a portion of the variant allele of TSP-4 (e.g., as exemplified by SEQ ID NO: 3). Preferred portions are at least 10 contiguous nucleotides and comprise the polymorphic site, e.g., a portion of SEQ ID NO: 1 which is at least 10 contiguous nucleotides and comprises the "G" at position 2210, or a portion of SEQ ID NO: 3 which is at least 10 contiguous nucleotides and  
10 comprises the "C" at position 1186. The invention further relates to isolated gene products, e.g., polypeptides or proteins, which are encoded by a nucleic acid molecule comprising all or a portion of the variant allele of TSP-1 or TSP-4 (e.g., SEQ ID NO: 1 or SEQ ID NO: 3, respectively). The invention also relates to nucleic acid molecules which hybridize to and/or share identity with the variant  
15 alleles identified herein (or their complements) and which also comprise the variant nucleotide at the SNP site.

The invention further relates to isolated proteins or polypeptides comprising all or a portion of the variant amino acid sequence of TSP-1 (e.g., as exemplified by SEQ ID NO: 2), and to isolated proteins or polypeptides comprising all or a portion  
20 of the variant amino acid sequence of TSP-4 (e.g., as exemplified by SEQ ID NO: 4). Preferred polypeptides are at least 10 contiguous amino acids and comprise the polymorphic amino acid, e.g., a portion of SEQ ID NO: 2 which is at least 10 contiguous amino acids and comprises the serine at residue 700, or a portion of SEQ ID NO: 4 which is at least 10 contiguous amino acids and comprises the proline at  
25 residue 387. The invention further relates to isolated nucleic acid molecules encoding such proteins and polypeptides, as well as to antibodies which bind, e.g., specifically, to such proteins and polypeptides.

The invention further relates to a method of diagnosing or aiding in the diagnosis of a disorder associated with the presence of one or more of (a) a G at  
30 nucleotide position 2210 of SEQ ID NO: 1; or (b) a C at nucleotide position 1186 of SEQ ID NO: 3 in an individual. The method comprises obtaining a nucleic acid sample from the individual and determining the nucleotide present at one or more of

the indicated nucleotide positions, wherein presence of one or more of (a) a G at nucleotide position 2210 of SEQ ID NO: 1; or (b) a C at nucleotide position 1186 of SEQ ID NO: 3 is indicative of increased likelihood of said disorder in the individual as compared with an appropriate control, *e.g.*, an individual having the reference nucleotide at one or more of said positions. In a particular embodiment the disorder is a vascular disease selected from the group consisting of atherosclerosis, coronary heart or artery disease, MI, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism. In a preferred embodiment, the vascular disease is selected from the group consisting of CAD and MI.

10       The invention further relates to a method of diagnosing or aiding in the diagnosis of a disorder associated with one or more of (a) a G at nucleotide position 2210 of SEQ ID NO: 1; or (b) a C at nucleotide position 1186 of SEQ ID NO: 3 in an individual. The method comprises obtaining a nucleic acid sample from the individual and determining the nucleotide present at one or more of the indicated  
15       nucleotide positions, wherein presence of one or more of (a) an A at nucleotide position 2210 of SEQ ID NO: 1; or (b) a G at nucleotide position 1186 of SEQ ID NO: 3 is indicative of decreased likelihood of said disorder in the individual as compared with an appropriate control, *e.g.*, an individual having the variant nucleotide at said position. In a particular embodiment the disorder is a vascular  
20       disease selected from the group consisting of atherosclerosis, coronary heart or artery disease, MI, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism. In a preferred embodiment, the vascular disease is selected from the group consisting of CAD and MI.

      In one embodiment, the invention relates to a method for predicting the  
25       likelihood that an individual will have a vascular disease (or aiding in the diagnosis of a vascular disease), comprising the steps of obtaining a DNA sample from an individual to be assessed and determining the nucleotide present at one or more of nucleotide positions 2210 of SEQ ID NO: 1 or 1186 of SEQ ID NO: 3. The presence of the reference nucleotide at one or more of these positions indicates that  
30       the individual has a lower likelihood of having a vascular disease than an individual having the variant nucleotide at one or more of these positions, or a lower likelihood

-7-

of having severe symptomology. In a particular embodiment, the individual is an individual at risk for development of a vascular disease.

The invention further relates to a method of diagnosing or aiding in the diagnosis of a disorder associated with the presence of one or more of (a) a serine at  
5 amino acid position 700 of SEQ ID NO: 2; or (b) a proline at amino acid position 387 of SEQ ID NO: 4 in an individual. The method comprises obtaining a biological sample containing the TSP-1 and/or TSP-4 protein or relevant portion thereof from the individual and determining the amino acid present at one or more of the indicated amino acid positions, wherein presence of one or more of (a) a serine at  
10 amino acid position 700 of SEQ ID NO: 2; or (b) a proline at amino acid position 387 of SEQ ID NO: 4 is indicative of increased likelihood of said disorder in the individual as compared with an appropriate control, *e.g.*, an individual having the reference amino acid at one or more of said positions.

The invention further relates to a method of diagnosing or aiding in the  
15 diagnosis of a disorder associated with one or more of (a) a serine at amino acid position 700 of SEQ ID NO: 2; or (b) a proline at amino acid position 387 of SEQ ID NO: 4 in an individual. The method comprises obtaining a biological sample containing the TSP-1 and/or TSP-4 protein or relevant portion thereof from the individual and determining the amino acid present at one or more of the indicated  
20 amino acid positions, wherein presence of one or more of (a) an asparagine at amino acid position 700 of SEQ ID NO: 2; or (b) an alanine at amino acid position 387 of SEQ ID NO: 4 is indicative of decreased likelihood of said disorder in the individual as compared with an appropriate control, *e.g.*, an individual having the variant amino acid at one or more of said positions.

25 In one embodiment, the invention relates to a method for predicting the likelihood that an individual will have a vascular disease (or aiding in the diagnosis of a vascular disease), comprising the steps of obtaining a biological sample comprising the TSP-1 and/or TSP-4 protein or relevant portion thereof from an individual to be assessed and determining the amino acid present at one or more of  
30 amino acid positions 700 of SEQ ID NO: 2 or 387 of SEQ ID NO: 4. The presence of the reference amino acid at one or more of these positions indicates that the individual has a lower likelihood of having a vascular disease than an individual

having the variant amino acid at one or more of these positions, or a lower likelihood of having severe symptomology. In a particular embodiment, the individual is an individual at risk for development of a vascular disease.

In another embodiment, the invention relates to pharmaceutical compositions comprising a reference TSP-1 and/or TSP-4 gene or gene product, or active portion thereof, for use in the treatment of vascular diseases. The invention further relates to the use of agonists and antagonists of TSP-1 and TSP-4 activity for use in the treatment of vascular diseases. In a particular embodiment the vascular disease is selected from the group consisting of atherosclerosis, coronary heart or artery disease, MI, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism. In a preferred embodiment, the vascular disease is selected from the group consisting of CAD and MI.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1A-1D show the reference nucleotide (SEQ ID NO: 1) and amino acid (SEQ ID NO: 2) sequences for TSP-1.

Figs. 2A-2C show the reference nucleotide (SEQ ID NO: 3) and amino acid (SEQ ID NO: 4) sequences for TSP-4.

Fig. 3 shows a table providing detailed information about the SNPs identified herein. Column one shows the internal polymorphism identifier. Column two shows the accession number for the reference sequence in the TIGR database ([http://www.tigr.org/tdb/hgi/searching/hgi\\_reports.html](http://www.tigr.org/tdb/hgi/searching/hgi_reports.html)). Column three shows the nucleotide position for the SNP site. Column four shows the gene in which the polymorphism was identified. Column five shows the polymorphic site and additional flanking sequence on each side of the polymorphism. Column six shows the type of mutation produced by the polymorphism. Columns seven and eight show the reference and alternate (variant) nucleotides, respectively, for the SNP. Columns nine and ten show the reference and alternate (variant) amino acids, respectively, encoded by the alleles of the gene.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a gene which comprises a single nucleotide polymorphism (SNP) at a specific location. The gene which includes the SNP has at least two alleles, referred to herein as the reference allele and the variant allele. The reference allele (prototypical or wild type allele) has been designated arbitrarily and typically corresponds to the nucleotide sequence of the gene which has been deposited with GenBank or TIGR under a given Accession number. The variant allele differs from the reference allele by one nucleotide at the site(s) identified in the Table. The present invention also relates to variant alleles of the described genes and to complements of the variant alleles. The invention also relates to nucleic acid molecules which hybridize to and/or share identity with the variant alleles identified herein (or their complements) and which also comprise the variant nucleotide at the SNP site.

The invention further relates to portions of the variant alleles and portions of complements of the variant alleles which comprise (encompass) the site of the SNP and are at least 5 nucleotides in length. Portions can be, for example, 5-10, 5-15, 10-20, 5-25, 10-30, 10-50 or 10-100 bases long. For example, a portion of a variant allele which is 21 nucleotides in length includes the single nucleotide polymorphism (the nucleotide which differs from the reference allele at that site) and twenty additional nucleotides which flank the site in the variant allele. These nucleotides can be on one or both sides of the polymorphism. Polymorphisms which are the subject of this invention are defined in the Table with respect to the reference sequence deposited in GenBank or TIGR under the Accession number indicated. For example, the invention relates to a portion of a gene (e.g., AT3) having a nucleotide sequence as deposited in GenBank (e.g., U11270) comprising a single nucleotide polymorphism at a specific position (e.g., nucleotide 11918). The reference nucleotide for AT3 is shown in column 8, and the variant nucleotide is shown in column 9 of the Table. The nucleotide sequences of the invention can be double- or single-stranded.

The invention further provides allele-specific oligonucleotides that hybridize to the reference or variant allele of a gene comprising a single nucleotide

-10-

polymorphism or to the complement thereof. These oligonucleotides can be probes or primers.

The invention further provides a method of analyzing a nucleic acid from an individual. The method determines which base is present at any one of the polymorphic sites shown in the Table and/or Fig. 3. Optionally, a set of bases occupying a set of the polymorphic sites shown in the Table and/or Fig. 3 is determined. This type of analysis can be performed on a number of individuals, who are tested for the presence of a disease phenotype. The presence or absence of disease phenotype is then correlated with a base or set of bases present at the polymorphic site or sites in the individuals tested.

Thus, the invention further relates to a method of predicting the presence, absence, likelihood of the presence or absence, or severity of a particular phenotype or disorder associated with a particular genotype. The method comprises obtaining a nucleic acid sample from an individual and determining the identity of one or more bases (nucleotides) at polymorphic sites of genes described herein, wherein the presence of a particular base is correlated with a specified phenotype or disorder, thereby predicting the presence, absence, likelihood of the presence or absence, or severity of the phenotype or disorder in the individual.

#### DEFINITIONS

A nucleic acid molecule or oligonucleotide can be DNA or RNA, and single- or double-stranded. Nucleic acid molecules and oligonucleotides can be naturally occurring or synthetic, but are typically prepared by synthetic means. Preferred nucleic acid molecules and oligonucleotides of the invention include segments of DNA, or their complements, which include any one of the polymorphic sites shown in the Table. The segments can be between 5 and 250 bases, and, in specific embodiments, are between 5-10, 5-20, 10-20, 10-50, 20-50 or 10-100 bases. For example, the segment can be 21 bases. The polymorphic site can occur within any position of the segment. The segments can be from any of the allelic forms of DNA shown in the Table.

As used herein, the terms "nucleotide", "base" and "nucleic acid" are intended to be equivalent. The terms "nucleotide sequence", "nucleic acid sequence", "nucleic acid molecule" and "segment" are intended to be equivalent.

Hybridization probes are oligonucleotides which bind in a base-specific manner to a complementary strand of nucleic acid. Such probes include peptide nucleic acids, as described in Nielsen *et al.*, *Science* 254, 1497-1500 (1991). Probes can be any length suitable for specific hybridization to the target nucleic acid sequence. The most appropriate length of the probe may vary depending upon the hybridization method in which it is being used; for example, particular lengths may be more appropriate for use in microfabricated arrays, while other lengths may be more suitable for use in classical hybridization methods. Such optimizations are known to the skilled artisan. Suitable probes and primers can range from about 5 nucleotides to about 30 nucleotides in length. For example, probes and primers can be 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 25, 26, 28 or 30 nucleotides in length. The probe or primer preferably overlaps at least one polymorphic site occupied by any of the possible variant nucleotides. The nucleotide sequence can correspond to the coding sequence of the allele or to the complement of the coding sequence of the allele.

As used herein, the term "primer" refers to a single-stranded oligonucleotide which acts as a point of initiation of template-directed DNA synthesis under appropriate conditions (*e.g.*, in the presence of four different nucleoside triphosphates and an agent for polymerization, such as DNA or RNA polymerase or reverse transcriptase) in an appropriate buffer and at a suitable temperature. The appropriate length of a primer depends on the intended use of the primer, but typically ranges from 15 to 30 nucleotides. Short primer molecules generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. A primer need not reflect the exact sequence of the template, but must be sufficiently complementary to hybridize with a template. The term primer site refers to the area of the target DNA to which a primer hybridizes. The term primer pair refers to a set of primers including a 5' (upstream) primer that hybridizes with the 5' end of the DNA sequence to be amplified and a 3' (downstream) primer that hybridizes with the complement of the 3' end of the sequence to be amplified.



-12-

As used herein, linkage describes the tendency of genes, alleles, loci or genetic markers to be inherited together as a result of their location on the same chromosome. It can be measured by percent recombination between the two genes, alleles, loci or genetic markers.

- 5 As used herein, polymorphism refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A
- 10 polymorphic locus may be as small as one base pair. Polymorphic markers include restriction fragment length polymorphisms, variable number of tandem repeats (VNTR's), hypervariable regions, minisatellites, dinucleotide repeats, trinucleotide repeats, tetranucleotide repeats, simple sequence repeats, and insertion elements such as Alu. The first identified allelic form is arbitrarily designated as the reference
- 15 form and other allelic forms are designated as alternative or variant alleles. The allelic form occurring most frequently in a selected population is sometimes referred to as the wildtype form. Diploid organisms may be homozygous or heterozygous for allelic forms. A diallelic or biallelic polymorphism has two forms. A triallelic polymorphism has three forms.
- 20 Work described herein pertains to the resequencing of large numbers of genes in a large number of individuals to identify polymorphisms which can predispose individuals to disease. For example, polymorphisms in genes which are expressed in liver may predispose individuals to disorders of the liver. By altering amino acid sequence, SNPs may alter the function of the encoded proteins. The discovery of
- 25 the SNP facilitates biochemical analysis of the variants and the development of assays to characterize the variants and to screen for pharmaceutical that would interact directly with one or another form of the protein. SNPs (including silent SNPs) also enable the development of specific DNA, RNA, or protein-based diagnostics that detect the presence or absence of the polymorphism in particular
- 30 conditions.

A single nucleotide polymorphism occurs at a polymorphic site occupied by a single nucleotide, which is the site of variation between allelic sequences. The site

-13-

is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations).

A single nucleotide polymorphism usually arises due to substitution of one nucleotide for another at the polymorphic site. A transition is the replacement of  
5 one purine by another purine or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine or vice versa. Single nucleotide polymorphisms can also arise from a deletion of a nucleotide or an insertion of a nucleotide relative to a reference allele. Typically the polymorphic site is occupied by a base other than the reference base. For example, where the  
10 reference allele contains the base "T" at the polymorphic site, the altered allele can contain a "C", "G" or "A" at the polymorphic site.

The invention also relates to nucleic acid molecules which hybridize to the variant alleles identified herein (or their complements) and which also comprise the variant nucleotide at the SNP site. Hybridizations are usually performed under  
15 stringent conditions, for example, at a salt concentration of no more than 1 M and a temperature of at least 25°C. For example, conditions of 5X SSPE (750 mM NaCl, 50 mM NaPhosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-30°C, or equivalent conditions, are suitable for allele-specific probe hybridizations. Equivalent conditions can be determined by varying one or more of the parameters  
20 given as an example, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleotide sequence and the primer or probe used.

The invention also relates to nucleic acid molecules which share substantial sequence identity to the variant alleles identified herein (or their complements) and  
25 which also comprise the variant nucleotide at the SNP site. Particularly preferred are nucleic acid molecules and fragments which have at least about 60%, preferably at least about 70, 80 or 85%, more preferably at least about 90%, even more preferably at least about 95%, and most preferably at least about 98% identity with nucleic acid molecules described herein. The percent identity of two nucleotide or  
30 amino acid sequences can be determined by aligning the sequences for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first sequence). The nucleotides or amino acids at corresponding positions are then

compared, and the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % identity = # of identical positions/total # of positions x 100). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, preferably at least 40%,  
5 more preferably at least 60%, and even more preferably at least 70%, 80% or 90% of the length of the reference sequence. The actual comparison of the two sequences can be accomplished by well-known methods, for example, using a mathematical algorithm. A preferred, non-limiting example of such a mathematical algorithm is described in Karlin *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:5873-5877 (1993). Such  
10 an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) as described in Altschul *et al.*, *Nucleic Acids Res.*, 25:389-3402 (1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (*e.g.*, NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>. In one embodiment, parameters for sequence  
15 comparison can be set at score=100, wordlength=12, or can be varied (*e.g.*, W=5 or W=20).

The term "isolated" is used herein to indicate that the material in question exists in a physical milieu distinct from that in which it occurs in nature. For example, an isolated nucleic acid of the invention may be substantially isolated with  
20 respect to the complex cellular milieu in which it naturally occurs. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstance, the material may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC. Preferably, an  
25 isolated nucleic acid comprises at least about 50, 80 or 90 percent (on a molar basis) of all macromolecular species present.

#### I. Novel Polymorphisms of the Invention

Some of the novel polymorphisms of the invention are shown in the Table. Columns one and two show designations for the indicated polymorphism. Column  
30 three shows the Genbank or TIGR Accession number for the wild type (or reference) allele. Column four shows the location of the polymorphic site in the nucleic acid

-15-

sequence with reference to the Genbank or TIGR sequence shown in column three. Column five shows common names for the gene in which the polymorphism is located. Column six shows the polymorphism and a portion of the 3' and 5' flanking sequence of the gene. Column seven shows the type of mutation; N, non-sense, S, 5 silent, M, missense. Columns eight and nine show the reference and alternate nucleotides, respectively, at the polymorphic site. Columns ten and eleven show the reference and alternate amino acids, respectively, encoded by the reference and variant, respectively, alleles. Other novel polymorphisms of the invention are shown in Fig. 3.

## 10 II. Analysis of Polymorphisms

### A. Preparation of Samples

Polymorphisms are detected in a target nucleic acid from an individual being analyzed. For assay of genomic DNA, virtually any biological sample (other than pure red blood cells) is suitable. For example, convenient tissue samples include 15 whole blood, semen, saliva, tears, urine, fecal material, sweat, buccal, skin and hair. For assay of cDNA or mRNA, the tissue sample must be obtained from an organ in which the target nucleic acid is expressed. For example, if the target nucleic acid is a cytochrome P450, the liver is a suitable source.

Many of the methods described below require amplification of DNA from 20 target samples. This can be accomplished by e.g., PCR. *See generally PCR Technology: Principles and Applications for DNA Amplification* (ed. H.A. Erlich, Freeman Press, NY, NY, 1992); *PCR Protocols: A Guide to Methods and Applications* (eds. Innis, et al., Academic Press, San Diego, CA, 1990); Mattila et al., *Nucleic Acids Res.* 19, 4967 (1991); Eckert et al., *PCR Methods and* 25 *Applications* 1, 17 (1991); *PCR* (eds. McPherson et al., IRL Press, Oxford); and U.S. Patent 4,683,202.

Other suitable amplification methods include the ligase chain reaction (LCR) (see Wu and Wallace, *Genomics* 4, 560 (1989), Landegren et al., *Science* 241, 1077 (1988), transcription amplification (Kwoh et al., *Proc. Natl. Acad. Sci. USA* 86, 30 1173 (1989)), and self-sustained sequence replication (Guatelli et al., *Proc. Nat. Acad. Sci. USA*, 87, 1874 (1990)) and nucleic acid based sequence amplification

-16-

(NASBA). The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

## 5           B. Detection of Polymorphisms in Target DNA

There are two distinct types of analysis of target DNA for detecting polymorphisms. The first type of analysis, sometimes referred to as *de novo* characterization, is carried out to identify polymorphic sites not previously characterized (i.e., to identify new polymorphisms). This analysis compares target  
10 sequences in different individuals to identify points of variation, i.e., polymorphic sites. By analyzing groups of individuals representing the greatest ethnic diversity among humans and greatest breed and species variety in plants and animals, patterns characteristic of the most common alleles/haplotypes of the locus can be identified, and the frequencies of such alleles/haplotypes in the population can be determined.  
15 Additional allelic frequencies can be determined for subpopulations characterized by criteria such as geography, race, or gender. The *de novo* identification of polymorphisms of the invention is described in the Examples section. The second type of analysis determines which form(s) of a characterized (known) polymorphism are present in individuals under test. There are a variety of suitable procedures,  
20 which are discussed in turn.

### 1. Allele-Specific Probes

The design and use of allele-specific probes for analyzing polymorphisms is described by e.g., Saiki *et al.*, *Nature* 324, 163-166 (1986); Dattagupta, EP 235,726, Saiki, WO 89/11548. Allele-specific probes can be designed that hybridize to a  
25 segment of target DNA from one individual but do not hybridize to the corresponding segment from another individual due to the presence of different polymorphic forms in the respective segments from the two individuals. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially  
30 binary response, whereby a probe hybridizes to only one of the alleles. Some probes

-17-

are designed to hybridize to a segment of target DNA such that the polymorphic site aligns with a central position (e.g., in a 15-mer at the 7 position; in a 16-mer, at either the 8 or 9 position) of the probe. This design of probe achieves good discrimination in hybridization between different allelic forms.

- 5        Allele-specific probes are often used in pairs, one member of a pair showing a perfect match to a reference form of a target sequence and the other member showing a perfect match to a variant form. Several pairs of probes can then be immobilized on the same support for simultaneous analysis of multiple polymorphisms within the same target sequence.

## 10        2. Tiling Arrays

- The polymorphisms can also be identified by hybridization to nucleic acid arrays, some examples of which are described in WO 95/11995. One form of such arrays is described in the Examples section in connection with de novo identification of polymorphisms. The same array or a different array can be used for analysis of
- 15       characterized polymorphisms. WO 95/11995 also describes subarrays that are optimized for detection of a variant form of a precharacterized polymorphism. Such a subarray contains probes designed to be complementary to a second reference sequence, which is an allelic variant of the first reference sequence. The second group of probes is designed by the same principles as described in the Examples,
- 20       except that the probes exhibit complementarity to the second reference sequence. The inclusion of a second group (or further groups) can be particularly useful for analyzing short subsequences of the primary reference sequence in which multiple mutations are expected to occur within a short distance commensurate with the length of the probes (e.g., two or more mutations within 9 to 21 bases).

## 25        3. Allele-Specific Primers

- An allele-specific primer hybridizes to a site on target DNA overlapping a polymorphism and only primes amplification of an allelic form to which the primer exhibits perfect complementarity. See Gibbs, *Nucleic Acid Res.* 17, 2427-2448 (1989). This primer is used in conjunction with a second primer which hybridizes at
- 30       a distal site. Amplification proceeds from the two primers, resulting in a detectable

-18-

product which indicates the particular allelic form is present. A control is usually performed with a second pair of primers, one of which shows a single base mismatch at the polymorphic site and the other of which exhibits perfect complementarity to a distal site. The single-base mismatch prevents amplification and no detectable product is formed. The method works best when the mismatch is included in the 3'-most position of the oligonucleotide aligned with the polymorphism because this position is most destabilizing to elongation from the primer (see, e.g., WO 93/22456).

#### 4. Direct-Sequencing

The direct analysis of the sequence of polymorphisms of the present invention can be accomplished using either the dideoxy chain termination method or the Maxam Gilbert method (see Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd Ed., CSHP, New York 1989); Zyskind *et al.*, *Recombinant DNA Laboratory Manual*, (Acad. Press, 1988)).

#### 5. Denaturing Gradient Gel Electrophoresis

Amplification products generated using the polymerase chain reaction can be analyzed by the use of denaturing gradient gel electrophoresis. Different alleles can be identified based on the different sequence-dependent melting properties and electrophoretic migration of DNA in solution. Erlich, ed., *PCR Technology, Principles and Applications for DNA Amplification*, (W.H. Freeman and Co, New York, 1992), Chapter 7.

#### 6. Single-Strand Conformation Polymorphism Analysis

Alleles of target sequences can be differentiated using single-strand conformation polymorphism analysis, which identifies base differences by alteration in electrophoretic migration of single stranded PCR products, as described in Orita *et al.*, *Proc. Nat. Acad. Sci.* 86, 2766-2770 (1989). Amplified PCR products can be generated as described above, and heated or otherwise denatured, to form single stranded amplification products. Single-stranded nucleic acids may refold or form secondary structures which are partially dependent on the base sequence. The

different electrophoretic mobilities of single-stranded amplification products can be related to base-sequence differences between alleles of target sequences.

### 7. Single-Base Extension

An alternative method for identifying and analyzing polymorphisms is based on single-base extension (SBE) of a fluorescently-labeled primer coupled with fluorescence resonance energy transfer (FRET) between the label of the added base and the label of the primer. Typically, the method, such as that described by Chen *et al.*, (*PNAS* 94:10756-61 (1997), incorporated herein by reference) uses a locus-specific oligonucleotide primer labeled on the 5' terminus with 5-carboxyfluorescein (FAM). This labeled primer is designed so that the 3' end is immediately adjacent to the polymorphic site of interest. The labeled primer is hybridized to the locus, and single base extension of the labeled primer is performed with fluorescently labeled dideoxynucleotides (ddNTPs) in dye-terminator sequencing fashion, except that no deoxynucleotides are present. An increase in fluorescence of the added ddNTP in response to excitation at the wavelength of the labeled primer is used to infer the identity of the added nucleotide.

### III. Methods of Use

After determining polymorphic form(s) present in an individual at one or more polymorphic sites, this information can be used in a number of methods.

#### 20 A. Forensics

Determination of which polymorphic forms occupy a set of polymorphic sites in an individual identifies a set of polymorphic forms that distinguishes the individual. See generally National Research Council, *The Evaluation of Forensic DNA Evidence* (Eds. Pollard *et al.*, National Academy Press, DC, 1996). The more sites that are analyzed, the lower the probability that the set of polymorphic forms in one individual is the same as that in an unrelated individual. Preferably, if multiple sites are analyzed, the sites are unlinked. Thus, polymorphisms of the invention are often used in conjunction with polymorphisms in distal genes. Preferred polymorphisms for use in forensics are biallelic because the population frequencies



-20-

of two polymorphic forms can usually be determined with greater accuracy than those of multiple polymorphic forms at multi-allelic loci.

The capacity to identify a distinguishing or unique set of forensic markers in an individual is useful for forensic analysis. For example, one can determine whether a blood sample from a suspect matches a blood or other tissue sample from a crime scene by determining whether the set of polymorphic forms occupying selected polymorphic sites is the same in the suspect and the sample. If the set of polymorphic markers does not match between a suspect and a sample, it can be concluded (barring experimental error) that the suspect was not the source of the sample. If the set of markers does match, one can conclude that the DNA from the suspect is consistent with that found at the crime scene. If frequencies of the polymorphic forms at the loci tested have been determined (e.g., by analysis of a suitable population of individuals), one can perform a statistical analysis to determine the probability that a match of suspect and crime scene sample would occur by chance.

$p(\text{ID})$  is the probability that two random individuals have the same polymorphic or allelic form at a given polymorphic site. In biallelic loci, four genotypes are possible: AA, AB, BA, and BB. If alleles A and B occur in a haploid genome of the organism with frequencies  $x$  and  $y$ , the probability of each genotype in a diploid organism is (see WO 95/12607):

$$\text{Homozygote: } p(\text{AA}) = x^2$$

$$\text{Homozygote: } p(\text{BB}) = y^2 = (1-x)^2$$

$$\text{Single Heterozygote: } p(\text{AB}) = p(\text{BA}) = xy = x(1-x)$$

$$\text{Both Heterozygotes: } p(\text{AB} + \text{BA}) = 2xy = 2x(1-x)$$

The probability of identity at one locus (i.e., the probability that two individuals, picked at random from a population will have identical polymorphic forms at a given locus) is given by the equation:

$$p(\text{ID}) = (x^2)^2 + (2xy)^2 + (y^2)^2.$$

These calculations can be extended for any number of polymorphic forms at a given locus. For example, the probability of identity  $p(\text{ID})$  for a 3-allele system

where the alleles have the frequencies in the population of  $x$ ,  $y$  and  $z$ , respectively, is equal to the sum of the squares of the genotype frequencies:

$$p(\text{ID}) = x^4 + (2xy)^2 + (2yz)^2 + (2xz)^2 + z^4 + y^4$$

In a locus of  $n$  alleles, the appropriate binomial expansion is used to calculate  
 5  $p(\text{ID})$  and  $p(\text{exc})$ .

The cumulative probability of identity ( $\text{cum } p(\text{ID})$ ) for each of multiple unlinked loci is determined by multiplying the probabilities provided by each locus.

$$\text{cum } p(\text{ID}) = p(\text{ID}1)p(\text{ID}2)p(\text{ID}3)\dots p(\text{ID}n)$$

The cumulative probability of non-identity for  $n$  loci (i.e. the probability that  
 10 two random individuals will be different at 1 or more loci) is given by the equation:

$$\text{cum } p(\text{nonID}) = 1 - \text{cum } p(\text{ID}).$$

If several polymorphic loci are tested, the cumulative probability of non-identity for random individuals becomes very high (e.g., one billion to one). Such probabilities can be taken into account together with other evidence in determining  
 15 the guilt or innocence of the suspect.

#### B. Paternity Testing

The object of paternity testing is usually to determine whether a male is the father of a child. In most cases, the mother of the child is known and thus, the mother's contribution to the child's genotype can be traced. Paternity testing  
 20 investigates whether the part of the child's genotype not attributable to the mother is consistent with that of the putative father. Paternity testing can be performed by analyzing sets of polymorphisms in the putative father and the child.

If the set of polymorphisms in the child attributable to the father does not match the set of polymorphisms of the putative father, it can be concluded, barring  
 25 experimental error, that the putative father is not the real father. If the set of polymorphisms in the child attributable to the father does match the set of polymorphisms of the putative father, a statistical calculation can be performed to determine the probability of coincidental match.

The probability of parentage exclusion (representing the probability that a  
 30 random male will have a polymorphic form at a given polymorphic site that makes him incompatible as the father) is given by the equation (see WO 95/12607):

-22-

$$p(\text{exc}) = xy(1-xy)$$

where x and y are the population frequencies of alleles A and B of a biallelic polymorphic site.

$$(\text{At a triallelic site } p(\text{exc}) = xy(1-xy) + yz(1-yz) + xz(1-xz) + 3xyz(1-xyz)),$$

5 where x, y and z are the respective population frequencies of alleles A, B and C).

The probability of non-exclusion is

$$p(\text{non-exc}) = 1 - p(\text{exc})$$

The cumulative probability of non-exclusion (representing the value obtained when n loci are used) is thus:

$$10 \quad \text{cum } p(\text{non-exc}) = p(\text{non-exc1})p(\text{non-exc2})p(\text{non-exc3})\dots p(\text{non-excn})$$

The cumulative probability of exclusion for n loci (representing the probability that a random male will be excluded)

$$\text{cum } p(\text{exc}) = 1 - \text{cum } p(\text{non-exc}).$$

15 If several polymorphic loci are included in the analysis, the cumulative probability of exclusion of a random male is very high. This probability can be taken into account in assessing the liability of a putative father whose polymorphic marker set matches the child's polymorphic marker set attributable to his/her father.

### C. Correlation of Polymorphisms with Phenotypic Traits

20 The polymorphisms of the invention may contribute to the phenotype of an organism in different ways. Some polymorphisms occur within a protein coding sequence and contribute to phenotype by affecting protein structure. The effect may be neutral, beneficial or detrimental, or both beneficial and detrimental, depending on the circumstances. For example, a heterozygous sickle cell mutation confers resistance to malaria, but a homozygous sickle cell mutation is usually lethal. Other

25 polymorphisms occur in noncoding regions but may exert phenotypic effects indirectly via influence on replication, transcription, and translation. A single polymorphism may affect more than one phenotypic trait. Likewise, a single phenotypic trait may be affected by polymorphisms in different genes. Further, some polymorphisms predispose an individual to a distinct mutation that is causally

30 related to a certain phenotype.

Phenotypic traits include diseases that have known but hitherto unmapped genetic components (e.g., agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial hypercholesterolemia, polycystic kidney disease, hereditary spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary hemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos syndrome, osteogenesis imperfecta, and acute intermittent porphyria). Phenotypic traits also include symptoms of, or susceptibility to, multifactorial diseases of which a component is or may be genetic, such as autoimmune diseases, inflammation, cancer, diseases of the nervous system, and infection by pathogenic microorganisms. Some examples of autoimmune diseases include rheumatoid arthritis, multiple sclerosis, diabetes (insulin-dependent and non-independent), systemic lupus erythematosus and Graves disease. Some examples of cancers include cancers of the bladder, brain, breast, colon, esophagus, kidney, leukemia, liver, lung, oral cavity, ovary, pancreas, prostate, skin, stomach and uterus. Phenotypic traits also include characteristics such as longevity, appearance (e.g., baldness, obesity), strength, speed, endurance, fertility, and susceptibility or receptivity to particular drugs or therapeutic treatments.

The correlation of one or more polymorphisms with phenotypic traits can be facilitated by knowledge of the gene product of the wild type (reference) gene. The genes in which cSNPs of the present invention have been identified are genes which have been previously sequenced and characterized in one of their allelic forms.

Correlation is performed for a population of individuals who have been tested for the presence or absence of a phenotypic trait of interest and for polymorphic markers sets. To perform such analysis, the presence or absence of a set of polymorphisms (i.e. a polymorphic set) is determined for a set of the individuals, some of whom exhibit a particular trait, and some of which exhibit lack of the trait. The alleles of each polymorphism of the set are then reviewed to determine whether the presence or absence of a particular allele is associated with the trait of interest. Correlation can be performed by standard statistical methods such as a  $\chi$ -squared test and statistically significant correlations between polymorphic form(s) and phenotypic characteristics are noted. For example, it might be found that the presence of allele A1 at polymorphism A correlates with heart disease. As a further

example, it might be found that the combined presence of allele A1 at polymorphism A and allele B1 at polymorphism B correlates with increased milk production of a farm animal.

Such correlations can be exploited in several ways. In the case of a strong  
 5 correlation between a set of one or more polymorphic forms and a disease for which treatment is available, detection of the polymorphic form set in a human or animal patient may justify immediate administration of treatment, or at least the institution of regular monitoring of the patient. Detection of a polymorphic form correlated with serious disease in a couple contemplating a family may also be valuable to the  
 10 couple in their reproductive decisions. For example, the female partner might elect to undergo *in vitro* fertilization to avoid the possibility of transmitting such a polymorphism from her husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic set and human disease, immediate therapeutic intervention or monitoring may not be justified.

15 Nevertheless, the patient can be motivated to begin simple life-style changes (e.g., diet, exercise) that can be accomplished at little cost to the patient but confer potential benefits in reducing the risk of conditions to which the patient may have increased susceptibility by virtue of variant alleles. Identification of a polymorphic set in a patient correlated with enhanced receptiveness to one of several treatment  
 20 regimes for a disease indicates that this treatment regime should be followed.

For animals and plants, correlations between characteristics and phenotype are useful for breeding for desired characteristics. For example, Beitz *et al.*, US 5,292,639 discuss use of bovine mitochondrial polymorphisms in a breeding program to improve milk production in cows. To evaluate the effect of mtDNA D-  
 25 loop sequence polymorphism on milk production, each cow was assigned a value of 1 if variant or 0 if wildtype with respect to a prototypical mitochondrial DNA sequence at each of 17 locations considered. Each production trait was analyzed individually with the following animal model:

$$Y_{ijkpn} = \mu + YS_i + P_j + X_k + \beta_1 + \dots \beta_{17} + PE_n + a_n + e_p$$

30 where  $Y_{ijkpn}$  is the milk, fat, fat percentage, SNF, SNF percentage, energy concentration, or lactation energy record;  $\mu$  is an overall mean;  $YS_i$  is the effect common to all cows calving in year-season;  $X_k$  is the effect common to cows in

either the high or average selection line;  $\beta_1$  to  $\beta_{17}$  are the binomial regressions of production record on mtDNA D-loop sequence polymorphisms;  $PE_n$  is permanent environmental effect common to all records of cow  $n$ ;  $a_n$  is effect of animal  $n$  and is composed of the additive genetic contribution of sire and dam breeding values and  
5 Mendelian sampling effect; and  $e_p$  is a random residual. It was found that eleven of seventeen polymorphisms tested influenced at least one production trait. Bovines having the best polymorphic forms for milk production at these eleven loci are used as parents for breeding the next generation of the herd.

#### D. Genetic Mapping of Phenotypic Traits

10 The previous section concerns identifying correlations between phenotypic traits and polymorphisms that directly or indirectly contribute to those traits. The present section describes identification of a physical linkage between a genetic locus associated with a trait of interest and polymorphic markers that are not associated with the trait, but are in physical proximity with the genetic locus responsible for the  
15 trait and co-segregate with it. Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander *et al.*, *Proc. Natl. Acad. Sci. (USA)* 83, 7353-7357 (1986); Lander *et al.*, *Proc. Natl. Acad. Sci. (USA)* 84, 2363-2367 (1987); Donis-Keller *et al.*, *Cell* 51, 319-337 (1987); Lander *et al.*, *Genetics* 121,  
20 185-199 (1989)). Genes localized by linkage can be cloned by a process known as directional cloning. See Wainwright, *Med. J. Australia* 159, 170-174 (1993); Collins, *Nature Genetics* 1, 3-6 (1992).

Linkage studies are typically performed on members of a family. Available members of the family are characterized for the presence or absence of a phenotypic  
25 trait and for a set of polymorphic markers. The distribution of polymorphic markers in an informative meiosis is then analyzed to determine which polymorphic markers co-segregate with a phenotypic trait. See, e.g., Kerem *et al.*, *Science* 245, 1073-1080 (1989); Monaco *et al.*, *Nature* 316, 842 (1985); Yamoka *et al.*, *Neurology* 40, 222-226 (1990); Rossiter *et al.*, *FASEB Journal* 5, 21-27 (1991).

30 Linkage is analyzed by calculation of LOD (log of the odds) values. A lod value is the relative likelihood of obtaining observed segregation data for a marker

- and a genetic locus when the two are located at a recombination fraction  $\theta$ , versus the situation in which the two are not linked, and thus segregating independently (Thompson & Thompson, *Genetics in Medicine* (5th ed, W.B. Saunders Company, Philadelphia, 1991); Strachan, "Mapping the human genome" in *The Human*
- 5 *Genome* (BIOS Scientific Publishers Ltd, Oxford), Chapter 4). A series of likelihood ratios are calculated at various recombination fractions ( $\theta$ ), ranging from  $\theta = 0.0$  (coincident loci) to  $\theta = 0.50$  (unlinked). Thus, the likelihood at a given value of  $\theta$  is: probability of data if loci linked at  $\theta$  to probability of data if loci unlinked. The computed likelihoods are usually expressed as the  $\log_{10}$  of this ratio
- 10 (i.e., a lod score). For example, a lod score of 3 indicates 1000:1 odds against an apparent observed linkage being a coincidence. The use of logarithms allows data collected from different families to be combined by simple addition. Computer programs are available for the calculation of lod scores for differing values of  $\theta$  (e.g., LIPED, MLINK (Lathrop, *Proc. Nat. Acad. Sci. (USA)* 81, 3443-3446 (1984)).
- 15 For any particular lod score, a recombination fraction may be determined from mathematical tables. See Smith *et al.*, *Mathematical tables for research workers in human genetics* (Churchill, London, 1961); Smith, *Ann. Hum. Genet.* 32, 127-150 (1968). The value of  $\theta$  at which the lod score is the highest is considered to be the best estimate of the recombination fraction.
- 20 Positive lod score values suggest that the two loci are linked, whereas negative values suggest that linkage is less likely (at that value of  $\theta$ ) than the possibility that the two loci are unlinked. By convention, a combined lod score of +3 or greater (equivalent to greater than 1000:1 odds in favor of linkage) is considered definitive evidence that two loci are linked. Similarly, by convention, a negative lod score of -
- 25 2 or less is taken as definitive evidence against linkage of the two loci being compared. Negative linkage data are useful in excluding a chromosome or a segment thereof from consideration. The search focuses on the remaining non-excluded chromosomal locations.

#### IV. Modified Polypeptides and Gene Sequences

- 30 The invention further provides variant forms of nucleic acids and corresponding proteins. The nucleic acids comprise one of the sequences described

in the Table, column 5, in which the polymorphic position is occupied by one of the alternative bases for that position. Some nucleic acids encode full-length variant forms of proteins. Similarly, variant proteins have the prototypical amino acid sequences encoded by nucleic acid sequences shown in the Table, column 5, (read  
5 so as to be in-frame with the full-length coding sequence of which it is a component) except at an amino acid encoded by a codon including one of the polymorphic positions shown in the Table. That position is occupied by the amino acid coded by the corresponding codon in any of the alternative forms shown in the Table.

Variant genes can be expressed in an expression vector in which a variant gene  
10 is operably linked to a native or other promoter. Usually, the promoter is a eukaryotic promoter for expression in a mammalian cell. The transcription regulation sequences typically include a heterologous promoter and optionally an enhancer which is recognized by the host. The selection of an appropriate promoter, for example trp, lac, phage promoters, glycolytic enzyme promoters and tRNA  
15 promoters, depends on the host selected. Commercially available expression vectors can be used. Vectors can include host-recognized replication systems, amplifiable genes, selectable markers, host sequences useful for insertion into the host genome, and the like.

The means of introducing the expression construct into a host cell varies  
20 depending upon the particular construction and the target host. Suitable means include fusion, conjugation, transfection, transduction, electroporation or injection, as described in Sambrook, *supra*. A wide variety of host cells can be employed for expression of the variant gene, both prokaryotic and eukaryotic. Suitable host cells include bacteria such as *E. coli*, yeast, filamentous fungi, insect cells, mammalian  
25 cells, typically immortalized, *e.g.*, mouse, CHO, human and monkey cell lines and derivatives thereof. Preferred host cells are able to process the variant gene product to produce an appropriate mature polypeptide. Processing includes glycosylation, ubiquitination, disulfide bond formation, general post-translational modification, and the like. As used herein, "gene product" includes mRNA, peptide and protein  
30 products.

The protein may be isolated by conventional means of protein biochemistry and purification to obtain a substantially pure product, *i.e.*, 80, 95 or 99% free of cell



component contaminants, as described in Jacoby, *Methods in Enzymology* Volume 104, Academic Press, New York (1984); Scopes, *Protein Purification, Principles and Practice*, 2nd Edition, Springer-Verlag, New York (1987); and Deutscher (ed), *Guide to Protein Purification, Methods in Enzymology*, Vol. 182 (1990). If the  
5 protein is secreted, it can be isolated from the supernatant in which the host cell is grown. If not secreted, the protein can be isolated from a lysate of the host cells.

The invention further provides transgenic nonhuman animals capable of expressing an exogenous variant gene and/or having one or both alleles of an endogenous variant gene inactivated. Expression of an exogenous variant gene is  
10 usually achieved by operably linking the gene to a promoter and optionally an enhancer, and microinjecting the construct into a zygote. See Hogan *et al.*, "Manipulating the Mouse Embryo, A Laboratory Manual," Cold Spring Harbor Laboratory. Inactivation of endogenous variant genes can be achieved by forming a transgene in which a cloned variant gene is inactivated by insertion of a positive  
15 selection marker. See Capecchi, *Science* 244, 1288-1292 (1989). The transgene is then introduced into an embryonic stem cell, where it undergoes homologous recombination with an endogenous variant gene. Mice and other rodents are preferred animals. Such animals provide useful drug screening systems.

In addition to substantially full-length polypeptides expressed by variant  
20 genes, the present invention includes biologically active fragments of the polypeptides, or analogs thereof, including organic molecules which simulate the interactions of the peptides. Biologically active fragments include any portion of the full-length polypeptide which confers a biological function on the variant gene product, including ligand binding, and antibody binding. Ligand binding includes  
25 binding by nucleic acids, proteins or polypeptides, small biologically active molecules, or large cellular structures.

Polyclonal and/or monoclonal antibodies that specifically bind to variant gene products but not to corresponding prototypical gene products are also provided. Antibodies can be made by injecting mice or other animals with the variant gene  
30 product or synthetic peptide fragments thereof. Monoclonal antibodies are screened as are described, for example, in Harlow & Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Press, New York (1988); Goding, *Monoclonal antibodies*,

*Principles and Practice* (2d ed.) Academic Press, New York (1986). Monoclonal antibodies are tested for specific immunoreactivity with a variant gene product and lack of immunoreactivity to the corresponding prototypical gene product. These antibodies are useful in diagnostic assays for detection of the variant form, or as an  
5 active ingredient in a pharmaceutical composition.

#### V. Kits

The invention further provides kits comprising at least one allele-specific oligonucleotide as described herein. Often, the kits contain one or more pairs of allele-specific oligonucleotides hybridizing to different forms of a polymorphism.  
10 In some kits, the allele-specific oligonucleotides are provided immobilized to a substrate. For example, the same substrate can comprise allele-specific oligonucleotide probes for detecting at least 10, 100 or all of the polymorphisms shown in the Table. Optional additional components of the kit include, for example, restriction enzymes, reverse-transcriptase or polymerase, the substrate  
15 nucleoside triphosphates, means used to label (for example, an avidin-enzyme conjugate and enzyme substrate and chromogen if the label is biotin), and the appropriate buffers for reverse transcription, PCR, or hybridization reactions. Usually, the kit also contains instructions for carrying out the methods.

The thrombospondins are a family of extracellular matrix (ECM)  
20 glycoproteins that modulate many cell behaviors including adhesion, migration, and proliferation. Thrombospondins (also known as thrombin sensitive proteins or TSPs) are large molecular weight glycoproteins composed of three identical disulfide-linked polypeptide chains. TSPs are stored in the alpha-granules of platelets and secreted by a variety of mesenchymal and epithelial cells (Majack *et al.*, *Cell Membrane* 3:57-77 (1987)). Platelets secrete TSPs when activated in the  
25 blood by such physiological agonists such as thrombin. TSPs have lectin properties and a broad function in the regulation of fibrinolysis and as a component of the ECM, and are one of a group of ECM proteins which have adhesive properties. TSPs bind to fibronectin and fibrinogen (Lahav *et al.*, *Eur J Biochem* 145:151-6  
30 (1984)), and these proteins are known to be involved in platelet adhesion to substratum and platelet aggregation (Leung, *J Clin Invest* 74:1764-1772 (1986)).

Recent work has implicated TSPs in response of cells to growth factors. Submitogenic doses of PDGF induce a rapid but transitory, increase in TSP synthesis and secretion by rat aortic smooth muscle cells (Majack *et al.*, *J Biol Chem* 101:1059-70 (1985)). PDGF responsiveness to TSP synthesis in glial cells has also  
5 been shown (Asch *et al.*, *Proc Natl Acad Sci* 83:2904-8 (1986)). TSP mRNA levels rise rapidly in response to PDGF (Majack *et al.*, *J Biol Chem* 262:8821-5 (1987)). TSPs act synergistically with epidermal growth factor to increase DNA synthesis in smooth muscle cells (Majack *et al.*, *Proc Natl Acad Sci* 83:9050-4 (1986)), and monoclonal antibodies to TSPs inhibit smooth muscle cell proliferation (Majack *et al.*, *J Biol Chem* 106:415-22 (1988)). TSPs modulate local adhesions in endothelial  
10 cells, and TSPs, particularly TSP-1 primarily derived from platelet granules, are known to be an important activator of transforming growth factor beta-1 (TGFB-1) (Crawford *et al.*, *Cell* 93:1159 (1998)) and appear to be a potential link between platelet-thrombosis and development of atherosclerosis.

15 To determine pivotal genes associated with premature coronary artery disease, we analyzed DNA from 347 patients with MI or coronary revascularization before age 40 (men) or 45 (women) and 422 general population controls. Cases were drawn (one per family) from a retrospective collection of sibling pairs with premature CAD. Controls were ascertained through random-digit dialing. Both  
20 cases and controls were Caucasian. A complete database of phenotypic and laboratory variables for the affected patients afforded logistic regression to control for age, diabetes, body mass index, gender.

Thrombospondin (TSP) 4 and 1 emerged as important SNPs associated with premature CAD and MI. For CAD, 148 of 347 patients carried at least one copy of  
25 the TSP-4 variant compared with 142 of 422 control subjects; adjusted odds ratio 1.47,  $p=0.01$ . For premature MI, the association was even stronger: 91 of 187 cases vs. 142 of 422 controls had the variant; adjusted odds ratio 2.08,  $p=0.0003$ . The TSP-1 SNP was rare. Nonetheless, homozygosity for the variant allele gave an adjusted odds ratio of 9.5,  $p=.04$ .

30 Specific reference nucleotide (SEQ ID NO: 1) and amino acid (SEQ ID NO: 2) sequences for TSP-1 are shown in Figs. 1A-1D. Specific reference nucleotide (SEQ ID NO: 3) and amino acid (SEQ ID NO: 4) sequences for TSP-4 are shown in

Figs. 2A-2C. It is understood that the invention is not limited by these exemplified reference sequences, as variants of these sequences which differ at locations other than the SNP sites identified herein can also be utilized. The skilled artisan can readily determine the SNP sites in these other reference sequences which correspond to the SNP sites identified herein by aligning the sequence of interest with the reference sequences specifically disclosed herein, and programs for performing such alignments are commercially available. For example, the ALIGN program in the GCG software package can be used, utilizing a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4, for example.

Two SNPs have been specifically studied as described herein. The first (G334u4) is a change from A (reference nucleotide) to G (alternate or variant nucleotide) at nucleotide position 2210 of the nucleic acid sequence of TSP-1 (Figs. 1A-1D), resulting in a missense amino acid mutation from asparagine (reference) to serine (alternate) at amino acid 700. The second SNP (G355u2) is a change from G (reference) to C (alternate) at nucleotide position 1186 of the nucleic acid sequence of TSP-4 (Figs. 2A-2C), resulting in a missense amino acid alteration from alanine (reference) to proline (alternate) at amino acid 387. With respect to the G355u2 SNP, individuals with CAD carried at least one copy of the variant "C" allele more frequently than control individuals (43% as compared with 34%). With respect to the G355u2 SNP, individuals with MI carried at least one copy of the variant "C" allele more frequently than control individuals (49% as compared with 34%). With respect to the G334u4 SNP, individuals with CAD carried two copies of the variant "G" allele more frequently than control individuals (1.7% as compared with 0.2%). With respect to the G334u4 SNP, individuals with MI carried two copies of the variant "G" allele more frequently than control individuals (2% as compared with 0.2%).

As used herein, the term "polymorphism" refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker or site is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%, and more preferably greater than 10% or 20% of a selected population. A

-32-

polymorphic locus may be as small as one base pair, in which case it is referred to as a single nucleotide polymorphism (SNP).

Thus, the invention relates to a method for predicting the likelihood that an individual will have a vascular disease, or for aiding in the diagnosis of a vascular disease, or predicting the likelihood of having altered symptomology associated with a vascular disease, comprising the steps of obtaining a DNA sample from an individual to be assessed and determining the nucleotide present at one or more of nucleotide positions 2210 of the TSP-1 gene or 1186 of the TSP-4 gene. In a preferred embodiment, the nucleotides present at both of these nucleotide positions are determined. In one embodiment the TSP-1 gene has the nucleotide sequence of SEQ ID NO: 1 and the TSP-4 gene has the nucleotide sequence of SEQ ID NO: 3. The presence of one or more of a G (the variant nucleotide) at position 2210 of SEQ ID NO: 1 or a C (the variant nucleotide) at position 1186 of SEQ ID NO: 1186 indicates that the individual has a greater likelihood of having a vascular disease, or a greater likelihood of having severe symptomology associated with a vascular disease, than if that individual had the reference nucleotide at one or more of these positions. Conversely, the presence of one or more of an A (the reference nucleotide) at position 2210 of SEQ ID NO: 1 or a G (the reference nucleotide) at position 1186 of SEQ ID NO: 3 indicates that the individual has a reduced likelihood of having a vascular disease or a likelihood of having reduced symptomology associated with a vascular disease than if that individual had the variant nucleotide at one or more of these positions.

In a particular embodiment, the individual is an individual at risk for development of a vascular disease. In another embodiment the individual exhibits clinical symptomology associated with a vascular disease. In one embodiment, the individual has been clinically diagnosed as having a vascular disease. Vascular diseases include, but are not limited to, atherosclerosis, coronary heart disease, myocardial infarction (MI), stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism. In preferred embodiments, the vascular disease is CAD or MI.

The genetic material to be assessed can be obtained from any nucleated cell from the individual. For assay of genomic DNA, virtually any biological sample

(other than pure red blood cells) is suitable. For example, convenient tissue samples include whole blood, semen, saliva, tears, urine, fecal material, sweat, skin and hair. For assay of cDNA or mRNA, the tissue sample must be obtained from a tissue or organ in which the target nucleic acid is expressed.

- 5        Many of the methods described herein require amplification of DNA from target samples. This can be accomplished by e.g., PCR. *See generally PCR Technology: Principles and Applications for DNA Amplification* (ed. H.A. Erlich, Freeman Press, NY, NY, 1992); *PCR Protocols: A Guide to Methods and Applications* (eds. Innis, *et al.*, Academic Press, San Diego, CA, 1990); Mattila *et*  
10 *al.*, *Nucleic Acids Res.* 19, 4967 (1991); Eckert *et al.*, *PCR Methods and Applications* 1, 17 (1991); *PCR* (eds. McPherson *et al.*, IRL Press, Oxford); and U.S. Patent 4,683,202.

- Other suitable amplification methods include the ligase chain reaction (LCR) (see Wu and Wallace, *Genomics* 4, 560 (1989), Landegren *et al.*, *Science* 241, 1077  
15 (1988), transcription amplification (Kwoh *et al.*, *Proc. Natl. Acad. Sci. USA* 86, 1173 (1989)), and self-sustained sequence replication (Guatelli *et al.*, *Proc. Nat. Acad. Sci. USA*, 87, 1874 (1990)) and nucleic acid based sequence amplification (NASBA). The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and  
20 double stranded DNA (dsDNA) as the amplification products in a ratio of about 30 or 100 to 1, respectively.

- The nucleotide which occupies the polymorphic site of interest (e.g., nucleotide position 2210 in TSP-1 and/or nucleotide position 1186 in TSP-4) can be identified by a variety of methods, such as Southern analysis of genomic DNA;  
25 direct mutation analysis by restriction enzyme digestion; Northern analysis of RNA; denaturing high pressure liquid chromatography (DHPLC); gene isolation and sequencing; hybridization of an allele-specific oligonucleotide with amplified gene products; single base extension (SBE). In a preferred embodiment, determination of the allelic form of TSP is carried out using SBE-FRET methods as described herein,  
30 or using chip-based oligonucleotide arrays as described herein.

The invention also relates to a method for predicting the likelihood that an individual will have a vascular disease, or for aiding in the diagnosis of a vascular

-34-

disease, or predicting the likelihood of having altered symptomology associated with a vascular disease, comprising the steps of obtaining a biological sample comprising TSP-1 and/or TSP-4 protein or relevant portion thereof from an individual to be assessed and determining the amino acid present at one or more of amino acid

5 positions 700 of the TSP-1 gene product (e.g., as exemplified by SEQ ID NO: 2) or 387 of the TSP-4 gene product (e.g., as exemplified by SEQ ID NO: 4). In a preferred embodiment, the amino acids present at both of these amino acid positions are determined. As used herein, the term "relevant portion" of the TSP-1 and TSP-4 proteins is intended to encompass any portion of the protein which comprises the

10 polymorphic amino acid positions. The presence of one or more of a serine (the variant amino acid) at position 700 of SEQ ID NO: 2, or a proline (the variant amino acid) at position 387 of SEQ ID NO: 4 indicates that the individual has a greater likelihood of having a vascular disease, or a greater likelihood of having severe symptomology associated with a vascular disease, than if that individual had the

15 reference amino acid at one or more of these positions. Conversely, the presence of one or more of an asparagine (the reference amino acid) at position 700 of SEQ ID NO: 2, or an alanine (the reference amino acid) at position 387 of SEQ ID NO: 4 indicates that the individual has a reduced likelihood of having a vascular disease or a likelihood of having reduced symptomology associated with a vascular disease,

20 than if that individual had the variant amino acid at one or more of these positions.

In a particular embodiment, the individual is an individual at risk for development of a vascular disease. In another embodiment the individual exhibits clinical symptomology associated with a vascular disease. In one embodiment, the individual has been clinically diagnosed as having a vascular disease.

25 In this embodiment of the invention, the biological sample contains protein molecules from the test subject. *In vitro* techniques for detection of protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. Furthermore, *in vivo* techniques for detection of protein include introducing into a subject a labeled anti-protein

30 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Polyclonal and/or monoclonal antibodies that specifically bind to variant gene

products but not to corresponding reference gene products, and vice versa, are also provided. Antibodies can be made by injecting mice or other animals with the variant gene product or synthetic peptide fragments thereof comprising the variant portion. Monoclonal antibodies are screened as are described, for example, in

5 Harlow & Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Press, New York (1988); Goding, *Monoclonal antibodies, Principles and Practice* (2d ed.) Academic Press, New York (1986). Monoclonal antibodies are tested for specific immunoreactivity with a variant gene product and lack of immunoreactivity to the corresponding prototypical gene product. These antibodies are useful in diagnostic

10 assays for detection of the variant form, or as an active ingredient in a pharmaceutical composition.

The polymorphisms of the invention may be associated with vascular disease in different ways. The polymorphisms may exert phenotypic effects indirectly via influence on replication, transcription, and translation. Additionally, the described

15 polymorphisms may predispose an individual to a distinct mutation that is causally related to a certain phenotype, such as susceptibility or resistance to vascular disease and related disorders. The discovery of the polymorphisms and their correlation with CAD and MI facilitates biochemical analysis of the variant and reference forms and the development of assays to characterize the variant and reference forms and to

20 screen for pharmaceutical agents that interact directly with one or another form of the protein.

Alternatively, these particular polymorphisms may belong to a group of two or more polymorphisms in the TSP gene(s) which contributes to the presence, absence or severity of vascular disease. An assessment of other polymorphisms within the

25 TSP gene(s) can be undertaken, and the separate and combined effects of these polymorphisms, as well as alternations in other, distinct genes, on the vascular disease phenotype can be assessed.

Correlation between a particular phenotype, e.g., the CAD or MI phenotype, and the presence or absence of a particular allele is performed for a population of

30 individuals who have been tested for the presence or absence of the phenotype. Correlation can be performed by standard statistical methods such as a Chi-squared test and statistically significant correlations between polymorphic form(s) and



phenotypic characteristics are noted. This correlation can be exploited in several ways. In the case of a strong correlation between a particular polymorphic form, e.g., the variant allele for TSP-1 and/or TSP-4, and a disease for which treatment is available, detection of the polymorphic form in an individual may justify immediate  
5 administration of treatment, or at least the institution of regular monitoring of the individual. Detection of a polymorphic form correlated with a disorder in a couple contemplating a family may also be valuable to the couple in their reproductive decisions. For example, the female partner might elect to undergo *in vitro* fertilization to avoid the possibility of transmitting such a polymorphism from her  
10 husband to her offspring. In the case of a weaker, but still statistically significant correlation between a polymorphic form and a particular disorder, immediate therapeutic intervention or monitoring may not be justified. Nevertheless, the individual can be motivated to begin simple life-style changes (e.g., diet modification, therapy or counseling) that can be accomplished at little cost to the  
15 individual but confer potential benefits in reducing the risk of conditions to which the individual may have increased susceptibility by virtue of the particular allele. Furthermore, identification of a polymorphic form correlated with enhanced receptiveness to one of several treatment regimes for a disorder indicates that this treatment regimen should be followed for the individual in question.

20 Furthermore, it may be possible to identify a physical linkage between a genetic locus associated with a trait of interest (e.g., CAD or MI) and polymorphic markers that are or are not associated with the trait, but are in physical proximity with the genetic locus responsible for the trait and co-segregate with it. Such analysis is useful for mapping a genetic locus associated with a phenotypic trait to a  
25 chromosomal position, and thereby cloning gene(s) responsible for the trait. See Lander *et al.*, *Proc. Natl. Acad. Sci. (USA)* 83, 7353-7357 (1986); Lander *et al.*, *Proc. Natl. Acad. Sci. (USA)* 84, 2363-2367 (1987); Donis-Keller *et al.*, *Cell* 51, 319-337 (1987); Lander *et al.*, *Genetics* 121, 185-199 (1989)). Genes localized by linkage can be cloned by a process known as directional cloning. See Wainwright,  
30 *Med. J. Australia* 159, 170-174 (1993); Collins, *Nature Genetics* 1, 3-6 (1992). Linkage studies are discussed in more detail above.

-37-

In another embodiment, the invention relates to pharmaceutical compositions comprising a reference TSP-1 and/or TSP-4 gene or gene product for use in the treatment of vascular disease, e.g., CAD and MI. As used herein, a reference TSP gene product is intended to mean gene products which are encoded by the reference  
5 allele of the TSP gene. In addition to substantially full-length polypeptides expressed by the genes, the present invention includes biologically active fragments of the polypeptides, or analogs thereof, including organic molecules which simulate the interactions of the peptides. Biologically active fragments include any portion of the full-length polypeptide which confers a biological function on the variant gene  
10 product, including ligand binding, and antibody binding. Ligand binding includes binding by nucleic acids, proteins or polypeptides, small biologically active molecules, or large cellular structures.

For instance, the polypeptide or protein, or fragment thereof, of the present invention can be formulated with a physiologically acceptable medium to prepare a  
15 pharmaceutical composition. The particular physiological medium may include, but is not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and dextrose solutions. The optimum concentration of the active ingredient(s) in the chosen medium can be determined empirically, according to procedures well known to medicinal chemists, and will depend on the  
20 ultimate pharmaceutical formulation desired. Methods of introduction of exogenous peptides at the site of treatment include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral and intranasal. Other suitable methods of introduction can also include rechargeable or biodegradable devices and slow release polymeric devices. The pharmaceutical compositions of  
25 this invention can also be administered as part of a combinatorial therapy with other agents and treatment regimens.

The invention further pertains to compositions, e.g., vectors, comprising a nucleotide sequence encoding reference or variant TSP-1 and/or TSP-4 gene products. For example, reference genes can be expressed in an expression vector in  
30 which a reference gene is operably linked to a native or other promoter. Usually, the promoter is a eukaryotic promoter for expression in a mammalian cell. The transcription regulation sequences typically include a heterologous promoter and

-38-

optionally an enhancer which is recognized by the host. The selection of an appropriate promoter, for example trp, lac, phage promoters, glycolytic enzyme promoters and tRNA promoters, depends on the host selected. Commercially available expression vectors can be used. Vectors can include host-recognized  
5 replication systems, amplifiable genes, selectable markers, host sequences useful for insertion into the host genome, and the like.

The means of introducing the expression construct into a host cell varies depending upon the particular construction and the target host. Suitable means include fusion, conjugation, transfection, transduction, electroporation or injection,  
10 as described in Sambrook, *supra*. A wide variety of host cells can be employed for expression of the variant gene, both prokaryotic and eukaryotic. Suitable host cells include bacteria such as *E. coli*, yeast, filamentous fungi, insect cells, mammalian cells, typically immortalized, *e.g.*, mouse, CHO, human and monkey cell lines and derivatives thereof. Preferred host cells are able to process the variant gene product  
15 to produce an appropriate mature polypeptide. Processing includes glycosylation, ubiquitination, disulfide bond formation, general post-translational modification, and the like.

It is also contemplated that cells can be engineered to express the reference allele of the invention by gene therapy methods. For example, DNA encoding the  
20 reference TSP gene product, or an active fragment or derivative thereof, can be introduced into an expression vector, such as a viral vector, and the vector can be introduced into appropriate cells in an animal. In such a method, the cell population can be engineered to inducibly or constitutively express active reference TSP gene product. In a preferred embodiment, the vector is delivered to the bone marrow, for  
25 example as described in Corey *et al.* (*Science* 244:1275-1281 (1989)).

The invention further relates to the use of compositions (*i.e.*, agonists) which enhance or increase the activity of the reference (or variant) TSP (*e.g.*, TSP-1 or TSP-4) gene product, or a functional portion thereof, for use in the treatment of vascular disease. The invention also relates to the use of compositions (*i.e.*,  
30 antagonists) which reduce or decrease the activity of the variant (or reference) TSP (*e.g.*, TSP-1 or TSP-4) gene product, or a functional portion thereof, for use in the treatment of vascular disease.

The invention also relates to constructs which comprise a vector into which a sequence of the invention has been inserted in a sense or antisense orientation. For example, a vector comprising a nucleotide sequence which is antisense to the variant TSP-1 or TSP-4 allele may be used as an antagonist of the activity of the TSP-1 or TSP-4 variant allele. Alternatively, a vector comprising a nucleotide sequence of the TSP-1 or TSP-4 reference allele may be used therapeutically to treat vascular diseases. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operably linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses) that serve equivalent functions.

Preferred recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell. This means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters,

-40-

enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, *Gene Expression Technology: Methods in Enzymology 185*, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a

5 nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.

10 The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein. The recombinant expression vectors of the invention can be designed for expression of a polypeptide of the invention in prokaryotic or eukaryotic cells, *e.g.*, bacterial cells such as *E. coli*, insect cells (using

15 baculovirus expression vectors), yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *supra*. Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Another aspect of the invention pertains to host cells into which a recombinant

20 expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may

25 not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, a nucleic acid of the invention can be expressed in bacterial cells (*e.g.*, *E. coli*), insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

30 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of

art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* 5 (*supra*), and other laboratory manuals.

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) a polypeptide of the invention. Accordingly, the invention further provides methods for producing a polypeptide using the host cells of the invention. In one embodiment, the method comprises 10 culturing the host cell of the invention (into which a recombinant expression vector encoding a polypeptide of the invention has been introduced) in a suitable medium such that the polypeptide is produced. In another embodiment, the method further comprises isolating the polypeptide from the medium or the host cell.

The host cells of the invention can also be used to produce nonhuman 15 transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which a nucleic acid of the invention has been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous nucleotide sequences have been introduced into their genome or homologous recombinant animals in which 20 endogenous nucleotide sequences have been altered. Such animals are useful for studying the function and/or activity of the nucleotide sequence and polypeptide encoded by the sequence and for identifying and/or evaluating modulators of their activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of 25 the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more 30 cell types or tissues of the transgenic animal. As used herein, an "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous

-42-

recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing a nucleic acid of the invention into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The sequence can be introduced as a transgene into the genome of a non-human animal. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of a polypeptide in particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191 and in Hogan, *Manipulating the Mouse Embryo* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding the transgene can further be bred to other transgenic animals carrying other transgenes.

The invention also relates to the use of the variant and reference gene products to guide efforts to identify the causative mutation for vascular diseases or to identify or synthesize agents useful in the treatment of vascular diseases, e.g., CAD and MI. Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science*, 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity *in vitro*, or *in vitro* activity. Sites that are critical for polypeptide activity can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling

(Smith *et al.*, *J. Mol. Biol.*, 224:899-904 (1992); de Vos *et al.* *Science*, 255:306-312 (1992)).

Another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of proteins of the invention in  
5 clinical trials. An exemplary method for detecting the presence or absence of proteins or nucleic acids of the invention in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting the protein, or nucleic acid (e.g., mRNA, genomic DNA) that encodes the protein, such that the presence of the protein or  
10 nucleic acid is detected in the biological sample. A preferred agent for detecting mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic DNA sequences described herein, preferably in an allele-specific manner. The nucleic acid probe can be, for example, a full-length nucleic acid, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500  
15 nucleotides in length and sufficient to specifically hybridize under stringent conditions to appropriate mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

The invention also encompasses kits for detecting the presence of proteins or nucleic acid molecules of the invention in a biological sample. For example, the kit  
20 can comprise a labeled compound or agent (e.g., nucleic acid probe) capable of detecting protein or mRNA in a biological sample; means for determining the amount of protein or mRNA in the sample; and means for comparing the amount of protein or mRNA in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using  
25 the kit to detect protein or nucleic acid.

The following Examples are offered for the purpose of illustrating the present invention and are not to be construed to limit the scope of this invention. The teachings of all references cited herein are hereby incorporated herein by reference.



## EXAMPLES

## Identification of Single Nucleotide Polymorphisms

The polymorphisms shown in the Table were identified by resequencing of target sequences from individuals of diverse ethnic and geographic backgrounds by hybridization to probes immobilized to microfabricated arrays. The strategy and principles for design and use of such arrays are generally described in WO 95/11995.

A typical probe array used in this analysis has two groups of four sets of probes that respectively tile both strands of a reference sequence. A first probe set comprises a plurality of probes exhibiting perfect complementarity with one of the reference sequences. Each probe in the first probe set has an interrogation position that corresponds to a nucleotide in the reference sequence. That is, the interrogation position is aligned with the corresponding nucleotide in the reference sequence, when the probe and reference sequence are aligned to maximize complementarity between the two. For each probe in the first set, there are three corresponding probes from three additional probe sets. Thus, there are four probes corresponding to each nucleotide in the reference sequence. The probes from the three additional probe sets are identical to the corresponding probe from the first probe set except at the interrogation position, which occurs in the same position in each of the four corresponding probes from the four probe sets, and is occupied by a different nucleotide in the four probe sets. In the present analysis, probes were 25 nucleotides long. Arrays tiled for multiple different reference sequences were included on the same substrate.

Publicly available sequences for a given gene were assembled into Gap4 (<http://www.biozentrum.unibas.ch/~biocomp/staden/Overview.html>). PCR primers covering each exon were designed using Primer 3 (<http://www-genome.wi.mit.edu/cgi-bin/primer/primer3.cgi>). Primers were not designed in regions where there were sequence discrepancies between reads. Genomic DNA was amplified in at least 50 individuals using 2.5 pmol each primer, 1.5 mM MgCl<sub>2</sub>, 100 μM dNTPs, 0.75 μM AmpliTaq GOLD polymerase, and 19 ng DNA in a 15 μl reaction. Reactions were assembled using a PACKARD MultiPROBE robotic pipetting station and then put in MJ 96-well tetrad thermocyclers (96°C for 10

-45-

minutes, followed by 35 cycles of 96°C for 30 seconds, 59°C for 2 minutes, and 72°C for 2 minutes). A subset of the PCR assays for each individual were run on 3% NuSieve gels in 0.5X TBE to confirm that the reaction worked.

For a given DNA, 5 µl (about 50 ng) of each PCR or RT-PCR product were  
5 pooled (Final volume = 150-200 µl). The products were purified using QiaQuick PCR purification from Qiagen. The samples were eluted once in 35 µl sterile water and 4 µl 10X One-Phor-All buffer (Pharmacia). The pooled samples were digested with 0.2 µ DNaseI (Promega) for 10 minutes at 37°C and then labeled with 0.5 nmols biotin-N6-ddATP and 15 µ Terminal Transferase (GibcoBRL Life  
10 Technology) for 60 minutes at 37°C. Both fragmentation and labeling reactions were terminated by incubating the pooled sample for 15 minutes at 100°C.

Low-density DNA chips (Affymetrix, CA) were hybridized following the manufacturer's instructions. Briefly, the hybridization cocktail consisted of 3M TMACl, 10 mM Tris pH 7.8, 0.01% Triton X-100, 100 mg/ml herring sperm DNA  
15 (Gibco BRL), 200 pM control biotin-labeled oligo. The processed PCR products were denatured for 7 minutes at 100°C and then added to prewarmed (37°C) hybridization solution. The chips were hybridized overnight at 44°C. Chips were washed in 1X SSPET and 6X SSPET followed by staining with 2 µg/ml SARPE and 0.5 mg/ml acetylated BSA in 200 µl of 6X SSPET for 8 minutes at room  
20 temperature. Chips were scanned using a Molecular Dynamics scanner.

Chip image files were analyzed using Ulysses (Affymetrix, CA) which uses four algorithms to identify potential polymorphisms. Candidate polymorphisms were visually inspected and assigned a confidence value: high confidence candidates displayed all three genotypes, while likely candidates showed only two  
25 genotypes (homozygous for reference sequence and heterozygous for reference and variant). Some of the candidate polymorphisms were confirmed by ABI sequencing. Identified polymorphisms were compared to several databases to determine if they were novel. Results are shown in the Table.

#### Association of Thrombospondin Gene Polymorphisms with Vascular Disease

30 To determine pivotal genes associated with premature coronary artery disease, we analyzed DNA from 347 patients with MI or coronary revascularization before age 40 (men) or 45 (women) and 422 general population controls. Cases were

drawn (one per family) from a retrospective collection of sibling pairs with premature CAD. Controls were ascertained through random-digit dialing. Both cases and controls were Caucasian. A complete database of phenotypic and laboratory variables for the affected patients afforded logistic regression to control  
5 for age, diabetes, body mass index, gender.

Thrombospondin (TSP) 4 and 1 emerged as important SNPs associated with premature CAD and MI. For CAD, 148 of 347 patients carried at least one copy of the TSP-4 variant compared with 142 of 422 control subjects; adjusted odds ratio 1.47,  $p=0.01$ . For premature MI, the association was even stronger: 91 of 187 cases  
10 vs. 142 of 422 controls had the variant; adjusted odds ratio 2.08,  $p=0.0003$ . The TSP-1 SNP was rare. Nonetheless, homozygosity for the variant allele gave an adjusted odds ratio of 9.5,  $p=.04$ .

-47-

Poly ID	WIAF ID	Genbank or TIGR Accession Number	Position in Sequence	Gene Description	Flanking Seq	Mutation Type	Ref NT	Alt NT	Ref AA	Alt AA
AT3a7	WIAF-13246	U11270	11918	AT3, antithrombin III	CTGCAGGAGT[G/A]GCTGGATGAA	N	G	A	W	*
DRD5u22	WIAF-12913	M67439	310	DRD1, dopamine receptor D1	CATCTGGACC[C/T]TGCTGGGCAA	S	C	T	L	L
DRD5u23	WIAF-12914	M67439	332	DRD1, dopamine receptor D1	GTGCTGGTGT[G/C]CGCAGCCATC	M	G	C	C	S
DRD5u24	WIAF-12915	M67439	369	DRD1, dopamine receptor D1	TGCCCGCCAA[C/G]ATGACCAACG	M	C	G	N	K
DRD5u25	WIAF-12916	M67439	522	DRD1, dopamine receptor D1	TGTGCTCCAC[T/C]GCCTCCATCC	S	T	C	T	T
DRD5u26	WIAF-12917	M67439	953	DRD1, dopamine receptor D1	GCAGAGCAGC[G/T]GCAGAGCTGC	M	C	T	A	V
DRD5u27	WIAF-12918	M67439	635	DRD1, dopamine receptor D1	ATGCTGGGCC[T/C]GGCATGGACC	M	T	C	L	P
DRD5u28	WIAF-12919	M67439	606	DRD1, dopamine receptor D1	GCAAGATGAC[T/C]CAGCGCATGG	S	T	C	T	T
DRD5u29	WIAF-12920	M67439	845	DRD1, dopamine receptor D1	TCGCTCATCA[G/A]CTTCTACATC	M	G	A	S	N
DRD5u30	WIAF-12921	M67439	720	DRD1, dopamine receptor D1	GGGCGGGCT[G/T]GACCTGCCAA	S	G	T	L	L
DRD5u31	WIAF-12922	M67439	1044	DRD1, dopamine receptor D1	AGACCTGTGC[G/A]GTGATCATGG	S	G	A	S	S
DRD5u32	WIAF-12923	M67439	766	DRD1, dopamine receptor D1	GGAGGAGGAC[T/G]TTTGGGAGCC	M	T	G	F	V

DRD5u33	WIAF-12924	M67439	777	DRD1, dopamine receptor D1	TTTGGAGCC [C/T] GACGTGAATG	S	C	T	P	P
DRD5u34	WIAF-12925	M67439	786	DRD1, dopamine receptor D1	CGAGGTGAA [T/G] GCAGAGAACT	M	T	G	N	K
DRD5u35	WIAF-12926	M67439	887	DRD1, dopamine receptor D1	ACCTACACGC [G/A] CATCTACCGC	M	G	A	R	H
DRD5u36	WIAF-12927	M67439	1279	DRD1, dopamine receptor D1	GTGCAGCCAC [T/G] TCTGCTCCCG	M	T	G	F	V
DRD5u37	WIAF-12928	M67439	1370	DRD1, dopamine receptor D1	GAAATCGCAG [C/T] TGCCTACATC	M	C	T	A	V
DRD5u38	WIAF-12929	M67439	1500	DRD1, dopamine receptor D1	ACCCTGTGTC [T/A] GAGTCTGTCT	S	T	A	A	A
DRD5u39	WIAF-12930	M67439	1338	DRD1, dopamine receptor D1	TCTCTACAA [C/T] CAAGACATCG	S	C	T	N	N
DRD5u40	WIAF-12931	M67439	1215	DRD1, dopamine receptor D1	CACCAACCC [C/A] GTCATCTATG	S	C	A	P	P
DRD5u41	WIAF-12932	M67439	1242	DRD1, dopamine receptor D1	ACGCCGACTT [T/C] CAGAAAGTGT	S	T	C	F	F
DRD5u42	WIAF-12933	M67439	1441	DRD1, dopamine receptor D1	CGAGGAGGAG [G/A] GTCCTTTGGA	M	G	A	G	S
DRD5u43	WIAF-12934	M67439	1460	DRD1, dopamine receptor D1	GATCGCATGT [T/C] CCAGATCTAT	M	T	C	F	S
DRD5u44	WIAF-12960	M67439	399	DRD1, dopamine receptor D1	TGTCTCTGGC [C/T] GTGCTGACC	S	C	T	A	A
DRD5u45	WIAF-12961	M67439	162	DRD1, dopamine receptor D1	TGCCGCCAGG [C/G] AGCAACGGCA	S	C	G	G	G
DRD5u46	WIAF-12962	M67439	195	DRD1, dopamine receptor D1	GGCAGTTCGC [T/G] CTATACCAGC	S	T	G	A	A
DRD5u47	WIAF-12963	M67439	264	DRD1, dopamine receptor D1	TGGGGCCCTC [A/G] CAGGTGGTCA	S	A	G	S	S
DRD5u48	WIAF-12964	M67439	455	DRD1, dopamine receptor D1	TGGCCGGTTA [C/T] TGGCCCTTTG	S	C	T	Y	Y
DRD5u49	WIAF-12965	M67439	511	DRD1, dopamine receptor D1	CTTCGACATC [A/T] TGTGCTCCAC	M	A	T	M	L
DRD5u50	WIAF-12966	M67439	557	DRD1, dopamine receptor D1	ATCAGCGTGG [A/G] CCGCTACTGG	M	A	G	D	G
DRD5u51	WIAF-12967	M67439	476	DRD1, dopamine receptor D1	TGGCCCTTTG [G/A] AGCGTCTTGC	M	G	A	G	E

DRD5u52	WIAF-12968	M67439	1004	DRD1, dopamine receptor D1	AGCTGCGCG [C/T] TTCCATCAAG	M	C	T	A	V
DRD5u53	WIAF-12969	M67439	1036	DRD1, dopamine receptor D1	GGTTCTCAAG [A/C] CCCTGTCCGT	M	A	C	T	P
DRD5u54	WIAF-12970	M67439	859	DRD1, dopamine receptor D1	CTACATCCCG [G/A] TTGCCATCAT	M	G	A	V	I
DRD5u55	WIAF-12971	M67439	931	DRD1, dopamine receptor D1	GATTTCTCC [C/T] TGGAGAGGCG	S	C	T	L	L
G10u1	WIAF-10234	J04111	1308	JUN, v-jun avian sarcoma virus 17 oncogene homolog	CCCTCAACGC [C/T] TCGTTCCTCC	S	C	T	A	A
G10u2	WIAF-10235	J04111	1471	JUN, v-jun avian sarcoma virus 17 oncogene homolog	GCTGCTCAAG [C/T] TGGCGTCGCC	S	C	T	L	L
G10u3	WIAF-10253	J04111	2010	JUN, v-jun avian sarcoma virus 17 oncogene homolog	TGGAGTCCCA [G/A] GAGCGGATCA	S	G	A	Q	Q
G1001u1	WIAF-13746	D26135	993	DGKG, diacylglycerol kinase, gamma (90kd)	CCCCAGTGGT [G/A] TACCTGAAGG	S	G	A	V	V
G1001u2	WIAF-13764	D26135	2313	DGKG, diacylglycerol kinase, gamma (90kd)	ATGTGATGAG [A/T] GAGAAACATC	M	A	T	R	S
G1002u1	WIAF-13918	X57206	334	ITPKB, inositol 1,4,5-trisphosphate 3-kinase B	CCCCNAGATC [A/C] GGACAAGCCT	M	A	C	Q	P
G1002u2	WIAF-13925	X57206	575	ITPKB, inositol 1,4,5-trisphosphate 3-kinase B	CCAACTCAGC [T/C] TTCCTGCATA	S	T	C	A	A
G1004u1	WIAF-13567	L36151	1854	PIK4CA, phosphatidylinositol 4-kinase, catalytic, alpha polypeptide	GCCGCTCAGA [C/T] TCCGAGGATG	S	C	T	D	D
G1006u1	WIAF-12375	HT2690	858	PRKCA, protein kinase C, alpha	GGTACAAGTT [G/A] CTTAAACCAAG	S	G	A	L	L
G1008u1	WIAF-12397	HT2136	300	PRKCZ, protein kinase C, zeta	CTGGCCTGCC [A/G] TGTCCGGGAG	S	A	G	P	P
G1008u2	WIAF-12398	HT2136	246	PRKCZ, protein kinase C, zeta	AGTCAGGGA [T/C] GAAGGCCCTCA	S	T	C	D	D
G1008u3	WIAF-12399	HT2136	504	PRKCZ, protein kinase C, zeta	GCTGCCACGG [C/T] CTCGTCCCGC	S	C	T	G	G
G1008u4	WIAF-12403	HT2136	807	PRKCZ, protein kinase C, zeta	AGAGAATGA [C/T] CAATTTACG	S	C	T	D	D
G1008u5	WIAF-12404	HT2136	1514	PRKCZ, protein kinase C, zeta	GGATTTTCTG [A/T] CATCAAGTCC	M	A	T	D	V

G1008u6	WIAF-12412	HT2136	166	PRKCZ, protein kinase C, zeta	CAAGTGGGTG[G/A]ACAGCGAAGG	M	G	A	D	N
G1008u7	WIAF-12418	HT2136	560	PRKCZ, protein kinase C, zeta	TCCCAAGAGC[C/T]TCCAGTAGAC	M	C	T	P	L
G1009u1	WIAF-12396	L05186	2495	PTK2, PTK2 protein tyrosine kinase 2	TCATCAACAA[G/A]ATGAACTGG	S	G	A	K	K
G1011u1	WIAF-11988	X07876	1250	WNT2, wingless-type MMTV integration site family member 2	TCCCATGTGCA[C/A]CCGGATGACC	M	C	A	T	N
G1011u2	WIAF-11997	X07876	788	WNT2, wingless-type MMTV integration site family member 2	GACTATGGGA[T/C]CAAAATTGGCC	M	T	C	I	T
G1011u3	WIAF-12014	X07876	1338	WNT2, wingless-type MMTV integration site family member 2	TGCACACATG[C/A]AAGGCCCCCA	N	C	A	C	*
G1011u4	WIAF-13475	X07876	856	WNT2, wingless-type MMTV integration site family member 2	CCTGATGAAT[C/T]TTCACAACAA	M	C	T	L	P
G1011u5	WIAF-13476	X07876	958	WNT2, wingless-type MMTV integration site family member 2	GACATGCTGG[C/T]TGGCCATGGC	S	C	T	L	L
G1011u6	WIAF-13477	X07876	789	WNT2, wingless-type MMTV integration site family member 2	ACTATGGGAT[C/T]AAATTTGCCC	S	C	T	I	I
G1011u7	WIAF-13478	X07876	823	WNT2, wingless-type MMTV integration site family member 2	TGCNAAAGGAA[A/G]GGAAAGGAAA	M	A	G	R	G
G1012u1	WIAF-12408	HT48910	1574	WNT2B, wingless-type MMTV integration site family, member 2B	ATACTTGCAA[A/G]GCCCCCAAGA	S	A	G	K	K
G1016a1	WIAF-12125	222534	793	ACVR1, activin A receptor, type I	GGCAAGGGGA[A/G]AATGTTGCGG	S	A	G	B	E
G1016u2	WIAF-12392	222534	373	ACVR1, activin A receptor, type I	CTGGCCCAAGC[T/C]GTGGAGTGCT	S	T	C	A	A
G1018u1	WIAF-12413	X74210	1150	ADCY2, adenylate cyclase 2 (brain)	CAAATTGCGA[G/T]TGGGTATTAA	M	G	T	V	L
G1019u1	WIAF-12394	UB3867	5475	SPTAN1, spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)	GGGACCTTAAC[T/C]GGCGTGCGAGA	S	T	C	T	T

G1019u2	WIAP-12406	U83867	1223	SPTAN1, spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)	GGCCTCATCA [A/G] TGCAGATGAG	M	A	G	N	S
G1019u3	WIAP-12409	U83867	3555	SPTAN1, spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)	CTGAAGGTCT [T/C] ATGGCAGAGG	S	T	C	L	L
G1019u4	WIAP-12415	U83867	3369	SPTAN1, spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)	TCCGTGAAGC [G/A] AATGAAC TAC	S	G	A	A	A
G1019u5	WIAP-12417	U83867	5839	SPTAN1, spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)	TGAGACAGAC [T/A] TCACCGTCCA	M	T	A	F	I
G1022u1	WIAP-12393	U45945	631	ATP1B2, ATPase, Na+/K+ transporting, beta 2 polypeptide	CATGAATGTT [A/G] CCTGTGCTGG	M	A	G	T	A
G1022u2	WIAP-12400	U45945	432	ATP1B2, ATPase, Na+/K+ transporting, beta 2 polypeptide	GGCGCCCTGG [G/A] CGCTATTACG	S	G	A	G	G
G1023u1	WIAP-12401	D89722	395	ARNTL, aryl hydrocarbon receptor nuclear translocator-like	AACATTAAGA [G/C] GTGCCACCNA	M	G	C	G	R
G1023u2	WIAP-12407	D89722	681	ARNTL, aryl hydrocarbon receptor nuclear translocator-like	CTCATAGATG [C/T] AAAA ACTGGA	M	C	T	A	V
G1024u1	WIAP-12410	U85946	731	Homo sapiens brain secretory protein hSec10p (HSEC10) mRNA, complete cds.	GATGATTTT [C/T] AGAAGTTAAA	M	C	T	S	L
G1027u1	WIAP-12402	L47647	1135	CKB, creatine kinase, brain	TCGAGATGGA [A/G] CAGCGGCTGG	S	A	G	E	E
G1027u2	WIAP-12405	L47647	499	CKB, creatine kinase, brain	GGGAGCGCG [A/C] GCCATCGAGA	S	A	C	R	R
G103u1	WIAP-10427	HT2269	335	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	GGGATCGCCA [T/C] GGGAACTCAA	S	T	C	H	H



G103u2	WIAF-10429	HT2269	1221	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	CCCTCCTTCT (C/T) CAAGAATTCT	M	C	T	P	S
G103u3	WIAF-10431	HT2269	1783	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	TCTCCAACCTT (G/C) TACAAATTCT	M	G	C	C	S
G103u4	WIAF-10432	HT2269	2077	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	ACTGAATCTG (C/A) AGGCCAGGAT	M	C	A	A	E
G103u5	WIAF-10446	HT2269	3338	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	AATTGAGCT (A/T) CTTGATAAGG	S	A	T	L	L
G103u6	WIAF-10447	HT2269	3487	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	TCAGAAATCAT (C/T) TGATGATCT	M	C	T	S	F

G103u7	WIAP-10448	HT2269	3507	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	TTC AAGTGA A [C/G] ATGCTGA AAG	M	C	G	H	D
G103u8	WIAP-10457	HT2269	1388	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	CTCTTGACGA [T/G] GACGAAGATG	M	T	G	D	E
G103u9	WIAP-10458	HT2269	1362	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	CCGGACTCTT [T/C] CAGCCATTAA	M	T	C	S	P
G103u10	WIAP-10459	HT2269	2357	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	CTGAGAAGA [T/C] GCGAAGATT	S	T	C	D	D
G103u11	WIAP-10462	HT2269	3109	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	TGGAACAGAA [C/T] GAAGACAGAT	M	C	T	T	M

G103u12	WIAF-10463	HT2269	3138	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	GTTTCCTGTA [T/C] TAAAGCAACT	S	T	C	L	L
G103u14	WIAF-10484	HT2269	3553	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	AGAACAGCTG [C/T] GAAAGAGCCA	M	C	T	A	V
G103u15	WIAF-10485	HT2269	1429	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	GATGTGCAGA [C/T] GGGAGGGCCA	M	C	T	T	M
G103a16	WIAF-12097	HT2269	3335	ERCC5, excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	AAGATTGGA [G/T] CTACTTGATA	M	G	T	E	D
G1030u1	WIAF-12411	U07358	203	ZPK, zipper (leucine) protein kinase	ACACTTCTGA [C/T] TGCACCTCCG	S	C	T	D	D
G1030u2	WIAF-12416	U07358	1806	ZPK, zipper (leucine) protein kinase	GCCACCCCAT [G/T] AACCTGGAGG	N	G	T	E	*
G1031a1	WIAF-12124	U87460	2825	GPR37, G protein-coupled receptor 37 (endothelin receptor type B-like)	GAGTCACCAC [C/T] TTCACCTTAT	S	C	T	T	T
G1032u1	WIAF-12381	U57911	926	C11ORF8, chromosome 11 open reading frame 8	ACGTACATCA [A/C] TGCCTCGACG	M	A	C	N	T

G1033u1	WIAP-12437	M65188	431 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	TCTGTACCCA [C/T] ACTCTTGATC	M	C	T	T	I
G1033u2	WIAP-12438	M65188	169 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	AGGCAACATG [G/C] GTGACTGGAG	M	G	C	G	R
G1033u3	WIAP-12439	M65188	467 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	TATGTGATGC [G/A] AAAAGGAAGAG	M	G	A	A	Q
G1033u4	WIAP-12440	M65188	263 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	TTCAATTTTCC [G/A] AATCCTGCTG	M	G	A	A	Q
G1033u5	WIAP-12441	M65188	218 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	CAAGCCTACT [C/T] AACTGCTGGA	M	C	T	S	L
G1033u6	WIAP-12442	M65188	498 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	AGAAAGAGGA [A/G] GAACCTAAGG	S	A	G	E	E
G1033u7	WIAP-12465	M65188	550 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	GCACTTGAAG [C/A] AGATTGAGAT	M	C	A	Q	K
G1033u8	WIAP-12466	M65188	548 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	ATGCACCTTGA [A/G] GCAGATTGAG	M	A	G	K	R
G1033u9	WIAP-12486	M65188	933 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	CGCTGAGCCC [T/C] GCCAAAGACT	S	T	C	P	P
G1033u10	WIAP-12487	M65188	990 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	CCTCACCAC [C/T] GCTCCCTCT	S	C	T	T	T
G1033u11	WIAP-12488	M65188	1034 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	AAGCTGGTTA [C/A] TGGCGACAGA	M	C	A	T	N
G1033u12	WIAP-12489	M65188	1158 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	CTAACTCCCA [T/C] GCACAGCCTT	S	T	C	H	H
G1033u13	WIAP-12490	M65188	1222 L, 43kD (connexin 43)	GJAL, gap junction protein, alpha	TGGACATGAA [T/C] TACAGCCACT	S	T	C	L	L

G1033u14	WIAF-12491	M65188		GJAL, gap junction protein, alpha 10691, 43kD (connexin 43)	CCGCATTAC [A/G] ACAAGCAAGC	M	A	G	N	D
G1033u15	WIAF-12492	M65188		GJAL, gap junction protein, alpha 12501, 43kD (connexin 43)	GTGGACCAGC [G/A] ACCTTCAAGC	M	G	A	R	Q
G1033u16	WIAF-12496	M65188		GJAL, gap junction protein, alpha 4231, 43kD (connexin 43)	TATTTGTGTC [T/C] GTACCCACAC	S	T	C	S	S
G1033u17	WIAF-12503	M65188		GJAL, gap junction protein, alpha 8801, 43kD (connexin 43)	CGTTAAGGAT [C/T] GGTTAAGGG	M	C	T	R	W
G1033u18	WIAF-12504	M65188		GJAL, gap junction protein, alpha 8551, 43kD (connexin 43)	AACTCTTCTA [T/C] GTTTCTTCA	S	T	C	Y	Y
G1033u19	WIAF-12505	M65188		GJAL, gap junction protein, alpha 5761, 43kD (connexin 43)	AGTTCAAGTA [C/T] GGTATTGAAG	S	C	T	Y	Y
G1033u20	WIAF-12512	M65188		GJAL, gap junction protein, alpha 12551, 43kD (connexin 43)	CCAGCGACCT [T/G] CAAGCAGAGC	M	T	G	S	A
G1033u21	WIAF-12513	M65188		GJAL, gap junction protein, alpha 10781, 43kD (connexin 43)	CAACAAGCAA [G/A] CAAGTGAGCA	M	G	A	A	T
G1033u22	WIAF-12514	M65188		GJAL, gap junction protein, alpha 10971, 43kD (connexin 43)	CAAACTGGG [C/G] TAATTACAGT	M	C	G	A	G
G1034u1	WIAF-12443	J03544		PYGB, phosphorylase, glycogen; 1201 brain	AGACCTGTGC [A/G] TACACCAACC	S	A	G	A	A
G1034u2	WIAF-12469	J03544		PYGB, phosphorylase, glycogen; 771 brain	GACACCCAG [T/C] GCCCGGCTAC	M	T	C	V	A
G1034u3	WIAF-12470	J03544		PYGB, phosphorylase, glycogen; 1465 brain	TCCACTCGGA [G/C] ATCGTGAAC	M	G	C	B	D
G1034u4	WIAF-12471	J03544		PYGB, phosphorylase, glycogen; 1583 brain	GGGGCTGGCC [G/A] ATACCATCGT	M	G	A	D	N
G1034u5	WIAF-12472	J03544		PYGB, phosphorylase, glycogen; 1774 brain	CCATGTTGGA [T/C] GTGCATGTGA	S	T	C	D	D
G1034u6	WIAF-12474	J03544		PYGB, phosphorylase, glycogen; 2449 brain	AGGTGGACCA [G/A] CTGTACCGGA	S	G	A	Q	Q

G1034u7	WIAP-12508	J03544	718	PYGB, phosphorylase, glycogen; brain	CCCCGACGG [C/T]GTGAAGTGGC	S	C	T	G	G
G1035u1	WIAP-12484	U97105	1962	DPYSL2, dihydropyrimidinase-like	GCAGAGGAGC [A/G]GCAGAGGATC	M	A	G	Q	R
G1035u2	WIAP-12485	U97105	2842	DPYSL2, dihydropyrimidinase-like	ATGACGGACC [T/C]GTGTGTGAAG	S	T	C	P	P
G1035u3	WIAP-12511	U97105	2062	DPYSL2, dihydropyrimidinase-like	CCATCACCAT [C/T]GCCAACCCAGA	S	C	T	I	I
G1036u1	WIAP-12444	D88460	311	WASL, Wiskott-Aldrich syndrome-like	ACGTGGGGTC [C/T]CTGTGTCTCA	S	C	T	S	S
G1038u1	WIAP-12445	HT2746	994	PCTK2, PCTAIRE protein kinase 2	TAGAAGAAAG [G/A]TATTGTGATCG	M	G	A	V	I
G1039u1	WIAP-12429	HT2747	955	serine/threonine kinase, PCTAIRE-3	ATCCAAGAGT [C/T]GCATGTGACG	M	C	T	R	C
G1039u2	WIAP-12458	HT2747	808	serine/threonine kinase, PCTAIRE-3	CACAGAAGAG [A/T]CGTGGCCCGG	M	A	T	T	S
G1041u1	WIAP-12459	X72886	544	H.sapiens TYRO3 mRNA.	CNAGTGGCTG [G/C]CCTGTGAGAG	M	G	C	A	P
G1041u2	WIAP-12460	X72886	693	H.sapiens TYRO3 mRNA.	TTGGGGGGAA [C/T]GSCCTGAAAC	S	C	T	N	N
G1041u3	WIAP-12502	X72886	561	H.sapiens TYRO3 mRNA.	AGAGCTGGC [C/T]GACAACTGT	S	C	T	A	A
G1043u1	WIAP-12448	M94055	5401	Human voltage-gated sodium channel mRNA, complete cds.	CTCTGAGTGA [G/A]GATGACTTTG	S	G	A	E	E
G1043u2	WIAP-12449	M94055	5205	Human voltage-gated sodium channel mRNA, complete cds.	TTGAGACCTT [T/C]GCCAACAGCA	S	T	C	P	P
G1043u3	WIAP-12450	M94055	5224	Human voltage-gated sodium channel mRNA, complete cds.	CATGATCTGC [C/T]TGTTCCAAAT	S	C	T	L	L
G1043u4	WIAP-12451	M94055	5514	Human voltage-gated sodium channel mRNA, complete cds.	AGGTTTGGGA [G/A]AAGTTTGATC	S	G	A	E	E
G1043u5	WIAP-12452	M94055	5217	Human voltage-gated sodium channel mRNA, complete cds.	GCAACAGCAT [G/C]ATCTGCCTGT	M	G	C	M	I
G1043u6	WIAP-12453	M94055	5334	Human voltage-gated sodium channel mRNA, complete cds.	GCTCAGTTAA [A/G]GGAGACTGTG	S	A	G	K	K

G1043u7	WIAF-12454	M94055	5424	Human voltage-gated sodium channel mRNA, complete cds.	TGTACATCGC[G/C]GTCATCCTGG	S	G	C	A	A
G1043u8	WIAF-12455	M94055	5322	Human voltage-gated sodium channel mRNA, complete cds.	ATCACCTGG[A/C]AGCTCAGTTA	S	A	C	G	G
G1043u9	WIAF-12456	M94055	1200	Human voltage-gated sodium channel mRNA, complete cds.	ATGCTACAC[G/A]AGCTTTGACA	S	G	A	T	T
G1043u10	WIAF-12499	M94055	1170	Human voltage-gated sodium channel mRNA, complete cds.	TCTGTGTGAA[G/T]GCTGGTAGAA	M	G	T	K	N
G1046a1	WIAF-13187	U50352	267	ACCN1, amiloride-sensitive cation channel 1, neuronal (degenerin)	TCCAGCTGT[G/A]ACCTCTGTGA	S	G	A	V	V
G1046a2	WIAF-13188	U50352	282	ACCN1, amiloride-sensitive cation channel 1, neuronal (degenerin)	TCTGTAACT[C/G]AATGGCTTCC	S	C	G	L	L
G1046a3	WIAF-13189	U50352	315	ACCN1, amiloride-sensitive cation channel 1, neuronal (degenerin)	TCACCACAA[C/t]GACCTGTACC	S	C	t	N	N
G1046a4	WIAF-13190	U50352	386	ACCN1, amiloride-sensitive cation channel 1, neuronal (degenerin)	CCCCATCTGG[C/a]TGACCCCTCC	M	C	a	A	D
G1046a5	WIAF-13191	U50352	417	ACCN1, amiloride-sensitive cation channel 1, neuronal (degenerin)	CCCTGCGCA[G/A]AAGCCCACT	S	G	A	Q	Q
G1048u1	WIAF-12641	HT5174S	3214	REST, RE1-silencing transcription factor	CAGTCAAAGC[G/A]GCTAAGGGAG	S	G	A	A	A
G1048u2	WIAF-12642	HT5174S	3199	REST, RE1-silencing transcription factor	CAAAGGAAGC[C/G]TTGGCACTCA	S	C	G	A	A
G1048u3	WIAF-12657	HT5174S	2125	REST, RE1-silencing transcription factor	CTCCCATGGA[G/T]ACTGCTCAGA	M	G	T	E	D
G1048u4	WIAF-12660	HT5174S	2333	REST, RE1-silencing transcription factor	GGAACTGT[A/C]AGATAGAGCT	M	A	C	K	Q
G1051u1	WIAF-12431	HT28321	658	SCNN1G, sodium channel, nonvoltage-gated 1, gamma	ATGACACCTC[C/T]GACTGTGCCA	S	C	T	S	S
G1051u2	WIAF-12434	HT28321	1735	SCNN1G, sodium channel, nonvoltage-gated 1, gamma	AAGCCAAGGA[G/A]TGGTGGCCT	S	G	A	E	E

G1051u3	WIAF-12473	HT28321	SCNN1G, sodium channel, nonvoltage-gated 1, gamma	409	AGTCCTGTGA [T/C]GGCTTTCAG	S	T	C	Y	Y
G1051u4	WIAF-12475	HT28321	SCNN1G, sodium channel, nonvoltage-gated 1, gamma	953	AGTCATTTTG [T/C]ACATRAACGA	M	T	C	Y	H
G1051u5	WIAF-12476	HT28321	SCNN1G, sodium channel, nonvoltage-gated 1, gamma	975	GAGGAATACA [A/G]CCCATTCTCTC	M	A	G	N	S
G1051u6	WIAF-12477	HT28321	SCNN1G, sodium channel, nonvoltage-gated 1, gamma	1192	CTGCCTACTC [G/A]CTCCAGATCT	S	G	A	S	S
G1053a1	WIAF-13192	HT2201	SCN5A, sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3)	4085	CGTCCTCTGA [G/A]AGCTCTGTCA	M	G	A	R	K
G1053a2	WIAF-13193	HT2201	SCN5A, sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3)	5607	ACTTTGCCGA [C/T]GCCCTGTCTG	S	C	T	D	D
G1053a3	WIAF-13194	HT2201	SCN5A, sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3)	5828	GAGCCCATCA [C/T]CACCACACTC	M	C	T	T	I
G1053a4	WIAF-13202	HT2201	SCN5A, sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3)	713	GGTTCACTT [T/A]CCTTCGGGAC	M	T	A	F	Y
G1053a5	WIAF-13203	HT2201	SCN5A, sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3)	6148	CCACAGTGAA [G/T]ATCTCGCCGA	M	G	T	D	Y
G1053a6	WIAF-13204	HT2201	SCN5A, sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3)	6217	GGCCTGGCTG [G/T]CCAGGACACA	-	G	T	-	-



G1053a7	WIAF-13205	HT2201	6324	SCN5A, sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3)	AATGGGCTC[G/A]GCCCGCGGA	-	G	A	-	-
G1054u1	WIAF-12419	HT2202	2252	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	TTGGCAAGAG[C/T]TACAGGAGT	S	C	T	S	S
G1054u2	WIAF-12423	HT2202	4559	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	TGGTCATGTT[C/T]ATCTACTCCA	S	C	T	F	F
G1054u3	WIAF-12424	HT2202	4856	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	TCACATGTA[C/G]ATCGCCATCA	N	C	G	Y	*
G1054u4	WIAF-12425	HT2202	4777	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	GTCAGGGGTG[A/G]GTGCGGCAAC	M	A	G	D	G
G1054u5	WIAF-12426	HT2202	4863	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	GTACATCGCC[A/G]TCATCTCTGGA	M	A	G	I	V
G1054u6	WIAF-12427	HT2202	4566	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	GTTTCATCTAC[T/G]CCATCTTCGG	M	T	G	S	A
G1054u7	WIAF-12428	HT2202	4923	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	TGGTGAAGAT[G/T]ACTTTGAGAT	M	G	T	D	Y
G1054u8	WIAF-12446	HT2202	3595	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	TTCTGGCTGA[T/C]CTTCAGCATC	M	T	C	I	T
G1054u9	WIAF-12447	HT2202	4203	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	GGAGACAGAC[G/A]ACCAGAGCCA	M	G	A	D	N
G1054u10	WIAF-12495	HT2202	4811	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	TCTGCTTCTT[C/A]TGCAGCTATA	M	C	A	F	L
G1054u11	WIAF-12497	HT2202	5555	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	CAGGCGAGAC[T/G]GTGCGCCGAG	S	T	G	T	T

G1054u12	WIAF-12498	HT2202	5480	SCN4A, sodium channel, voltage-gated, type IV, alpha polypeptide	CAGGGGACGC [C/T] GGACCCACTA	S	C	T	A	A
G1059u1	WIAF-12432	HT33704	112	APLP1, amyloid beta (A4) precursor-like protein 1	CGCTGCTGCT [G/A] CCACTATTGC	S	G	A	L	L
G1059u2	WIAF-12433	HT33704	140	APLP1, amyloid beta (A4) precursor-like protein 1	TCTGCGGCG [C/T] AGCCCGCCAT	N	C	T	Q	*
G1059u3	WIAF-12435	HT33704	1344	APLP1, amyloid beta (A4) precursor-like protein 1	CACATGTGG [C/T] CGCCGTGGAT	M	C	T	A	V
G1059u4	WIAF-12457	HT33704	1687	APLP1, amyloid beta (A4) precursor-like protein 1	ATGAGCGAAA [G/A] GTGAATGCGT	S	G	A	K	K
G1059u5	WIAF-12500	HT33704	976	APLP1, amyloid beta (A4) precursor-like protein 1	GGTTCCTGAG [A/G] GCCAAGATGG	S	A	G	R	R
G1059u6	WIAF-12501	HT33704	1786	APLP1, amyloid beta (A4) precursor-like protein 1	GTGAGGCTGT [A/G] TCGGGTCTGC	S	A	G	V	V
G1060u1	WIAF-12436	HT1418	1744	APLP2, amyloid beta (A4) precursor-like protein 2	CCAAGNAATT [C/G] AACAGGGAAT	M	C	G	Q	E
G1060u2	WIAF-12467	HT1418	2213	APLP2, amyloid beta (A4) precursor-like protein 2	ATCAGCTGGT [T/G] GATGCTGAGG	M	T	G	V	G
G1060u3	WIAF-12468	HT1418	2256	APLP2, amyloid beta (A4) precursor-like protein 2	GCCACGGGAT [C/T] GTGGAGTTG	S	C	T	I	I
G1066a1	WIAF-13195	HT3538	566	CCKBR, cholecystokinin B receptor	CTTTGGCACCC [G/A] TCATCTGCAA	M	G	A	V	I
G1066a2	WIAF-13196	HT3538	607	CCKBR, cholecystokinin B receptor	GGGTGTCTGT [G/A] AGTGTGTCCA	S	G	A	V	V
G1066a3	WIAF-13206	HT3538	864	CCKBR, cholecystokinin B receptor	CTGTGCTTTC [T/A] GCTCTTGTTC	M	T	A	L	Q
G1067u1	WIAF-12478	HT0830	684	KCNA1, potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia)	AACGCTGTG [C/T] ATCATCTGGT	S	C	T	C	C
G1067u2	WIAF-12479	HT0830	722	KCNA1, potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia)	GTGCGCTTCT [T/C] CGCCTGCCCC	M	T	C	F	S

G1067u3	WIAF-12480	HT0830	804	KCNA1, potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia)	ATTTCATCAC [C/G] CTGGGCACCG	S	C	G	T	T
G1067u4	WIAF-12509	HT0830	690	KCNA1, potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia)	TGTGCATCAT [C/T] TGGTTCTCCT	S	C	T	I	I
G1068u1	WIAF-12493	HT0831	774	KCNA2, potassium voltage-gated channel, shaker-related subfamily, member 2	TGAACATCAT [T/A] GACATTGTGG	S	T	A	I	I
G1070a1	WIAF-13197	HT2728	522	KCNJ6, potassium inwardly-rectifying channel, subfamily J, member 6	CACAGTGACC [T/C] GGGTCTTTT	M	T	C	W	R
G1070a2	WIAF-13201	HT2728	1244	KCNJ6, potassium inwardly-rectifying channel, subfamily J, member 6	CCCTGGAGGA [T/C] GGGTCTTACG	S	T	C	D	D
G1070a3	WIAF-13207	HT2728	707	KCNJ6, potassium inwardly-rectifying channel, subfamily J, member 6	ATAATGCCCC [G/A] GAGGGAATTA	S	G	A	P	P
G1071u1	WIAF-12422	HT48672	1534	KCNJ3, potassium inwardly-rectifying channel, subfamily J, member 3	TTCCGGGCAA [C/T] TCAGAGAGAA	S	C	T	N	N
G1073u1	WIAF-12461	HT4556	1127	KCNJ1, potassium inwardly-rectifying channel, subfamily J, member 1	CACGTGTCCA [T/C] GTGCTTTTAT	M	T	C	M	T
G1074u1	WIAF-12462	HT27804	289	KCNAB2, potassium voltage-gated channel, shaker-related subfamily, beta member 2	ACCTCTTCGA [T/C] ACAGCAGAG	S	T	C	D	D
G1079u1	WIAF-12463	HT27383	1130	potassium channel, inwardly rectifying (GB:D50582)	ACCTGGCCGA [T/A] GAGATCCTGT	M	T	A	D	E
G1079u2	WIAF-12464	HT27383	1192	potassium channel, inwardly rectifying (GB:D50582)	CGTTACTCTG [T/G] GGACTACTCC	M	T	G	V	G

G1079u3	WIAF-12481	HT27383	708	potassium channel, inwardly rectifying (GB:D50582)	GCTTGCTGCTG[A/G]TCTTCATGAA	M	A	G	I	V
G1079u4	WIAF-12482	HT27383	779	potassium channel, inwardly rectifying (GB:D50582)	CGGTGATCGG[T/C]CTGCGCCACG	S	T	C	A	A
G1079u5	WIAF-12483	HT27383	276	potassium channel, inwardly rectifying (GB:D50582)	GGACCCCTGCC[G/A]AGCCCCAGGTA	M	G	A	E	K
G1079u6	WIAF-12510	HT27383	489	potassium channel, inwardly rectifying (GB:D50582)	GTGGCTCATC[G/A]CCTTCGCCCA	M	G	A	A	T
G1080u1	WIAF-12536	HT4412	1099	KCNJ4, potassium inwardly-rectifying channel, subfamily J, member 4	TGGACTACTC[A/G]CGTTTTCACA	S	A	G	S	S
G1080u2	WIAF-12537	HT4412	1050	KCNJ4, potassium inwardly-rectifying channel, subfamily J, member 4	GGCCACCGCT[T/A]TGAGCCTGTG	M	T	A	P	Y
G1081u1	WIAF-12538	HT27724	1090	KCNJ2, potassium inwardly-rectifying channel, subfamily J, member 2	GGCCACCGCT[A/T]TGAGCCTGTG	M	A	T	Y	P
G1082u1	WIAF-12662	HT28319	768	potassium channel, inwardly rectifying, high conductance, alpha subunit	CGGGGTCAC[C/T]GAGGAGGGCG	S	C	T	T	T
G1082u2	WIAF-12663	HT28319	854	potassium channel, inwardly rectifying, high conductance, alpha subunit	CTGGTCTCGC[C/T]CATCACCATC	M	C	T	P	L
G1082u3	WIAF-12679	HT28319	471	potassium channel, inwardly rectifying, high conductance, alpha subunit	TCTCCATCGA[G/C]ACGACACCA	M	G	C	E	D
G1084a1	WIAF-13198	HT0383	2028	KCNB1, potassium voltage-gated channel, Shab-related subfamily, member 1	CACTCCCCAG[C/A]AGACTGGGG	M	C	A	S	R
G1084a2	WIAF-13199	HT0383	2033	KCNB1, potassium voltage-gated channel, Shab-related subfamily, member 1	CCAGCAAGA[C/G]TGGGGGCGGC	M	C	G	T	S

G1084a3	WIAF-13200	HT0383		KCNB1, potassium voltage-gated channel, Shab-related subfamily, member 1	2321		GAGTGTGCCA[C/A]GCTTTTGAC	M	C	A	T	K
G1084a4	WIAF-13208	HT0383		KCNB1, potassium voltage-gated channel, Shab-related subfamily, member 1	870		ACNACCCCA[G/A]CTGGCCACG	S	G	A	Q	Q
G1088u1	WIAF-12516	HT0522		KCN5, potassium voltage-gated channel, shaker-related subfamily, member 5	1503		TCCTGGGCAA[G/A]ACCTTGACG	S	G	A	K	K
G1088u2	WIAF-12519	HT0522		KCN5, potassium voltage-gated channel, shaker-related subfamily, member 5	1249		CGAGCTGCTC[G/A]TGGGCTTCTT	M	G	A	V	M
G1088u3	WIAF-12520	HT0522		KCN5, potassium voltage-gated channel, shaker-related subfamily, member 5	973		CTCTGGGTCC[G/A]CGGGGCCAT	M	G	A	A	T
G1088u4	WIAF-12521	HT0522		KCN5, potassium voltage-gated channel, shaker-related subfamily, member 5	1013		GTTATCCTCA[T/C]CTCCATCATC	M	T	C	I	T
G1090u1	WIAF-12651	HT1497		KCN6, potassium voltage-gated channel, shaker-related subfamily, member 6	1836		CAACCAGCCA[G/A]TGGAGGAGGC	M	G	A	S	N
G1091u1	WIAF-12714	HT0222		KCN3, potassium voltage-gated channel, shaker-related subfamily, member 3	843		CATCATCTGG[T/C]TCTCCTTGA	M	T	C	P	L
G1094a1	WIAF-13218	HT27381		KCNJ8, potassium inwardly-rectifying channel, subfamily J, member 8	1280		GTCTATTCTG[T/a]GGATTACTCC	M	T	a	V	E

G1095u1	WIAF-12532	HT2629		765	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member	TTCTCTACTT [C/T] GGCTTGGGT	S	C	T	F	F
G1095u2	WIAF-12533	HT2629		2441	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member	GTGCTCTGCA [T/C] CTTTGGGAC	M	T	C	I	T
G1095u3	WIAF-12534	HT2629		2714	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member	GATGATACTT [C/G] GCTGCAGGAC	M	C	G	S	W
G1095u4	WIAF-12535	HT2629		2439	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member	TCGTGGTCTG [C/T] ATCTTTGGCG	S	C	T	C	C
G1095u5	WIAF-12539	HT2629		3048	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member	CACTCATGAG [C/T] GCGACGTACT	S	C	T	S	S
G1095u6	WIAF-12544	HT2629		2352	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member	GGATGTTTCA [C/T] TGGTGTGCAC	S	C	T	H	H
G1095u7	WIAF-12545	HT2629		2392	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member	CATCTGACT [C/T] GAAGTGAAGC	N	C	T	R	*

G1095u8	WIAP-12546	HT2629		2295	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member 1	CTGGCAATGA [T/C] CAGATTGACA	S	T	C	D	D
G1095u9	WIAP-12548	HT2629		2949	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member 1	AGTTTTTGGG [C/T] CAAGACGATG	S	C	T	D	D
G1095u10	WIAP-12549	HT2629		2865	KCNMA1, potassium large conductance calcium-activated channel, subfamily M, alpha member 1	TGCACGGGAT [G/A] TTACGTCAAC	M	G	A	M	I
G1096u1	WIAP-12547	L26318		930	PRKM8, protein kinase mitogen-activated 8 (MAP kinase)	TGCTGGTAAT [A/T] GATGCATCTA	S	A	T	I	I
G1098u1	WIAP-12515	L19711		2650	DAG1, dystroglycan 1 (dystrophin-associated glycoprotein 1)	TCTACCTGCA [C/T] ACAGTCATTC	S	C	T	H	H
G110u1	WIAP-10385	HT27392		230	meiosis-specific recA homolog, HsLim15	CAAAGGTATA [C/T] AGATGACAAC	N	C	T	Q	*
G110u2	WIAP-10397	HT27392		1050	meiosis-specific recA homolog, HsLim15	CCTGAAAATG [A/G] AGCCACCTTC	M	A	G	E	G
G110u3	WIAP-10399	HT27392		674	meiosis-specific recA homolog, HsLim15	TGAACATCAG [A/G] TGGAGCTACT	M	A	G	M	V
G1106u1	WIAP-12647	HT5073		5781	MAP1B, microtubule-associated protein 1B	ACTATGAGAA [G/A] ATAGAGAGNA	S	G	A	K	K
G1106u2	WIAP-12648	HT5073		5916	MAP1B, microtubule-associated protein 1B	CTGAAGAGGG [C/T] GGGTACTCAT	S	C	T	G	G
G1106u3	WIAP-12650	HT5073		1837	MAP1B, microtubule-associated protein 1B	AGACAAAGCCA [G/A] TAAAAACAGA	M	G	A	V	I
G1106u4	WIAP-12653	HT5073		2476	MAP1B, microtubule-associated protein 1B	CACCACAGCA [G/A] CTGTCTATGGC	M	G	A	A	T
G1106u5	WIAP-12656	HT5073		3913	MAP1B, microtubule-associated protein 1B	GCCCAATGAG [A/G] TTAAGTCTC	M	A	G	I	V
G1106u6	WIAP-12667	HT5073		559	MAP1B, microtubule-associated protein 1B	GATTTTCACC [G/A] ATCAGAGAT	M	G	A	D	N

G1106u7	WIAF-12668	HT5073	570	MAP1B, microtubule-associated protein 1B	ATCAAGAGAT [C/T] GGGAGTTAC	S	C	T	I	I
G1106u8	WIAF-12669	HT5073	6175	MAP1B, microtubule-associated protein 1B	TACTTCCACA [T/C] ACTGTTACGA	M	T	C	Y	H
G1106u9	WIAF-12670	HT5073	1215	MAP1B, microtubule-associated protein 1B	TCACTCTCCA [G/C] TACCTTAACA	M	G	C	Q	H
G1106u10	WIAF-12672	HT5073	1821	MAP1B, microtubule-associated protein 1B	AGTAATGGT [G/A] AAAAAGACA	S	G	A	V	V
G1106u11	WIAF-12673	HT5073	2727	MAP1B, microtubule-associated protein 1B	GTCTGCGGA [G/T] TCCCTGTATG	M	G	T	E	D
G1106u12	WIAF-12674	HT5073	2739	MAP1B, microtubule-associated protein 1B	CCCTGTATGA [G/A] GGAATCACTA	S	G	A	E	E
G1106u13	WIAF-12676	HT5073	3643	MAP1B, microtubule-associated protein 1B	AGATGCCACT [G/A] ATGGCAAGGA	M	G	A	D	N
G1106u14	WIAF-12677	HT5073	3609	MAP1B, microtubule-associated protein 1B	CACGCTCAA [C/T] GGATTTTCTG	S	C	T	N	N
G1106u15	WIAF-12682	HT5073	4752	MAP1B, microtubule-associated protein 1B	TTCCAGAGCC [A/T] ACAACAGATG	S	A	T	P	P
G1110u1	WIAF-12517	HT1096	1527	myelin associated glycoprotein	GCGGCCTCGT [G/C] CTCACAGCA	S	G	C	V	V
G1110u2	WIAF-12518	HT1096	1678	myelin associated glycoprotein	TGTGGGCGCC [G/T] TGGTCGCTT	M	G	T	V	L
G1110u3	WIAF-12522	HT1096	1271	myelin associated glycoprotein	GCGGTGTAC [C/T] CGAGGATGAT	M	C	T	P	L
G1113u1	WIAF-12523	HT2242	353	myelin transcription factor 1	AATTCGATC [G/T] GATCCTCAGG	M	G	T	R	L
G1116a1	WIAF-13217	HT28451	417	myelin oligodendrocyte glycoprotein (MOG)	CAAGCTTATC [G/A] AGACCCCTCTC	S	G	A	S	S
G1116a2	WIAF-13219	HT28451	913	myelin oligodendrocyte glycoprotein (MOG)	GCAGATCACT [C/G] TTGGCCTCGT	M	C	G	L	V
G1116a3	WIAF-13220	HT28451	922	myelin oligodendrocyte glycoprotein (MOG)	TCTTGGCCTC [G/A] TCTTCTCTCTG	M	G	A	V	I
G1120u1	WIAF-12525	HT3695	1200	neurofilament, subunit H	TAGAGATAGC [T/C] GCTTACAGAA	S	T	C	A	A
G1123u1	WIAF-12542	HT2569	2269	OMG, oligodendrocyte myelin glycoprotein	CAGCTGCAAC [T/C] CTRACTATTTC	S	T	C	T	T
G1126u1	WIAF-12526	HT28354	626	PSEN2, presenilin 2 (Alzheimer disease 4)	GAGCGAAGCA [T/C] GTGATCATGTC	S	T	C	H	H
G1126u2	WIAF-12527	HT28354	494	PSEN2, presenilin 2 (Alzheimer disease 4)	ATGGAGAGAA [T/C] ACTGCCCACT	S	T	C	N	N



G1126u3	WIAF-12528	HT28354	434	PSN2, presenilin 2 (Alzheimer disease 4)	TAATGTCGGC [C/T] GAGAGCCCCA	S	C	T	A	A
G1126u4	WIAF-12543	HT28354	550	PSN2, presenilin 2 (Alzheimer disease 4)	GACCCGACCC [G/A] CTATGTCGT	M	G	A	R	H
G117u1	WIAF-10391	HT27765	156	GTBP, G/T mismatch-binding protein	ACTTCTCACC [A/G] GGAGATTGG	S	A	G	P	P
G117u2	WIAF-10392	HT27765	420	GTBP, G/T mismatch-binding protein	AACGTGCAGA [T/C] GAAGCCTTAA	S	T	C	D	D
G117u3	WIAF-10407	HT27765	939	GTBP, G/T mismatch-binding protein	CCCACGTTAG [T/C] GGAGGTGGTG	S	T	C	S	S
G117u4	WIAF-10411	HT27765	1622	GTBP, G/T mismatch-binding protein	CATTGTTCCA [G/A] ATTAGGACT	M	G	A	R	K
G117u5	WIAF-10412	HT27765	2405	GTBP, G/T mismatch-binding protein	GACAGCAGGG [C/T] TATAATGTAT	M	C	T	A	V
G117u6	WIAF-10413	HT27765	2387	GTBP, G/T mismatch-binding protein	AAGAGTCAGA [A/T] CCACCCAGAC	M	A	T	N	I
G125u1	WIAF-10371	HT28632	1999	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	CAGTAATTTT [C/T] CTCATCTTGT	M	C	T	P	S
G125u2	WIAF-10372	HT28632	2631	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	TAATGAATGA [C/A] ATTGCAGATA	M	C	A	D	E
G125u3	WIAF-10373	HT28632	3084	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	CAATGGAAGA [T/G] GTTCTTGAAC	M	T	G	D	E
G125u5	WIAF-10375	HT28632	4767	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	CACCTATACC [C/T] CTTGTGTATG	S	C	T	P	P
G125u6	WIAF-10383	HT28632	8713	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	ATTCTTGGAT [C/T] CAGCTATTTG	M	C	T	P	S

G125u7	WIAF-10396	HT28632		1825	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	GACTTTGGCA [C/G] TGACCACCAG	M	C	G	L	V
G125u8	WIAF-10398	HT28632		2924	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	ACTACTGCTC [A/G] GACCAATACT	M	A	G	Q	R
G125u9	WIAF-10405	HT28632		8967	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	TTGAAGGTGT [C/T] TTCAGAAGAT	S	C	T	V	V
G125u10	WIAF-10408	HT28632		6954	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	CCAAACACCT [T/C] GTAGAACTCT	S	T	C	L	L
G125u11	WIAF-10409	HT28632		6855	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	TTCAGGAGCC [T/C] ATCATGGCTC	S	T	C	P	P
G125u12	WIAF-10410	HT28632		6801	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	TATATATTAA [G/T] TGGCAGAAAC	M	G	T	K	N
G125u13	WIAF-10421	HT28632		335	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	CATTGAGATT [C/G] CAAACAGGA	M	C	G	S	C
G125u14	WIAF-11607	HT28632		3966	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	TTCCACATCT [G/A] GTGATTAGAA	S	G	A	L	L
G125a15	WIAF-11130	HT28632		8642	ATM, ataxia telangiectasia mutated (includes complementation groups A, C and D)	GAGAAATATG [A/C] AGTCTTCATG	M	A	C	E	A
G136u1	WIAF-10388	HT3337		535 [2]	MLH1, mutL (E. coli) homolog 1 (colon cancer, nonpolyposis type)	AGGAGAAAAG [C/T] TTTAAAAAAT	M	C	T	A	V

G136u2	WIAF-10389	HT3337	MLH1, mutL (E. coli) homolog 1 (colon cancer, nonpolyposis type 769 2)	TTCAAAATGA [A/G] TGGTTACATA	M	A	G	N	S
G144u1	WIAF-11638	HT3625	FOS, v-fos FBJ murine osteosarcoma viral oncogene 1129 homolog	CCTGTGCACT [C/T] CGGTGGTCAC	M	C	T	P	S
G1461u1	WIAF-12562	HT0329	684 PRB-binding protein	TTGCCAAGAA [G/A] TCCAGAACC	S	G	A	K	K
G1466u1	WIAF-12571	HT27849	2128 API2, apoptosis inhibitor 2	ATGATCCATG [G/C] GTAGAACATG	M	G	C	W	C
G1468u1	WIAF-12563	HT4986	1928 apoptosis inhibitor, neuronal	CCACCAGACC [A/T] GACGAGGGC	S	A	T	P	P
G1468u2	WIAF-12564	HT4986	3057 apoptosis inhibitor, neuronal	TTTGCAATTC [C/G] TTCAAGGGAG	M	C	G	L	V
G1472u1	WIAF-12565	HT28478	242 BAK1, BCL2-antagonist/killer 1	GGCAGGAGTG [C/T] GGAGAGCCTG	S	C	T	C	C
G1472u2	WIAF-12572	HT28478	509 BAK1, BCL2-antagonist/killer 1	TGCAGCCAC [G/A] GCAGAGAAATG	S	G	A	T	T
G1473u1	WIAF-12568	HT28606	CASP6, caspase 6, apoptosis-related cysteine protease 394 related cysteine protease	GGTGTCAACT [G/C] TTAGCCACGC	M	G	C	V	L
G1473u2	WIAF-12576	HT28606	CASP6, caspase 6, apoptosis-related cysteine protease 411 related cysteine protease	ACGCAGATGC [C/T] GATTGCTTTG	S	C	T	A	A
G1479u1	WIAF-12550	Y09077	ATR, ataxia telangiectasia and Rad3 related 711 Rad3 related	ACTTTATTAA [T/C] GGTCTTACT	M	T	C	M	T
G1479u2	WIAF-12551	Y09077	ATR, ataxia telangiectasia and Rad3 related 4303 Rad3 related	TTGCGTATGC [T/C] GATAAAGCC	S	T	C	A	A
G1479u3	WIAF-12552	Y09077	ATR, ataxia telangiectasia and Rad3 related 1894 Rad3 related	ATTCTGATGA [T/C] GGCTGTTAA	S	T	C	D	D
G1479u4	WIAF-12553	Y09077	ATR, ataxia telangiectasia and Rad3 related 1855 Rad3 related	ATTTATGTGG [T/A] ATGCTCTCAC	S	T	A	G	G
G1479u5	WIAF-12558	Y09077	ATR, ataxia telangiectasia and Rad3 related 5287 Rad3 related	TCATTCAATTA [T/C] CATGGTGATG	S	T	C	Y	Y

G1479u6	WIAF-12559	Y09077		5539	ATR, ataxia telangiectasia and Rad3 related	CAGCTTTTGA [T/C] GACTCACTGA	S	T	C	Y	Y
G1479u7	WIAF-12569	Y09077		1540	ATR, ataxia telangiectasia and Rad3 related	ATCCTGTTAT [T/C] GAGATGTTAG	S	T	C	I	I
G1479u8	WIAF-12570	Y09077		2521	ATR, ataxia telangiectasia and Rad3 related	ATTTAATGGA [A/G] GATCCAGACA	S	A	G	E	E
G1482u1	WIAF-12560	HT27870		3176	BLM, Bloom syndrome	AAAATATAAC [G/A] GAATGCAGGA	S	G	A	T	T
G1482u2	WIAF-12561	HT27870		3605	BLM, Bloom syndrome	GAAATRAAGC [C/A] CAAACTGTAC	S	C	A	A	A
G1482u3	WIAF-12573	HT27870		2677	BLM, Bloom syndrome	TATGTATTAC [C/T] GAAAAAGCCT	M	C	T	P	L
G1483u1	WIAF-12597	HT1470		1910	MYBL2, v-myb avian myeloblastosis viral oncogene homolog-like 2	GGATGAGGAT [G/A] TGAAGCTGAT	M	G	A	V	M
G1483u2	WIAF-12610	HT1470		244	MYBL2, v-myb avian myeloblastosis viral oncogene homolog-like 2	ATGAGGAGGA [C/T] GAGCAGCTGA	S	C	T	D	D
G1483u3	WIAF-12611	HT1470		1406	MYBL2, v-myb avian myeloblastosis viral oncogene homolog-like 2	CACGTAGAAT [A/G] GCACACAGTCT	M	A	G	S	G
G1485u1	WIAF-12581	HT1432		1941	BCR, breakpoint cluster region	TGGAGATGAG [A/G] AAATGGGTCC	S	A	G	R	R
G1485u2	WIAF-12582	HT1432		3144	BCR, breakpoint cluster region	TGACCATCAA [T/C] AAGGAGATG	S	T	C	N	N
G1485u3	WIAF-12583	HT1432		3777	BCR, breakpoint cluster region	ATAACAAGGA [T/C] GTGTCGGTGA	S	T	C	D	D
G1485u4	WIAF-12603	HT1432		2831	BCR, breakpoint cluster region	CAGATCAAGA [G/A] TGACATCCAG	M	G	A	S	N
G1485u5	WIAF-12608	HT1432		4217	BCR, breakpoint cluster region	ATCCTGCCCC [C/T] GGACAGCAG	M	C	T	P	L
G1486u1	WIAF-12578	HT33770		1909	BRCA2, breast cancer 2, early onset	ATTGATAATG [G/A] AAGCTGGCCA	M	G	A	G	E
G1486u2	WIAF-12579	HT33770		3623	BRCA2, breast cancer 2, early onset	AGTTTAGAAA [A/G] CCAAGCTACA	S	A	G	K	K
G1486u3	WIAF-12586	HT33770		1341	BRCA2, breast cancer 2, early onset	AAATGTAGCA [A/C] ATCAGAGCC	M	A	C	N	H
G1486u4	WIAF-12594	HT33770		446	BRCA2, breast cancer 2, early onset	CTTATAATCA [G/A] CTGGCTTCAA	S	G	A	Q	Q

G1486u5	W1AF-12598	HT33770	BRCA2, breast cancer 2, early onset	3013	BRCA2, breast cancer 2, early onset	ACCATGGTTT [T/C] ATATGAGAC	M	T	C	L	S
G1486u6	W1AF-12599	HT33770	BRCA2, breast cancer 2, early onset	3187	BRCA2, breast cancer 2, early onset	GAAAAAATA [A/T] TGATTACATG	M	A	T	N	I
G1486u7	W1AF-12604	HT33770	BRCA2, breast cancer 2, early onset	4971	BRCA2, breast cancer 2, early onset	AGCATGTGAG [A/C] CCATTGAGAT	M	A	C	T	P
G1486u8	W1AF-12607	HT33770	BRCA2, breast cancer 2, early onset	4034	BRCA2, breast cancer 2, early onset	ATGATTCTGT [C/T] GTTCAATGT	S	C	T	V	V
G1487u1	W1AF-12584	HT27632	BRCA1, breast cancer 1, early onset	2536	BRCA1, breast cancer 1, early onset	AGTCAGTGTG [C/G] AGCATTGAA	M	C	G	A	G
G1487u2	W1AF-12587	HT27632	BRCA1, breast cancer 1, early onset	4697	BRCA1, breast cancer 1, early onset	CATCTCAAGA [G/C] GAGCTCAITTA	M	G	C	E	D
G1487u3	W1AF-12595	HT27632	BRCA1, breast cancer 1, early onset	469	BRCA1, breast cancer 1, early onset	TCTCCTGAAC [A/G] TCTAAAGAT	M	A	G	H	R
G1487u4	W1AF-12600	HT27632	BRCA1, breast cancer 1, early onset	3667	BRCA1, breast cancer 1, early onset	AGCGTCCAGA [A/G] AGGAGAGCTT	M	A	G	K	R
G1487u5	W1AF-12601	HT27632	BRCA1, breast cancer 1, early onset	3537	BRCA1, breast cancer 1, early onset	TATGGGAAGT [A/G] GTCATGCATC	M	A	G	S	G
G1487u6	W1AF-12602	HT27632	BRCA1, breast cancer 1, early onset	4956	BRCA1, breast cancer 1, early onset	ATCTGCCAG [A/G] GTCCAGCTGC	M	A	G	S	G
G1487u7	W1AF-12605	HT27632	BRCA1, breast cancer 1, early onset	2090	BRCA1, breast cancer 1, early onset	AGTACAAACCA [A/G] ATGCCAGTCA	S	A	G	Q	Q
G1487u8	W1AF-12614	HT27632	BRCA1, breast cancer 1, early onset	233	BRCA1, breast cancer 1, early onset	TCTCCACAAA [G/A] TGTGACCACA	S	G	A	K	K
G1492u1	W1AF-12585	HT3506	cell death-associated kinase	3912	cell death-associated kinase	TCCAGGTCCG [T/C] GGCCTGGAGA	S	T	C	R	R
G1492u2	W1AF-12593	HT3506	cell death-associated kinase	4352	cell death-associated kinase	TACACACCA [A/G] TAACGGGGCT	M	A	G	N	S
G1492u3	W1AF-12606	HT3506	cell death-associated kinase	2127	cell death-associated kinase	GCAATTTGGA [C/T] ATCTCCAACA	S	C	T	D	D
G1492u4	W1AF-12612	HT3506	cell death-associated kinase	1605	cell death-associated kinase	TGAAATTCTT [C/T] AGTGAGAACA	S	C	T	L	L
G1494u1	W1AF-12589	HT28507	cell death-inducing protein Bik	366	cell death-inducing protein Bik	TTCAACACAC [T/C] TAAGGAGAAC	M	T	C	L	P
G1495u1	W1AF-12580	HT27803	CSE1L, chromosome segregation 1 (yeast homolog)-like	759	CSE1L, chromosome segregation 1 (yeast homolog)-like	TTTCTTCCCT [G/C] ATCTGATCT	S	G	C	L	L
G1501u1	W1AF-13502	HT1949	MCC, mutated in colorectal cancers	1181	MCC, mutated in colorectal cancers	CAGCAATGAC [A/C] TTCCCATCGC	M	A	C	I	L

G1501u2	WIAF-13503	HT1949	MCC, mutated in colorectal cancers	1753	CAGCTGAGAA [C/T]GCTGCCAAGG	S	C	T	N	N
G1501u3	WIAF-13504	HT1949	MCC, mutated in colorectal cancers	2344	TGTCCTAGC [T/C]GAACCTCAGA	S	T	C	A	A
G1501u4	WIAF-13521	HT1949	MCC, mutated in colorectal cancers	445	AGCGAACGAC [G/A]CTTCGCTATG	S	G	A	T	T
G1501u5	WIAF-13522	HT1949	MCC, mutated in colorectal cancers	1504	AAAGCAATGC [T/C]GAGAGGATGA	S	T	C	A	A
G1501u6	WIAF-13527	HT1949	MCC, mutated in colorectal cancers	2511	TTCTGGAATG [A/G]TCTAAAGCGG	M	A	G	D	G
G1502u1	WIAF-12633	HT1547	CCND1, cyclin D1 (PRAD1; parathyroid adenomatosis 1)	870	AGTGTGACCC [A/G]GACTGCCTCC	S	A	G	P	P
G1503u1	WIAF-13741	U37022	CDK4, cyclin-dependent kinase 4	1151	CATGCCAATT [G/A]CATCGTTCCAC	M	G	A	C	Y
G1503u2	WIAF-13742	U37022	CDK4, cyclin-dependent kinase 4	1410	CTGAAGCCGA [C/T]CAGTTGGGCA	S	C	T	D	D
G1503u3	WIAF-13743	U37022	CDK4, cyclin-dependent kinase 4	1328	TATGCAACAC [C/T]TGTGGACATG	M	C	T	P	L
G1503u4	WIAF-13780	U37022	CDK4, cyclin-dependent kinase 4	1194	TTCTGGTGAC [A/G]AGTGGTGGAA	S	A	G	T	T
G1503u5	WIAF-13781	U37022	CDK4, cyclin-dependent kinase 4	1443	TGATTTGGGCT [G/A]CCTCCAGAGG	S	G	A	L	L
G1503u6	WIAF-13787	U37022	CDK4, cyclin-dependent kinase 4	1633	CTCTTATCTA [C/T]ATAAGGATGA	M	C	T	H	Y
G1517u1	WIAF-12618	HT1132	ERBB3, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3	3894	CAGACCTCAG [T/C]GCCTCTCTGG	S	T	C	S	S
G152u1	WIAF-11608	HT3854	HSPALL, heat shock 70kD protein-like 1	1673	GTGAGTGATG [A/C]AGGTTTGAAG	M	A	C	E	A
G152u2	WIAF-11629	HT3854	HSPALL, heat shock 70kD protein-like 1	1683	AAGTTTGAAG [G/A]GGCAAGATTA	S	G	A	K	K
G152u3	WIAF-11609	HT3854	HSPALL, heat shock 70kD protein-like 1	1478	GTCACAGCCA [C/T]GGACAGAGGC	M	C	T	T	M
G152u4	WIAF-11610	HT3854	HSPALL, heat shock 70kD protein-like 1	1443	TGACGTTTGA [C/T]ATTGATGCCA	S	C	T	D	D
G1520u1	WIAF-12162	HT1175	DNA excision repair protein ERCC2, 5' end	2211	TGACCGTGGA [C/T]CAGGGTGTCC	S	C	T	D	D

G1520u2	WIAF-12166	HT1175		546	DNA excision repair protein ERCC2, 5' end	CCCACTCCG [A/C] TTCTATGAGG	S	A	C	R	R
G1527u1	WIAF-12168	HT0086		577	GSTM2, glutathione S-transferase (muscle)	TCATCTCCG [A/C] TTTGAGGGCT	S	A	C	R	R
G1527u2	WIAF-12169	HT0086		644	GSTM2, glutathione S-transferase (muscle)	ACCTGTGTTT [A/T] CAAAGATGGC	M	A	T	T	S
G1527u3	WIAF-12171	HT0086		100	GSTM2, glutathione S-transferase (muscle)	ACTCAAGCTA [C/T] GAGGAAAGA	S	C	T	Y	Y
G1527u4	WIAF-12172	HT0086		41	GSTM2, glutathione S-transferase (muscle)	GGGTACTGG [A/G] ACATCCCGG	M	A	G	N	D
G1527u5	WIAF-12173	HT0086		215	GSTM2, glutathione S-transferase (muscle)	GATTGATGGG [A/G] CTCACAAGAT	M	A	G	T	A
G1527u6	WIAF-12194	HT0086		238	GSTM2, glutathione S-transferase (muscle)	CCAGAGCAA [T/C] GCCATCCTGC	S	T	C	N	N
G1528u1	WIAF-11950	HT1811		529	GSTM3, glutathione S-transferase (brain)	GTATATTGTA [C/G] CCCAAGTGCC	M	C	G	D	E
G1528u2	WIAF-11951	HT1811		674	GSTM3, glutathione S-transferase (brain)	CAACAAGCT [G/A] TATGCTGAGC	M	G	A	V	I
G1528u3	WIAF-11989	HT1811		572	GSTM3, glutathione S-transferase (brain)	GGCTTTCATG [T/G] GCCGTTTGA	M	T	G	C	G
G1528u4	WIAF-13470	HT1811		240	GSTM3, glutathione S-transferase (brain)	CAGAGCAATG [C/A] CATCTTGGC	M	C	A	A	D
G1529u1	WIAF-14146	HT2006		797	GSTM4, glutathione S-transferase	TGGACGCCTT [C/T] CCAAACTCTGA	S	C	T	F	F
G153u1	WIAF-12163	HT3856		1212	HSPA1B, heat shock 70kD protein 1	TGGGGCTGGA [G/A] ACGGCCGGAG	S	G	A	E	E
G153u2	WIAF-12182	HT3856		676	HSPA1B, heat shock 70kD protein 1	GGCCGGGAC [A/G] CCCACCTGGG	M	A	G	T	A
G153u3	WIAF-12183	HT3856		1695	HSPA1B, heat shock 70kD protein 1	TCAGCGAGGC [C/G] GACAAGAAGA	S	C	G	A	A
G153u4	WIAF-12189	HT3856		330	HSPA1B, heat shock 70kD protein 1	ACAGGGGGA [G/C] ACCNAGGNT	M	G	C	E	D
G153u5	WIAF-12190	HT3856		1053	HSPA1B, heat shock 70kD protein 1	AGTGTGTCGA [A/G] GACTTCTTCA	S	A	G	Q	Q
G1530u1	WIAF-11964	HT3010		673	GSTM5, glutathione S-transferase	ATTCCTCGA [G/A] GTCTTTTGT	M	G	A	G	S
G1530u2	WIAF-11995	HT3010		593	GSTM5, glutathione S-transferase	GACGCCTTCC [T/C] AAACCTGAAG	M	T	C	L	P

G1530U3	WIAF-13473	HT3010	693 MS	GSTM5, glutathione S-transferase	TTGGNAAGTC [A/G] GCTACATGGA	S	A	G	S	S
G1533U1	WIAF-13458	HT27460	543	GSTT2, glutathione S-transferase	CTCTCGGCTA [C/T] GAAGTGTG	S	C	T	Y	Y
G1533U2	WIAF-13460	HT27460	417	GSTT2, glutathione S-transferase	GGACTGCCAT [G/A] GACCAGGCC	M	G	A	M	I
G1533U3	WIAF-13461	HT27460	359	GSTT2, glutathione S-transferase	CAGGTGTTGG [G/A] GCCACTCAT	M	G	A	G	E
G1533U4	WIAF-13462	HT27460	363	GSTT2, glutathione S-transferase	TGTTGGGGCC [A/C] CTCATTGGGG	S	A	C	P	P
G1533U5	WIAF-13463	HT27460	385	GSTT2, glutathione S-transferase	CCAGGTGCC [G/A] AGGAGAAGGT	M	G	A	E	K
G1535U1	WIAF-11952	HT0436	517	HCK, hemopoietic cell kinase	CGCGTTTGAC [T/C] CTCGTGAGAC	M	T	C	S	P
G1535U2	WIAF-12013	HT0436	783	HCK, hemopoietic cell kinase	TGACCCACTA [C/T] AGAAGGGGA	S	C	T	Y	Y
G1535U3	WIAF-13464	HT0436	357	HCK, hemopoietic cell kinase	TCATCGTGGT [T/C] GCCCTGTATG	S	T	C	V	V
G1535U4	WIAF-13465	HT0436	387	HCK, hemopoietic cell kinase	CCATTACCA [C/T] GAAGACTCA	S	C	T	H	H
G1535U5	WIAF-13466	HT0436	471	HCK, hemopoietic cell kinase	CCCTGGCCAC [C/G] CGAAGGAGG	S	C	G	T	T
G1535U6	WIAF-13467	HT0436	240	HCK, hemopoietic cell kinase	CCAGCGCCAG [C/T] CCACACTGTC	S	C	T	S	S
G1535U7	WIAF-13468	HT0436	394	HCK, hemopoietic cell kinase	CCACGAAGAC [C/T] TCAGCTTCCA	M	C	T	L	F
G1537U1	WIAF-12020	U04045	1514	MSH2, muts (E. coli) homolog 2 (colon cancer, nonpolypoid type)	GTGAATTAG [A/G] GAAATATGA	S	A	G	R	R
G1537U2	WIAF-12044	U04045	599	MSH2, muts (E. coli) homolog 2 (colon cancer, nonpolypoid type)	GACTGTGTGA [A/T] TTCCTGTGTA	M	A	T	E	D
G1537U3	WIAF-12045	U04045	1452	MSH2, muts (E. coli) homolog 2 (colon cancer, nonpolypoid type)	AGATATGGAT [C/T] AGGTGGAATA	N	C	T	Q	*
G1537U4	WIAF-12076	U04045	938	MSH2, muts (E. coli) homolog 2 (colon cancer, nonpolypoid type)	GACAGTTTGA [A/T] CTGACTACTT	M	A	T	E	D



G1537u5	WIAF-12077	U04045		MSH2, muts (E. coli) homolog 2 (colon cancer, nonpolyposis type 18781)		TCAGCTAGAT [G/A] CTGTTGTGCTCAG	M	G	A	A	T
G1543u1	WIAF-13856	J00119		MOS, v-mos Moloney murine sarcoma viral oncogene homolog 553		GAGTTTCTGG [G/T] CTGAGCTCAA	M	G	T	A	S
G1543u2	WIAF-13857	J00119		MOS, v-mos Moloney murine sarcoma viral oncogene homolog 621		GCACGGCAC [G/A] CCCGAGGGT	S	G	A	T	T
G1544u1	WIAF-12018	U59464		PTCH, patched (Drosophila) homolog 3821		CATCCGAAT [C/T] CAGGCATCAC	M	C	T	S	F
G1544u2	WIAF-12019	U59464		PTCH, patched (Drosophila) homolog 3618		GCGTGGTCCG [C/T] TTGGCCATGC	S	C	T	R	R
G1544u3	WIAF-12027	U59464		PTCH, patched (Drosophila) homolog 1761		ATTTTGCCAT [G/T] GTTCTGCTCA	M	G	T	M	I
G1544u4	WIAF-12029	U59464		PTCH, patched (Drosophila) homolog 4074		CTGCCATGGG [C/T] AGCTCCGTGC	S	C	T	G	G
G1544u5	WIAF-12043	U59464		PTCH, patched (Drosophila) homolog 3845		CCCTCGAACC [C/T] GAGACAGCAG	M	C	T	P	L
G1544u6	WIAF-12056	U59464		PTCH, patched (Drosophila) homolog 1433		CTGCTGGTTG [C/T] ACTGTGCTG	M	C	T	A	V
G1544u7	WIAF-12058	U59464		PTCH, patched (Drosophila) homolog 3298		CACCGTTTAC [G/C] TTGCTTTTGGC	M	G	C	V	L
G1544u8	WIAF-12062	U59464		PTCH, patched (Drosophila) homolog 3986		TCTACTGAAG [G/A] GCATTCTGGC	M	G	A	G	E
G1544u9	WIAF-13489	U59464		PTCH, patched (Drosophila) homolog 1665		CCATCAGCAA [T/C] GTCACAGCCT	S	T	C	N	N
G1544u10	WIAF-13490	U59464		PTCH, patched (Drosophila) homolog 2396		AAATACTTTT [C/T] TTTCTACAAC	M	C	T	S	F
G1544u11	WIAF-13491	U59464		PTCH, patched (Drosophila) homolog 2199		GGACACTCTC [A/G] TCTTTTGGTG	S	A	G	S	S
G1544u12	WIAF-13492	U59464		PTCH, patched (Drosophila) homolog 2222		AAGCACTATG [C/T] TCCTTTTCCTC	M	C	T	A	V
G1544u13	WIAF-13500	U59464		PTCH, patched (Drosophila) homolog 1686		TCTTCATGGC [C/T] GCGTTAATCC	S	C	T	A	A
G1545u1	WIAF-12032	HT0473		RAG1, recombination activating gene 1 1835		GGACATGGAA [G/A] AAGACATCTT	M	G	A	E	K
G1545u2	WIAF-12035	HT0473		RAG1, recombination activating gene 1 2519		TGACATTTGGC [A/G] ATGCAGCTGA	M	A	G	N	D

G1545u3	WIAF-12046	HT0473	3045	RAG1, recombination activating gene 1	CGAATAATGA[A/G]TGCCAGGCAG	M	A	G	N	S
G1545u4	WIAF-12047	HT0473	3146	RAG1, recombination activating gene 1	TCATAATGCA[T/C]TAAACCTTC	S	T	C	L	L
G1545u5	WIAF-12075	HT0473	2513	RAG1, recombination activating gene 1	CCACTGTGAC[A/T]TTGGCAATGC	M	A	T	I	F
G1545u6	WIAF-13484	HT0473	1322	RAG1, recombination activating gene 1	GTGCTGACT[C/T]GGAGAGCTCA	M	C	T	R	W
G1545u7	WIAF-13494	HT0473	2571	RAG1, recombination activating gene 1	GAAGTGATATA[A/G]GAATCCCAAT	M	A	G	K	R
G1545u8	WIAF-13498	HT0473	1018	RAG1, recombination activating gene 1	TTCTGGCTGA[C/A]CCTGTGGAGA	M	C	A	D	E
G1545u9	WIAF-13499	HT0473	2782	RAG1, recombination activating gene 1	ATCTTTTACCT[G/C]AAGATGAAC	S	G	C	L	L
G1548u1	WIAF-12015	HT4999	133	IFI27, interferon, alpha-inducible protein 27	CTCTGCCGTA[G/A]TTTGGCCCT	M	G	A	V	I
G1548u2	WIAF-13482	HT4999	380	IFI27, interferon, alpha-inducible protein 27	ATCCTGGGCT[C/T]CATTGGGTCT	M	C	T	S	F
G1548u3	WIAF-13483	HT4999	135	IFI27, interferon, alpha-inducible protein 27	CTGCCGTAGT[T/C]TTGCCCTGG	S	T	C	V	V
G155u1	WIAF-11634	HT3962	991	CHC1, chromosome condensation 1	AGCTGGATGT[G/A]CCTGTGGTAA	S	G	A	V	V
G155u2	WIAF-11635	HT3962	1271	CHC1, chromosome condensation 1	CGGCTTGGGC[C/T]TCTCCAATA	M	C	T	L	P
G155u3	WIAF-11636	HT3962	1192	CHC1, chromosome condensation 1	GCCGGGCCA[C/T]GTGAGATTCC	S	C	T	H	H
G155u4	WIAF-11637	HT3962	1267	CHC1, chromosome condensation 1	TGTACGGCTT[C/T]GGCCTCTCCA	S	C	T	F	F
G155u5	WIAF-11649	HT3962	1657	CHC1, chromosome condensation 1	TGATGGCAA[A/G]CAGCTGGAGA	S	A	G	K	K
G1550u1	WIAF-12057	M16038	611	LYN, v-yes-1 Yamaguchi sarcoma viral related oncogene homolog	GCAAAGTCCC[T/G]TTTACAAAA	M	T	G	L	R
G1550u2	WIAF-12061	M16038	1371	LYN, v-yes-1 Yamaguchi sarcoma viral related oncogene homolog	TGGCATAAT[C/T]GAGCGGAAGA	S	C	T	I	I
G1550u3	WIAF-12080	M16038	1059	LYN, v-yes-1 Yamaguchi sarcoma viral related oncogene homolog	AAAGGCTTGG[C/T]GCTGGCAGT	S	C	T	G	G

-78-

G1550u4	WIAP-12081	M16038	996	LYN, v-yes-1 Yamaguchi sarcoma viral related oncogene homolog	AGCCACAGAA [G/A] CCTATGGGATA	S	G	A	K	K
G1552u1	WIAP-12030	HT4578	2355	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	CTGCTATTT [A/T] AAAGACTTCT	N	A	T	K	*
G1552u2	WIAP-12031	HT4578	2231	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	ACAAAGTTGA [C/T] TTAGAAGAGA	S	C	T	D	D
G1552u3	WIAP-12040	HT4578	617	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	TCATGAGCTT [T/C] GGTATCCTTA	S	T	C	F	F
G1552u4	WIAP-12063	HT4578	1723	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	TCATGTAACA [A/G] AAAATCAAT	M	A	G	K	R
G1552u5	WIAP-12064	HT4578	1732	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	AAAAATCAA [A/G] TGTAAATAGAT	M	A	G	N	S
G1552u6	WIAP-12065	HT4578	1660	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	TTACCATGTA [A/G] AGTAAGTAAT	M	A	G	K	R
G1552u7	WIAP-12066	HT4578	1975	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	GAACGATACA [A/G] TAGTCAAAATG	M	A	G	N	S
G1552u8	WIAP-12067	HT4578	1881	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	TTTAGAGGAT [G/T] CAACACTACA	M	G	T	A	S
G1552u9	WIAP-12068	HT4578	2454	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	TTTAGACGTT [T/A] TATATAAAT	M	T	A	L	I
G1552u10	WIAP-12069	HT4578	2457	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	AGACGTTTAA [T/C] ATAAATGAC	M	T	C	Y	H
G1552u11	WIAP-12082	HT4578	2557	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	ATACCAGGAG [T/C] TTCAATTAAT	M	T	C	V	A
G1552u12	WIAP-12083	HT4578	971	PMS1, postmeiotic segregation increased (S. cerevisiae) 1	TTTTCTTTCT [G/T] AAAATCGATG	S	G	T	L	L

G1554u1	WIAF-12028	HT4161		ELK3, ELK3, ETS-domain protein (SRF accessory protein 2) NOTE: Symbol and name provisional.	1500	CTCAGAAATC [C/T]TGATGACGTC	S	C	T	S	S
G1554u2	WIAF-12059	HT4161		ELK3, ELK3, ETS-domain protein (SRF accessory protein 2) NOTE: Symbol and name provisional.	1380	CTGCCAGGCT [G/A]CAAGGGCCAA	S	G	A	L	L
G1554u3	WIAF-12060	HT4161		ELK3, ELK3, ETS-domain protein (SRF accessory protein 2) NOTE: Symbol and name provisional.	1436	CACATGCCAG [T/C]GCCAATCCCC	M	T	C	V	A
G1562u1	WIAF-12024	HT28220		PDCD1, programmed cell death 1	804	GGGCTCAGC [T/C]GACGGCCCTC	S	T	C	A	A
G1562u2	WIAF-13488	HT28220		PDCD1, programmed cell death 1	644	GACCCCTCAG [C/T]CGTGCTGTG	M	C	T	A	V
G1563u1	WIAF-13493	HT1187		EGFR, epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog)	1748	CCGAGGCCCA [G/A]GGACTGCGTC	M	G	A	R	K
G1563u2	WIAF-13497	HT1187		EGFR, epidermal growth factor receptor (avian erythroblastic leukemia viral (v-erb-b) oncogene homolog)	2073	ACGGATGCAC [T/A]GGGCCAGGTC	S	T	A	T	T
G1566u1	WIAF-12016	HT27594		PDCD2, programmed cell death 2	235	GCGCGCTGC [C/G]TGGCGCCCG	M	C	G	P	R
G1566u2	WIAF-12033	HT27594		PDCD2, programmed cell death 2	904	TTGGAATTCC [A/G]GGTCATGCCT	M	A	G	Q	R
G1566u3	WIAF-12041	HT27594		PDCD2, programmed cell death 2	331	AATCACTAC [C/T]CAGGAAAAC	M	C	T	P	L
G1566u4	WIAF-12071	HT27594		PDCD2, programmed cell death 2	649	CCTGAGGTTG [T/C]GGAAAAGGA	M	T	C	V	A
G1566u5	WIAF-12072	HT27594		PDCD2, programmed cell death 2	633	AGAAGATGAG [A/T]TTATGCCCTGA	M	A	T	I	F
G1567u1	WIAF-12042	M95936		AKT2, v-akt murine thymoma viral oncogene homolog 2	293	GAGAGGCCGC [G/A]ACCCACACCC	M	G	A	R	Q

G1572u1	WIAF-12212	HT3998		1894	proto-oncogene c-abl, tyrosine protein kinase, alt. transcript 2	TGTTCCAGGA [A/G]TCCAGTATCT	S	A	G	E	E
G1572u2	WIAF-12233	HT3998		3694	proto-oncogene c-abl, tyrosine protein kinase, alt. transcript 2	AGCTTCAGAT [C/T]TGCCCGCGA	S	C	T	I	I
G1572u3	WIAF-12234	HT3998		3721	proto-oncogene c-abl, tyrosine protein kinase, alt. transcript 2	GCAGTGTGCTCC [G/A]GCGGCCACTC	S	G	A	P	P
G1573u1	WIAF-12021	HT0642		343	CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence	TCATGGACAA [G/C]GTGGTGGGT	M	G	C	K	N
G1573u2	WIAF-12022	HT0642		363	CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence	TTGTGTGAGA [A/T]CCCAAAGCTG	M	A	T	N	I
G1573u3	WIAF-12034	HT0642		2364	CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence	AATATTGAGT [C/T]CCAGGGGCCA	M	C	T	S	F
G1573u4	WIAF-12049	HT0642		387	CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence	CTAAAGAATA [G/A]CCACACCTTAT	M	G	A	S	N
G1573u5	WIAF-12050	HT0642		947	CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence	AACATATCCT [G/A]GCTACATGGC	M	G	A	G	S
G1573u6	WIAF-12070	HT0642		2740	CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence	TCGAGAAACCT [C/T]ATGAGTCAGG	S	C	T	L	L
G1573u7	WIAF-12073	HT0642		661	CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence	TCTTTCCAAG [T/C]GGACTCTTTC	S	T	C	S	S
G1573u8	WIAF-12074	HT0642		2569	CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence	CTCTGGATGG [T/C]GATCCTACAA	S	T	C	G	G
G1573u9	WIAF-13486	HT0642		2006	CBL, Cas-Br-M (murine) ecotropic retroviral transforming sequence	CCGGCACTCA [C/T]TTCCATTTTC	M	C	T	L	P

G1574u1	WIAF-12037	HT1508	2493	FES, feline sarcoma (Snyder-Theillen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fes) oncogene homolog	AGCGGCCAG [C/T] TTCAGCACCA	S	C	T	S	S
G1574u2	WIAF-12051	HT1508	189	FES, feline sarcoma (Snyder-Theillen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fes) oncogene homolog	CCGAGCGGT [C/T] AAGAGTGACA	S	C	T	V	V
G1574u3	WIAF-12052	HT1508	1441	FES, feline sarcoma (Snyder-Theillen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fes) oncogene homolog	GAAGCCCTG [C/T] ATGAGCAGCT	M	C	T	H	Y
G1574u4	WIAF-12053	HT1508	2202	FES, feline sarcoma (Snyder-Theillen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fes) oncogene homolog	GAGAGGAAG [C/T] GATGGGTCT	S	C	T	A	A
G1574u5	WIAF-12054	HT1508	2088	FES, feline sarcoma (Snyder-Theillen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fes) oncogene homolog	CTGCTGGCAT [G/T] GAGTACTGG	M	G	T	M	I
G1574u6	WIAF-12078	HT1508	1577	FES, feline sarcoma (Snyder-Theillen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fes) oncogene homolog	GATGGTCTGG [C/T] CCGGCACCTTC	M	C	T	P	L
G1574u7	WIAF-13495	HT1508	579	FES, feline sarcoma (Snyder-Theillen) viral (v-fes)/Fujinami avian sarcoma (PRCII) viral (v-fes) oncogene homolog	GTGACAAGG [T/C] AAGGACAAGT	S	T	C	A	A
G1575u1	WIAF-12079	HT1052	983	FGR, Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog	TGGGCAACCG [C/T] TGCTTCGGGG	S	C	T	G	G



G1604u1	WIAF-12319	HT2788	REL, v-rel avian reticuloendotheliosis viral 1182 oncogene homolog		CCTCCCAAG [T/C] GCTGGATTG	S	T	C	S	S
G1609u1	WIAF-12358	HT33646	RIPK1, receptor (TNFRSF) - interacting serine-threonine kinase 1	348	GACGAGGGT [C/T] TCCATGACC	S	C	T	V	V
G161u1	WIAF-11654	HT4251	DNA repair and recombination homolog RAD52	1522	TATGATCCAT [C/T] TTAAGTGGG	M	C	T	S	F
G1610a1	WIAF-12101	HT27727	501 replication protein Rpa4, 30 kDa		TGCAACTCCT [G/A] CTATTAAAGAC	M	G	A	A	T
G1610a2	WIAF-12102	HT27727	554 replication protein Rpa4, 30 kDa		TACCGGTAA [C/T] GTGAACGAC	S	C	T	N	N
G1610u3	WIAF-12307	HT27727	450 replication protein Rpa4, 30 kDa		TTCTGCTGCT [G/A] ATGGAGCGAG	M	G	A	D	N
G1610u4	WIAF-12320	HT27727	1037 replication protein Rpa4, 30 kDa		TGATTCATGA [G/C] TGTCTCATC	M	G	C	E	D
G1610u5	WIAF-12321	HT27727	857 replication protein Rpa4, 30 kDa		TAGAGGACAT [G/A] AACGAGTTCA	M	G	A	M	I
G1610u6	WIAF-12343	HT27727	539 replication protein Rpa4, 30 kDa		GAATTCAGGA [C/T] GTTGATCCGT	S	C	T	D	D
G1630u1	WIAF-12302	HT3563	DCC, deleted in colorectal carcinoma	4312	ACTCATGAAG [C/T] AGCTTAATGC	N	C	T	Q	*
G1632u1	WIAF-13572	HT27355	tumor suppressor, PDGF receptor beta-like	742	TTTATGACAT [G/C] AAGCGGGCT	M	G	C	M	I
G1632u2	WIAF-13584	HT27355	tumor suppressor, PDGF receptor beta-like	1102	TGGRAGACTT [C/T] GAGAGGATTG	S	C	T	F	F
G1632u3	WIAF-13601	HT27355	tumor suppressor, PDGF receptor beta-like	258	AAGACGAGT [C/T] TATCATGATG	M	C	T	S	F
G1633u1	WIAF-13957	HT1778	FER, fer (fps/fes related) tyrosine kinase (phosphoprotein NCP94)	1263	TTGAGGAAA [T/C] GAGATCATGT	S	T	C	N	N
G1633u2	WIAF-13958	HT1778	FER, fer (fps/fes related) tyrosine kinase (phosphoprotein NCP94)	2407	TATGTTGAT [C/T] TCGAGAGTAA	M	C	T	L	F
G1634u1	WIAF-13505	HT3216	ELK1, ELK1, member of ETS oncogene family	1569	TCTCGACCCC [C/T] GTGGTGCTCT	S	C	T	P	P
G1634u2	WIAF-13858	HT3216	ELK1, ELK1, member of ETS oncogene family	456	GGCTGTGGGG [A/G] CTACGCAAGA	S	A	G	G	G



G1634u3	WIAF-13859	HT3216	745	ELK1, ELK1, member of ETS oncogene family	AGCCCCAGGC [G/A] GTTTGGCAGC	M	G	A	G	S
G1638u1	WIAF-14172	HT1224	98	uracil-DNA glycosylase	GCTGGGACCT [G/C] TTCACAAAT	-	G	C	-	-
G1643u1	WIAF-13517	HT3751	629	DXS648E, DNA segment on chromosome X (unique) 648 expressed sequence	TACATCCCCA [G/A] TCGTGGCCCT	M	G	A	S	N
G1645u1	WIAF-14087	D21089	363	XPC, xeroderma pigmentosum, complementation group C	AAAACCTCAA [G/A] GTTATAAAGG	S	G	A	K	K
G1645u2	WIAF-14088	D21089	2166	XPC, xeroderma pigmentosum, complementation group C	TGCATTCCAG [G/A] GACACGTGGC	S	G	A	R	R
G1645u3	WIAF-14089	D21089	1580	XPC, xeroderma pigmentosum, complementation group C	GGAGGCCATC [G/A] TAAGGACCCA	M	G	A	R	H
G1645u4	WIAF-14090	D21089	1601	XPC, xeroderma pigmentosum, complementation group C	AGCTTGCAG [T/C] GGCATCCTCA	M	T	C	V	A
G1645u5	WIAF-14091	D21089	2920	XPC, xeroderma pigmentosum, complementation group C	CCATTGTGAG [A/C] AGCTGTGAGC	M	A	C	K	Q
G1645u6	WIAF-14103	D21089	405	XPC, xeroderma pigmentosum, complementation group C	ATGACCTCAG [G/A] GACTTTCCAA	S	G	A	R	R
G1645u7	WIAF-14104	D21089	151	XPC, xeroderma pigmentosum, complementation group C	GGACGCGAA [C/G] TCGCAGCCA	M	C	G	L	V
G1645u8	WIAF-14105	D21089	2133	XPC, xeroderma pigmentosum, complementation group C	AAGCGGTCTA [C/T] TCCAGGGATT	S	C	T	Y	Y
G167u1	WIAF-11632	HT4579	83	PMS2L8, postmeiotic segregation increased 2-like 8	CCTATTGATC [G/A] GAATCAGTC	M	G	A	R	Q
G167u2	WIAF-11633	HT4579	219	PMS2L8, postmeiotic segregation increased 2-like 8	GAGTGGATCT [T/C] ATTGAAGTTT	S	T	C	L	L
G167u3	WIAF-11644	HT4579	768	PMS2L8, postmeiotic segregation increased 2-like 8	TGCCCCCTAG [T/C] GACTCGGTGT	S	T	C	S	S

G167u4	WIAF-11622	HT4579	1645	PMS2L8, postmeiotic segregation increased 2-like 8	GAAAGCGCT [G/A] AAAGTGAAGA	M	G	A	B	K
G167u5	WIAF-11645	HT4579	1512	PMS2L8, postmeiotic segregation increased 2-like 8	ACTCGGGCA [C/T] GGCAGCACTT	S	C	T	H	H
G167u6	WIAF-11646	HT4579	1619	PMS2L8, postmeiotic segregation increased 2-like 8	TGCAGGAAC [A/G] TGTGGACTCT	M	A	G	H	R
G167u7	WIAF-11647	HT4579	1432	PMS2L8, postmeiotic segregation increased 2-like 8	CGTCTGAGA [C/T] CTCAGAAAGA	M	C	T	P	S
G167u8	WIAF-11625	HT4579	2490	PMS2L8, postmeiotic segregation increased 2-like 8	GGACTGCTCT [T/C] AACACAAGCG	S	T	C	L	L
G167u9	WIAF-11619	HT4579	804	PMS2L8, postmeiotic segregation increased 2-like 8	TGAGCTGTTT [G/C] GATGCTCTGC	S	G	C	S	S
G167u10	WIAF-11623	HT4579	1555	PMS2L8, postmeiotic segregation increased 2-like 8	CATCCCAGAC [A/G] CGGGCAGTCA	M	A	G	T	A
G167u11	WIAF-11624	HT4579	2364	PMS2L8, postmeiotic segregation increased 2-like 8	CCTTCGGACC [C/T] CAGGACGTCG	S	C	T	P	P
G167u12	WIAF-11626	HT4579	2348	PMS2L8, postmeiotic segregation increased 2-like 8	ACTAGTAAA [A/G] CTGGACCTTC	M	A	G	N	S
G181u1	WIAF-11697	HT48793	311 <sup>4</sup>	ERCC4, excision repair cross-complementing rodent repair deficiency, complementation group	ATATTTCGA [C/T] AACTAGGATA	M	C	T	T	I
G181u2	WIAF-11698	HT48793	295 <sup>4</sup>	ERCC4, excision repair cross-complementing rodent repair deficiency, complementation group	CACACAAGGT [G/C] GTGTTATATT	M	G	C	G	R
G181u3	WIAF-11699	HT48793	234 <sup>4</sup>	ERCC4, excision repair cross-complementing rodent repair deficiency, complementation group	TTGACACCT [C/T] CCTCGCGGTG	S	C	T	L	L

G181u4	WIAF-11704	HT48793		808	ERCC4, excision repair cross-complementing rodent repair deficiency, complementation group 4	TTTGTGGCAC[C/T]AGCTTGGAGC	N	C	T	Q	*
G181u5	WIAF-11705	HT48793		640	ERCC4, excision repair cross-complementing rodent repair deficiency, complementation group 4	TTCTATGACA[C/T]CTACCATGCT	M	C	T	P	S
G181u6	WIAF-11670	HT48793		1117	ERCC4, excision repair cross-complementing rodent repair deficiency, complementation group 4	AGAAAGCAAC[C/T]CAAAGTGGGA	M	C	T	P	S
G185u1	WIAF-11668	HT5122		319	ACVR2B, activin A receptor, type IIB	TCTGCAACGA[G/A]CGCTTCACTC	S	G	A	E	E
G185u2	WIAF-11707	HT5122		70	ACVR2B, activin A receptor, type IIB	AGACACGGGA[G/C]TGCATCTACT	M	G	C	E	D
G185u3	WIAF-11672	HT5122		812	ACVR2B, activin A receptor, type IIB	CCTCACGGAT[T/C]ACCTCAAGGG	M	T	C	Y	H
G185u4	WIAF-13542	X77533		1109	ACVR2B, activin A receptor, type IIB	GGCTCCTGAG[G/A]TGCTCGAGGG	M	G	A	V	M
G185u5	WIAF-13558	X77533		997	ACVR2B, activin A receptor, type IIB	TGCTGAAGAG[C/T]GACTCACAG	S	C	T	S	S
G187u1	WIAF-11669	HT97400		183	androgen	CCAGAGACAG[C/T]GCGACCCGGA	M	C	T	R	C
G191u1	WIAF-10176	AF025375		414	CXCR4, chemokine (C-X-C motif), receptor 4 (fusin)	ACCTGGCCAT[C/T]GTCCACGCCA	S	C	T	I	I
G193u1	WIAF-10178	D29984		231	CCR2, chemokine (C-C motif) receptor 2	AGTGCTTGAC[T/A]GACATTTACC	S	T	A	T	T
G193u2	WIAF-10179	D29984		190	CCR2, chemokine (C-C motif) receptor 2	CATGCTGGTC[G/A]TCCTCATCTT	M	G	A	V	I
G194u1	WIAF-10211	D43767		121	SCYA17, small inducible cytokine subfamily A (Cys-Cys), member 17	ACATCCACGC[A/C]GCTCGAGGGA	S	A	C	A	A
G197u1	WIAF-10167	D50403		1515	NRAMP1, natural resistance-associated macrophage protein 1 (might include Leishmaniasis)	GGTGCTAGTC[T/C]GGCCATCAA	M	T	C	C	R

G197u2	WIAP-10173	D50403			NRAMP1, natural resistance-associated macrophage protein 1 (might include Leishmaniasis)	1629			CACCTACCTG [G/C] TCTGACCTG	M	G	C	V	L
G20u1	WIAP-10249	U14722			ACVR1B, activin A receptor, type IB	896			CGGTACACAG [T/C] GACAATTGAG	M	T	C	V	A
G20u2	WIAP-10250	U14722			ACVR1B, activin A receptor, type IB	866			GAGCACGGGT [C/T] CCTGTTTGAT	M	C	T	S	F
G20u3	WIAP-10251	U14722			ACVR1B, activin A receptor, type IB	1391			CAGAGTTATG [A/T] GGCACCTCGG	M	A	T	E	V
G20u4	WIAP-10252	U14722			ACVR1B, activin A receptor, type IB	1236			TATATTGGGA [G/C] ATTGCTCGAA	M	G	C	E	D
G20u5	WIAP-10261	U14722			ACVR1B, activin A receptor, type IB	518			GAGATGTGTC [T/C] CTCNAAGAC	M	T	C	L	P
G207a1	WIAP-10516	L25259			Human CTLA4 counter-receptor (B7-2) mRNA, complete cds.	866			AGCTGTACTT [C/T] CAACAGTTAT	M	C	T	P	S
G208u1	WIAP-10204	L31581			CCR7, chemokine (C-C motif) receptor 7	85			GGGGAAACCA [A/G] TGAAGACGCT	M	A	G	M	V
G211u1	WIAP-10213	M24545			SCYA2, small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je)	174			TCACCTGCTG [T/C] TATAACTTCA	S	T	C	C	C
G214u1	WIAP-10191	M27533			CD80, CD80 antigen (CD28 antigen ligand 1, B7-1 antigen)	452			TGAAGAAAGT [G/A] GCAACGCTGT	S	G	A	V	V
G215u1	WIAP-11659	M28393			PRF1, perforin 1 (preforming protein)	822			GCATCTCTGC [C/T] GAAGCCAAGG	S	C	T	A	A
G215u2	WIAP-11723	M28393			PRF1, perforin 1 (preforming protein)	159			TGACCAGCCT [C/T] CGCCGCTCGG	S	C	T	L	L
G215u3	WIAP-11724	M28393			PRF1, perforin 1 (preforming protein)	96			CAGAGTGCAA [G/A] CGCAGCCACA	S	G	A	K	K
G215u4	WIAP-11725	M28393			PRF1, perforin 1 (preforming protein)	1377			ATAACAACCC [C/T] ATCTGTGTGAG	S	C	T	P	P
G215u5	WIAP-11726	M28393			PRF1, perforin 1 (preforming protein)	1326			TGAAGCTCTT [C/T] TTGGTGCC	S	C	T	F	F

G215u6	WIAP-11727	M28393	1076	PRF1, perforin 1 (preforming protein)	CGCGGGAGG[C/T]ACTGAGGAGG	M	C	T	A	V
G217u1	WIAP-11691	M31932	649	FCGR2B, Fc fragment of IgG, low affinity IIB, receptor for (CD32)	GCACTCTTC[A/G]CCAATGGGA	S	A	G	S	S
G217u2	WIAP-11692	M31932	625	FCGR2B, Fc fragment of IgG, low affinity IIB, receptor for (CD32)	TCACTGTCCA[A/G]GTGCCAGCA	S	A	G	Q	Q
G217u3	WIAP-11712	M31932	332	FCGR2B, Fc fragment of IgG, low affinity IIB, receptor for (CD32)	GACTGGCCAG[A/C]CCAGCCTCAG	M	A	C	T	P
G217u4	WIAP-11713	M31932	101	FCGR2B, Fc fragment of IgG, low affinity IIB, receptor for (CD32)	GGCTTCTGCA[G/T]ACAGTCAAGC	M	G	T	D	Y
G218u1	WIAP-10184	M36712	677	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	TTTTACAAAT[A/G]AGCAGAGAAT	N	A	G	*	*
G218u2	WIAP-10188	M36712	326	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	GCTCTGTTC[G/C]GGATGCAAGC	M	G	C	R	P
G218u3	WIAP-10189	M36712	196	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	CAGTAACATG[C/T]GCATCTACTG	M	C	T	R	C
G218u4	WIAP-10190	M36712	225	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	AGCCCCAGGC[A/C]CCGAGCAGTG	S	A	C	A	A
G218u5	WIAP-10194	M36712	583	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	GGTGGCTGGC[G/A]TCCTGGTTCT	M	G	A	V	I
G218u6	WIAP-10208	M36712	372	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	TGAAGCCGGA[A/G]GACAGTGCCA	S	A	G	E	E
G218u7	WIAP-10209	M36712	400	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	CTGCATGATC[G/T]TCGGGAGCCC	M	G	T	V	F
G218u8	WIAP-10210	M36712	270	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	TCTGGGATTC[C/T]GCAAAAGGGA	S	C	T	S	S
G218a9	WIAP-10518	M36712	618	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	GAGTGGCCAT[C/G]CACCTGTGCT	M	C	G	I	M
G218a10	WIAP-13223	M36712	556	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	TTCTAGCCCC[A/G]TCACCCCTGG	M	A	G	I	V
G218a11	WIAP-13224	M36712	836	CD8B1, CD8 antigen, beta polypeptide 1 (p37)	CTGTGTGTGA[T/C]GTGCATGGGA	-	T	C	-	-
G22u1	WIAP-10301	U86136	6719	Human telomerase-associated protein TP-1 mRNA, complete cds.	GGTGGTAAACC[G/A]TCGGGCTAGA	M	G	A	V	I

G22u2	WIAF-10302	U86136	7537	Human telomerase-associated protein TP-1 mRNA, complete cds.	CTGATGGAT[C/G]CTATGGAACC	M	C	G	I	M
G22u3	WIAF-10311	U86136	1798	Human telomerase-associated protein TP-1 mRNA, complete cds.	ATGATGCCAT[T/C]GATGCCCTCG	S	T	C	I	I
G22u4	WIAF-10312	U86136	2397	Human telomerase-associated protein TP-1 mRNA, complete cds.	CTGTCTCTGG[C/T]TGGCCAAAGG	M	C	T	A	V
G22u5	WIAF-10313	U86136	3289	Human telomerase-associated protein TP-1 mRNA, complete cds.	AGAAAGGGAT[A/C]ACCTGCCGCA	S	A	C	I	I
G22u6	WIAF-10314	U86136	3242	Human telomerase-associated protein TP-1 mRNA, complete cds.	AGAGGCCGCA[T/C]GTGGGATCTC	M	T	C	C	R
G22u7	WIAF-10315	U86136	4482	Human telomerase-associated protein TP-1 mRNA, complete cds.	CCGTTTGCT[G/A]CCTCGTCCAG	M	G	A	C	Y
G22u8	WIAF-10316	U86136	4363	Human telomerase-associated protein TP-1 mRNA, complete cds.	GTTTGACTGT[G/A]GACCAGCTGC	S	G	A	V	V
G22u9	WIAF-10317	U86136	4230	Human telomerase-associated protein TP-1 mRNA, complete cds.	GTGTCTGAGA[G/A]ACTCCGGACC	M	G	A	R	K
G22u10	WIAF-10318	U86136	4419	Human telomerase-associated protein TP-1 mRNA, complete cds.	GGGACTAAGA[G/C]CTGGGAAGAA	M	G	C	S	T
G22u11	WIAF-10319	U86136	5269	Human telomerase-associated protein TP-1 mRNA, complete cds.	TCTCCGATGA[T/C]ACACTCTTTC	S	T	C	D	D
G22u12	WIAF-10320	U86136	5015	Human telomerase-associated protein TP-1 mRNA, complete cds.	GCTGCTCTCC[C/T]GGAGATGGCA	M	C	T	R	W
G22u13	WIAF-10321	U86136	5133	Human telomerase-associated protein TP-1 mRNA, complete cds.	GTGGCTTCT[C/T]CACCAATGGG	M	C	T	S	F
G22u14	WIAF-10322	U86136	7764	Human telomerase-associated protein TP-1 mRNA, complete cds.	ACAGCCCTCC[A/G]TGTGTACCT	M	A	G	H	R

G22u15	WIAF-10323	U86136	7884	Human telomerase-associated protein TP-1 mRNA, complete cds.	TGCTTGAAC [C/T] TTGGCTGGGC	M	C	T	P	L
G22u16	WIAF-10324	U86136	7744	Human telomerase-associated protein TP-1 mRNA, complete cds.	AGATTCACTC [G/A] GGCTCTGTCA	S	G	A	S	S
G22u17	WIAF-10337	U86136	1018	Human telomerase-associated protein TP-1 mRNA, complete cds.	CCATTGCTGC [T/C] TTCTTGCGG	S	T	C	A	A
G22u18	WIAF-10338	U86136	1000	Human telomerase-associated protein TP-1 mRNA, complete cds.	TGCCCAATAA [C/A] ATCTTGSCCA	M	C	A	N	K
G22u19	WIAF-10339	U86136	1182	Human telomerase-associated protein TP-1 mRNA, complete cds.	ATGACGGACA [A/G] ATTGCCCCAG	M	A	G	K	R
G22u20	WIAF-10340	U86136	1939	Human telomerase-associated protein TP-1 mRNA, complete cds.	AGCAGCTTCG [T/G] ATGGCAATGA	S	T	G	R	R
G22u21	WIAF-10341	U86136	2227	Human telomerase-associated protein TP-1 mRNA, complete cds.	TCACGAGGGC [G/A] GAGCAGGTGG	S	G	A	A	A
G22u22	WIAF-10342	U86136	2776	Human telomerase-associated protein TP-1 mRNA, complete cds.	GGCGCAGCAT [C/T] CGGCTTTTCA	S	C	T	I	I
G22u23	WIAF-10343	U86136	2877	Human telomerase-associated protein TP-1 mRNA, complete cds.	GCCCTCACC [G/A] TATCAGCCTT	M	G	A	R	H
G22u24	WIAF-10344	U86136	3087	Human telomerase-associated protein TP-1 mRNA, complete cds.	TCAGGGCGCT [C/T] TGTGACAGAG	M	C	T	S	F
G22u25	WIAF-10345	U86136	3662	Human telomerase-associated protein TP-1 mRNA, complete cds.	CAAGGTGGCA [C/T] CATTAGTCTT	M	C	T	P	S
G22u26	WIAF-10346	U86136	4762	Human telomerase-associated protein TP-1 mRNA, complete cds.	TTTCGAAGTT [C/T] CTTACCAACC	S	C	T	P	P
G22u27	WIAF-10351	U86136	1737	Human telomerase-associated protein TP-1 mRNA, complete cds.	CTCCAGCATG [G/C] GAAGTCGGTG	M	G	C	G	A

G22u28	WIAP-10352	U86136		3543	Human telomerase-associated protein TP-1 mRNA, complete cds.	ACAGTGCAC [A/G]CTGATGCTG	M	A	G	Q	R
G22u29	WIAP-10353	U86136		4232	Human telomerase-associated protein TP-1 mRNA, complete cds.	GTCTGAGAGA [C/T]TCCGACCCCT	M	C	T	L	F
G22u30	WIAP-10354	U86136		4523	Human telomerase-associated protein TP-1 mRNA, complete cds.	GGAGGGCCCT [C/T]TGGAGCGCCC	S	C	T	L	L
G22u31	WIAP-10355	U86136		5333	Human telomerase-associated protein TP-1 mRNA, complete cds.	TGGTTGTCTGG [G/T]TGCTGCAGAC	M	G	T	V	L
G22u32	WIAP-10356	U86136		6208	Human telomerase-associated protein TP-1 mRNA, complete cds.	AGCTGCTGAC [G/A]CGGCCACACA	S	G	A	T	T
G22u33	WIAP-10357	U86136		7703	Human telomerase-associated protein TP-1 mRNA, complete cds.	TAGTGAGCCA [A/G]CACCACATCT	M	A	G	T	A
G22u34	WIAP-10360	U86136		3881	Human telomerase-associated protein TP-1 mRNA, complete cds.	CATCGATGGG [G/A]CTGATAGGTT	M	G	A	A	T
G22u1	WIAP-11700	M57230		697	IL6ST, interleukin 6 signal transducer (gp130, oncostatin M receptor)	TGAGTGGGAT [G/C]GTGGAAGGGA	M	G	C	G	R
G22u2	WIAP-11701	M57230		708	IL6ST, interleukin 6 signal transducer (gp130, oncostatin M receptor)	GTGGAAGGGA [A/G]ACACACTTGG	S	A	G	E	E
G22u3	WIAP-11702	M57230		677	IL6ST, interleukin 6 signal transducer (gp130, oncostatin M receptor)	GAGGGGAAGA [A/G]AATGAGGTGT	M	A	G	K	R
G22u4	WIAP-11706	M57230		1616	IL6ST, interleukin 6 signal transducer (gp130, oncostatin M receptor)	AAGAAATATA [T/C]ACTTGAGTGG	M	T	C	I	T
G22u5	WIAP-11667	M57230		1444	IL6ST, interleukin 6 signal transducer (gp130, oncostatin M receptor)	TGATCGCTAT [C/G]TAGCAACCCCT	M	C	G	L	V
G22u6	WIAP-11708	M57230		981	IL6ST, interleukin 6 signal transducer (gp130, oncostatin M receptor)	TCTTAAATTT [G/C]ACATGGACCA	M	G	C	L	F



G226u1	WIAP-11714	M85079		869	TGFB2, transforming growth factor, beta receptor II (70-80kd)	CACTGGAGT [T/C]GCCATATCTG	S	T	C	V	V
G226u2	WIAP-11715	M85079		1749	TGFB2, transforming growth factor, beta receptor II (70-80kd)	AGATTATGAG [C/T]CTCCATTGG	M	C	T	P	S
G226u3	WIAP-11716	M85079		1601	TGFB2, transforming growth factor, beta receptor II (70-80kd)	TGGNACTGC [A/G]AGATACATGG	S	A	G	A	A
G226u4	WIAP-11721	M85079		1256	TGFB2, transforming growth factor, beta receptor II (70-80kd)	TACTCCAGTT [C/G]CTGACGGCTG	M	C	G	F	L
G226u5	WIAP-11722	M85079		1502	TGFB2, transforming growth factor, beta receptor II (70-80kd)	TCGTGAAGAA [C/T]GACCTAACCT	S	C	T	N	N
G226u6	WIAP-11671	M85079		888	TGFB2, transforming growth factor, beta receptor II (70-80kd)	TGTCATCATC [A/C]TCTTCTACTG	M	A	C	I	L
G226u7	WIAP-11674	M85079		1425	TGFB2, transforming growth factor, beta receptor II (70-80kd)	CCTCCACAGT [G/A]ATCACACTCC	M	G	A	D	N
G227u1	WIAP-10197	M86511		685	CD14, CD14 antigen	CCTGTCTGAC [A/G]ATCCTGGACT	M	A	G	N	D
G227u2	WIAP-10212	M86511		497	CD14, CD14 antigen	GAAGCCACAG [G/A]ACTTGCACCT	M	G	A	G	E
G2278u1	WIAP-14117	AF034611		959	CUBN, cubilin (intrinsic factor-cobalamin receptor)	AGATAAATAA [T/C]GCGCGCTGTT	S	T	C	N	N
G2278u2	WIAP-14118	AF034611		781	CUBN, cubilin (intrinsic factor-cobalamin receptor)	GGTGGATGT [C/T]TTCACCCCAAC	M	C	T	S	F
G2278u3	WIAP-14119	AF034611		641	CUBN, cubilin (intrinsic factor-cobalamin receptor)	CTGAGACGTA [C/T]GGACCCCACT	S	C	T	Y	Y
G2278u4	WIAP-14121	AF034611		1185	CUBN, cubilin (intrinsic factor-cobalamin receptor)	TGGTTATGGG [C/A]CAAATGGATG	M	C	A	P	T
G2278u5	WIAP-14133	AF034611		1532	CUBN, cubilin (intrinsic factor-cobalamin receptor)	TCTGGTTAT [C/G]AAAACCTGAAA	M	C	G	I	M
G2278u6	WIAP-14134	AF034611		2208	CUBN, cubilin (intrinsic factor-cobalamin receptor)	GCCTTTCAC [C/T]ACACCCAGCA	M	C	T	H	Y
G228u1	WIAP-10199	U00672		586	IL10RA, interleukin 10 receptor, alpha	GCAAGGTGCC [G/A]GGAACCTTCA	S	G	A	P	P
G228u2	WIAP-10200	U00672		731	IL10RA, interleukin 10 receptor, alpha	AGAGGAGTGC [A/G]TCTCCTCAC	M	A	G	I	V

G2280u1	WIAF-13970	AJ001515	1747	RVR3, ryanodine receptor 3	CAGTATCTT [G/A] GAAGTTTTC	S	G	A	L	L
G2280u2	WIAF-13974	AJ001515	8593	RVR3, ryanodine receptor 3	TAGAAGCCAT [T/C] GTCAGCAGTG	S	T	C	I	I
G2282u1	WIAF-12694	D00726	263	FECH, ferrochelatase (protoporphyrin)	ACATGGGAGG [C/T] CCTGAAACTC	S	C	T	G	G
G2282u2	WIAF-12695	D00726	514	FECH, ferrochelatase (protoporphyrin)	TACTATATTG [G/A] ATTTCGGTAC	M	G	A	G	B
G2285u1	WIAF-12688	D16611	673	CPO, coproporphyrinogen oxidase (coproporphyrin, harderoporphyrin)	AGAAGACGCT [G/A] TCCATTTTCA	M	G	A	V	I
G2285u2	WIAF-12689	D16611	783	CPO, coproporphyrinogen oxidase (coproporphyrin, harderoporphyrin)	ATCGTGGAGA [G/A] CGCGGGGCA	S	G	A	E	E
G2287u1	WIAF-12687	D28472	502	PTGER4, prostaglandin E receptor 4 (subtype EP4)	GGGCTTCACG [C/T] TCTTTCAGT	M	C	T	L	F
G2287u2	WIAF-12691	D28472	1309	PTGER4, prostaglandin E receptor 4 (subtype EP4)	TGAAATGGC [C/T] TTGGAGGCAG	M	C	T	L	F
G2287u3	WIAF-12707	D28472	243	PTGER4, prostaglandin E receptor 4 (subtype EP4)	AGGAGACGAC [C/T] TTCTACACGC	S	C	T	T	T
G2287u4	WIAF-12710	D28472	1343	PTGER4, prostaglandin E receptor 4 (subtype EP4)	GGTGTGCTG [G/A] CATGGGCTTG	M	G	A	G	D
G229u1	WIAF-10185	U16752	202	SDF1, stromal cell-derived factor 1	CATGTTGCCA [G/A] AGCCACGTC	M	G	A	R	K
G2295u1	WIAF-12727	D89079	613	LTB4R, leukotriene b4 receptor (chemokine receptor-like 1)	CTATGTCTGC [G/C] GAGTCAGCAT	M	G	C	G	R
G2295u2	WIAF-12728	D89079	1248	LTB4R, leukotriene b4 receptor (chemokine receptor-like 1)	AGGGCACGGG [T/C] TCCGAGGCGT	S	T	C	G	G
G2295u3	WIAF-12753	D89079	1348	LTB4R, leukotriene b4 receptor (chemokine receptor-like 1)	CCTCACTGCC [T/G] CCAGCCCTCT	M	T	G	S	A
G230u1	WIAF-10201	U31628	627	IL15RA, interleukin 15 receptor, alpha	ACAGCCAGA [A/C] CTGGGAATC	M	A	C	N	T
G2300u1	WIAF-12735	J02959	102	LTA4H, leukotriene A4 hydrolase	ACCTGCACCT [G/T] CGCTGCAGCG	S	G	T	L	L
G2300u2	WIAF-12738	J02959	1380	LTA4H, leukotriene A4 hydrolase	CCTGGCTCTA [C/T] TCTCTGGAC	S	C	T	Y	Y

G2302u1	WIAF-12741	J03037	627	CA2, carbonic anhydrase II	TCTGAATCC [C/T] TGGATTACTG	S	C	T	L	L
G2302u2	WIAF-12742	J03037	819	CA2, carbonic anhydrase II	GCACCTGAAG [A/G] ACAGGCAAAAT	M	A	G	N	D
G2303u1	WIAF-12751	J03571	304	ALOX5, arachidonate 5-lipoxygenase	CGCTGAAGAC [G/A] CCCACGGGG	S	G	A	T	T
G2303u2	WIAF-12752	J03571	794	ALOX5, arachidonate 5-lipoxygenase	AGAGCTGCC [G/A] AGAAGCTCCC	M	G	A	E	K
G2304u1	WIAF-12772	J03575	840	PDH1, pyruvate dehydrogenase (lipoamide) alpha 1	TCCGAGAGGC [A/G] ACAAGGTTTG	S	A	G	A	A
G2304u2	WIAF-12779	J03575	1044	PDH1, pyruvate dehydrogenase (lipoamide) alpha 1	CCAGTGTTGA [A/C] GAACTAAAGG	M	A	C	E	D
G2305u1	WIAF-12763	J03576	456	PDHB, pyruvate dehydrogenase (lipoamide) beta	TCTTCAGGGG [A/G] CCCAATGGTG	S	A	G	G	G
G2305u2	WIAF-12764	J03576	650	PDHB, pyruvate dehydrogenase (lipoamide) beta	GTTCCTTTTG [A/C] ATTTCCTCCG	M	A	C	E	A
G231u1	WIAF-10202	U32324	734	IL1RA, interleukin 11 receptor, alpha	CCAGGGCCTG [C/T] GGGTAGAGTC	M	C	T	R	W
G2312u1	WIAF-12762	J05096	3726	ATP1A2, ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide	TCAAGRACCA [C/T] ACAGAGATCG	S	C	T	H	H
G2313u1	WIAF-12760	J05200	6141	RYR1, ryanodine receptor 1 (skeletal)	TGCAATTCAA [A/G] GATGGTACAG	S	A	G	K	K
G2313u2	WIAF-12767	J05200	3048	RYR1, ryanodine receptor 1 (skeletal)	CGGCGCAGAC [A/G] ACACTGGTGG	S	A	G	T	T
G2313u3	WIAF-12768	J05200	3084	RYR1, ryanodine receptor 1 (skeletal)	ATGGGCACAA [C/T] GTGTGGGCCC	S	C	T	N	N
G2313u4	WIAF-12777	J05200	5667	RYR1, ryanodine receptor 1 (skeletal)	GCATCTTTGG [C/T] GATGAGGATG	S	C	T	G	G
G2313u5	WIAF-12780	J05200	6600	RYR1, ryanodine receptor 1 (skeletal)	GCTGCTGCT [C/T] ATCGTGCGAG	S	C	T	L	L
G2313u6	WIAF-12781	J05200	7191	RYR1, ryanodine receptor 1 (skeletal)	AGCTGAGTG [C/T] TTCGGACCCG	S	C	T	C	C
G2313u7	WIAF-12782	J05200	7602	RYR1, ryanodine receptor 1 (skeletal)	ACCACAAAGGC [G/A] TCCATGGTGC	S	G	A	A	A

G2313u8	WIAF-12784	J05200	9288	RYR1, ryanodine receptor 1 (skeletal)	CAGACGCCCC[A/G]GCTGTGTCTCA	S	A	G	P	P
G2313u9	WIAF-12786	J05200	13690	RYR1, ryanodine receptor 1 (skeletal)	TCCAAAGAAG[G/A]AGGAAGCTGG	M	G	A	E	K
G2313u10	WIAF-12789	J05200	3147	RYR1, ryanodine receptor 1 (skeletal)	ACATCCAGC[G/A]CGCCGAAACC	S	G	A	A	A
G2314u1	WIAF-12771	J05272	1920	IMPDH1, IMP (inosine monophosphate) dehydrogenase 1	TGAAGATCG[A/G]CAGGGTGTCT	S	A	G	A	A
G2319u1	WIAF-12814	K03191	651	CYP1A1, cytochrome P450, subfamily I (aromatic compound- inducible), polypeptide 1	CCCCTACAGG[T/C]ATGTGTGGT	M	T	C	Y	H
G232u1	WIAF-11657	U58917	1490	Homo sapiens IL-17 receptor mRNA, complete cds.	TGAACATGAT[C/T]CTCCCGGACT	S	C	T	I	I
G232u2	WIAF-11677	U58917	1293	Homo sapiens IL-17 receptor mRNA, complete cds.	GCAGGCCATC[T/C]CGGAGGCAGG	M	T	C	S	P
G232u3	WIAF-11658	U58917	1132	Homo sapiens IL-17 receptor mRNA, complete cds.	GGCCTGCCTG[C/T]GGCTGACCTG	M	C	T	A	V
G232u4	WIAF-11679	U58917	905	Homo sapiens IL-17 receptor mRNA, complete cds.	GCAGCTGCCT[C/T]ATGACTGCC	S	C	T	L	L
G232u5	WIAF-11682	U58917	1794	Homo sapiens IL-17 receptor mRNA, complete cds.	GTTCGATGAT[G/T]AGAACCTCTA	N	G	T	E	*
G232u7	WIAF-11660	U58917	743	Homo sapiens IL-17 receptor mRNA, complete cds.	TGACCATGTTT[T/C]CGGCACATGG	S	T	C	P	P
G2322u1	WIAF-12853	L01406	1316	GHRHR, growth hormone releasing hormone receptor	CTGACATCTA[T/C]GTGCTAGGCT	M	T	C	M	T
G2328u1	WIAF-12845	L20316	1285	GCGR, glucagon receptor	TGCGGGCAG[G/C]CAGATGCACC	S	G	C	R	R
G2329u1	WIAF-12850	L22214	713	ADORA1, adenosine A1 receptor	TGCTGGCAAT[T/C]GCTGTGGACC	S	T	C	I	I
G2329u2	WIAF-12851	L22214	716	ADORA1, adenosine A1 receptor	TGGCAATTGC[T/G]GTGGACCGCT	S	T	G	A	A

G2335a1	WIAP-12136	L32961	265	ABAT, 4-aminobutyrate aminotransferase	CCTAGATCTC [A/G]GGAGTTAATG	M	A	G	Q	R
G2335a2	WIAP-12137	L32961	407	ABAT, 4-aminobutyrate aminotransferase	TCTCTCTGT [T/C]CCCATAGGTT	S	T	C	V	V
G2335u3	WIAP-12838	L32961	365	ABAT, 4-aminobutyrate aminotransferase	TGATGTGGA [C/T]GGCAACCGAA	S	C	T	D	D
G2335u4	WIAP-12839	L32961	583	ABAT, 4-aminobutyrate aminotransferase	ATCACCATGG [C/T]CTGGCGCTCC	M	C	T	A	V
G2335u5	WIAP-12841	L32961	1082	ABAT, 4-aminobutyrate aminotransferase	TGGACGAGGT [C/A]CAGACCGGAG	S	C	A	V	V
G2335u6	WIAP-12852	L32961	227	ABAT, 4-aminobutyrate aminotransferase	ATTATGATGG [G/A]CCTCTGATGA	S	G	A	G	G
G2337u1	WIAP-13577	L34820	149	ALDH5A1, aldehyde dehydrogenase 5 family, member A1 (succinate-semialdehyde dehydrogenase)	TGTTCTCGAA [A/G]GAATGCCAAG	M	A	G	K	R
G2342a1	WIAP-12138	M12530	1602	TF, transferrin	GCCTAAACCT [G/C]TGTGAACCCA	S	G	C	L	L
G2342a2	WIAP-12139	M12530	1795	TF, transferrin	TACCAGGAAA [C/T]CTGTGGAGGA	M	C	T	P	S
G2346u1	WIAP-12829	M13928	234	ALAD, aminolevulinate, delta-, dehydratase	TGGCCAGGTA [T/C]GGTGTGAAGC	S	T	C	Y	Y
G2346u2	WIAP-12830	M13928	529	ALAD, aminolevulinate, delta-, dehydratase	TGAGGTGGCA [T/C]TGGCGTATGC	S	T	C	L	L
G2346u3	WIAP-12843	M13928	480	ALAD, aminolevulinate, delta-, dehydratase	TGAGTGA AAA [C/T]GGAGCATTTCC	S	C	T	N	N
G2348u1	WIAP-12835	M14016	621	UROD, uroporphyrinogen decarboxylase	CTCTGGTCCC [A/G]TATCTGTGTAG	S	A	G	P	P
G235u1	WIAP-11678	U83171	100	SCYA22, small inducible cytokine subfamily A (Cys-Cys), member 22	CAGGCCCTTA [C/T]GGCGCCAACA	S	C	T	Y	Y
G2363a1	WIAP-10519	M37435	596	CSF1, colony stimulating factor 1 (macrophage)	GACAAGGACT [G/T]GAATATTTC	M	G	T	W	L
G2363a2	WIAP-13225	M37435	498	CSF1, colony stimulating factor 1 (macrophage)	AAGACATGA [C/T]AAGGCTGCG	S	C	T	D	D
G2363a3	WIAP-13226	M37435	712	CSF1, colony stimulating factor 1 (macrophage)	CAGTGACCG [G/T]CCTCTGTCTC	M	G	T	A	S

							S	C	T	D	D
G2369u1	WIAP-12854	M30773	857	PPP3R1, protein phosphatase 3 (formerly 2B), regulatory subunit B (19kD), alpha isoform	TTGATTGGAC [C/T] AATCTGGTTC	-	C	T	-	-	D
G2369u2	WIAP-12855	M30773	1274	PPP3R1, protein phosphatase 3 (formerly 2B), regulatory subunit B (19kD), alpha isoform	ATGTGTGACT [C/T] TTATCAGAGA	-	C	T	-	-	D
G237u1	WIAP-11662	U86358	311	SCYA25, small inducible cytokine subfamily A (Cys-Cys), member 25	CACCACAACA [T/C] GCAGACCTTC	M	T	C	M	T	D
G237u2	WIAP-11680	U86358	134	SCYA25, small inducible cytokine subfamily A (Cys-Cys), member 25	GTGCTCGGC [G/A] CGCCTGGACT	M	G	A	R	H	D
G237u3	WIAP-11681	U86358	133	SCYA25, small inducible cytokine subfamily A (Cys-Cys), member 25	TGTGTCCGG [C/T] GCGCCTGGAC	M	C	T	R	C	D
G237u5	WIAP-11661	U86358	302	SCYA25, small inducible cytokine subfamily A (Cys-Cys), member 25	GCAAAGCTCC [A/G] CCACAACATG	M	A	G	H	R	D
G237u6	WIAP-11663	U86358	378	SCYA25, small inducible cytokine subfamily A (Cys-Cys), member 25	AGTTATCATC [A/G] TCCAAGTTTA	S	A	G	S	S	D
G2373u1	WIAP-12870	M36035	500	BZRP, benzodiazepine receptor (peripheral)	GCTGGCCTTC [G/A] CGACCACT	M	G	A	A	T	D
G2376u1	WIAP-13025	M57414	979	TACR2, tachykinin receptor 2	CTGCTGCCCA [T/C] GGGTCACACC	M	T	C	W	R	D
G238u1	WIAP-10177	X01394	239	TNF, tumor necrosis factor (TNF superfamily, member 2)	GCTCCAGGCG [G/T] TGCTTGTTCC	S	G	T	R	R	D
G2381u1	WIAP-12894	M59941	730	CSF2RB, colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)	CAGAGGTTTT [C/T] TGGGACTCCC	S	C	T	C	C	D

G2381u2	WIAP-12896	M59941			CSF2RB, colony stimulating factor 2 receptor, beta, low-affinity 1306 (granulocyte-macrophage)	GGATCTGGAG [C/T] GACTGGAGTG	S	C	T	S	S
G2381u3	WIAP-12900	M59941			CSF2RB, colony stimulating factor 2 receptor, beta, low-affinity 1972 (granulocyte-macrophage)	CGATGGGACC [G/A] GGACAGGCCG	S	G	A	P	P
G2381u4	WIAP-12901	M59941			CSF2RB, colony stimulating factor 2 receptor, beta, low-affinity 1982 (granulocyte-macrophage)	GGACAGGCC [G/A] TGAAGTGA	M	G	A	V	M
G2381u5	WIAP-12942	M59941			CSF2RB, colony stimulating factor 2 receptor, beta, low-affinity 773 (granulocyte-macrophage)	CCAGAACCTG [G/C] AGTGCTCTT	M	G	C	E	Q
G2381u6	WIAP-12946	M59941			CSF2RB, colony stimulating factor 2 receptor, beta, low-affinity 2458 (granulocyte-macrophage)	CCCCACAGCC [C/A] GAGGGCCTCC	S	C	A	P	P
G2384u1	WIAP-12908	M61831			AHCY, S-adenosylhomocysteine hydrolase 1000	GCCGTGGAGA [A/C] GGTGAACATC	M	A	C	K	T
G2387u1	WIAP-12910	M63967			ALDH5, aldehyde dehydrogenase 5 2585	CTGCTGAACC [T/G] CCTGGCAGAC	M	T	G	L	R
G2387u2	WIAP-12911	M63967			ALDH5, aldehyde dehydrogenase 5 2996	TATGGCCCAA [C/G] AGCAGGTGCG	M	C	G	T	R
G2387u3	WIAP-12954	M63967			ALDH5, aldehyde dehydrogenase 5 2522	GCCCGGAAG [C/T] CTTCGGCTG	M	C	T	A	V
G2387u4	WIAP-12955	M63967			ALDH5, aldehyde dehydrogenase 5 2448	ACCCTACCAC [C/T] GGGAGGTCA	S	C	T	T	T
G2387u5	WIAP-12956	M63967			ALDH5, aldehyde dehydrogenase 5 2460	GGGAGGTGAT [C/T] GGGCACCTGG	S	C	T	I	I

G2387u6	WIAP-12957	M63967	2991	ALDH5, aldehyde dehydrogenase 5	CGGGGTATGG [C/T] CCAACAGCAG	S	C	T	G	G
G2387u7	WIAP-12958	M63967	3022	ALDH5, aldehyde dehydrogenase 5	CGCCACGAC [A/G] TGGATGTTGA	M	A	G	M	V
G2387u8	WIAP-12959	M63967	2943	ALDH5, aldehyde dehydrogenase 5	CCCTCATCA [G/C] GAGCAGGCT	M	G	C	K	N
G2388u1	WIAP-12888	M64590	588	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	TGCCACAGAC [G/A] ATTTTGGGA	S	G	A	T	T
G2388u2	WIAP-12889	M64590	651	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	ACCAGCCTGA [G/A] GTGTCTCAGG	S	G	A	E	E
G2388u3	WIAP-12890	M64590	698	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	CAGACCATGG [T/C] GTGTGACATC	M	T	C	V	A
G2388u4	WIAP-12891	M64590	557	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	TATATTGGCA [T/C] GGGCTATTAT	M	T	C	M	T
G2388u5	WIAP-12938	M64590	587	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	GTGCCACAGA [C/G] GATTTTGGCG	M	C	G	T	R
G2388u6	WIAP-12939	M64590	518	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	CTGCATGCCA [T/C] TTCAAGCAAA	M	T	C	I	T



G2388u7	WIAP-12940	M64590		810	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	GGAAATTCT[C/T]GTGATCCCC	S	C	T	L	L
G2388u8	WIAP-12941	M64590		1481	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	CATTGTGGCT[G/A]CTCAGTGAAG	M	G	A	C	Y
G2388u9	WIAP-12947	M64590		1841	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	AAACTGAACA[G/A]TTGCTCTGAA	M	G	A	S	N
G2388u10	WIAP-12948	M64590		2325	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	GACAGTCTA[C/T]CTAGACGGG	S	C	T	Y	Y
G2388u11	WIAP-12949	M64590		2362	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	GGTGGGATC[T/A]GTGCGCCTGG	M	T	A	C	S
G2388u12	WIAP-12950	M64590		3220	GLDC, glycine dehydrogenase (decarboxylating; glycine decarboxylase, glycine cleavage system protein P)	TTAGTCCTCT[C/G]TCCCTAAGTT	-	C	G	-	-
G2391u1	WIAP-12998	M69238		623	ARNT, aryl hydrocarbon receptor nuclear translocator	TGCTGTATGT[G/C]TCTGACTCCG	S	G	C	V	V
G2391u2	WIAP-13002	M69238		1072	ARNT, aryl hydrocarbon receptor nuclear translocator	TGCCTAGTGG[C/T]CATTGGCAGA	M	C	T	A	V
G2391u3	WIAP-13021	M69238		966	ARNT, aryl hydrocarbon receptor nuclear translocator	ACCTCACTTC[G/A]TGCTGTGCTCA	M	G	A	V	M

G2394u1	WIAF-13003	M73747	2061	TSHR, thyroid stimulating hormone receptor	TTGCTGGTAC [T/A] CTTCTATCCA	M	T	A	L	H
G2394u2	WIAF-13004	M73747	2248	TSHR, thyroid stimulating hormone receptor	TTACCCACGA [C/G] ATGAGCAGG	M	C	G	D	E
G2396u1	WIAF-12995	M74542	1027	ALDH3, aldehyde dehydrogenase 3	CCCCAGTCC [C/G] CGGTGATGCA	M	C	G	P	A
G2396u2	WIAF-13019	M74542	1295	ALDH3, aldehyde dehydrogenase 3	GGCAAGAAGA [G/A] CTTCCAGACT	M	G	A	S	N
G2403u1	WIAF-13583	M83670	280	CA4, carbonic anhydrase IV	TACGATAAGA [A/T] GCAAACTGG	M	A	T	K	M
G2409u1	WIAF-10010	HT2156	1268	AGTR1, angiotensin receptor 1	CCACTCAAAC [C/T] TTTCACAAA	M	C	T	L	F
G2411u1	WIAF-13541	M97759	210	ADORA2B, adenosine A2b receptor	TGGCGGGCAA [C/T] GTGCTGGTGT	S	C	T	N	N
G2422u1	WIAF-14077	S90469	375	POR, P450 (cytochrome) oxidoreductase	GCAGCCTGCC [A/G] GAGATCGACA	S	A	G	P	P
G2422u2	WIAF-14078	S90469	852	POR, P450 (cytochrome) oxidoreductase	TCCTGGCTGC [A/G] GTCACCACCA	S	A	G	A	A
G2422u3	WIAF-14082	S90469	1496	POR, P450 (cytochrome) oxidoreductase	AAGGAGCCTG [T/C] CGGGGAGAAC	M	T	C	V	A
G2422u4	WIAF-14099	S90469	1443	POR, P450 (cytochrome) oxidoreductase	AGACCAAGGC [C/T] GGCCGCATCA	S	C	T	A	A
G2422u5	WIAF-14100	S90469	1704	POR, P450 (cytochrome) oxidoreductase	GCCGCCGCTC [G/A] CATGAGGACT	S	G	A	S	S
G2427u1	WIAF-14079	U07919	1369	ALDH6, aldehyde dehydrogenase 6	ACTATGGACT [C/T] ACAGCAGCGG	S	C	T	L	L
G2427u2	WIAF-14096	U07919	1347	ALDH6, aldehyde dehydrogenase 6	ATAAAAAGAG [C/T] GAATAGCACC	M	C	T	A	V
G243u1	WIAF-11684	X57522	926	TAP1, transporter 1, ABC (ATP binding cassette)	ATAGCCAGTG [C/G] AGTGTGTGAG	M	C	G	A	G
G243u2	WIAF-11685	X57522	627	TAP1, transporter 1, ABC (ATP binding cassette)	ACCTTACCAG [C/T] TTCGTTGTCA	S	C	T	A	A
G243u3	WIAF-11686	X57522	538	TAP1, transporter 1, ABC (ATP binding cassette)	CCTGCCGGGA [C/G] TTGCCTTGT	M	C	G	L	V
G243u4	WIAF-11687	X57522	798	TAP1, transporter 1, ABC (ATP binding cassette)	TGGTGTCTCT [C/G] TCCTCTCTTG	S	C	G	L	L
G243u5	WIAF-11689	X57522	1465	TAP1, transporter 1, ABC (ATP binding cassette)	TAGTATTCCA [G/T] GTATGCTGTCT	M	G	T	G	C

G243u6	WIAF-11690	X57522		TAP1, transporter 1, ABC (ATP binding cassette)	177	AGAGTCCCAG [A/G] CCGGCGCGG	S	A	G	R	R
G243u7	WIAF-11693	X57522		TAP1, transporter 1, ABC (ATP binding cassette)	1067	AACATCATGT [C/T] TCGGTAACA	M	C	T	S	F
G243u8	WIAF-11665	X57522		TAP1, transporter 1, ABC (ATP binding cassette)	1207	GGTCACCTG [A/G] TCACCTGCC	M	A	G	I	V
G243u9	WIAF-11664	X57522		TAP1, transporter 1, ABC (ATP binding cassette)	1757	CCAAACCGCC [C/T] AGATGCTTA	M	C	T	P	L
G244u1	WIAF-10174	X60592		TNFRSF5, tumor necrosis factor receptor superfamily, member 5	239	CTTGGCGTGA [A/G] AGCGAATTCC	S	A	G	E	E
G2441u1	WIAF-13682	U30246		SLC12A2, solute carrier family 12 (sodium/potassium/chloride transporters), member 2	1355	TGCTTAAGGA [A/G] CATTCATAC	S	A	G	E	E
G2441u2	WIAF-13714	U30246		SLC12A2, solute carrier family 12 (sodium/potassium/chloride transporters), member 2	2691	AGCCAAATAT [C/G] AGCGATGCT	M	C	G	Q	E
G2443u1	WIAF-14004	U37143		CYP2J2, cytochrome P450, subfamily IIJ (arachidonic acid epoxidase) polypeptide 2	1456	CTGAAATTTA [G/A] AATGGGTATC	M	G	A	R	K
G2443u2	WIAF-14032	U37143		CYP2J2, cytochrome P450, subfamily IIJ (arachidonic acid epoxidase) polypeptide 2	376	TTTAAGAAA [A/G] TGGATTGATT	M	A	G	N	S
G2443u3	WIAF-14033	U37143		CYP2J2, cytochrome P450, subfamily IIJ (arachidonic acid epoxidase) polypeptide 2	1502	TCTGCGTGT [T/A] CCTCAGGTGT	S	T	A	V	V
G2444u1	WIAF-14065	U37519		ALDH3, aldehyde dehydrogenase 3	771	CCCGCAGGGA [A/G] TTGCGTGTG	M	A	G	N	S
G2444u2	WIAF-14066	U37519		ALDH3, aldehyde dehydrogenase 3	1698	AAGGAGATCC [G/A] CTACCCACCC	M	G	A	R	H
G2445u1	WIAF-14114	U38178		CNP, 2',3'-cyclic nucleotide 3' phosphodiesterase	236	TGCCGGGCGC [G/A] CCTCTCGCTG	M	G	A	R	H

G2445u2	WIAF-14115	U38178		849	CNP, 2',3'-cyclic nucleotide 3' phosphodiesterase	GTGCCGCCGA [A/G] GAAAAGTGC	S	A	G	E	E
G2445u3	WIAF-14122	U38178		1655	CNP, 2',3'-cyclic nucleotide 3' phosphodiesterase	GTTATCTTGC [A/T] GAGATCTCTG	M	A	T	Q	L
G2445u4	WIAF-14241	X95520		941	CNP, 2',3'-cyclic nucleotide 3' phosphodiesterase	TGCNAAATAT [T/C] CAGGAGACCG	?	T	C	?	?
G2445u5	WIAF-14242	X95520		1057	CNP, 2',3'-cyclic nucleotide 3' phosphodiesterase	TGGAGTTGAT [C/T] TTTCAGTGCT	?	C	T	?	?
G2445u6	WIAF-14243	X95520		1583	CNP, 2',3'-cyclic nucleotide 3' phosphodiesterase	TCTACTGGCT [C/G] TCTAACTAAT	?	C	G	?	?
G2448u1	WIAF-13973	U46689		1895	ALDH10, aldehyde dehydrogenase 10 (fatty aldehyde dehydrogenase)	TTGTCAAGGC [A/T] GAATATTACT	S	A	T	A	A
G2457u1	WIAF-13898	U90277		1304	GRIN2A, glutamate receptor, ionotropic, N-methyl D-aspartate 2A	GCTCCCGATG [C/T] ACACCTTGCA	M	C	T	H	Y
G2457u2	WIAF-13899	U90277		1934	GRIN2A, glutamate receptor, ionotropic, N-methyl D-aspartate 2A	AAGAAGTAAT [G/T] GCACCGTCTC	M	G	T	G	C
G2457u3	WIAF-13900	U90277		2230	GRIN2A, glutamate receptor, ionotropic, N-methyl D-aspartate 2A	TCGCTGTTCAT [A/G] TTCTGGCTA	M	A	G	I	M
G2457u4	WIAF-13902	U90277		2916	GRIN2A, glutamate receptor, ionotropic, N-methyl D-aspartate 2A	GGCATCTACA [G/A] CTGCATTTCAT	M	G	A	S	N
G2457u5	WIAF-13903	U90277		3251	GRIN2A, glutamate receptor, ionotropic, N-methyl D-aspartate 2A	CTATGTATTTC [C/T] AGGGACAACA	N	C	T	Q	*
G2457u6	WIAF-13917	U90277		2756	GRIN2A, glutamate receptor, ionotropic, N-methyl D-aspartate 2A	GGACATTGAC [A/G] ACATGGCGGG	M	A	G	N	D
G2468u1	WIAF-13642	X04011		1017	CYBB, cytochrome b-245, beta polypeptide (chronic granulomatous disease)	ACGTGTCCAA [G/A] CTGGAGTGCC	S	G	A	K	K

G2473u1	WIAF-13670	X06990		1417	ICAM1, intercellular adhesion molecule 1 (CD54), human rhinovirus receptor	GGTCACCGC [G/A] AGGTGACCGT	M	G	A	E	K
G2473u2	WIAF-13695	X06990		179	ICAM1, intercellular adhesion molecule 1 (CD54), human rhinovirus receptor	GACCAGCCCA [A/T] GTTGTGGGC	M	A	T	K	M
G2480u1	WIAF-14148	X55330		800	AGA, aspartylglucosaminidase	TTGCCATGGT [T/G] GTAATCCATA	S	T	G	V	V
G2480u2	WIAF-14149	X55330		852	AGA, aspartylglucosaminidase	AAATGGTATA [A/T] AATTCAAAT	N	A	T	K	*
G2480u3	WIAF-14158	X55330		616	AGA, aspartylglucosaminidase	TTATCTACCA [G/C] TGCTTCTCAA	M	G	C	S	T
G2485u1	WIAF-13612	X59543		2301	RRM1, ribonucleotide reductase M1 polypeptide	ATTGATCAAA [G/A] CCAATCTTTG	M	G	A	S	N
G2485u2	WIAF-13613	X59543		2410	RRM1, ribonucleotide reductase M1 polypeptide	ATTTAAGGAC [G/A] AGACCAGCAG	S	G	A	T	T
G2485u3	WIAF-13651	X59543		548	RRM1, ribonucleotide reductase M1 polypeptide	CAAGTCAACA [T/C] TGGATATTGT	S	T	C	L	L
G2485u4	WIAF-13652	X59543		199	RRM1, ribonucleotide reductase M1 polypeptide	TGCATGTGAT [C/T] AAGCGAGATG	S	C	T	I	I
G2485u5	WIAF-13653	X59543		1037	RRM1, ribonucleotide reductase M1 polypeptide	CAACACAGCT [C/A] GATATGTGGA	S	C	A	R	R
G2485u6	WIAF-13660	X59543		1955	RRM1, ribonucleotide reductase M1 polypeptide	GAAGATTGCA [A/C] AGTATGGTAT	M	A	C	K	Q
G2485u7	WIAF-13877	X59543		860	RRM1, ribonucleotide reductase M1 polypeptide	CAGTATGAAA [G/C] ATGACAGCAT	M	G	C	D	H
G2486u1	WIAF-14075	X59618		543	RRM2, ribonucleotide reductase M2 polypeptide	TCAGCACTGG [G/C] AATCCCTGAA	M	G	C	E	Q
G2486u2	WIAF-14076	X59618		189	RRM2, ribonucleotide reductase M2 polypeptide	TCGCTGGGCC [T/G] CCACTATGCT	-	T	G	-	-
G2486u3	WIAF-14092	X59618		524	RRM2, ribonucleotide reductase M2 polypeptide	TTGACCTCTC [C/G] AAGGACATTC	S	C	G	S	S
G2488u1	WIAF-13585	X63563		1633	POLR2B, polymerase (RNA) II (DNA directed) polypeptide B (140kD)	CCTTGATGGC [G/A] TATATTTCAG	S	G	A	A	A

G2488u2	WIAF-13586	XG3563		POLR2B, polymerase (RNA) II (DNA directed) polypeptide B (140kD)	2452	CTGTAGACCG [C/T]GGCTTCTTCA	S	C	T	R	R
G2488u3	WIAF-13587	XG3563		POLR2B, polymerase (RNA) II (DNA directed) polypeptide B (140kD)	2740	TCAGAACTAG [T/C]GAGACGGCA	S	T	C	S	S
G2488u4	WIAF-13602	XG3563		POLR2B, polymerase (RNA) II (DNA directed) polypeptide B (140kD)	1411	GGGGTGATCA [A/G]AAGAAAGCTC	S	A	G	Q	Q
G2488u5	WIAF-13603	XG3563		POLR2B, polymerase (RNA) II (DNA directed) polypeptide B (140kD)	2366	CAATTGTGSC [C/T]ATTGCATCAT	S	C	T	A	A
G2489u1	WIAF-14181	XG3564		POLR2A, polymerase (RNA) II (DNA directed) polypeptide A (220kD)	1346	TGGTGGCAA [T/C]GAGCTGCCCTG	S	T	C	N	N
G2489u2	WIAF-14236	XG3564		POLR2A, polymerase (RNA) II (DNA directed) polypeptide A (220kD)	1847	TGAATCTTAG [C/T]GTGCAAACTC	?	C	T	?	?
G2489u3	WIAF-14237	XG3564		POLR2A, polymerase (RNA) II (DNA directed) polypeptide A (220kD)	2678	CTGAATAACAA [C/T]AACTTCAAGT	?	C	T	?	?
G2489u4	WIAF-14238	XG3564		POLR2A, polymerase (RNA) II (DNA directed) polypeptide A (220kD)	3059	AGCTGGCTA [C/T]GGCGAAGACG	?	C	T	?	?
G2489u5	WIAF-14239	XG3564		POLR2A, polymerase (RNA) II (DNA directed) polypeptide A (220kD)	3827	TGGGCCAGTC [C/T]GCTCGAGATG	?	C	T	?	?
G2489u6	WIAF-14240	XG3564		POLR2A, polymerase (RNA) II (DNA directed) polypeptide A (220kD)	3992	TGCCTGACTT [T/C]GATGTGGCC	?	T	C	?	?
G2489u7	WIAF-14245	XG3564		POLR2A, polymerase (RNA) II (DNA directed) polypeptide A (220kD)	3938	CCCAGAGCAC [G/A]GTGGTGGCAG	?	G	A	?	?
G250u1	WIAF-11696	HT0155		IL3RA, interleukin 3 receptor, alpha (low affinity)	1113	CTGTGTCTTC [G/C]TGATCTGCAG	M	G	C	V	L
G251u1	WIAF-11666	HT0240		179 interleukin 1 beta convertase	179	TGGATAAGAC [C/T]CGAGCTTTGA	S	C	T	T	T

G251u2	WIAF-11694	HT0240	973	interleukin 1 beta convertase	GATGCTATTA [A/G] GAAAGCCAC	M	A	G	K	R
G251u3	WIAF-11695	HT0240	783	interleukin 1 beta convertase	CCCAGATATA [C/T] TACAACTCAA	S	C	T	L	L
G2513u1	WIAF-13736	HT27365	1721	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	AACTATCTAT [G/A] AAAAGCCAAA	M	G	A	M	I
G2513u2	WIAF-13737	HT27365	1741	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	AACTATTGGG [A/T] AATGTGTTC	M	A	T	E	V
G2513u3	WIAF-13738	HT27365	1697	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	AATCTGTTC [A/G] TACAGGAGTT	S	A	G	Q	Q
G2513u4	WIAF-13739	HT27365	1908	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	CTGTCAAGATT [G/A] TAGCAATGAA	M	G	A	V	I
G2513u5	WIAF-13740	HT27365	2172	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	TATAGAGATA [C/T] ACGGAATTCC	M	C	T	H	Y
G2513u6	WIAF-13744	HT27365	3019	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	TTGAAGGGCC [A/G] AGGAGATCTG	M	A	G	Q	R
G2513u7	WIAF-13745	HT27365	3024	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	GGCCCAAGGA [G/A] ATCTGTTGAA	M	G	A	D	N
G2513u8	WIAF-13771	HT27365	1079	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	ACATTTTGA [T/C] CCTGAGCCAA	S	T	C	D	D

G2513u9	WIAF-13772	HT27365	1546	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	AAGTTGCCTT [C/T] TGATCCAGAT	M	C	T	S	F
G2513u10	WIAF-13773	HT27365	1514	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	AATTAAAAAG [A/T] ATGATCATTG	M	A	T	R	S
G2513u11	WIAF-13774	HT27365	1445	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	AGGTCTTTGG [C/T] AATAAATCT	S	C	T	G	G
G2513u12	WIAF-13778	HT27365	2087	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	TTCATATCAA [G/A] ATCATCAGTG	S	G	A	K	K
G2513u13	WIAF-13779	HT27365	2367	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	TGAATGTTTG [C/T] AGCCTGGATA	N	C	T	Q	*
G2513u14	WIAF-13782	HT27365	2719	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	CTCATCACCA [G/A] TGACAACTACT	M	G	A	S	N
G2513u15	WIAF-13783	HT27365	2567	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	TTGATGACAT [C/T] TTAAAAATAG	S	C	T	I	I
G2513u16	WIAF-13784	HT27365	2864	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	TGAAATGGC [G/A] GACACAGTCC	S	G	A	A	A
G2513u17	WIAF-13785	HT27365	2571	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	TGACATCTTT [A/T] AAATAGCGGT	N	A	T	K	*



G2513u18	WIAF-113786	HT27365	2706	PLCB3, phospholipase C, beta 3 (phosphatidylinositol-specific)	TCGTGTCATCT [C/T] GGCTCATCAC	M	C	T	R	W
G252u1	WIAF-10195	HT0425	397	FCER2, Fc fragment of IgE, low affinity II, receptor for (CD23A)	GAGGGCTGCC [C/T] GGNACGTCTC	M	C	T	R	W
G252u2	WIAF-10206	HT0425	930	FCER2, Fc fragment of IgE, low affinity II, receptor for (CD23A)	ATGGGAGCCA [T/C] GTGGACTACA	S	T	C	H	H
G253u1	WIAF-10175	HT0573	228	IFNB1, interferon, beta 1, fibroblast	GGCTTGAATA [C/T] TGCCTCAAGG	S	C	T	Y	Y
G254u1	WIAF-10196	HT0611	466	IL4R, interleukin 4 receptor	TCAGTCCGGA [T/C] AACTATACAC	S	T	C	D	D
G254u2	WIAF-10198	HT0611	1474	IL4R, interleukin 4 receptor	CATGCCCTTCT [T/C] CCACCTTCGG	S	T	C	L	L
G254u3	WIAF-10207	HT0611	1902	IL4R, interleukin 4 receptor	AGTGGCTATC [A/G] GGAGTTTGTA	M	A	G	Q	R
G260u1	WIAF-10186	HT1090	453	IL1R1, interleukin 1 receptor, type I	TGTTATAATG [C/G] ACAAGCCATA	M	C	G	A	G
G261u1	WIAF-10187	HT1101	434	IL7R, interleukin 7 receptor	CCTGAGTGTC [A/G] TCTATCGGGA	M	A	G	I	V
G261u2	WIAF-10203	HT1101	517	IL7R, interleukin 7 receptor	TTTATATGCA [T/C] GATGTAGCTT	S	T	C	H	H
G267u1	WIAF-11735	HT1877	881	IL2RB, interleukin 2 receptor, beta	TCCTCGTGGG [C/T] CTCAGCGGGG	S	C	T	G	G
G267u2	WIAF-11759	HT1877	379	IL2RB, interleukin 2 receptor, beta	AGTCAAGCAT [C/T] CTGGGGCTGC	M	C	T	S	F
G268u1	WIAF-11758	HT1985	568	CD19 antigen	GCCTCCGTGT [G/C] TCCCACCGAG	M	G	C	V	L
G268u2	WIAF-11734	HT1985	783	CD19 antigen	ACGATCGCCC [G/T] GCCAGAGATA	S	G	T	P	P
G270u1	WIAF-11736	HT2415	530	IL6R, interleukin 6 receptor	AGGAGTGGC [A/G] AGAGGCGTGC	S	A	G	A	A
G270u2	WIAF-11760	HT2415	1590	IL6R, interleukin 6 receptor	CATTGCCATT [G/A] TTCTGAGGTT	M	G	A	V	I
G270u3	WIAF-11737	HT2415	1510	IL6R, interleukin 6 receptor	CCAGTGCAG [A/C] TTCTTCTTCA	M	A	C	D	A
G270u4	WIAF-11761	HT2415	1451	IL6R, interleukin 6 receptor	CTACTAATAA [A/T] GACGATGATA	M	A	T	K	N

G270u5	WIAP-11766	HT2415	1843	IL6R, interleukin 6 receptor	TTCCCCAGAT [A/G] GCTGGTGCGG	N	A	G	*	W
G270u6	WIAP-11767	HT2415	1829	IL6R, interleukin 6 receptor	ATACAGACTA [C/T] TTCTTCCCA	S	C	T	Y	Y
G271u1	WIAP-11762	HT2531	577	CD2, CD2 antigen (p50), sheep red blood cell receptor	TCAGAGGGTC [A/G] TCACACACAA	M	A	G	I	V
G271u2	WIAP-11739	HT2531	861	CD2, CD2 antigen (p50), sheep red blood cell receptor	GGAGCCCCA [A/C] CAAATTCAG	M	A	C	X	H
G271u3	WIAP-11768	HT2531	818	CD2, CD2 antigen (p50), sheep red blood cell receptor	CTGGAGACAA [G/A] AGCCCCACAGA	M	G	A	R	K
G271u4	WIAP-11738	HT2531	736	CD2, CD2 antigen (p50), sheep red blood cell receptor	CCTCTTGATG [G/A] TCTTTGTGGC	M	G	A	V	I
G273u1	WIAP-11783	HT3139	667	IL2RA, interleukin 2 receptor, alpha	ATCATGTGTC [C/T] TGGCTGCCAG	M	C	T	P	L
G273u2	WIAP-11764	HT3139	956	IL2RA, interleukin 2 receptor, alpha	AAATCCAAAT [G/C] CAGCCAGTGG	M	G	C	M	I
G273u3	WIAP-11765	HT3139	701	IL2RA, interleukin 2 receptor, alpha	ACGATGACCC [G/A] CCAGAGATCC	S	G	A	P	P
G273u4	WIAP-11740	HT3139	1133	IL2RA, interleukin 2 receptor, alpha	AAATGACCCA [C/T] GGGAGACAA	S	C	T	H	H
G273u5	WIAP-11769	HT3139	1163	IL2RA, interleukin 2 receptor, alpha	AGCCCCAGCT [C/A] ATATGCCACAG	S	C	A	L	L
G276u1	WIAP-10192	HT3670	644	CD4 antigen	CTGGTAGTAG [C/G] CCTCAGTGC	M	C	G	S	R
G276u2	WIAP-10193	HT3670	1535	CD4 antigen	CCTGCCAGTG [T/C] CCTCACCGGT	S	T	C	C	C
G276u3	WIAP-10205	HT3670	1217	CD4 antigen	TGATGCTGAG [T/C] TTGAAACTGG	S	T	C	S	S
G277u1	WIAP-10007	D10232	851	RENBP, renin-binding protein	CACGTGATTG [A/G] CAAGTTCCTA	M	A	G	D	G
G277u2	WIAP-10032	D10232	842	RENBP, renin-binding protein	CTTCAGGCC [A/G] CGTGATTGAC	M	A	G	H	R
G277u3	WIAP-10042	D10232	634	RENBP, renin-binding protein	GCTGGGGGC [A/G] AATAGCAGA	M	A	G	K	E
G279u1	WIAP-10047	K01740	1658(A)	F8C, coagulation factor VIIc, procoagulant component (hemophilia)	ACTGATGTCC [G/A] TCCTTTGTAT	M	G	A	R	H

G279u2	WIAF-10049	K01740	2328 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	CCTTACTGAA [G/A] GTTCTAGTT	S	G	A	K	K
G279u3	WIAF-10050	K01740	4650 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	CTGTTCTCCC [G/A] AAACCAGACT	S	G	A	P	P
G279u4	WIAF-10061	K01740	6919 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	CCAGAGACA [A/G] TGAAGTCAC	M	A	G	M	V
G279u5	WIAF-10080	K01740	480 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	TTAAGAACAT [G/A] GCTTCCCATC	M	G	A	M	I
G279u6	WIAF-10082	K01740	2129 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	TGATTCTTAA [G/A] CATGGAGCA	M	G	A	S	N
G279u7	WIAF-10084	K01740	2533 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	GTTGCACAC [A/G] GACACCTAT	M	A	G	R	G
G279u8	WIAF-10086	K01740	6639 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	ACCTCCAAT [T/C] ATTGCTGAT	S	T	C	I	I
G279u9	WIAF-10087	K01740	5957 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	GAGAATTATC [G/A] CTTCCATGCA	M	G	A	R	H
G279a10	WIAF-10495	K01740	5829 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	TGACAGTACA [G/A] GAATTGCTC	S	G	A	Q	Q
G279a11	WIAF-10496	K01740	5852 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	TTTTTCACCA [T/G] CTTTGATGAG	M	T	G	I	S
G279a12	WIAF-10502	K01740	2492 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	ACCACRAATC [C/T] AGAARATGAC	M	C	T	P	L
G279a13	WIAF-10503	K01740	6906 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	TGCAAGTGGA [C/T] TTCCAGAAGA	S	C	T	D	D
G279a14	WIAF-13120	K01740	1980 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia)	CAGAGAATAT [A/C] CAACGCTTTC	S	A	C	I	I

-111-

G272a15	WIAF-13121	K01740	1982 A)	F8C, coagulation factor VIIIc, procoagulant component (hemophilia A)	GAGAATATAC [A/C] ACCTTTCTC	M	A	C	Q	P
G282u1	WIAF-10067	L25615	976	AVPR1A, arginine vasopressin receptor 1A	CGCTTTCTT [C/A] ATCATCCAGA	M	C	A	F	L
G282u2	WIAF-10070	L25615	460	AVPR1A, arginine vasopressin receptor 1A	TCCGCATGTT [T/C] GCCTCGCCT	S	T	C	F	F
G282u3	WIAF-10071	L25615	343	AVPR1A, arginine vasopressin receptor 1A	GCCTGGCCGA [C/T] CTGGCCGTGG	S	C	T	D	D
G282u4	WIAF-10072	L25615	68	AVPR1A, arginine vasopressin receptor 1A	TCTCTCGCC [G/A] GTCCCGACGC	M	G	A	G	S
G282u5	WIAF-10073	L25615	535	AVPR1A, arginine vasopressin receptor 1A	AGACTCTGCA [A/G] CAGCCCGCGC	S	A	G	Q	Q
G282u6	WIAF-10092	L25615	1075	AVPR1A, arginine vasopressin receptor 1A	CCTTGATAG [C/A] TGCTGTATC	M	C	A	S	R
G282a7	WIAF-10499	L25615	1089	AVPR1A, arginine vasopressin receptor 1A	TGTAATCCCT [G/A] GATATACATG	N	G	A	W	*
G284u1	WIAF-10182	M16827	1179	ACADM, acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain	AATATCTCTGT [A/G] GAAAAACTAA	S	A	G	V	V
G284a2	WIAF-10515	M16827	696	ACADM, acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain	TTGTGGAGGC [A/G] GATACCCAG	S	A	G	A	A
G285u1	WIAF-10108	M28172	258	ZNF9, zinc finger protein 9 (a cellular retroviral nucleic acid binding protein)	CTCTCCAGA [T/C] ATTTGTATC	S	T	C	D	D
G289u1	WIAF-10041	M63012	172	PON1, paraoxonase 1	CTCTGAAGAC [A/T] TGGAGATACT	M	A	T	M	L
G290u1	WIAF-10085	M63959	354	LRPAP1, low density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1)	CTCATAGCA [A/G] CCTCAATGTC	M	A	G	N	S

G290a2	WIAF-13122	M63959			LRPAP1, low density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1)	223	AGCGACTGCA [T/A] CTTCCTCCCG	M	T	A	H	Q
G292u1	WIAF-10180	M74096			ACADL, acyl-Coenzyme A dehydrogenase, long chain	1002	AGTGCAACAT [A/C] AATTAGCAGA	M	A	C	K	Q
G293u1	WIAF-10068	M74775			LIPA, lipase A, lysosomal acid, cholesterol esterase (Wolman disease)	723	AAGGACTTAT [T/C] TGGAGACAAA	M	T	C	F	S
G293a2	WIAF-10497	M74775			LIPA, lipase A, lysosomal acid, cholesterol esterase (Wolman disease)	107	TGAGGGGTCT [G/A] GAGGAAACT	M	G	A	G	R
G293a3	WIAF-10498	M74775			LIPA, lipase A, lysosomal acid, cholesterol esterase (Wolman disease)	86	GGTTCTCTGG [C/A] CCCTGCATTC	M	C	A	P	T
G295u1	WIAF-10057	U04270			KCNH2, potassium voltage-gated channel, subfamily H, member 2	1282	AAAGGAGCGA [A/T] CCCACAATGT	M	A	T	T	S
G295u2	WIAF-10062	U04270			KCNH2, potassium voltage-gated channel, subfamily H, member 2	1875	CGCACTGGCT [A/G] GCCTGCATCT	S	A	G	L	L
G295u3	WIAF-10064	U04270			KCNH2, potassium voltage-gated channel, subfamily H, member 2	2040	ACTTCACCTT [C/T] AGCAGCCTCA	S	C	T	P	F
G295u4	WIAF-10088	U04270			KCNH2, potassium voltage-gated channel, subfamily H, member 2	1650	CCGGCCGCAT [C/T] GCCGTCCACT	S	C	T	I	I
G295u5	WIAF-10090	U04270			KCNH2, potassium voltage-gated channel, subfamily H, member 2	2139	CCCTCATGTA [T/C] GCTAGCATCT	S	T	C	Y	Y
G2951u1	WIAF-14147	HT0030			ZNF42, zinc finger protein 42 (myeloid-specific retinoic acid-responsive)	1334	CCCTGCTCTG [A/G] TCACCACCG	M	A	G	I	V

G2951u2	WIAF-14157	HT0030		1558	ZNF42, zinc finger protein 42 (myeloid-specific retinoic acid- responsive)	ACCAGCTTAC [G/A] CACACGAGG	S	G	A	T	T
G2959u1	WIAF-13501	HT0134		1014	GRLF1, glucocorticoid receptor DNA binding factor 1	GTGGAGAGAC [T/C] CTGCATAGCT	S	T	C	T	T
G2959u2	WIAF-13518	HT0134		1853	GRLF1, glucocorticoid receptor DNA binding factor 1	GAGCCATCTT [A/C] CAGCCTGTTT	M	A	C	Y	S
G296a1	WIAF-10514	U12778		961	ACADSB, acyl-Coenzyme A dehydrogenase, short/branched chain	TATTCATAT [A/G] TTAAGAAG	M	A	G	I	V
G2968u1	WIAF-12699	HT0244		1754	SMARCA1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1	CAGAAGAAAC [C/T] AGTACGTGTA	M	C	T	P	L
G2968u2	WIAF-12716	HT0244		2624	SMARCA1, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1	TGGGAACGTT [G/T] CAATGAATTA	M	G	T	C	P
G297u1	WIAF-10109	U16660		402	ECH1, enoyl Coenzyme A hydratase 1, peroxisomal	ACATGGCTTC [G/A] GACATCCTGC	S	G	A	S	S
G297u2	WIAF-10110	U16660		149	ECH1, enoyl Coenzyme A hydratase 1, peroxisomal	GCACAAGAGG [A/C] GGCCTCCGGA	M	A	C	E	A
G2970u1	WIAF-12746	HT0281		682	BR140: bromodomain-containing protein, 140kD (peregryn)	ATGACATGGA [C/T] GAGGAGGACT	S	C	T	D	D
G2975u1	WIAF-12729	HT0334		1104	B-cell-specific transcription factor	AGTTTCCCG [G/A] AGTCCCTACA	S	G	A	G	G
G2975u2	WIAF-12730	HT0334		1185	B-cell-specific transcription factor	GCTCCCCCTA [C/T] TATTATAGCG	S	C	T	Y	Y
G2976a1	WIAF-12129	HT0340		1600	SATB1, special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaffold- associating DNA's)	GTCTGCCCC [C/A] CTCATCAGCA	S	C	A	P	P

G2976u2	WIAF-12743	HT0340	2116	SATB1, special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaffold-associating DNA's)	TGGCCTCTCC [A/G]GCAGAGTCAG	S	A	G	P	P
G2978u1	WIAF-12721	HT0346	1140	MSX1, msh (Drosophila) homeo box homolog 1 (formerly homeo box 7)	CATAGAGGGT [C/T]CCAGGTCCCC	-	C	T	-	-
G298u1	WIAF-10048	U33837	8995	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	CCGGACAGGA [G/A]GTGCATTCCC	M	G	A	R	K
G298u2	WIAF-10051	U33837	13217	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	ATGCAGCCAT [C/T]GAACGCGCTA	S	C	T	I	I
G298u3	WIAF-10077	U33837	6298	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	AACTCTTTCA [T/C]TGTTGTTTCA	M	T	C	I	T
G298u4	WIAF-10078	U33837	6371	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	CCATGGTGCC [G/A]GTGGCAGGCC	S	G	A	P	P
G298u5	WIAF-10079	U33837	6914	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	ACTCTGAAGT [G/A]ATTGCTTATG	S	G	A	V	V
G298u6	WIAF-10081	U33837	8718	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	GTTCCAAATGC [G/A]CATCTGGCG	M	G	A	A	T
G298u7	WIAF-10083	U33837	9088	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	ACTTGCTCTG [A/G]AAATGAATTC	M	A	G	E	G
G298u8	WIAF-10096	U33837	6949	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	ACTCCTTATG [G/C]CATCACTGTT	M	G	C	G	A
G298u9	WIAF-10097	U33837	7149	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	TTGCTTGGAA [A/G]ACAATGGTGG	M	A	G	N	D
G298u10	WIAF-10100	U33837	8590	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	TACACAAAT [G/A]TCATAATTCA	M	G	A	C	Y

G2980u1	WIAF-10101	U33837	12948	Human glycoprotein receptor gp330 precursor, mRNA, complete cds.	CATCTTTGAA[G/C]ACCAGTTATA	M	G	C	D	H
G2980u1	WIAF-12723	HT0356	437 E(spl)	TLE1, transducin-like enhancer of split 1, homolog of Drosophila	TCATGCCAC[G/A]GACCCCACTG	M	G	A	G	R
G2980u2	WIAF-12726	HT0356	2044 E(spl)	TLE1, transducin-like enhancer of split 1, homolog of Drosophila	ACTGGCTGGC[A/G]GTGGGCATGG	S	A	G	A	A
G2980u3	WIAF-12747	HT0356	379 E(spl)	TLE1, transducin-like enhancer of split 1, homolog of Drosophila	CCATGGCAGA[G/A]TTGAATGCCA	S	G	A	B	B
G2980u4	WIAF-12748	HT0356	276 E(spl)	TLE1, transducin-like enhancer of split 1, homolog of Drosophila	ATCGCCCAAG[G/A]ATTGAATACG	M	G	A	R	K
G2980u5	WIAF-12749	HT0356	1876 E(spl)	TLE1, transducin-like enhancer of split 1, homolog of Drosophila	GCCACACAGA[C/T]GGAGCCAGCT	S	C	T	D	D
G2980u6	WIAF-12750	HT0356	1759 E(spl)	TLE1, transducin-like enhancer of split 1, homolog of Drosophila	CCGCCCTGCTA[C/T]GCCCTGGCCA	S	C	T	Y	Y
G2981u1	WIAF-12720	HT0357	2206 E(spl)	TLE2, transducin-like enhancer of split 2, homolog of Drosophila	ACAAATACAT[T/C]GTGACAGGCT	S	T	C	I	I
G2981u2	WIAF-12737	HT0357	1036 E(spl)	TLE2, transducin-like enhancer of split 2, homolog of Drosophila	CGGACAGCGT[C/T]GCCCTGAGGA	S	C	T	V	V
G2981u3	WIAF-12740	HT0357	2181 E(spl)	TLE2, transducin-like enhancer of split 2, homolog of Drosophila	CTGAGTTGTG[A/T]CATCTCCAGA	M	A	T	D	V



G2983u1	WIAF-12833	HT0360		636 E(sp1)	TLE3, transducin-like enhancer of split 3, homolog of Drosophila	TGTCACCCCTC[G/C]GAAAGCCTCC	S	G	C	S	S
G2983u2	WIAF-12834	HT0360		1944 E(sp1)	TLE3, transducin-like enhancer of split 3, homolog of Drosophila	TGGACAACAC[G/A]GTGGCTCCT	S	G	A	T	T
G2983u3	WIAF-12848	HT0360		1710 E(sp1)	TLE3, transducin-like enhancer of split 3, homolog of Drosophila	ACCTGGCCTC[G/A]CCCAGCCCC	S	G	A	S	S
G2985u1	WIAF-12724	HT0421		995	homeotic protein D3	GGCTTGGCCA[G/A]CGCCACCTG	M	G	A	S	N
G2985u2	WIAF-12725	HT0421		1003	homeotic protein D3	CAGCGCAAC[C/T]TGCAGGGCAG	S	C	T	L	L
G2986u1	WIAF-14124	HT0468		1197	CSDA, cold shock domain protein A	GCCGTGGATA[C/T]CGGCGTCCCT	S	C	T	Y	Y
G2987u1	WIAF-12758	HT0474		2068	ZNF7, zinc finger protein 7 (KOX 4, clone HF.16)	AGTGGTTTTC[C/T]GAATATGGGA	S	C	T	Y	Y
G2987u2	WIAF-12773	HT0474		985	ZNF7, zinc finger protein 7 (KOX 4, clone HF.16)	GAGAGAAGCC[G/C]TACGAATGTG	S	G	C	P	P
G2987u3	WIAF-12775	HT0474		1278	ZNF7, zinc finger protein 7 (KOX 4, clone HF.16)	AGCCAGCAGT[C/T]GCAGCTGGTT	M	C	T	S	L
G3005a1	WIAF-12133	HT0735		1441	homeotic protein 5.1	GAGGCAGCGG[C/T]CCCGGGCCTG	S	C	T	G	G
G3008a1	WIAF-12134	HT0753		1850	ATF4, activating transcription factor 4 (tax-responsive enhancer element B67)	TAAAGAGAG[G/A]CCGGATTCCC	S	G	A	R	R
G3008u2	WIAF-12798	HT0753		946	ATF4, activating transcription factor 4 (tax-responsive enhancer element B67)	CCCTTCGACC[C/A]GTCGGGTTTG	M	C	A	P	Q
G3008u3	WIAF-12812	HT0753		1482	ATF4, activating transcription factor 4 (tax-responsive enhancer element B67)	CACTGCTTAC[G/A]TTGCCATGAT	M	G	A	V	I
G3008u4	WIAF-12813	HT0753		1847	ATF4, activating transcription factor 4 (tax-responsive enhancer element B67)	CTCTAAAGA[G/C]AGGCGGATT	M	G	C	E	D

G3301u1	WIAP-10127	U71295			3639	MTR, 5-methyltetrahydrofolate-homocysteine methyltransferase	TGTGGAGACT [C/T] GCAGACATCG	S	C	T	L	L
G33012u1	WIAP-12794	HT0873			402	MAD, MAX dimerization protein	TGGTGCCACT [G/T] GGACCCGAAT	S	G	T	L	L
G3014u1	WIAP-14183	HT0899			274	homeotic protein 2, distal-less	AAAAGACTCA [G/A] TACTTGGCCT	S	G	A	Q	Q
G3020u1	WIAP-12797	HT0956			852	MLLT3, myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 3	GTGCTTCAA [A/G] GAACCTTCCA	S	A	G	K	K
G3023u1	WIAP-13724	HT0966			391	zinc finger, X-linked, duplicated	GCTGCAGCAA [G/A] CAATATGACA	S	G	A	K	K
G3023u2	WIAP-13725	HT0966			220	zinc finger, X-linked, duplicated	GGCCAAATCT [G/A] GCGCCACCA	M	G	A	G	S
G3023u3	WIAP-13726	HT0966			69	zinc finger, X-linked, duplicated	AGTCGCACGA [T/C] AAATCGGCGC	S	T	C	D	D
G3023u4	WIAP-13727	HT0966			249	zinc finger, X-linked, duplicated	ACTTCGAACC [C/T] GAGAGGCCTT	S	C	T	P	P
G3023u5	WIAP-13765	HT0966			661	zinc finger, X-linked, duplicated	CAGGTTCTCT [G/A] CTCGCAGTAG	M	G	A	A	T
G3023u6	WIAP-13766	HT0966			1302	zinc finger, X-linked, duplicated	TGACTCTTTC [G/T] AGCACCCTTT	S	G	T	S	S
G3027u1	WIAP-12800	HT1035			124	HOXB7, homeo box B7	TTATCGGAAT [G/A] CTTATTTTC	M	G	A	A	T
G3027u2	WIAP-12816	HT1035			450	HOXB7, homeo box B7	GGGACTCGGA [C/T] TTGGCGGCG	S	C	T	D	D
G3028u1	WIAP-12806	HT1037			701	homeotic protein C8	AGACCTTGA [A/G] CTGGAGAAGG	S	A	G	E	E
G3029u1	WIAP-14153	HT1100			441	zinc finger protein 8	TCAGACTCAG [G/A] GAAAACTGGG	S	G	A	R	R
G3029u2	WIAP-14155	HT1100			1416	zinc finger protein 8	GGCGTGAACA [A/G] TCCTCGAGCA	S	A	G	Q	Q
G303u1	WIAP-10000	X13916			4110	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	ATGGAGCTGG [G/A] GCCCGACAAAC	M	G	A	G	E
G303u2	WIAP-10001	X13916			4012	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	GCGAGCTCTG [C/T] GACCAGTGCT	S	C	T	C	C

-118-

G303u3	WIAP-10002	X13916	4702	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	GCCTGCCCG [C/T]ATTGAGCAG	S	C	T	R	R
G303u4	WIAP-10003	X13916	6395	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	CTGGATCGCA [G/A]GCAACATCTA	M	G	A	G	S
G303u5	WIAP-10004	X13916	6937	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	AAGCACCAA [C/T]GTGTGCGCG	S	C	T	N	N
G303u6	WIAP-10005	X13916	9391	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	GGCTGAAGGA [T/C]GACGGCCGGA	S	T	C	D	D
G303u7	WIAP-10011	X13916	766	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	ACTGCATGGA [C/T]GGCTCAGATG	S	C	T	D	D
G303u8	WIAP-10015	X13916	9040	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	ACCCGACCTG [C/T]GGCCGCCAGTG	S	C	T	C	C
G303u9	WIAP-10019	X13916	11749	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	CCCTGGCGTG [C/T]AACATGTTTG	S	C	T	C	C
G303u10	WIAP-10020	X13916	1917	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	GACCAGTATG [G/A]GAAGCCGGGT	M	G	A	G	E
G303u11	WIAP-10021	X13916	4810	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	AGAAGGCCAT [C/T]CTTTGGATTG	S	C	T	I	I

-119-

G303u12	WIAP-10022	X13916		6367	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	TTGGCCGTGT [G/C] GAGGGCATTG	S	G	C	V	V
G303u13	WIAP-10023	X13916		6247	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	CTGTGGCAT [C/T] GACTTCCACG	S	C	T	I	I
G303u14	WIAP-10024	X13916		8371	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	ACGCCTCAGA [T/C] GAGATGAACT	S	T	C	D	D
G303u15	WIAP-10030	X13916		11395	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	ACGGCAGCGA [C/T] GAGGAGGCCT	S	C	T	D	D
G303u16	WIAP-10031	X13916		12763	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	ACGTCTTTGA [G/A] GATTACATCT	S	G	A	E	E
G303u17	WIAP-10035	X13916		640	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	ACGGATCTGA [C/T] GAGGCCCTCG	S	C	T	D	D
G303u18	WIAP-10037	X13916		1609	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	GCCGCTTGT [C/T] TACTGGGCAG	S	C	T	V	V
G303u19	WIAP-10038	X13916		1629	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	GATGCTATC [T/G] GGACTATATT	M	T	G	L	R
G303u20	WIAP-10039	X13916		2210	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	CACGAGCTAC [C/T] TCATTGGCCG	M	C	T	L	F

G303u21	WIAF-10043	X13916		7287	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	GATGGCTCCA [G/A]GAGGATCACC	M	G	A	R	K
G303u22	WIAF-10044	X13916		8258	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	CTCTGAGGAG [A/G]TCCCTTGCAA	M	A	G	I	V
G303u23	WIAF-10045	X13916		11871	LRP1, low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)	GTGCGCAGG [A/G]GAAAGCGGCC	M	A	G	E	G
G3031u1	WIAF-14097	HT1128		611	PSMC3, proteasome (prosome, macropain) 26S subunit, ATPase, 3	TGGGATCCA [A/G]CCTCCAAAAG	S	A	G	Q	Q
G3034u1	WIAF-12836	HT1182		137	TCF12, transcription factor 12 (HTF4, helix-loop-helix transcription factors 4)	ATAAGGGAGC [G/A]TGAGGAGTCT	M	G	A	R	H
G3034u2	WIAF-12837	HT1182		421	TCF12, transcription factor 12 (HTF4, helix-loop-helix transcription factors 4)	ATCTTCAATT [A/G]TGGGTTCCCTT	M	A	G	M	V
G3038u1	WIAF-12864	HT1373		1700	NFKB1, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	AGAGAAGGCT [A/G]TGCAGCTTGC	M	A	G	M	V
G3038u2	WIAF-12881	HT1373		1936	NFKB1, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	TGTACCAGAC [G/A]CCCTTGCACT	S	G	A	T	T
G3038u3	WIAF-12882	HT1373		2641	NFKB1, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	AGCTGCAGCT [G/C]TATAAGTTAC	S	G	C	L	L
G3039u1	WIAF-13027	HT1375		3761	GLI3, GLI-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome)	AACAGCCCCG [G/T]AAGTGGCACC	M	G	T	G	V

G3039u2	WIAF-13028	HT1375	3933	GLI3, Gli-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome)	CGCCAAATGA [G/T]TCAGCTGGCA	M	G	T	E	D
G3040u1	WIAF-12242	HT637	158	FABP3, fatty acid binding protein 3, muscle and heart (mammary- derived growth inhibitor)	CTCACCCCTAA [A/G]AACACACAGC	M	A	G	K	R
G3043u1	WIAF-12867	HT1486	842	IRF2, interferon regulatory factor 2	GTGCCGAGGG [G/A]CGGCCACACT	S	G	A	G	G
G3047u1	WIAF-12875	HT1518	1233	transcription factor 1, nucleolar	TCCGTTTCCT [C/T]GAGAGCCTGC	S	C	T	L	L
G3047u2	WIAF-12876	HT1518	1746	transcription factor 1, nucleolar	GGATTAAGAA [G/A]GCAGCCGAAG	S	G	A	K	K
G3047u3	WIAF-12877	HT1518	1829	transcription factor 1, nucleolar	TCCAAGAGA [T/C]GAAATTCAG	M	T	C	M	T
G3048u1	WIAF-12884	HT1530	628	transcription factor USF	AGTGAGCGT [C/T]GCCGCCGAGA	M	C	T	R	C
G305u1	WIAF-10150	HT0034	777	prolyl 4-hydroxylase, beta subunit/protein disulfide isomerase/thyroid hormone-binding protein, alt. transcript 1	CCCTTGTCAT [C/T]GAGTTCACCG	S	C	T	I	I
G305u2	WIAF-10154	HT0034	186	prolyl 4-hydroxylase, beta subunit/protein disulfide isomerase/thyroid hormone-binding protein, alt. transcript 1	TGGCGGCCCA [C/A]AAGTACCTGC	M	C	A	H	Q
G305u3	WIAF-10155	HT0034	1428	prolyl 4-hydroxylase, beta subunit/protein disulfide isomerase/thyroid hormone-binding protein, alt. transcript 1	GGACGTCAT [T/C]GATTACACG	S	T	C	I	I
G3050u1	WIAF-12860	HT1558	2098	FSRG1: female sterile homeotic- related gene 1 (mouse homolog)	AACATTGCAA [T/C]GSCATTTTGA	S	T	C	N	N
G3050u2	WIAF-12861	HT1558	2845	FSRG1: female sterile homeotic- related gene 1 (mouse homolog)	TAGGCCCTTC [T/C]GGCTTTGGAC	S	T	C	S	S

G3050u3	WIAF-12862	HT1558		3409	FSRG1: female sterile homeotic-related gene 1 (mouse homolog)	CCTCGTGTGTC [G/A] TCTTCAGACA	S	G	A	S	S
G3050u4	WIAF-12874	HT1558		1699	FSRG1: female sterile homeotic-related gene 1 (mouse homolog)	TCTCTTCTGT [G/C] TCACACACAG	S	G	C	V	V
G3050u5	WIAF-12878	HT1558		2093	FSRG1: female sterile homeotic-related gene 1 (mouse homolog)	GTAAACAT [T/C] GCAATGGCAT	M	T	G	C	G
G3050u6	WIAF-12879	HT1558		2746	FSRG1: female sterile homeotic-related gene 1 (mouse homolog)	CTGGGGCCGA [C/T] GAAGATGACA	S	C	T	D	D
G3051u1	WIAF-12866	HT1569		1423	MEF2B, MADS box transcription enhancer factor 2, polypeptide B (myocyte enhancer factor 2B)	CTTGGCCGAC [G/A] GCTGGCCCG	S	G	A	T	T
G3051u2	WIAF-13022	HT1569		661	MEF2B, MADS box transcription enhancer factor 2, polypeptide B (myocyte enhancer factor 2B)	CAGAGTACAG [C/T] GAGCCCCACG	S	C	T	S	S
G3057a1	WIAF-12142	HT1669		5565	alpha-fetoprotein enhancer-binding protein	AGACTGTCTT [T/C] GAGGCTCATA	S	T	C	L	L
G3057a2	WIAF-12143	HT1669		5634	alpha-fetoprotein enhancer-binding protein	CTCTGTCTGC [G/A] ATGCTCTTAG	S	G	A	A	A
G3057a3	WIAF-12144	HT1669		5664	alpha-fetoprotein enhancer-binding protein	GGGACTCCA [G/T] ATGAAGGAG	M	G	T	Q	H
G3057a4	WIAF-12145	HT1669		5703	alpha-fetoprotein enhancer-binding protein	GCTTTTCCA [C/T] CTACCCCAA	S	C	T	H	H
G3057u5	WIAF-12885	HT1669		2227	alpha-fetoprotein enhancer-binding protein	TCTGGAGATC [C/T] ATATGAGGTC	M	C	T	H	Y
G3057u6	WIAF-12892	HT1669		3720	alpha-fetoprotein enhancer-binding protein	AGACTTGGC [G/A] GCTCAGCTAC	S	G	A	P	P
G3057u7	WIAF-12893	HT1669		4137	alpha-fetoprotein enhancer-binding protein	CAAGTTTAC [G/A] GACTACCAGC	S	G	A	T	T
G3057u8	WIAF-12897	HT1669		4783	alpha-fetoprotein enhancer-binding protein	GAAGACCAAC [A/C] CTCGCCAGCA	M	A	C	T	P

G3057u9	WIAP-12898	HT1669	5215	alpha-fetoprotein enhancer-binding protein	TCCACCTCC[A/C]CAATGAACAC	M	A	C	T	P
G3057u10	WIAP-12904	HT1669	7266	alpha-fetoprotein enhancer-binding protein	CCCTGCAGC[C/T]GCGTTGACTT	S	C	T	A	A
G3057u11	WIAP-12907	HT1669	8345	alpha-fetoprotein enhancer-binding protein	CCAACAGAGC[A/C]CTATTGCGAG	M	A	C	D	A
G3057u12	WIAP-12943	HT1669	4257	alpha-fetoprotein enhancer-binding protein	TGGTGTGCTT[T/C]CAGAATGCC	S	T	C	F	F
G3057u13	WIAP-12951	HT1669	7333	alpha-fetoprotein enhancer-binding protein	ACCAGGCTT[T/A]CTCCTTATTA	M	T	A	S	T
G3057u14	WIAP-13030	HT1669	303	alpha-fetoprotein enhancer-binding protein	GCAGCTGTC[G/A]GAGGACGAGT	S	G	A	S	S
G3057u15	WIAP-13031	HT1669	777	alpha-fetoprotein enhancer-binding protein	GCTTCCAGA[G/A]GAGGACGAGG	S	G	A	E	E
G306u1	WIAP-10118	HT0040	1618	CPT2, carnitine palmitoyltransferase II	CTCTACTGCC[G/A]TCCACTTTGA	M	G	A	V	I
G307u1	WIAP-10076	HT0114	110	EDN2, endothelin 2	CGTTGCGCTA[G/A]CCCTGCTGCT	M	G	A	A	T
G3070u1	WIAP-12972	HT2085	625	pre-B-cell leukemia transcription factor 3	AGAAATATGA[A/G]CAGGCATGTA	S	A	G	E	E
G3070u2	WIAP-12973	HT2085	841	pre-B-cell leukemia transcription factor 3	GTAACCTTCAG[T/C]AAACAGGCCA	S	T	C	S	S
G3071u1	WIAP-12886	HT2086	995	AGER, advanced glycosylation end product-specific receptor	CCTGCGAGGC[T/C]GTGATGATCC	S	T	C	A	A
G3071u2	WIAP-12887	HT2086	1475	AGER, advanced glycosylation end product-specific receptor	GAGGCCAGAT[C/G]TACAGCCAC	M	C	G	I	M
G3071u3	WIAP-12935	HT2086	933	AGER, advanced glycosylation end product-specific receptor	ACGCATGCTG[A/G]GCATCATCCA	M	A	G	S	G
G3071u4	WIAP-12936	HT2086	1052	AGER, advanced glycosylation end product-specific receptor	GTAACCTTCAG[C/T]AAACAGGCCA	S	C	T	S	S
G3071u5	WIAP-12937	HT2086	836	AGER, advanced glycosylation end product-specific receptor	AGAAATATGA[G/A]CAGGCATGTA	S	G	A	E	E
G308u1	WIAP-10094	HT0192	484	ANX4, annexin IV (placental anticoagulant protein II)	ATGGACGGAG[C/G]CTTGAAGATG	M	C	G	S	R



G308u2	WIAF-10095	HT0192	333	ANX4, annexin IV (placental anticoagulant protein II)	GGGATGATGA[C/T]GCCACGGTG	M	C	T	T	M
G308u1	WIAF-12997	HT2188	689	PSMC2, proteasome (prosome, macropain) 26S subunit, ATPase, 2	GGCATTGAGC[C/T]TCCCAAGGC	M	C	T	P	L
G308u1	WIAF-12976	HT2228	106	IGHMBP2, immunoglobulin mu binding protein 2	TGCTGGAGCT[T/C]GAGAGAGACG	S	T	C	L	L
G308u2	WIAF-12985	HT2228	2260	IGHMBP2, immunoglobulin mu binding protein 2	TGGAGTTCTAT[G/C]GCCAGCAAGA	M	G	C	M	I
G308u3	WIAF-12986	HT2228	2060	IGHMBP2, immunoglobulin mu binding protein 2	GGGACCTGCT[A/G]CGTCCACCAG	M	A	G	T	A
G308u4	WIAF-12987	HT2228	2365	IGHMBP2, immunoglobulin mu binding protein 2	ACGACAGTTC[C/T]GGGGAAGGGA	S	C	T	S	S
G308u5	WIAF-13005	HT2228	411	IGHMBP2, immunoglobulin mu binding protein 2	TTTGATGAGT[C/T]CCAGATTTC	M	C	T	S	F
G308u6	WIAF-13006	HT2228	272	IGHMBP2, immunoglobulin mu binding protein 2	ATACGGGTCC[G/A]CGGCAGCTCT	M	G	A	A	T
G308u7	WIAF-13010	HT2228	2581	IGHMBP2, immunoglobulin mu binding protein 2	TCAGGAGCGC[G/A]CAGGGCAGC	S	G	A	A	A
G308u8	WIAF-13011	HT2228	2594	IGHMBP2, immunoglobulin mu binding protein 2	GGGCGAGCCCC[G/A]CCAGCAAGGA	M	G	A	A	T
G308u1	WIAF-12984	HT2318	884	HIVEP1, human immunodeficiency virus type I enhancer-binding protein 1	TGTGGCACTA[C/T]GTCCCCCTCC	M	C	T	T	M
G308u2	WIAF-12988	HT2318	2469	HIVEP1, human immunodeficiency virus type I enhancer-binding protein 1	TCTTGTCACTA[A/G]CGTCAACACC	S	A	G	P	P
G308u3	WIAF-12989	HT2318	3066	HIVEP1, human immunodeficiency virus type I enhancer-binding protein 1	TTCTTGGTAC[T/C]GGACAGTCCC	S	T	C	T	T
G308u4	WIAF-12991	HT2318	4008	HIVEP1, human immunodeficiency virus type I enhancer-binding protein 1	TTATCCGGCA[G/T]CACAACATCC	M	G	T	Q	H

-125-

G3088u5	WIAF-12992	HT2318	4880	HIVEp1, human immunodeficiency virus type I enhancer-binding protein 1	CAATCCATG [C/G] ACCGCCTAGC	M	C	G	A	G
G3088u6	WIAF-12993	HT2318	5148	HIVEp1, human immunodeficiency virus type I enhancer-binding protein 1	TTGACAGCAT [G/A] TCTAATTCGC	M	G	A	M	I
G3088u7	WIAF-12999	HT2318	5834	HIVEp1, human immunodeficiency virus type I enhancer-binding protein 1	CCAGCTGATA [A/G] TTCATCAACA	M	A	G	N	S
G3088u8	WIAF-13000	HT2318	6065	HIVEp1, human immunodeficiency virus type I enhancer-binding protein 1	CAAAAGTCAAC [G/A] GCCAGTCACT	M	G	A	R	Q
G3088u9	WIAF-13001	HT2318	7652	HIVEp1, human immunodeficiency virus type I enhancer-binding protein 1	CATAGGAATA [C/T] GGTCAAGAA	M	C	T	T	M
G3088u10	WIAF-13008	HT2318	741	HIVEp1, human immunodeficiency virus type I enhancer-binding protein 1	TTCTGCAGCA [A/G] CCACTGTAAC	S	A	G	Q	Q
G3088u11	WIAF-13009	HT2318	948	HIVEp1, human immunodeficiency virus type I enhancer-binding protein 1	CAGAACTGAG [C/T] ACCTGTGAC	S	C	T	S	S
G3088u12	WIAF-13012	HT2318	1909	HIVEp1, human immunodeficiency virus type I enhancer-binding protein 1	TGAACCTTA [C/T] TAAATCAAG	S	C	T	L	L
G3088u13	WIAF-13013	HT2318	2803	HIVEp1, human immunodeficiency virus type I enhancer-binding protein 1	TCTTCTGTCT [G/A] TACCTTCACT	M	G	A	V	I

G3088u14	WIAF-13015	HT2318	3342	HIVBP1, human immunodeficiency virus type I enhancer-binding protein 1	GCGGTCTGCA [A/G] CCTCAGATTC	S	A	G	Q	Q
G3088u15	WIAF-13016	HT2318	3542	HIVBP1, human immunodeficiency virus type I enhancer-binding protein 1	CCTAAACATA [G/A] TGTTACCATA	M	G	A	S	N
G3088u16	WIAF-13017	HT2318	4972	HIVBP1, human immunodeficiency virus type I enhancer-binding protein 1	TGGGTCTTCT [A/G] AAAGTGAGGA	M	A	G	K	E
G3095u1	WIAF-12994	HT2435	701	TCF2, transcription factor 2, hepatic; LF-B3; variant hepatic nuclear factor	CGCTCTGTGA [C/T] ACCTGGTACG	S	C	T	Y	Y
G3095u2	WIAF-13018	HT2435	362	TCF2, transcription factor 2, hepatic; LF-B3; variant hepatic nuclear factor	GGCCGAGCC [C/T] GACACCAAGC	S	C	T	P	P
G3095u3	WIAF-13020	HT2435	1620	TCF2, transcription factor 2, hepatic; LF-B3; variant hepatic nuclear factor	CCAGTTCTCC [C/T] AGCAGCTGCA	N	C	T	Q	*
G3100a1	WIAF-12147	HT2483	526	ZNF141, zinc finger protein 141 (clone pHS-44)	GAATGAGTGT [A/G] AGTTGCAGAA	M	A	G	K	E
G3102u1	WIAF-12975	HT2508	259	NRF1, nuclear respiratory factor 1	CGCCTTCTTC [G/T] CCGAGGACA	S	G	T	S	S
G3103u1	WIAF-13617	HT2511	1106	E2F2, E2F transcription factor 2	CCTGGACCA [G/T] CTCATCCAGA	M	G	T	Q	H
G3103u2	WIAF-13659	HT2511	1154	E2F2, E2F transcription factor 2	CTGAGGACAA [G/A] GCCAACAA	S	G	A	K	K
G311u1	WIAF-10291	HT0402	1339	A2M, alpha-2-macroglobulin	GTCCCTGTGA [C/T] GGCTACCAGT	S	C	T	Y	Y
G311u2	WIAF-10292	HT0402	1201	A2M, alpha-2-macroglobulin	TCATATTTCAT [C/T] AGAGGAATG	S	C	T	I	I
G311u3	WIAF-10293	HT0402	3041	A2M, alpha-2-macroglobulin	TACTCCAGAG [G/A] TCAAGTCCAA	M	G	A	V	I

G311u4	WIAF-10294	HT0402	3676	A2M, alpha-2-macroglobulin	TGACATCCTA [T/C] GTGCTCCTCG	S	T	C	Y	Y
G311u5	WIAF-10296	HT0402	3364	A2M, alpha-2-macroglobulin	ATATCACCAT [C/T] GCCCTTCTGG	S	C	T	I	I
G311u6	WIAF-10297	HT0402	3203	A2M, alpha-2-macroglobulin	CCAAGCTCGA [G/T] CCTACATCTT	M	G	T	A	S
G311a7	WIAF-10494	HT0402	1122	A2M, alpha-2-macroglobulin	TCACACTTTC [G/A] ACAGGGAATT	M	G	A	R	Q
G3119u1	WIAF-13947	HT2654	2876	GLI, glioma-associated oncogene homolog (zinc finger protein)	TTTCTGGGG [G/A] TTCCAGGTT	M	G	A	G	D
G3119u2	WIAF-13959	HT2654	654	GLI, glioma-associated oncogene homolog (zinc finger protein)	ACTGCCGGGA [G/A] GAACCTTTGG	S	G	A	E	E
G3119u3	WIAF-13965	HT2654	3376	GLI, glioma-associated oncogene homolog (zinc finger protein)	TGGGGAARCA [G/C] AATTCTCAA	M	G	C	E	Q
G312u1	WIAF-10006	HT0428	898	PLAU, plasminogen activator, urokinase	CTCACCACAA [C/T] GACATTGCCT	S	C	T	N	N
G312u2	WIAF-10029	HT0428	498	PLAU, plasminogen activator, urokinase	GGCTAAAGC [C/T] GCTTCTCCAA	M	C	T	P	L
G312a3	WIAF-10521	HT0428	767	PLAU, plasminogen activator, urokinase	TGATTACCCA [A/C] AGAAGGAGGA	M	A	C	K	Q
G3125u1	WIAF-13675	HT2674	740	GTF2F2, general transcription factor IIF, polypeptide 2 (30KD subunit)	ACATCACAAA [A/G] CAACCTGTGG	S	A	G	K	K
G313u1	WIAF-10129	HT0462	3086	platelet-derived growth factor, alpha polypeptide (GB:M21574)	CATGCGTGTG [G/A] ACTCAGACAA	M	G	A	D	N
G313u2	WIAF-10130	HT0462	1078	platelet-derived growth factor, alpha polypeptide (GB:M21574)	ATGAGAAAGG [T/G] TTCATTGAAA	S	T	G	G	G
G313u3	WIAF-10133	HT0462	1571	platelet-derived growth factor, alpha polypeptide (GB:M21574)	GGAGATCCAC [T/C] CCGGAGACAG	M	T	C	S	P
G313u4	WIAF-10135	HT0462	2611	platelet-derived growth factor, alpha polypeptide (GB:M21574)	CTCGCAACGT [C/T] CTCTGGCAC	S	C	T	V	V

G314u1	WIAF-10069	HT0467	1890	ALOX15, arachidonate 15-lipoxygenase	TCAGGAGGA [G/A] CTGGCTGCC	S	G	A	E	E
G314u1	WIAF-13934	HT27498	878	NPATC3, nuclear factor of activated T-cells, cytoplasmic 3	CCAGAGGATA [G/A] CTGGCTACTC	M	G	A	S	N
G314u2	WIAF-13936	HT27498	1189	NPATC3, nuclear factor of activated T-cells, cytoplasmic 3	GCCTGCTCA [T/C] GCAATGGAA	M	T	C	C	R
G314u3	WIAF-13938	HT27498	2241	NPATC3, nuclear factor of activated T-cells, cytoplasmic 3	CTCTGGGGG [T/C] TTCCCTTCAG	S	T	C	G	G
G314u4	WIAF-13944	HT27498	702	NPATC3, nuclear factor of activated T-cells, cytoplasmic 3	ATGCCTCTGA [C/T] GAGGACGCC	S	C	T	D	D
G315u1	WIAF-13891	HT2757	523	SP4, Sp4 transcription factor	CTTCAAAAGA [G/A] AATAAGTTT	S	G	A	E	E
G315u2	WIAF-13892	HT2757	1514	SP4, Sp4 transcription factor	ACAGAATGTT [C/T] AACTTCAAGC	N	C	T	Q	*
G315u3	WIAF-13893	HT2757	2236	SP4, Sp4 transcription factor	TGTTTGTGG [C/T] AAAGATTCA	S	C	T	G	G
G315u1	WIAF-13860	HT27636	437	transcription factor B-ATF	AGCAGCTCAC [A/G] GAGGAACTGA	S	A	G	T	T
G315u2	WIAF-13861	HT27636	512	transcription factor B-ATF	CCAGCACGCC [C/G] TCGCCCCCG	S	C	G	P	P
G317u1	WIAF-13556	HT2772	1686	ZNFX4, zinc finger protein 74 (Cof52)	TGCACAGCGA [G/A] GGGAAAGCCT	S	G	A	E	E
G317u1	WIAF-13948	HT2776	2037	transcriptional regulator, via glucocorticoid receptor	TGTTGGGACC [A/G] GAAGCACCCA	S	A	G	P	P
G318u1	WIAF-14036	HT2783	1614	MHC2TA, MHC class II transactivator	ATCCTAGACG [C/G] CTTGAGGAG	M	C	G	A	G
G318u2	WIAF-14037	HT2783	2791	MHC2TA, MHC class II transactivator	TGACCGACAC [G/A] GTGGCGCTGT	S	G	A	T	T
G318u3	WIAF-14059	HT2783	1657	MHC2TA, MHC class II transactivator	TGCACAGCAC [G/A] TGCGGACCGG	S	G	A	T	T
G318u4	WIAF-14060	HT2783	1606	MHC2TA, MHC class II transactivator	TTCTGCTCAT [C/T] CTAGACGCT	S	C	T	I	I
G318u1	WIAF-13950	HT27861	392	zinc finger protein C2H2-150	TACTCTAGAG [G/A] AGCCTGTGG	M	G	A	E	K
G318u1	WIAF-13864	HT27862	271	zinc finger protein C2H2-171	GAACCTCCAG [T/G] TCAAGACTT	M	T	G	F	V

G3184u2	WIAP-13865	HT27862	248	zinc finger protein C2H2-171	CTGCTTGAAT [T/C] CATGTATGAR	M	T	C	F	S
G320u1	WIAP-10136	HT0791	552	ANX7, annexin VII (synexin)	CCAACTTCGA [T/C] GCTATTAAGAG	S	T	C	D	D
G320u2	WIAP-10137	HT0791	1350	ANX7, annexin VII (synexin)	TTGACCTTGT [A/G] CAAATAAAAC	S	A	G	V	V
G3208u1	WIAP-14186	HT27930	485	zinc finger protein ZNF37A	GTGAGAAGTC [A/G] GGCCTTAATG	S	A	G	S	S
G3218u1	WIAP-13526	HT28104	187	zinc finger protein ZNF169, Krueppel-type	CCGACAGCT [C/T] ATTAAGAAAG	M	C	T	H	Y
G323u1	WIAP-10066	HT0915	1361	Homo sapiens inducible nitric oxide synthase (NOS) mRNA, complete cds.	ACTTCTGTGA [C/T] GTCCAGCGCT	S	C	T	D	D
G325u1	WIAP-10106	HT0962	3817	FN1, fibrillin 1 (Marfan syndrome)	TGTGAATGCC [C/T] GCCTGGCCAT	M	C	T	P	L
G325u2	WIAP-10113	HT0962	722	FN1, fibrillin 1 (Marfan syndrome)	AGATAGCTCC [T/G] TCTGTGGCT	S	T	G	P	P
G325u3	WIAP-10114	HT0962	2022	FN1, fibrillin 1 (Marfan syndrome)	GATCTGCAAT [A/C] ATGGACGCTG	M	A	C	N	H
G325u4	WIAP-10116	HT0962	3603	FN1, fibrillin 1 (Marfan syndrome)	GAACTGCACA [G/C] ACATTGACGA	M	G	C	D	H
G325u5	WIAP-10117	HT0962	2270	FN1, fibrillin 1 (Marfan syndrome)	TCTGCATGAA [C/T] GGCGTTGCG	S	C	T	N	N
G326u1	WIAP-10036	HT1009	1854	KLKB1, kallikrein B plasma, (Fletcher factor) 1	GCAAACACAA [C/T] GGAATGTGGC	S	C	T	N	N
G327u1	WIAP-10052	HT1011	1599	HRG, histidine-rich glycoprotein	AAGCCAGACA [A/T] TCAGCCCTTT	M	A	T	N	I
G327u2	WIAP-10054	HT1011	1083	HRG, histidine-rich glycoprotein	CCACTATTGC [C/T] CATGTCTCTGC	M	C	T	P	L
G327u3	WIAP-10055	HT1011	1140	HRG, histidine-rich glycoprotein	GCCCAAAGAC [A/G] TTCTCATAAT	M	A	G	H	R
G328u1	WIAP-10145	HT1087	255	SAAL, serum amyloid A1	GTGCTGGGC [T/C] GCAGAAGTGA	S	T	C	A	A
G328a2	WIAP-10511	HT1087	248	SAAL, serum amyloid A1	CCTGGGGGTG [C/T] CTGGGCTGCA	M	C	T	A	V
G328a3	WIAP-10512	HT1087	305	SAAL, serum amyloid A1	TTCTTTGGCC [A/G] TGGTGGGAG	M	A	G	H	R
G328a4	WIAP-13126	HT1087	295	SAAL, serum amyloid A1	TATCCAGAGA [T/C] TCTTTGGCCA	M	T	C	F	L
G328a5	WIAP-13127	HT1087	82	SAAL, serum amyloid A1	CTTGGTCTGTG [G/A] GTGTCACAG	M	G	A	G	S
G329u1	WIAP-10140	HT1141	2514	PLCG1, phospholipase C, gamma 1 (formerly subtype 148)	CTGACCTTCA [T/C] CAAGAGCGCC	M	T	C	I	T

G329u2	WIAP-10162	HT1141	1036	PLC $\beta$ 1, phospholipase C, gamma 1 (formerly subtype 148)	TATGCCCGGA [C/A] ACCATGAACA	M	C	A	D	E
G329u3	WIAP-10163	HT1141	911	PLC $\beta$ 1, phospholipase C, gamma 1 (formerly subtype 148)	GTTTCATGCTC [A/G] GCTTCCTCCG	M	A	G	S	G
G3295u1	WIAP-14017	HT3460	1229	FUBP, far upstream element binding protein	CCATATAAAG [C/T] ATAGCCAGC	S	C	T	S	S
G3296u1	WIAP-14168	HT3466	6289	transcription factor TFIIC, RNA polymerase III, alpha subunit	CAGCCTGGAC [G/A] AGAGCCCAT	M	G	A	E	K
G3296u2	WIAP-14179	HT3466	235	transcription factor TFIIC, RNA polymerase III, alpha subunit	GGGCATCAG [T/A] TCTATGAGGA	M	T	A	F	I
G3298u1	WIAP-13523	HT3504	1803	DNA-binding protein HRFX2	ACTTGCCTAA [C/T] GTGAGGAGC	S	C	T	N	N
G3298u2	WIAP-13524	HT3504	1743	DNA-binding protein HRFX2	GGCGGTGCT [G/A] CAGACACGT	S	G	A	L	L
G3298u3	WIAP-13528	HT3504	2002	DNA-binding protein HRFX2	GTCTTTGCTG [A/G] AATGGTCCTT	M	A	G	K	E
G33u1	WIAP-10254	X82540	1044	INHBC, inhibin, beta C	AAGCCCAACA [C/T] AGCTGCAGGC	M	C	T	T	I
G33u2	WIAP-10255	X82540	1136	INHBC, inhibin, beta C	CAGCAACATT [G/A] TCAGACTGA	M	G	A	V	I
G33u3	WIAP-10256	X82540	1185	INHBC, inhibin, beta C	GGTGCAGTT [A/G] GTCTATGTGT	N	A	G	A	M
G33u4	WIAP-10259	X82540	892	INHBC, inhibin, beta C	TTTTTGTGGA [C/T] TTCCGTGAGA	S	C	T	D	D
G3303u1	WIAP-13566	HT3523	981	POU6F1, POU domain, class 6, transcription factor 1	CAGGCCAGGA [G/A] ATCACTGAAA	S	G	A	E	E
G3304u1	WIAP-13932	HT3544	970	SP2, SP2 transcription factor	TCAACACCT [C/T] GTGAACGCCA	S	C	T	L	L
G3304u2	WIAP-13935	HT3544	1891	SP2, SP2 transcription factor	AGAAGCACGT [T/G] TGCCACATCC	S	T	G	V	V
G3304u3	WIAP-13943	HT3544	920	SP2, SP2 transcription factor	TGTGTGTAAG [T/C] TGACAGGTGG	S	T	C	L	L
G3311u1	WIAP-13839	HT3585	757	GATA3, GATA-binding protein 3	CCCACTCCCG [T/C] GGCAGCATGA	S	T	C	R	R
G3311u2	WIAP-13840	HT3585	901	GATA3, GATA-binding protein 3	TCGGATGCMA [G/A] TCCAGGCCCA	S	G	A	K	K
G3316u1	WIAP-13818	HT3607	282	zinc finger protein HKE-T1, Kruppel-like	AAAGAGTTTC [A/G] GTCAGAGTTC	M	A	G	S	G

G3319u1	WIAP-14214	HT3613			1086	SMARCA3, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 3	AACTCTTAC[A/G]GCCATTGCCAG	S	A	G	T	T
G3319u2	WIAP-14221	HT3613			1261	SMARCA3, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 3	TAGATGTAGT[G/C]AACAACCCAG	M	G	C	E	Q
G3320u1	WIAP-13692	HT3622			624	BCL6, B-cell CLL/lymphoma 6 (zinc finger protein 51)	ATTGCGGGA[G/C]GGCAACATCA	M	G	C	E	D
G3320u2	WIAP-13717	HT3622			1062	BCL6, B-cell CLL/lymphoma 6 (zinc finger protein 51)	ACAGCCGGC[G/A]ACTTTGGAGG	S	G	A	P	P
G3321u1	WIAP-13761	HT3641			235	STAT2, signal transducer and activator of transcription 2, 113kD	TCTTGGATCA[G/C]CTGAACTATG	M	G	C	Q	H
G3321u2	WIAP-13762	HT3641			774	STAT2, signal transducer and activator of transcription 2, 113kD	CAAAAAGCCT[G/C]CATCAGAGCT	M	G	C	C	S
G3328u1	WIAP-13543	HT3681			1550	transcription factor znf6	CCACAATGGT[A/G]TCAGAGGAGG	S	A	G	V	V
G3328u2	WIAP-13544	HT3681			1389	transcription factor znf6	ACAGGATTTA[G/C]AGGAAGATGA	M	G	C	E	Q
G3336u1	WIAP-13848	HT3732			216	XBPI, X-box binding protein 1	ACCTGAGCCC[C/T]GAGGAGAAG	S	C	T	P	P
G334u1	WIAP-10008	HT1220			893	THBS1, thrombospondin 1	TACATTGGCC[A/C]CAGACAAAG	M	A	C	H	P
G334u2	WIAP-10009	HT1220			2000	THBS1, thrombospondin 1	TCACAGCCCT[T/C]CGGCCAGGT	M	T	C	F	S
G334u3	WIAP-10016	HT1220			1521	THBS1, thrombospondin 1	CCCAGATGAA[T/C]GGGAACCCCT	S	T	C	N	N
G334u4	WIAP-10017	HT1220			2210	THBS1, thrombospondin 1	GGCTGGCCCA[A/G]TGAGAACCTG	M	A	G	N	S
G334u5	WIAP-10018	HT1220			2979	THBS1, thrombospondin 1	GTGAGACCGA[T/C]TTCCGCCGAT	S	T	C	D	D
G334u6	WIAP-10033	HT1220			1136	THBS1, thrombospondin 1	TGTCACTGTC[A/G]GAACTCAGTT	M	A	G	Q	R
G334u7	WIAP-10034	HT1220			1859	THBS1, thrombospondin 1	AGTGGAAATG[G/A]CATCCAGTGC	M	G	A	G	D
G3343u1	WIAP-13545	HT3770			1104	ZNFR76, zinc finger protein 76 (expressed in testis)	GCAGTCCCA[C/T]GGCGAGCTGG	S	C	T	H	H
G3343u2	WIAP-13561	HT3770			425	ZNFR76, zinc finger protein 76 (expressed in testis)	GAGCAGTATG[C/A]CAGCAGGTT	M	C	A	A	D



G3343u3	WIAF-13562	HT3770	143	ZNF76, zinc finger protein 76 (expressed in testis)	CACCAGGTGA [C/T]GGTACAGAAA	M	C	T	T	M
G3343u4	WIAF-13563	HT3770	646	ZNF76, zinc finger protein 76 (expressed in testis)	GAAGAGCCAC [G/T]TTCGTACCCA	M	G	T	V	F
G3343u5	WIAF-13564	HT3770	611	ZNF76, zinc finger protein 76 (expressed in testis)	AGCTGTGGAA [A/G]GGCCTTTGCC	M	A	G	K	R
G3344u1	WIAF-13664	HT3772	925	zinc finger protein MAZ	AGCTGTCGCA [C/T]TCGGACGAGA	S	C	T	H	H
G3345u1	WIAF-13508	HT3823	315	TCF6L1, transcription factor 6- like 1 (mitochondrial transcription factor 1-like)	TTCGATTTTC [T/C]AAAGAACAAC	S	T	C	S	S
G3345u2	WIAF-13509	HT3823	167	TCF6L1, transcription factor 6- like 1 (mitochondrial transcription factor 1-like)	GGCGTGTGA [G/C]TGCCCTGGGA	M	G	C	S	T
G3345u3	WIAF-13531	HT3823	625	TCF6L1, transcription factor 6- like 1 (mitochondrial transcription factor 1-like)	TTATAACGTT [T/G]ATGTAGCTGA	M	T	G	Y	D
G3352u1	WIAF-13589	HT4005	1190	MITF, microphthalmia-associated transcription factor	CTCGAACTG [G/A]CACTGAGGCC	M	G	A	G	E
G3352u2	WIAF-13604	HT4005	1156	MITF, microphthalmia-associated transcription factor	TCTCAGGAT [G/A]GCACCATCAC	M	G	A	G	S
G3353u1	WIAF-13937	HT4010	360	GTF2H3, general transcription factor IIF, polypeptide 3 (34kD subunit)	ATCTAATGAC [C/A]AAAGTGACA	S	C	A	T	T
G3358u1	WIAF-13671	HT4187	398	ETS5, ets variant gene 5 (ets- related molecule)	GATGATGAAC [A/G]GTTTGTCCCA	M	A	G	Q	R
G3358u2	WIAF-13672	HT4187	223	ETS5, ets variant gene 5 (ets- related molecule)	TCAGCAAGTC [C/T]CTTTATGGT	M	C	T	P	S

G3358u3	WIAP-13673	HT4187	1236	ETS5, ets variant gene 5 (ets-related molecule)	GACTGGAGG[C/G]AAGTCAAC	S	C	G	G	G
G3358u4	WIAP-13674	HT4187	1678	ETS5, ets variant gene 5 (ets-related molecule)	TTACTCTCTG[G/A]ACATGGACCG	M	G	A	D	N
G3358u5	WIAP-13706	HT4187	414	ETS5, ets variant gene 5 (ets-related molecule)	TCCAGATT[T/C]CAGTCTGATA	S	T	C	F	F
G3358u6	WIAP-13707	HT4187	1238	ETS5, ets variant gene 5 (ets-related molecule)	CTGGAAGGCA[A/G]AGTCAACAG	M	A	G	K	R
G336u1	WIAP-10152	HT1258	566	ACAT1, acetyl-Coenzyme A acetyltransferase 1 (acetoacetyl Coenzyme A thiolase)	AGAGCATGTC[C/A]AATGTTCCAT	S	C	A	S	S
G3369u1	WIAP-14047	HT4302	614	zinc finger protein DB1	ATCTCAATCG[A/G]CACAAGCTCT	S	A	G	R	R
G337u1	WIAP-10268	HT1259	464	EDNRB, endothelin receptor type B	AAAGGAGACA[G/T]GACGGCAGGA	M	G	T	R	M
G337u2	WIAP-10298	HT1259	1281	EDNRB, endothelin receptor type B	TGAAGCTCAC[T/A]CTTTATAATC	S	T	A	T	T
G3373u1	WIAP-14203	HT4342	1253	MTF1, metal-regulatory transcription factor 1	CTCAACAGAC[A/G]GCTTCTTGA	S	A	G	T	T
G3390u1	WIAP-14182	HT4483	680	ZNF133, zinc finger protein 133 (clone pHZ-13)	AGAGCCAGAG[C/T]TCTACTCTGA	M	C	T	L	F
G3390u2	WIAP-14184	HT4483	1026	ZNF133, zinc finger protein 133 (clone pHZ-13)	GCTCAGACAG[G/A]GAACCCCTGAG	M	G	A	G	E
G3390u3	WIAP-14185	HT4483	1423	ZNF133, zinc finger protein 133 (clone pHZ-13)	AAAAGCCTTA[T/C]GTGTGCCGG	S	T	C	Y	Y
G3390u4	WIAP-14197	HT4483	811	ZNF133, zinc finger protein 133 (clone pHZ-13)	CTGGGATCC[A/G]GCCCCAGGG	S	A	G	P	P
G3390u5	WIAP-14198	HT4483	1420	ZNF133, zinc finger protein 133 (clone pHZ-13)	GGGAAAAGCC[T/G]TATGTGTGCC	S	T	G	P	P
G3390u6	WIAP-14199	HT4483	2143	ZNF133, zinc finger protein 133 (clone pHZ-13)	CAGCTCTAAT[C/T]ACACACAAGC	S	C	T	I	I
G3391u1	WIAP-13631	HT4484	391	ZNF136, zinc finger protein 136 (clone pHZ-20)	AGCATTGTAT[A/G]TGGAGAAGTC	M	A	G	Y	C
G3396u1	WIAP-13978	HT4491	1283	ZNF135, zinc finger protein 135 (clone pHZ-17)	CACAGTCTCT[C/T]GCTCAGCCAG	M	C	T	S	L
G3396u2	WIAP-13979	HT4491	1296	ZNF135, zinc finger protein 135 (clone pHZ-17)	TCAGCCAGCA[C/T]GAAAGGACGC	S	C	T	H	H
G3396u3	WIAP-13980	HT4491	1028	ZNF135, zinc finger protein 135 (clone pHZ-17)	AGTCACAGCT[C/T]GTCCCTCACC	M	C	T	S	L

G3396u4	WIAF-13981	HT4491		1057	ZNF135, zinc finger protein 135 (clone pHZ-17)	GGAATCCAC [A/G] CTGGGAGAA	M	A	G	T	A
G3396u5	WIAF-13982	HT4491		1152	ZNF135, zinc finger protein 135 (clone pHZ-17)	CAGGAGAGAA [A/G] CCCTATGAAT	S	A	G	K	K
G3396u6	WIAF-13983	HT4491		1243	ZNF135, zinc finger protein 135 (clone pHZ-17)	AAAGCGTAT [G/C] GGTCAATGA	M	G	C	G	R
G3396u7	WIAF-13984	HT4491		1045	ZNF135, zinc finger protein 135 (clone pHZ-17)	CACCAACAT [C/T] AGCGAATCCA	N	C	T	Q	*
G340u1	WIAF-10139	HT1386		459	CYP27A1, cytochrome P450, subfamily XXVIIA (steroid 27- hydroxylase, cerebrotendinous xanthomatosis), polypeptide 1	CCTATGGGC [G/A] TTCACACGG	S	G	A	P	P
G340u2	WIAF-10160	HT1386		801	CYP27A1, cytochrome P450, subfamily XXVIIA (steroid 27- hydroxylase, cerebrotendinous xanthomatosis), polypeptide 1	TCCCAAGTG [G/A] ACTCGCCCG	N	G	A	W	*
G341u1	WIAF-10121	HT1388		912	MUT, methylmalonyl Coenzyme A mutase	GAGCTGGCCT [A/G] TACTTTAGCA	M	A	G	Y	C
G341u2	WIAF-10128	HT1388		2087	MUT, methylmalonyl Coenzyme A mutase	TGCTGTGGGC [G/A] TAAGCACCTT	M	G	A	V	I
G3410u1	WIAF-13749	HT4550		1720	zinc finger homeodomain protein	TGAGTCCTCT [G/T] TTTCATCAGC	M	G	T	V	F
G3410u2	WIAF-13750	HT4550		2843	zinc finger homeodomain protein	AAACATCATT [T/C] GATTGAACAC	M	T	C	L	S
G3410u3	WIAF-13751	HT4550		2745	zinc finger homeodomain protein	AGATATTCCA [A/T] AAGAGTAGTT	M	A	T	Q	H
G3410u4	WIAF-13775	HT4550		236	zinc finger homeodomain protein	AGAGAGAGGA [A/C] TGCTAAGAAC	M	A	C	N	T
G3410u5	WIAF-13776	HT4550		195	zinc finger homeodomain protein	TGCCAACAGA [C/T] CAGACAGTGT	S	C	T	D	D
G3410u6	WIAF-13777	HT4550		606	zinc finger homeodomain protein	ATAACTTTAG [T/C] TGCTCCCTGT	S	T	C	S	S
G3410u7	WIAF-13793	HT4550		2073	zinc finger homeodomain protein	CAGTTTACC [A/G] GTGGGATCAA	S	A	G	P	P
G343u1	WIAF-10120	HT1552		561	HK1, hexokinase 1	CTTGCCAACA [A/G] TCCAAATAG	S	A	G	Q	Q

G343u2	WIAF-10124	HT1552	159	HK1, hexokinase 1	ACAAGTATCT (G/C) TATGCCATGC	S	G	C	L	L
G348u1	WIAF-10269	HT1906	2212	PECAM1, platelet/endothelial cell adhesion molecule (CD31 antigen)	TGACGATGTC (A/G) GAAACCATGC	S	A	G	G	G
G348u2	WIAF-10277	HT1906	1656	PECAM1, platelet/endothelial cell adhesion molecule (CD31 antigen)	GCCATTCCCA (C/T) GCCAAAATGT	S	C	T	H	H
G348u3	WIAF-10283	HT1906	577	PECAM1, platelet/endothelial cell adhesion molecule (CD31 antigen)	AGAGTACCAG (C/G) TGTTCGTGGA	S	C	G	V	V
G348a5	WIAF-13119	HT1906	?	PECAM1, platelet/endothelial cell adhesion molecule (CD31 antigen)	ATTGTTCCC (C/G)	?	C	G		
G351u1	WIAF-10123	HT1990	1047	OSBP, oxysterol binding protein	TGCTGGCAGA (G/A) TCAGATGAAT	S	G	A	E	E
G351u2	WIAF-10132	HT1990	1023	OSBP, oxysterol binding protein	TGGCCAGGC (C/A) AAGCTGTGA	S	C	A	A	A
G355u1	WIAF-10146	HT2143	1670	THBS4, thrombospondin 4	AACTGCTGA (G/A) TGTCTTAAAT	M	G	A	S	N
G355u2	WIAF-10165	HT2143	1186	THBS4, thrombospondin 4	TCGAAATGGA (G/C) CGTGCCTTC	M	G	C	A	P
G355a3	WIAF-10510	HT2143	1962	THBS4, thrombospondin 4	ACTGCCAC (C/G) GTCATTAACA	S	C	G	T	T
G355a4	WIAF-13125	HT2143	1963	THBS4, thrombospondin 4	CTGCCCCACC (G/A) TCATTAACAG	M	G	a	V	I
G3552u1	WIAF-12701	HT28101	1006	CLCN2, chloride channel 2	AAGAGACTAT (T/C) ACAGCCCTCT	S	T	C	I	I
G3552u2	WIAF-12731	HT28101	1823	CLCN2, chloride channel 2	CCGCCACAG (C/T) AGTACCGGT	N	C	T	Q	*
G3552u3	WIAF-12736	HT28101	2254	CLCN2, chloride channel 2	GGAGGCAGA (G/C) TCGGCAGCA	M	G	C	E	D
G3555u1	WIAF-12744	HT2896	334	calyculin	GCCCTCAGG (G/A) CTGAAATAA	M	G	A	G	D
G357u1	WIAF-10267	HT2244	4300	C4B, complement component 4B	ATGAGTACGA (T/C) GAGCTTCCAG	S	T	C	D	D
G357u2	WIAF-10280	HT2244	5095	C4B, complement component 4B	TCATGGGTCT (G/A) GATGGGCCA	S	G	A	L	L
G357u3	WIAF-10295	HT2244	2996	C4B, complement component 4B	CTCAGATCCA (T/C) TGGACACTTT	S	T	C	L	L
G359u1	WIAF-10026	HT2411	936	PLAT, plasminogen activator, tissue	CGCAGGCTGA (A/G) GTGGGAGTAC	M	A	G	T	M
G359a2	WIAF-10520	HT2411	1444	PLAT, plasminogen activator, tissue	AGGCTTCTGC (T/C) CCTTTCTATT	S	T	C	S	S

G3592u1	WIAF-12759	HT4214	743	CLCN4, chloride channel 4	CTTCTAACGA [G/A] ACCACTTTTG	S	G	A	E	B
G3592u2	WIAF-12761	HT4214	835	CLCN4, chloride channel 4	GCTTACATTC [T/G] GAATTACTTA	M	T	G	L	R
G361u1	WIAF-10053	HT2479	857	cystathionine beta synthase, alt. transcript 1	TGGCTCACTA [C/T] GACACCCACG	S	C	T	Y	Y
G361u2	WIAF-10056	HT2479	1097	cystathionine beta synthase, alt. transcript 1	TCATCCCCAC [G/A] GTGCTGGACA	S	G	A	T	T
G362u1	WIAF-10058	HT2638	223	ADRB2, adrenergic, beta-2-, receptor, surface	GGCACCCCAAT [G/A] GAAGCCATGC	M	G	A	G	R
G362u2	WIAF-10059	HT2638	429	ADRB2, adrenergic, beta-2-, receptor, surface	TCATGGGCCT [G/A] GCAGTGTGTC	S	G	A	L	L
G362u3	WIAF-10060	HT2638	256	ADRB2, adrenergic, beta-2-, receptor, surface	CGTCACGCAG [G/C] AAAGGGACGA	M	G	C	E	Q
G362u4	WIAF-10093	HT2638	1230	ADRB2, adrenergic, beta-2-, receptor, surface	AGGCCTATGG [G/C] AATGGCTACT	S	G	C	G	G
G362u1	WIAF-12808	HT97200	458	ACATN, acetyl-Coenzyme A transporter	CACCTCTCTGG [A/G] TATGAAGAGC	M	A	G	D	G
G3627u1	WIAF-12820	HT97387	347	NAPG, N-ethylmaleimide-sensitive factor attachment protein, gamma	GCAGAAACTA [C/T] CAGAGGCCGT	M	C	T	P	S
G366u1	WIAF-10046	HT2764	987	BDKRB2, bradykinin receptor B2	GCCTCCTTCA [T/C] GGCTACAGC	M	T	C	M	T
G366a2	WIAF-10500	HT2764	820	BDKRB2, bradykinin receptor B2	AGATCCAGAC [G/A] GAGAGGAGGG	S	G	A	T	T
G366a3	WIAF-10501	HT2764	961	BDKRB2, bradykinin receptor B2	GCATCATCGA [T/C] GTATACACAC	S	T	C	D	D
G367u1	WIAF-10156	HT27685	6965	ACACA, acetyl-Coenzyme A carboxylase alpha	ATCATCCATA [T/C] GACGCGACAC	N	T	C	*	C
G370u1	WIAF-10281	HT27888	3250	LEPR, leptin receptor	AAATTTCTCC [G/A] TTGAGGATT	S	G	A	P	P
G370u2	WIAF-10282	HT27888	3229	LEPR, leptin receptor	TCACCAAGTG [C/T] TTCTCTAGCA	S	C	T	C	C
G370u3	WIAF-10284	HT27888	1005	LEPR, leptin receptor	CAATATCAAG [T/C] GAAATATTC	M	T	C	V	A
G370u4	WIAF-10285	HT27888	1894	LEPR, leptin receptor	CACAGATTA [C/T] CTTCAATCC	S	C	T	N	N
G370u5	WIAF-10299	HT27888	1222	LEPR, leptin receptor	TTCTGACAAG [T/C] GTTGGGCTA	S	T	C	S	S
G370u6	WIAF-10300	HT27888	2161	LEPR, leptin receptor	CTATGAAAAA [G/C] GAGAAAAATG	M	G	C	K	N
G371u1	WIAF-10107	HT27943	349	CRAT, carnitine acetyltransferase	TCATCTACTC [G/C] AGCCCGAGCG	S	G	C	S	S
G371a2	WIAF-12093	HT27943	287	CRAT, carnitine acetyltransferase	GGAGAACTGG [C/T] TGCTGTGAGTG	S	C	T	L	L

G372a1	WIAF-10506	HT28247	1099	HADHA, hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit	TGGAGCTCCA [C/A] AGAAGGATGT	M	C	A	Q	K
G374u1	WIAF-10103	HT28496	4435	FASN, fatty acid synthase	CACCTCCAC [G/A] TCCCGAGGT	M	G	A	V	I
G374u2	WIAF-10104	HT28496	5996	FASN, fatty acid synthase	CTGGACAGG [T/C] GACCCGAGAG	M	T	C	V	A
G374u3	WIAF-10105	HT28496	5644	FASN, fatty acid synthase	CAAGAGCTAC [A/G] TCATCGCTGG	M	A	G	I	V
G374u4	WIAF-10115	HT28496	6387	FASN, fatty acid synthase	TGGCACAT [C/T] CTGGGCATCC	S	C	T	I	I
G374u5	WIAF-10119	HT28496	567	FASN, fatty acid synthase	GGGGCATCAA [C/T] GTCTGCTGA	S	C	T	N	N
G374a6	WIAF-12094	HT28496	5520	FASN, fatty acid synthase	ACATGCCCA [A/G] GGAAGCACA	S	A	G	Q	Q
G377u1	WIAF-10142	HT2996	929	PCCB, propionyl Coenzyme A carboxylase, beta polypeptide	GGACCCGGCT [T/C] CGTCCGTGA	M	T	C	S	P
G377u2	WIAF-10143	HT2996	1416	PCCB, propionyl Coenzyme A carboxylase, beta polypeptide	CACCTTGTG [G/A] TGATACCAAC	M	G	A	G	D
G380u1	WIAF-10122	HT3159	831	INSR, insulin receptor	TCTACTTGA [C/T] GGCAGGTGTG	S	C	T	D	D
G380u2	WIAF-10126	HT3159	1698	INSR, insulin receptor	GGCAGATGC [A/G] TGTGTTCCA	S	A	G	A	A
G380u4	WIAF-11605	HT3159	2382	INSR, insulin receptor	GGTGCCCA [G/A] AGTCCGAGG	S	G	A	T	T
G383u1	WIAF-10125	HT33546	3633	phospholipase C, beta 3, alt. transcript 2	AGCAGCGGC [G/A] AGGCTCCCC	M	G	A	R	Q
G385u1	WIAF-10141	HT3383	1505	PRCP, prolylcarboxypeptidase (angiotensinase C)	ATGACAGTGC [A/G] GGAAGCAGC	S	A	G	A	A
G385u2	WIAF-10157	HT3383	1360	PRCP, prolylcarboxypeptidase (angiotensinase C)	ATCAGACAC [C/G] TCTGGTTGCA	M	C	G	T	S
G387u1	WIAF-11729	HT3439	2697	SREBF2, sterol regulatory element binding transcription factor 2	CACTCTCCAG [G/C] AGCTCCGTGC	M	G	C	R	S
G387u2	WIAF-11770	HT3439	1901	SREBF2, sterol regulatory element binding transcription factor 2	GCTGTGCGC [C/G] CAACCTACAA	M	C	G	A	G
G388u1	WIAF-10270	HT3440	245	SELPLG, selectin P ligand	CTCCAGAAAT [G/A] CTGAGGAACA	M	G	A	M	I
G390u1	WIAF-10276	HT3568	2049	NOS3, nitric oxide synthase 3 (endothelial cell)	TTGCTGTGTC [C/G] GTGGACACAC	S	C	G	A	A

G391u1	WIAF-10013	HT3630	6205	VNF, von Willebrand factor	AGGACCTGGA [G/C] GTGATTCTCC	M	G	C	E	D
G391u2	WIAF-10265	HT3630	4554	VNF, von Willebrand factor	GCCCTGAGA [A/G] CRAAGCCTTC	M	A	G	N	S
G391u3	WIAF-10266	HT3630	7489	VNF, von Willebrand factor	TGGCCTCAAC [C/T] GCCACCAATG	S	C	T	T	T
G391u4	WIAF-10272	HT3630	2470	VNF, von Willebrand factor	ACTGTACCAT [G/A] AGTGGAGTCC	M	G	A	M	I
G391u5	WIAF-10273	HT3630	2615	VNF, von Willebrand factor	GCTCGAGTGT [A/G] CCAAAACGTG	M	A	G	T	A
G391u6	WIAF-10274	HT3630	2635	VNF, von Willebrand factor	GCCAGAACTA [T/C] GACCTGGAGT	S	T	C	Y	Y
G391u7	WIAF-10275	HT3630	4045	VNF, von Willebrand factor	TCTCGGAACC [G/A] CCGTTGCACG	S	G	A	P	P
G391u8	WIAF-10278	HT3630	4446	VNF, von Willebrand factor	AACTTTGTCC [G/A] CTACGTCCAG	M	G	A	R	H
G391u9	WIAF-10279	HT3630	5152	VNF, von Willebrand factor	GCCTAATGC [C/T] AACGTGCAGS	S	C	T	A	A
G391u10	WIAF-10286	HT3630	3448	VNF, von Willebrand factor	TTACCACTGA [C/T] GTCTTCCAGG	S	C	T	D	D
G391u11	WIAF-10287	HT3630	4891	VNF, von Willebrand factor	ACATGGTGAC [C/T] GTGGAGTACC	S	C	T	T	T
G391u12	WIAF-10288	HT3630	4805	VNF, von Willebrand factor	CAGGACAAG [G/A] AGTTTCATGA	M	G	A	E	K
G391u13	WIAF-10289	HT3630	4943	VNF, von Willebrand factor	CCTGCAGCG [G/T] TCGAGAGAT	M	G	T	V	L
G391u14	WIAF-10290	HT3630	4915	VNF, von Willebrand factor	TCAGCCAGGC [A/C] CAGTCCAAAG	S	A	C	A	A
G391a15	WIAF-10517	HT3630	6194	VNF, von Willebrand factor	AAACAGGAG [C/T] AGGACCTGGA	N	C	T	Q	*
G391a16	WIAF-13222	HT3630	6419	VNF, von Willebrand factor	TCACCTTGGT [C/T] ACATCTTCAC	M	C	T	H	Y
G394u1	WIAF-14123	HT3464	1265	mannosidase, alpha, lysosomal	CAGGTGTGCA [A/G] CCAGCTGGAG	M	A	G	N	S
G394u2	WIAF-14135	HT3464	965	mannosidase, alpha, lysosomal	ACCAACCACA [C/T] TGTGATGACC	M	C	T	T	I
G395u1	WIAF-10271	HT4158	1627	ECe1, endothelin converting enzyme 1	TCACCTGCCGA [T/C] CAGCTCAGGA	S	T	C	D	D

-139-

G395a2	WIAF-13110	HT4158	1493	ECB1, endothelin converting enzyme 1	CATCTACAC(A/T)TGATAGATA	M	A	T	M	L
G3959u1	WIAF-13634	HT4490	250	ADTB1, adaptin, beta 1 (beta prime)	TGAAGAAGCT(G/A)GTATACCTCT	S	G	A	L	L
G3959u2	WIAF-13640	HT4490	2029	ADTB1, adaptin, beta 1 (beta prime)	TTCTTGGCGG(T/C)GGCCTTGACA	S	T	C	G	G
G3959u3	WIAF-13641	HT4490	2395	ADTB1, adaptin, beta 1 (beta prime)	AGGTCCACGC(G/A)CCACTCAGCC	S	G	A	A	A
G3967u1	WIAF-13997	HT2958	918	ACTC, actin, alpha, cardiac muscle	GAGCACACAC(T/C)ATGTACCTGT	S	T	C	T	T
G3968u1	WIAF-14159	HT1986	1747	ACTN3, actinin, alpha 3	CGAGGCTGAC(C/T)GAGAGCGAGG	N	C	T	R	*
G3968u2	WIAF-14164	HT1986	1900	ACTN3, actinin, alpha 3	GGTGCCAGC(C/T)GTGACCAAGC	M	C	T	R	C
G3968u3	WIAF-14165	HT1986	2184	ACTN3, actinin, alpha 3	ACACGCTTA(C/T)AGCATGGAGC	S	C	T	Y	Y
G3968u4	WIAF-14167	HT1986	2557	ACTN3, actinin, alpha 3	GATCTTGCA(G/A)GAGACAAGAA	M	G	A	G	R
G3968u5	WIAF-14175	HT1986	1212	ACTN3, actinin, alpha 3	GGCTGCTCTC(G/A)GAGATCCGGC	S	G	A	S	S
G3979u1	WIAF-13884	HT0623	776	GPCI, glypican 1	TGCTGCTGCC(T/G)GATGACTACC	S	T	G	P	P
G3979u2	WIAF-13885	HT0623	680	GPCI, glypican 1	TGTACTACCG(C/T)GGTGCCAAAC	S	C	T	R	R
G3979u3	WIAF-13886	HT0623	1361	GPCI, glypican 1	AGCTGCTCTC(T/C)GAAGCCAAAG	S	T	C	S	S
G3979u4	WIAF-13887	HT0623	1163	GPCI, glypican 1	AGAGTGTCTAT(C/T)GGCAGCGTGC	S	C	T	I	I
G3979u5	WIAF-13888	HT0623	1670	GPCI, glypican 1	ACGCCAGTGA(C/T)GACGGCAGCG	S	C	T	D	D
G3979u6	WIAF-13905	HT0623	1069	GPCI, glypican 1	CTTGCCAAACC(A/T)GGCCGACCTG	M	A	T	Q	L
G3979u7	WIAF-13906	HT0623	1514	GPCI, glypican 1	TCATGGGTGA(C/T)GGCCTGGCCA	S	C	T	D	D
G3979u8	WIAF-13907	HT0623	1720	GPCI, glypican 1	GACCTCTGGG(G/C)CCGGAAGGTC	M	G	C	G	A
G3979u9	WIAF-13908	HT0623	1676	GPCI, glypican 1	GTGACGACGG(C/T)AGCGGCTCGG	S	C	T	G	G
G3979u10	WIAF-13909	HT0623	1719	GPCI, glypican 1	TGACCTCTGC(G/A)GCCGGAAGGT	M	G	A	G	S
G399u1	WIAF-10102	HT48511	450	AQP3, aquaporin 3	TCTGGCACTT(T/C)GCCGACAACC	S	T	C	F	F
G399u2	WIAF-10111	HT48511	192	AQP3, aquaporin 3	GCTCCGTGGC(C/T)CAGGTTGTGC	S	C	T	A	A
G399u3	WIAF-10112	HT48511	165	AQP3, aquaporin 3	CCCTCATCCT(C/G)GTGATGTTTG	S	C	G	L	L
G3997u1	WIAF-13649	HT27682	473	MFAP2, microfibrillar-associated protein 2	TGTGTGCCCA(C/T)GAGGAGCTCC	S	C	T	H	H
G3997u2	WIAF-13650	HT27682	377	MFAP2, microfibrillar-associated protein 2	CCATACACAG(G/T)CCTTGCAAAC	M	G	T	R	S
G3997u3	WIAF-13876	HT27682	453	MFAP2, microfibrillar-associated protein 2	GGAGATCTGT(G/T)TTCGTACAGT	M	G	T	V	F
G4022u1	WIAF-14020	HT2426	240	TGM1, transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase)	TGGTGTCTGT(T/C)CATGCCGAAA	M	T	C	S	P



G4022u2	WIAF-14021	HT2426			TGM1, transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase)	371	CCGGGGCAG [C/T] GGTGTCATG	S	C	T	S	S
G4022u3	WIAF-14022	HT2426			TGM1, transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase)	506	ACGAGCTGAT [A/G] GTGCGCGCG	M	A	G	I	M
G4022u4	WIAF-14031	HT2426			TGM1, transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase)	2491	GCTGGAGGTG [A/T] CAGTCACTTA	M	A	T	D	V
G4038u1	WIAF-13998	HT4211			LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	411	GGTGGCAGTC [C/A] CAGAAATGATG	S	C	A	S	S
G4038u2	WIAF-13999	HT4211			LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	258	CTTCATCTAC [C/T] TGTGGACTGA	S	C	T	T	T
G4038u3	WIAF-14002	HT4211			LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	1830	GAGGCTACTG [C/T] AATCGCTACC	S	C	T	C	C
G4038u4	WIAF-14003	HT4211			LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	2668	GACCAGGCAG [A/T] TGATTAGGGC	M	A	T	M	L
G4038u5	WIAF-14018	HT4211			LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	248	TTTCTCCGAC [C/T] TTCATCTACC	M	C	T	A	V
G4038u6	WIAF-14019	HT4211			LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	887	CACGGCCATG [C/T] TGATCGCTGC	M	C	T	A	V
G4038u7	WIAF-14023	HT4211			LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	1266	AGTGTGATCC [G/A] GATGGGGCAG	S	G	A	P	P
G4038u8	WIAF-14025	HT4211			LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	1693	CTATGGAGAC [G/A] TGGCCACAGG	M	G	A	V	M
G4038u9	WIAF-14026	HT4211			LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	1553	GGCTGTGAAC [C/T] GTGTGCTGTC	M	C	T	P	L

G4038u10	WIAP-14029	HT4211		LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	3562	CCTGACAGGA [C/T] TGGAGAGCG	S	C	T	L	L
G4038u11	WIAP-14030	HT4211		LAMB3, laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	3546	TGCTGCGCTC [A/G] GCGGACCTGA	S	A	G	S	S
G4045u1	WIAP-13571	HT0552		adducin, beta subunit	1266	TGGAGCAGGA [G/T] AACACCGGC	M	G	T	E	D
G4050u1	WIAP-14106	HT1466		villin	1366	CGTTGGCAG [G/A] GCAGCCAGGC	M	G	A	G	S
G4050u2	WIAP-14107	HT1466		villin	1468	GGTCCCAATG [G/A] GCAAGGAGCC	M	G	A	G	S
G4050u3	WIAP-14108	HT1466		villin	1932	CCACAGAGAT [C/T] CCTGACTTCA	S	C	T	I	I
G4050u4	WIAP-14110	HT1466		villin	2438	TTTGGGATGA [C/T] TCCAGCTGCC	M	C	T	T	I
G4057u1	WIAP-13648	HT33633		CNN3, calponin 3, acidic	371	TTCAGGCTTA [T/C] GTGATGAGC	S	T	C	Y	Y
G4066u1	WIAP-13676	HT4301		troponin T, beta, skeletal	654	AGATTGACAA [G/A] TTGAGTTTG	S	G	A	K	K
G4066u2	WIAP-13677	HT4301		troponin T, beta, skeletal	774	GCAAGTCGG [C/T] GGGCGCTGGA	S	C	T	G	G
G4066u3	WIAP-13708	HT4301		troponin T, beta, skeletal	625	GGAGCTCTGG [G/C] AGACCCCTGCA	M	G	C	E	Q
G4080u1	WIAP-14142	HT1396		HSPG2, heparan sulfate	13130	GATTCTCCTC [G/A] GGCATCACAG	S	G	A	S	S
G4080u2	WIAP-14150	HT1396		HSPG2, heparan sulfate	10340	TTGAGTTCCA [C/T] TGTGCTGTGC	S	C	T	H	H
G4080u3	WIAP-14151	HT1396		HSPG2, heparan sulfate	12392	AATGCTATGA [T/C] AGCTCCCAT	S	T	C	D	D
G4080u4	WIAP-14152	HT1396		HSPG2, heparan sulfate	3416	TGGCTGTGCC [C/T] GAGGAAACCG	S	C	T	P	P
G4080u5	WIAP-14154	HT1396		HSPG2, heparan sulfate	4588	GTGCCGCTGG [T/C] GGCCAGCATC	M	T	C	V	A
G4080u6	WIAP-14156	HT1396		HSPG2, heparan sulfate	9582	GGACAGCCAC [G/A] CGGTGCTGCA	M	G	A	A	T
G4096u1	WIAP-13890	HT4237		motor protein	394	CNAAGNAATC [G/A] ATTCAGTCGG	S	G	A	S	S
G4096u2	WIAP-13910	HT4237		motor protein	455	ATCTAAGACAG [C/T] CTGCTCACA	M	C	T	P	S
G4096u3	WIAP-13911	HT4237		motor protein	1150	CTAAGTTGT [A/G] TCTCAGTATC	S	A	G	V	V
G4109u1	WIAP-14034	HT28223		phosphoglucosyltransferase-related protein	1238	TACAGCGTGG [C/T] GAAGACGGAT	M	C	T	A	V
G4109u2	WIAP-14035	HT28223		phosphoglucosyltransferase-related protein	1043	ATTATTGCTG [C/A] CCGGAAGCAG	M	C	A	A	D
G4112u1	WIAP-13615	HT4401		KIF5A, kinesin family member 5A	374	AGATGTCCTT [G/A] CTGCTACAA	M	G	A	A	T
G4112u2	WIAP-13623	HT4401		KIF5A, kinesin family member 5A	2767	AGAGATTAA [G/T] GCCCTGAGG	M	G	T	K	N

G4114u1	WIAP-14113	HT4160	830 fibrinogen-like protein p749	AACTTCACCA[G/A]AACATGGCAA	M	G	A	R	K
G4118u1	WIAP-14010	HT0841	MYL5, myosin, light polypeptide 564 5, regulatory	TCGATCTGGC[G/A]GGCAACCTGG	S	G	A	A	A
G4118u2	WIAP-14011	HT0841	MYL5, myosin, light polypeptide 368 5, regulatory	TTACCATGTT[T/C]TCTGAACCTG	M	T	C	F	S
G4118u3	WIAP-14012	HT0841	MYL5, myosin, light polypeptide 533 5, regulatory	GAGCTGGACC[A/G]GATGTTCCAG	M	A	G	Q	R
G4122u1	WIAP-13955	HT97538	161 myosin-I	TCGAGAACCT[A/G]CGGGGGCAT	S	A	G	L	L
G4124u1	WIAP-13895	HT0925	TGM3, transglutaminase 3 (E polypeptide, protein-glutamine- gamma-glutamyltransferase) 1517	TCGCTGGCAT[G/A]CTGSCAGTAG	M	G	A	M	I
G4124u2	WIAP-13896	HT0925	TGM3, transglutaminase 3 (E polypeptide, protein-glutamine- gamma-glutamyltransferase) 1433	AACCCAAACAC[G/A]CCATTTCGG	S	G	A	T	T
G4126u1	WIAP-13830	HT2465	1039 myosin binding protein H	ACTCGTACTC[C/G]TTCGGGTCT	S	C	G	S	S
G4126u2	WIAP-13853	HT2465	369 myosin binding protein H	AGAGAGGAG[G/C]CTCGGAGTGG	M	G	C	G	A
G4130u1	WIAP-13614	HT1657	198 CFL1, cofilin 1 (non-muscle)	CTGTGACGA[T/C]CCCTACGCCA	S	T	C	D	D
G4138u1	WIAP-13598	HT33664	MAGP2: Microfibril-associated glycoprotein-2 601	GAAGATGAG[C/T]TTTGCCCTCA	M	C	T	L	F
G4138u2	WIAP-13599	HT33664	MAGP2: Microfibril-associated glycoprotein-2 405	ATGACTTGGC[C/T]TCCCTCAGTG	S	C	T	A	A
G4138u3	WIAP-13600	HT33664	MAGP2: Microfibril-associated glycoprotein-2 327	AAGATCCTAA[T/C]CTGCTGAATG	S	T	C	N	N
G4159u1	WIAP-14048	HT3443	SNL, singed (Drosophila)-like 1119 (sea urchin fascin homolog like)	GCTGCTACTT[T/C]GACATCGAGT	S	T	C	F	F
G4170u1	WIAP-13580	HT5069	Golgi protein, peripheral, brefeldin A-sensitive 1131	GAATATACC[A/G]TAAGTATGGA	M	A	G	I	V
G4170u2	WIAP-13581	HT5069	Golgi protein, peripheral, brefeldin A-sensitive 930	GTATATAAAA[C/T]TCCTGGAGTT	M	C	T	L	F
G4170u3	WIAP-13582	HT5069	Golgi protein, peripheral, brefeldin A-sensitive 2312	AGCAGCCTTA[A/G]GCATCTTGGG	N	A	G	*	*
G4170u4	WIAP-13596	HT5069	Golgi protein, peripheral, brefeldin A-sensitive 359	TCAACCACTT[T/G]TCTGTGCCTT	S	T	G	L	L

G4170u5	WIAP-13597	HT5069	1007	Golgi protein, peripheral, brefeldin A-sensitive	AAAAAGGCAA [T/A] ACTGTTCTCG	M	T	A	N	K
G4171u1	WIAP-13688	HT1587	667	KIF5B, kinesin family member 5B	TTTTTAATTA [T/C] ATTTACTCCA	S	T	C	Y	Y
G4171u2	WIAP-13689	HT1587	1036	KIF5B, kinesin family member 5B	TTAGTAAAC [T/C] GGAGCTGAAG	S	T	C	T	T
G4176u1	WIAP-14204	HT33754	130	TNR, tenascin R (restrictin, janusin)	GCTCATTGGC [G/A] TCAACTGAT	M	G	A	V	I
G4176u2	WIAP-14205	HT33754	463	TNR, tenascin R (restrictin, janusin)	CTGTCCATGT [G/T] CCAAGTTCAGC	M	G	T	A	S
G4176u3	WIAP-14206	HT33754	249	TNR, tenascin R (restrictin, janusin)	ACTACAACAC [G/A] TCCAGCAAAG	S	G	A	T	T
G4176u4	WIAP-14208	HT33754	2009	TNR, tenascin R (restrictin, janusin)	CTGGTCCCCA [G/A] GGGCATTTGT	M	G	A	R	K
G4176u5	WIAP-14209	HT33754	2175	TNR, tenascin R (restrictin, janusin)	CAGCCTCCTC [G/A] GAGACCTCCA	S	G	A	S	S
G4176u6	WIAP-14210	HT33754	3318	TNR, tenascin R (restrictin, janusin)	AATCCAGCGA [C/T] GGAAGCCGCA	S	C	T	D	D
G4176u7	WIAP-14211	HT33754	3221	TNR, tenascin R (restrictin, janusin)	CCGGCAAAAC [T/C] GACAGCCAGT	M	T	C	L	P
G4176u8	WIAP-14217	HT33754	1635	TNR, tenascin R (restrictin, janusin)	TCTCGGACAC [C/T] GTGGCTTTTG	S	C	T	T	T
G4178u1	WIAP-14138	HT0224	2827	ACTN2, actinin, alpha 2	GCTGCGTTCT [C/T] TTCCGCACTC	M	C	T	S	F
G4178u2	WIAP-14139	HT0224	2818	ACTN2, actinin, alpha 2	CTGGATTACG [C/T] TCGGTTCTCT	M	C	T	A	V
G418u1	WIAP-11750	L07594	2370	TGFBR3, transforming growth factor, beta receptor III (betaglycan, 300kD)	GAGTGCACTT [C/T] CCTATCCGCG	S	C	T	F	F
G418u2	WIAP-11751	L07594	2586	TGFBR3, transforming growth factor, beta receptor III (betaglycan, 300kD)	AGAAGACGTT [C/T] ACCAAGCCCC	S	C	T	F	F
G418u3	WIAP-11752	L07594	2671	TGFBR3, transforming growth factor, beta receptor III (betaglycan, 300kD)	AATTTCTCCA [C/T] CAATTTTCCA	M	C	T	P	S

G418u4	WIAF-11771	L07594		TGFB3, transforming growth factor, beta receptor III (betaglycan, 300kD)	438		TGTTGAACT [G/T] TCACCTGTCA	S	G	T	L	L
G418u5	WIAF-11744	L07594		TGFB3, transforming growth factor, beta receptor III (betaglycan, 300kD)	392		CTGATGAGCT [T/C] CTGTTAGCC	M	T	C	P	S
G418u6	WIAF-11772	L07594		TGFB3, transforming growth factor, beta receptor III (betaglycan, 300kD)	1470		AGCTACGGAT [C/T] CTGCTGAGCC	S	C	T	I	I
G418u7	WIAF-11773	L07594		TGFB3, transforming growth factor, beta receptor III (betaglycan, 300kD)	1170		TCTTGAAGTG [C/A] AAAAGTCTG	N	C	A	C	*
G418u8	WIAF-11745	L07594		TGFB3, transforming growth factor, beta receptor III (betaglycan, 300kD)	1463		CCTCTGAGC [T/C] ACGATCCTG	M	T	C	L	P
G418u9	WIAF-11746	L07594		TGFB3, transforming growth factor, beta receptor III (betaglycan, 300kD)	2211		ATGTTGAGGT [A/G] TCTGTACTA	S	A	G	V	V
G4181u1	WIAF-14207	HT2008		SPTBN1, spectrin, beta, non-erythrocytic 1	425		CTCTGCGCG [C/T] TTTTTCGCG	M	C	T	L	F
G4181u2	WIAF-14213	HT2008		SPTBN1, spectrin, beta, non-erythrocytic 1	3565		AGACAGCGAT [C/T] GCCTCGGAGG	S	C	T	I	I
G4181u3	WIAF-14218	HT2008		SPTBN1, spectrin, beta, non-erythrocytic 1	1258		ACCTTCTGGA [A/G] TGGATTGAAC	S	A	G	E	E
G4181u4	WIAF-14219	HT2008		SPTBN1, spectrin, beta, non-erythrocytic 1	1780		AGCTCGAGG [C/T] GAGAATTACC	S	C	T	A	A
G4181u5	WIAF-14220	HT2008		SPTBN1, spectrin, beta, non-erythrocytic 1	3637		ACATCAAGAA [T/C] GAGATCGACA	S	T	C	N	N
G4183u1	WIAF-13976	HT2640		TPM4, tropomyosin 4	404		CCAAGCACAT [T/C] GCGGAAGAGG	S	T	C	I	I
G4185u1	WIAF-13554	HT3451		MFAP1, microfibrillar-associated protein 1	257		AAGGCCAGAC [T/G] ATGCCCTAT	M	T	G	Y	D
G4185u2	WIAF-13555	HT3451		MFAP1, microfibrillar-associated protein 1	1108		CCAACAAGC [T/G] GTTAAGGGCA	S	T	G	A	A

G4185u3	WIAP-13570	HT3451	MPAP1, microfibrillar-associated	CTATGGAGTC [C/T] TCAGATGAGG	S	C	T	S	S
G4196u1	WIAP-13665	HT97558	274 protein 1	GGGTCCATTG [C/A] CCATGCATCT	M	C	A	A	D
G4196u2	WIAP-13666	HT97558	941 NUP88, nucleoporin 88kD	ATGACACAC [G/A] TCAGAAAGT	S	G	A	T	T
G4196u3	WIAP-13667	HT97558	1092 NUP88, nucleoporin 88kD	TCCATCCAGC [G/A] TCTCTCCCC	S	G	A	A	A
G4196u4	WIAP-13668	HT97558	1551 NUP88, nucleoporin 88kD	AGGTGAACA [T/C] ATAAGGAAA	S	T	C	H	H
G4196u5	WIAP-13669	HT97558	2205 NUP88, nucleoporin 88kD	CCATCTGAA [A/G] GAGGAGGTG	S	A	G	K	K
G4208u1	WIAP-13921	HT1122	1329 VCL, vinculin	TGATCTTAA [G/C] AAAGAGATGA	M	G	C	E	Q
G4208u2	WIAP-13922	HT1122	2438 VCL, vinculin	CCATCTCCC [A/G] ATGGTATGG	S	A	G	P	P
G4208u3	WIAP-13941	HT1122	818 VCL, vinculin	GGGATGAAGA [T/C] GCCTGGGCA	S	T	C	D	D
G4208u4	WIAP-13942	HT1122	1556 VCL, vinculin	AAGCACAGCG [G/A] TGGATTGATA	S	G	A	R	R
G4213u1	WIAP-13605	HT2813	153 NUP153, nucleoporin 153kD	GCCAGGTGG [T/C] TACAAAGATA	S	T	C	L	L
G4213u2	WIAP-13606	HT2813	742 NUP153, nucleoporin 153kD	GAATCTTCA [A/G] TCCTTAAAC	M	A	G	I	V
G4213u3	WIAP-13609	HT2813	1800 NUP153, nucleoporin 153kD	TTAGACCTGC [A/C] GAAATCCTGA	S	A	C	A	A
G4213u4	WIAP-13627	HT2813	1829 NUP153, nucleoporin 153kD	AGTGTCTAG [A/C] TATTCGTAAA	M	A	C	D	A
G4213u5	WIAP-13632	HT2813	3258 NUP153, nucleoporin 153kD	CTTTGGCAA [C/T] GTGGAGCCTG	S	C	T	N	N
G4213u6	WIAP-13635	HT2813	4162 NUP153, nucleoporin 153kD	CTCTGGAACA [A/G] CTCCTAATTC	M	A	G	T	A
G4218u1	WIAP-13854	HT1681	phosphatidylinositol glycan, Class A	AACCTTATTA [T/C] TTTATGTGAG	M	T	C	I	T
G4223u1	WIAP-14160	HT1684	CD36L2, CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integral membrane protein II)	ATTAGATGAC [T/C] TTGTTGAAAC	M	T	C	F	L
G4223u2	WIAP-14173	HT1684	CD36L2, CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integral membrane protein II)	GTGCTCCAG [G/A] TGCACCTTCCT	M	G	A	V	M
G4223u3	WIAP-14174	HT1684	CD36L2, CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integral membrane protein II)	CAGACAAGTG [C/T] AATATGATTA	S	C	T	C	C
G4223u4	WIAP-14176	HT1684	CD36L2, CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2 (lysosomal integral membrane protein II)	AGATGACTTT [G/A] TTGAACGGG	M	G	A	V	I

G4227u1	WIAF-14056	HT1929	912	proteoglycan 2	ATGCTTCCAA [G/A] AAAGATGGG	S	G	A	K	K
G4227u2	WIAF-14057	HT1929	1254	proteoglycan 2	GGAACTTGG [G/A] TACTGGGCTG	S	G	A	A	A
G4227u3	WIAF-14058	HT1929	1321	proteoglycan 2	CGAGAGGCG [T/C] ACTGCGCTG	M	T	C	Y	H
G4229u1	WIAF-13961	HT1689	74	syndecan 4 (amphiglycan, 74 trydodan)	GCTGCTGCTG [T/C] TCTTCTAGG	M	T	C	P	L
G4230u1	WIAF-13525	HT4995	602	TRAM protein	CCATAACCTG [A/C] TCACATTTCA	M	A	C	M	L
G4243u1	WIAF-14169	HT2901	406	KRT17, keratin 17	AGCTGAGGT [G/A] AAGATCCGTG	S	G	A	V	V
G4243u2	WIAF-14170	HT2901	478	KRT17, keratin 17	ACAGACAT [T/C] GAGGAGCTGC	S	T	C	I	I
G4243u3	WIAF-14171	HT2901	389	KRT17, keratin 17	GGAGGAGGC [A/G] ACACCTGAGCT	M	A	G	N	D
G4243u4	WIAF-14178	HT2901	564	KRT17, keratin 17	CTGGCTGCTG [A/C] TGACTTCCGC	M	A	C	D	A
G4244u1	WIAF-14086	HT1056	386	clathrin, light polypeptide a	ATCGATTGCA [G/C] TCAGAGCCCTG	M	G	C	Q	H
G4246u1	WIAF-14044	HT97492	259	SLN, sarcophilin	GTCTATCAG [T/C] ACTGAGAGGC	M	T	C	Y	H
G4246u2	WIAF-14045	HT97492	189	SLN, sarcophilin	ACACCGGGA [G/A] CTGTTTCTCA	S	G	A	E	E
G4254u1	WIAF-13546	HT3393	86	TNNI2, troponin I, skeletal, fast	ACCTGAAGAG [C/T] GTGATGCTGC	S	C	T	S	S
G4254u2	WIAF-13553	HT3393	530	TNNI2, troponin I, skeletal, fast	TCGAGGAGAA [G/C] TCTGGCATGG	M	G	C	K	N
G4255u1	WIAF-13644	HT2907	562	CRYAB, crystallin, alpha B	AGTTCCACAG [G/A] AAATACCGGA	S	G	A	R	R
G4255u2	WIAF-13645	HT2907	367	CRYAB, crystallin, alpha B	CCTCCTTCT [G/A] CGGGCACCCA	S	G	A	L	L
G4255u3	WIAF-13872	HT2907	271	CRYAB, crystallin, alpha B	CCAGCCGCCT [C/T] TTTGACCAGT	S	C	T	L	L
G4255u4	WIAF-13873	HT2907	580	CRYAB, crystallin, alpha B	GGATCCCAGC [T/C] GATGTAGACC	S	T	C	A	A
G4257u1	WIAF-14052	HT1694	394	PIGF, phosphatidylinositol glycan, class F	TAGAGTTGGC [A/G] TTGGAACAT	S	A	G	A	A
G4257u2	WIAF-14053	HT1694	252	PIGF, phosphatidylinositol glycan, class F	TATTAGTAG [T/C] GAAACCAAT	M	T	C	V	A
G4257u3	WIAF-14069	HT1694	291	PIGF, phosphatidylinositol glycan, class F	TCATTATCAC [A/G] CAAGGTAAC	M	A	G	H	R
G4264u1	WIAF-13519	HT0968	1720	TJPI, tight junction protein 1 (zona occludens 1)	CGGTCACTGG [C/T] TTCCAGCCAG	M	C	T	A	V

G4264u2	WIAF-13520	HT0968	2272	TJPI1, tight junction protein 1 (zona occludens 1)	CATGCTGATG[A/G]TCACACACCT	M	A	G	D	G
G4264u3	WIAF-13529	HT0968	5408	TJPI1, tight junction protein 1 (zona occludens 1)	AGCCTCCTGA[A/T]GCTGATGGTG	M	A	T	E	D
G434u1	WIAF-11748	M21121	286	SCYA5, small inducible cytokine A5 (RANTES)	TACATCAACT[C/T]TTGGAGATG	M	C	T	S	F
G434u2	WIAF-11749	M21121	137	SCYA5, small inducible cytokine A5 (RANTES)	GCTTTCCTA[C/T]ATTGCCCGCC	S	C	T	Y	Y
G435u1	WIAF-11741	M31933	754	FCGR2B, Fc fragment of IgG, low affinity IIB, receptor for (CD32)	GTCACGTGGG[A/T/C]TGCTGTAGCG	M	T	C	I	T
G435u2	WIAF-11743	M31933	395	FCGR2B, Fc fragment of IgG, low affinity IIB, receptor for (CD32)	GGGAGTACAC[G/A]TGCCAGACTG	S	G	A	T	T
G435u3	WIAF-11742	M31933	673	FCGR2B, Fc fragment of IgG, low affinity IIB, receptor for (CD32)	TACACGCTGT[T/A]CTCATCCAAG	M	T	A	F	Y
G4369u1	WIAF-13728	HT0900	1176	GBE1, glucan (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen disease, glycogen storage disease type IV)	TTACGTCCAT[G/A]CTTTATCATC	M	G	A	M	I
G4369u2	WIAF-13729	HT0900	1609	GBE1, glucan (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen disease, glycogen storage disease type IV)	GAGTGTCCCTG[A/G]CTCCTTTTAC	M	A	G	T	A
G4373u1	WIAF-13559	HT0940	1117	HSD17B2, hydroxysteroid (17-beta) dehydrogenase 2	GCCAGCAAGG[A/T]CTTCTCTCCG	M	A	T	D	V
G4373u2	WIAF-13560	HT0940	1195	HSD17B2, hydroxysteroid (17-beta) dehydrogenase 2	CCAGGGAAG[G/A]CGCTTACTTG	M	G	A	G	D
G438u1	WIAF-11830	M63121	583	TNFRSF1A, tumor necrosis factor receptor superfamily, member 1A	ACCGTGTGTG[G/A]CTGCAGGAAG	M	G	A	G	D



G438u2	WIAP-11790	M63121			TNFRSF1A, tumor necrosis factor receptor superfamily, member 1A	618	TTATTGGAGT[G/A]AAACCTTTT	M	G	A	B	K
G440u1	WIAP-11806	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	261	TGCTAAAGCT[A/G]AGAGGCTGC	S	A	G	L	L
G440u2	WIAP-11807	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	2089	CAGCTGCAG[G/A]CAGTTTCAGCG	M	G	A	A	T
G440u3	WIAP-11808	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	2155	TGCCCAGCTC[C/T]AGGAGGGACA	N	C	T	Q	*
G440u4	WIAP-11818	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	1789	GAACACACATT[G/A]CTTATGGCT	M	G	A	A	T
G440u5	WIAP-11819	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	1565	AAGGGGCTGA[C/T]GTTTACCCTA	M	C	T	T	M
G440u6	WIAP-11820	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	1254	TGCACCTGGG[G/T]GTGCAGATGC	S	G	T	G	G
G440u7	WIAP-11788	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	1231	GTACCTGCTC[A/G]TAAGGAGGGT	M	A	G	I	V
G440u8	WIAP-11821	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	1404	TGCTCAGCAA[C/T]GTGGGAGCTG	S	C	T	N	N
G440u9	WIAP-11783	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	2187	CCCGCCTGGT[T/G]CAGCAGCGGC	S	T	G	V	V
G440u10	WIAP-11786	M74447			TAP2, transporter 2, ABC (ATP binding cassette)	1825	TGATAAGGTG[A/G]TGCGGCTGC	M	A	G	M	V
G440u11	WIAP-14007	HT97396			839 A33	839	GCCAATCAAA[G/T]GAGGGCTCAC	M	G	T	K	N
G440u1	WIAP-14013	HT1215			ACP2, acid phosphatase 2, lysosomal	109	CCGCCACCCC[G/A]GGCCCCGAGT	M	G	A	R	Q
G440u2	WIAP-14016	HT1215			ACP2, acid phosphatase 2, lysosomal	1271	ACGCCACGT[C/T]GCAGATGGGG	S	C	T	V	V
G440u1	WIAP-13661	HT3564			ACP2, acid phosphatase 2, lysosomal	872	ACAAAACCT[T/C]ATCATGTATT	S	T	C	L	L
G440u2	WIAP-13662	HT3564			ACP2, acid phosphatase 2, lysosomal	839	ATCATGAA[G/A]AGAGCAACTC	S	G	A	K	K
G440u3	WIAP-13881	HT3564			ACP2, acid phosphatase 2, lysosomal	741	AGATTGTCA[G/T]AATTGTCCCT	N	G	T	E	*
G441u1	WIAP-10166	M77349			TGFB1, transforming growth factor, beta-induced, 68kD	698	GTGCCCGGCT[C/G]CTGAAGCCG	S	C	G	L	L

G441u2	WIAF-10168	M77349	1028	TGPI, transforming growth factor, beta-induced, 68kD	GGCTGTCTGT [A/G] GAGACCTGG	S	A	G	V	V
G441u3	WIAF-10169	M77349	1667	TGPI, transforming growth factor, beta-induced, 68kD	ACACAGTCTT [T/C] GCTCCACAA	S	T	C	F	P
G441u4	WIAF-10171	M77349	1463	TGPI, transforming growth factor, beta-induced, 68kD	GTAATAGCCT [C/T] TGCATTGAGA	S	C	T	L	L
G441u1	WIAF-14005	HT97468	492	acyl-CoA	GCTGACCAAT [A/G] AGGCCACCT	M	A	G	K	B
G441u2	WIAF-14008	HT97468	1076	acyl-CoA	TGCCGAGAC [C/T] GAGGACGAGA	S	C	T	T	T
G4412u1	WIAF-13576	HT1882	657	ACADS, acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain	GCAAAACAAG [G/A] GCATCAGTGC	M	G	A	G	S
G4412u2	WIAF-13579	HT1882	1022	ACADS, acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain	TGACCTGGCG [C/T] GCTGCCATGC	S	C	T	R	R
G4415u1	WIAF-14080	HT2503	2170	acyl-Coenzyme A:cholesterol acyltransferase	TCATTATATT [C/T] GAGCAGATTC	S	C	T	F	F
G4415u2	WIAF-14081	HT2503	1993	acyl-Coenzyme A:cholesterol acyltransferase	TTTCAGTTCC [C/T] TATTTTCTGT	S	C	T	P	P
G4415u3	WIAF-14098	HT2503	2006	acyl-Coenzyme A:cholesterol acyltransferase	TTTTCTGTTC [C/G] AACATTGGCG	M	C	G	Q	E
G4415u4	WIAF-14101	HT2503	2365	acyl-Coenzyme A:cholesterol acyltransferase	GGGTTATGT [C/T] GCTATGAAGT	S	C	T	V	V
G4417u1	WIAF-13819	HT0542	356	AOAH, acyl-CoA:cholesterol hydrolase (neutrophil)	TCCAGCCAAC [G/A] ATGACCAGTC	M	G	A	D	N
G4417u2	WIAF-13820	HT0542	340	AOAH, acyl-CoA:cholesterol hydrolase (neutrophil)	TTTCTCTCTC [G/A] GCCTCTCCAG	S	G	A	S	S
G4417u3	WIAF-13824	HT0542	1595	AOAH, acyl-CoA:cholesterol hydrolase (neutrophil)	GCTAAATAAA [G/A] ACATGACCTA	M	G	A	D	N
G4417u4	WIAF-13841	HT0542	382	AOAH, acyl-CoA:cholesterol hydrolase (neutrophil)	CCAGCTCTCTC [G/A] AATGGGCACA	S	G	A	S	S
G4417u5	WIAF-13842	HT0542	458	AOAH, acyl-CoA:cholesterol hydrolase (neutrophil)	CAACTCGACG [G/A] TCCAGGCCTC	M	G	A	V	I

G4417u6	WIAF-13843	HT0542	1201	AOAH, acyloxyacyl hydrolase (neutrophil)	GAATTCGTGA [C/T] TCCACGTGTG	S	C	T	D	D
G4417u7	WIAF-13844	HT0542	1321	AOAH, acyloxyacyl hydrolase (neutrophil)	ACCTAAGAA [A/G] TTTATAGAAA	S	A	G	K	K
G4417u8	WIAF-13845	HT0542	1404	AOAH, acyloxyacyl hydrolase (neutrophil)	GATGCTGCA [G/A] TGGGAGAGT	M	G	A	S	N
G4417u9	WIAF-13846	HT0542	1759	AOAH, acyloxyacyl hydrolase (neutrophil)	AATTTACAAA [C/T] TTCAATCTTT	S	C	T	N	N
G4417u10	WIAF-13847	HT0542	1644	AOAH, acyloxyacyl hydrolase (neutrophil)	CTCCAGGTCA [G/A] CCCCTGCCAC	M	G	A	S	N
G442u1	WIAF-11828	M94582	933	IL8RA, interleukin 8 receptor, alpha	CACATCGACC [G/A] GGTCTCTGGAT	M	G	A	R	Q
G442u2	WIAF-11829	M94582	721	IL8RA, interleukin 8 receptor, alpha	TCATCGTGCC [A/G] CTGCTGATCA	S	A	G	P	P
G442u3	WIAF-11780	M94582	1027	IL8RA, interleukin 8 receptor, alpha	GCCATGGAACT [C/T] CTCAGATTTC	S	C	T	L	L
G442u4	WIAF-11792	M94582	78	IL8RA, interleukin 8 receptor, alpha	ATGGAGAGTG [A/G] CAGCTTTGAA	M	A	G	D	G
G4423u1	WIAF-13752	HT2216	71	ADSL, adenylosuccinate lyase	GCTATGCCAG [C/T] CCGGAGATGT	S	C	T	S	S
G4423u2	WIAF-13794	HT2216	126	ADSL, adenylosuccinate lyase	ATGGCGGCAG [C/T] TGTGGCTGTG	S	C	T	L	L
G4423u3	WIAF-13795	HT2216	674	ADSL, adenylosuccinate lyase	AGCTTGACAA [G/A] ATGGTGACAG	S	G	A	K	K
G4428u1	WIAF-13954	HT97524	57	ADFP, adipose differentiation-related protein; adipophilin	TGGTCAACCT [G/A] CCCTTGGTGA	S	G	A	L	L
G4434u1	WIAF-13506	HT0863	551	ARF3, ADP-ribosylation factor 3	TCTGGAGACA [C/T] TACTTCCAGA	S	C	T	H	H
G444u1	WIAF-10172	U28694	398	CCR3, chemokine (C-C motif) receptor 3	CGAGATCTTT [T/G] TCATAATCCT	M	T	G	F	V
G444u2	WIAF-10181	U28694	214	CCR3, chemokine (C-C motif) receptor 3	TCCTCATAAA [A/G] TACAGGAGGC	S	A	G	K	K
G4440u1	WIAF-14054	HT1392	136	ADRBK1, adrenergic, beta, receptor kinase 1	GCAAGAAGAT [A/C] CTGCTGCCCG	S	A	C	I	I
G445u1	WIAF-10183	U40373	319	Human cell surface glycoprotein CD44 mRNA, complete cds.	TAGAAGGACA [C/T] GTGGTGATTC	S	C	T	H	H

-151-

G4456u1	WIAP-113629	HT0626	796	ALDOC, aldolase C, fructose-bisphosphate	CCCTGCTCAA [G/A] CCCAACATGG	S	G	A	K	K
G446u1	WIAP-11832	U64198	754	IL12RB2, interleukin 12 receptor, beta 2	TGAAGCCTTC [C/G] CATGTAATTT	S	C	G	S	S
G446u2	WIAP-11795	U64198	2569	IL12RB2, interleukin 12 receptor, beta 2	TTTTCTCAAC [G/A] CATTACTTCC	S	G	A	T	T
G446u3	WIAP-11833	U64198	2500	IL12RB2, interleukin 12 receptor, beta 2	TGCAAGGTAA [A/G] GCCAATTGGA	S	A	G	K	K
G446u4	WIAP-11835	U64198	1918	IL12RB2, interleukin 12 receptor, beta 2	CTCCTCGCCA [G/C] GTCTCTGCAA	M	G	C	Q	H
G446u5	WIAP-11793	U64198	991	IL12RB2, interleukin 12 receptor, beta 2	GTGGAGCAGA [G/A] ATCTTCGTTG	S	G	A	E	E
G446u6	WIAP-11794	U64198	2469	IL12RB2, interleukin 12 receptor, beta 2	AGTTCCACAG [G/C] AAATGAGAGG	M	G	C	G	A
G446a7	WIAP-13128	U64198	1964	IL12RB2, interleukin 12 receptor, beta 2	GGTGACTTGG [C/G] AGCCTCCAG	M	C	G	Q	E
G446a8	WIAP-13129	U64198	2060	IL12RB2, interleukin 12 receptor, beta 2	TCTAAACTGG [C/G] TAGGGAGTCG	M	C	G	L	V
G447u1	WIAP-11796	X03663	384	CSF1R, colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog	CCAGTGTCCTC [C/T] GAGCTGGTCG	S	C	T	P	P
G447u2	WIAP-11836	X03663	1026	CSF1R, colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog	ACAACAACAC [T/C] AAGCTCGCAA	S	T	C	T	T
G447u3	WIAP-11837	X03663	886	CSF1R, colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog	GCTGAAGTGG [C/A] AGAAAGTCAT	M	C	A	Q	K
G447u4	WIAP-11797	X03663	2425	CSF1R, colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog	GAAGAAATAT [G/A] TCCGCAGGGA	M	G	A	V	I

G4473u1	WIAF-13904	HT1352	860	FUCAL, fucosidase, alpha-L-1, tissue	TTCAAGCCAC [A/G] GAGCTTGCCA	M	A	G	Q	R
G4473u2	WIAF-13916	HT1352	440	FUCAL, fucosidase, alpha-L-1, tissue	ACAACTGGC [C/T] GAGTCCTGTG	M	C	T	P	L
G4479u1	WIAF-13637	HT1995	2465	AMPD2, adenosine monophosphate deaminase 2 (isoform L)	GCCTCAATGA [G/T] CCTGGTCCAT	-	G	T	-	-
G4479u2	WIAF-13866	HT1995	1258	AMPD2, adenosine monophosphate deaminase 2 (isoform L)	TGGATGTGCA [T/C] GCGGACAGGA	S	T	C	H	H
G4479u3	WIAF-13867	HT1995	1280	AMPD2, adenosine monophosphate deaminase 2 (isoform L)	CACCTTCCAT [C/T] GCTTTGACAA	M	C	T	R	C
G4479u4	WIAF-13868	HT1995	1201	AMPD2, adenosine monophosphate deaminase 2 (isoform L)	TGCGGGAGGT [C/T] TTTGAGAGCA	S	C	T	V	V
G4479u5	WIAF-13869	HT1995	1579	AMPD2, adenosine monophosphate deaminase 2 (isoform L)	GTACCAAGGG [C/T] CAGCTGGCCA	S	C	T	G	G
G4492u1	WIAF-14084	HT3390	866	ANX11, annexin XI (56kD autoantigen)	CCTGGGGAGT [C/T] GCTCCAACAA	M	C	T	R	C
G4492u2	WIAF-14085	HT3390	850	ANX11, annexin XI (56kD autoantigen)	AGGCCATCAT [T/C] GACTGCCTGG	S	T	C	I	I
G450u1	WIAF-10170	X85740	1196	CCR4, chemokine (C-C motif) receptor 4	TCCAAATTTA [C/T] TCTGCTGACA	S	C	T	Y	Y
G4502u1	WIAF-13510	HT4840	165	ASS, argininosuccinate synthetase	AAGGCTATGA [C/T] GTCATTTGCCT	S	C	T	D	D
G4502u2	WIAF-13511	HT4840	369	ASS, argininosuccinate synthetase	GGCCCTGCAT [C/T] GCCCGCAAC	S	C	T	I	I
G4502u3	WIAF-13512	HT4840	73	ASS, argininosuccinate synthetase	AATCCCAGAC [G/A] CTATGTCCAG	-	G	A	-	-
G4502u4	WIAF-13513	HT4840	129	ASS, argininosuccinate synthetase	TGGACACCTC [G/C] TGCATCCTCG	S	G	C	S	S
G4502u5	WIAF-13514	HT4840	285	ASS, argininosuccinate synthetase	AGTTTGTTGA [G/A] GAGTTTCATCT	S	G	A	E	E
G4502u6	WIAF-13515	HT4840	234	ASS, argininosuccinate synthetase	AGGCACTGAA [G/A] CTTGGGGCCA	S	G	A	K	K
G4502u7	WIAF-13516	HT4840	316	ASS, argininosuccinate synthetase	CCAGTCCAGC [G/A] CACTGTATGA	M	G	A	A	T

G4502u8	WIAP-13537	HT4840	426 ASS, argininosuccinate synthetase	TCCTCCACGG[C/T]GCCACAGGAA	S	C	T	G	G
G4502u9	WIAP-13538	HT4840	530 ASS, argininosuccinate synthetase	GAATCTACA[A/G]CCGGTTCAAG	M	A	G	N	S
G4502u10	WIAP-13539	HT4840	750 ASS, argininosuccinate synthetase	TTCTCGAGAT[C/T]GAGTTCAAA	S	C	T	I	I
G4502u11	WIAP-13540	HT4840	960 ASS, argininosuccinate synthetase	ATGCTCATTT[A/G]GACATCGAGG	S	A	G	L	L
G4508u1	WIAP-13663	HT28557	1767 ARSD, arylsulfatase D	CAGTTTTCCTCA[T/C]GAGCAACATC	M	T	C	M	T
G4508u2	WIAP-13693	HT28557	433 ARSD, arylsulfatase D	TTCAAGTGGAA[C/T]GCAGGCTCAG	S	C	T	N	N
G4508u3	WIAP-13694	HT28557	747 ARSD, arylsulfatase D	GGTTCTTCT[C/G]TGTCTCGGG	M	C	G	S	C
G4508u4	WIAP-13696	HT28557	1012 ARSD, arylsulfatase D	CCACGAGTGC[A/G]TTCCTGGGA	S	A	G	A	A
G4508u5	WIAP-13697	HT28557	1302 ARSD, arylsulfatase D	CGAGTGATTG[G/A]AGAGCCACG	M	G	A	G	E
G4508u6	WIAP-13698	HT28557	1285 ARSD, arylsulfatase D	GGTGCTCCC[G/A]GCCGCCGAG	S	G	A	P	P
G4508u7	WIAP-13699	HT28557	1807 ARSD, arylsulfatase D	AGCCGTGCTG[C/T]GGACATTTCC	S	C	T	C	C
G4508u8	WIAP-13718	HT28557	483 ARSD, arylsulfatase D	GCAAGAATCT[T/C]GCAGCAGCAT	M	T	C	L	S
G4518u1	WIAP-13809	HT3430	ASPA, aspartoacylase	ACAACACCAC[C/T]TCTACATGG	S	C	T	T	T
G4518u2	WIAP-13810	HT3430	851 ASPA, aspartoacylase	AAGTTGATTA[C/T]CCCCGGGATG	S	C	T	Y	Y
G4518u3	WIAP-13811	HT3430	787 ASPA, aspartoacylase	CATCATTTCA[A/G]TGAAGGAAAA	M	A	G	N	S
G4518u4	WIAP-13837	HT3430	618 ASPA, aspartoacylase	ACCCTGCTAC[G/A]TTTATCTGAT	M	G	A	V	I
G452a1	WIAP-10509	HT0695	553 APOA4, apolipoprotein A-IV	ACCCAGGTCA[A/G]CAGCGAGGCC	M	A	G	N	S
G452a2	WIAP-13124	HT0695	563 APOA4, apolipoprotein A-IV	ACACGCAGGC[C/T]GAGCAGCTGC	S	C	T	A	A
G4524u1	WIAP-14120	HT1541	726 ATP5A1, ATP synthase, H <sup>+</sup> transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle	CTCAATTGCT[A/G]TTGACACAAT	M	A	G	I	V

G4524u2	WIAF-14131	HT1541		153	ATP5A1, ATP synthase, H <sup>+</sup> transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle	ATCTTTCAAT [G/T] CTGCAAGGAA	M	G	T	A	S
G4526u1	WIAF-14130	HT4994		400	ATP5D, ATP synthase, H <sup>+</sup> transporting, mitochondrial F1 complex, delta subunit	TCCATCGCAG [T/C] GNAACCGGAC	M	T	C	V	A
G453u1	WIAF-10138	HT0768		1747	PDGFRB, platelet-derived growth factor receptor, beta polypeptide	CTGCCGCCCA [C/T] GCTGCTGGGG	M	C	T	T	M
G453u2	WIAF-10147	HT0768		2957	PDGFRB, platelet-derived growth factor receptor, beta polypeptide	TTTTGCCTTT [A/G] AAGTGGATGG	S	A	G	L	L
G453u3	WIAF-10148	HT0768		3608	PDGFRB, platelet-derived growth factor receptor, beta polypeptide	AGCCGGAGCC [A/G] GAGCTGGAAC	S	A	G	P	P
G453u4	WIAF-10149	HT0768		457	PDGFRB, platelet-derived growth factor receptor, beta polypeptide	CAGGGCCTGG [T/G] CGTCACACCC	M	T	G	V	G
G453u5	WIAF-10151	HT0768		1505	PDGFRB, platelet-derived growth factor receptor, beta polypeptide	AGCTGACACT [G/C] GTTCGGGTGA	S	G	C	L	L
G453u6	WIAF-10153	HT0768		3446	PDGFRB, platelet-derived growth factor receptor, beta polypeptide	ACCCCAAACC [C/T] GAGGTTGCTG	S	C	T	P	P
G453u7	WIAF-10161	HT0768		2030	PDGFRB, platelet-derived growth factor receptor, beta polypeptide	TTTGGCAGAA [G/A] AAGCCACGTT	S	G	A	K	K
G4533u1	WIAF-13616	HT1618		343	ATP synthase, H <sup>+</sup> transporting, subunit D, vacuolar	GTTACATGAT [C/T] GACAACGTGA	S	C	T	I	I
G4534u1	WIAF-13569	HT3556		654	ATP6E, ATPase, H <sup>+</sup> transporting, lysosomal (vacuolar proton pump) 31kD	TAAAGGTTTC [C/T] AACACCTCGG	S	C	T	S	S

G4535u1	WIAF-13747	HT27972	357	ATP50, ATP synthase, H <sup>+</sup> transporting, mitochondrial F1 complex, O subunit (oligomycin sensitivity conferring protein)	TCACTACCAA [C/T] CTGATCAATT	S	C	T	N	N
G4535u2	WIAF-13748	HT27972	144	ATP50, ATP synthase, H <sup>+</sup> transporting, mitochondrial F1 complex, O subunit (oligomycin sensitivity conferring protein)	AGGTATACGG [T/C] ATTGAAGTTC	S	T	C	G	G
G4535u3	WIAF-13792	HT27972	329	ATP50, ATP synthase, H <sup>+</sup> transporting, mitochondrial F1 complex, O subunit (oligomycin sensitivity conferring protein)	ATCACAGCAA [A/G] AGAGAGTTTC	M	A	G	K	R
G4539u1	WIAF-13711	HT48520	288	ATPase, 14 kDa subunit, vacuolar	TGCCCTGGAC [G/A] CCCACGACGA	M	G	A	A	T
G4548u1	WIAF-14127	HT1574	3138	ATPase, Ca <sup>2+</sup> transporting, plasma membrane, isoform 2	CGCAATGTCT [T/C] TGACGGCATC	M	T	C	F	S
G4548u2	WIAF-14137	HT1574	2089	ATPase, Ca <sup>2+</sup> transporting, plasma membrane, isoform 2	GCACTATCTG [C/T] GTGGCCTACC	S	C	T	C	C
G4548u3	WIAF-14140	HT1574	2924	ATPase, Ca <sup>2+</sup> transporting, plasma membrane, isoform 2	CAGGACCATG [A/T] TGAAGACAT	M	A	T	M	L
G4549u1	WIAF-14161	HT1346	524	ATP2B4, ATPase, Ca <sup>++</sup> transporting, plasma membrane 4	TGCACGTACC [C/T] AGATTATGT	N	C	T	Q	*
G4549u2	WIAF-14162	HT1346	715	ATP2B4, ATPase, Ca <sup>++</sup> transporting, plasma membrane 4	ATGTCACGCT [C/T] ATCATCCTGG	S	C	T	L	L
G4549u3	WIAF-14163	HT1346	508	ATP2B4, ATPase, Ca <sup>++</sup> transporting, plasma membrane 4	AGCTGCGTTC [G/A] AGGGATGCAC	S	G	A	S	S
G4549u4	WIAF-14166	HT1346	1084	ATP2B4, ATPase, Ca <sup>++</sup> transporting, plasma membrane 4	TGATCCAAGG [G/A] AATGATCTGA	S	G	A	G	G



G4552u1	WIAF-13630	HT0867			ATP7A, ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome)	710		TACTACACT [A/G] TTGAAGGAAA	M	A	G	I	V
G456u1	WIAF-10074	HT2834			EDN1, endothelin 1	408		CCTGGGGCT [T/G] CGCCGGTCCA	S	T	G	L	L
G456u2	WIAF-10075	HT2834			EDN1, endothelin 1	585		CAGACGTGA [A/G] AATAGATGCC	S	A	G	E	E
G456a3	WIAF-10507	HT2834			EDN1, endothelin 1	861		TGAAAGGCAA [T/G] CCCTCCAGAG	M	T	G	K	N
G4565u1	WIAF-14041	HT28561			ATP1G1, ATPase, Na+/K+ transporting, gamma 1 polypeptide	320		CGAGGCTGCT [G/A] TTACGGCTCA	S	G	A	L	L
G4565u2	WIAF-14062	HT28561			ATP1G1, ATPase, Na+/K+ transporting, gamma 1 polypeptide	216		CAGTGACGG [G/A] ACAAGGTCT	M	G	A	D	N
G4565u3	WIAF-14063	HT28561			ATP1G1, ATPase, Na+/K+ transporting, gamma 1 polypeptide	315		ACCGCCGAGG [C/A] TGCTGTACG	M	C	A	L	M
G4565u4	WIAF-14064	HT28561			ATP1G1, ATPase, Na+/K+ transporting, gamma 1 polypeptide	531		TTTCCCCAGG [T/C] GAATGGGCTG	N	T	C	*	R
G4568u1	WIAF-14212	HT0082			AMFR, autocrine motility factor receptor	717		TGCTCATGC [A/G] TACGTCCAC	M	A	G	I	V
G457a1	WIAF-10489	HT2903			SELL, selectin L (lymphocyte adhesion molecule 1)	321		ACAAATCTCT [C/T] ACTGAAGAAG	S	C	T	L	L
G457a2	WIAF-10490	HT2903			SELL, selectin L (lymphocyte adhesion molecule 1)	577		CCAGTGTCTAG [T/C] TTGTGATTCA	M	T	C	F	L
G457a3	WIAF-10491	HT2903			SELL, selectin L (lymphocyte adhesion molecule 1)	601		TGAGCCTTTG [G/C] AGGCCCCAGA	M	G	C	E	Q
G457a4	WIAF-10492	HT2903			SELL, selectin L (lymphocyte adhesion molecule 1)	637		CTGTACTCAC [C/T] CTTTGGGAAA	M	C	T	P	S
G4573u1	WIAF-13568	HT28320			MGAT2, mannosyl (alpha-1,6-) - glycoprotein beta-1,2-N-acetylglucosaminyltransferase	943		CGGACAACT [G/T] ACGCTGCGGT	S	G	T	L	L

G4574u1	WIAF-13805	HT0198	163	beta-1,4 N-acetylglactosaminyltransferase	CGGCTCCGG [C/G]TACCTCTTGC	M	C	G	L	V
G4574u2	WIAF-13806	HT0198	415	beta-1,4 N-acetylglactosaminyltransferase	TGCCACAAGA [G/A]AGCAGGAGTT	M	G	A	E	K
G4574u3	WIAF-13807	HT0198	726	beta-1,4 N-acetylglactosaminyltransferase	AACTACAACT [G/T]GTCACCTTACA	S	G	T	L	L
G4574u4	WIAF-13836	HT0198	559	beta-1,4 N-acetylglactosaminyltransferase	AGGCTGAGC [C/A]TTCAGGCAGC	M	C	A	L	I
G4575u1	WIAF-13626	HT0341	1251	CCNT1, glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-acetylglucosaminyltransferase)	AGTATGATCT [A/G]TCTGACATGC	S	A	G	L	L
G4577u1	WIAF-13971	HT1495	1268	SIAT1, sialyltransferase 1 (beta-galactoside alpha-2,6-sialyltransferase)	ATTCTTTTAA [C/T]AATCAACAAGA	S	C	T	N	N
G458u1	WIAF-10063	HT2968	1464	ALB, albumin	GTCCAGAGA [C/A]TATCTATCCG	M	C	A	D	E
G458u2	WIAF-10089	HT2968	1470	ALB, albumin	AAGACTATCT [A/C]TCCGTGGTCC	S	A	C	L	L
G458u3	WIAF-10091	HT2968	1707	ALB, albumin	TGTTGAGCT [C/T]GTGAACACA	S	C	T	L	L
G458a4	WIAF-10504	HT2968	889	ALB, albumin	CAGGCGGAC [C/T]TTGCCAAGTA	M	C	T	L	F
G458a5	WIAF-10508	HT2968	1475	ALB, albumin	TATCTATCCG [T/A]GGTCTGAAC	M	T	A	V	E
G458a6	WIAF-12091	HT2968	1330	ALB, albumin	CCAGATGCG [C/T]TATTAGTTCCG	S	C	T	L	L
G458a7	WIAF-12092	HT2968	1408	ALB, albumin	CCTAGGAAA [G/a]TGGGCAGCAA	M	G	a	V	M
G4592u1	WIAF-14126	HT2128	985	branched-chain keto acid dehydrogenase E1, alpha polypeptide	ACCAGCCCTT [T/C]CTCATCGAGG	S	T	C	F	F
G4593u1	WIAF-13574	HT97373	1743	BRCA1, BRCA1 associated RING domain 1	CCTAGCCACT [G/C]CTCAGTAATG	M	G	C	C	S
G4593u2	WIAF-13592	HT97373	1167	BRCA1, BRCA1 associated RING domain 1	TGTTCTTCAC [C/T]ACCTTCATGC	M	C	T	P	L
G4593u3	WIAF-13593	HT97373	1591	BRCA1, BRCA1 associated RING domain 1	AGAATGGCA [C/T]GTGGATATAG	S	C	T	H	H
G4593u4	WIAF-13594	HT97373	2030	BRCA1, BRCA1 associated RING domain 1	AAAGTATGAA [A/G]TTCCTGAAGG	M	A	G	I	V

G4593u5	WIAF-13595	HT97373	2006	BARD1, BRCA1 associated RING domain 1	AAGAAAAAGTA [T/C]GTGAACAGGA	M	T	C	C	R
G4599u1	WIAF-13920	HT4273	1803	CDH13, cadherin 13, H-cadherin (heart)	TCGTACCCGA [C/T]GTCTCTACG	S	C	T	D	D
G4614u1	WIAF-13733	HT4835	91	S100A3, S100 calcium-binding protein A3	AGATGGCCA [G/A]GCCTCTGGAG	M	G	A	R	K
G4614u2	WIAF-13734	HT4835	203	S100A3, S100 calcium-binding protein A3	TGCTGCAGAA [G/A]GAGCTGGCCA	S	G	A	K	K
G4614u3	WIAF-13769	HT4835	344	S100A3, S100 calcium-binding protein A3	TCTACTGCCA [C/T]GAGTACTTCA	S	C	T	H	H
G462u1	WIAF-10134	HT4753	600	PDGFA, platelet-derived growth factor alpha polypeptide	ACGGGTCCA [C/T]GCCACTAAGC	S	C	T	H	H
G4627u1	WIAF-14042	HT0771	186	ANX6, annexin VI (p68)	GGAGGCCATA [C/T]TGGACATAAT	S	C	T	L	L
G4627u2	WIAF-14043	HT0771	1664	ANX6, annexin VI (p68)	CAGACACACC [T/C]AGTGGAGACA	S	T	C	P	P
G4627u3	WIAF-14067	HT0771	1498	ANX6, annexin VI (p68)	AAGGAGGACTIA [G/T]CAACAATCC	M	A	G	Y	C
G4644u1	WIAF-13801	HT1736	1990	CPS1, carbamoyl-phosphate synthetase 1, mitochondrial	TGGTGGAGAA [G/A]TCAGTGACAG	S	G	A	K	K
G4644u2	WIAF-13802	HT1736	1866	CPS1, carbamoyl-phosphate synthetase 1, mitochondrial	ATTGGCTACC [C/T]AGTGTGATC	M	C	T	P	L
G4644u3	WIAF-13803	HT1736	1993	CPS1, carbamoyl-phosphate synthetase 1, mitochondrial	TGGAGAAGTC [A/C]GTGACAGGTT	S	A	C	S	S
G4644u4	WIAF-13804	HT1736	1860	CPS1, carbamoyl-phosphate synthetase 1, mitochondrial	GACACCATTTG [G/A]CTACCCAGTG	M	G	A	G	D
G4644u5	WIAF-13831	HT1736	1087	CPS1, carbamoyl-phosphate synthetase 1, mitochondrial	AGCCTGTTTT [G/T]AATATCACAA	M	G	T	L	F
G4644u6	WIAF-13835	HT1736	1958	CPS1, carbamoyl-phosphate synthetase 1, mitochondrial	CACAAGGCC [T/C]TTGCTATGAC	M	T	C	F	L
G4644u7	WIAF-13855	HT1736	1332	CPS1, carbamoyl-phosphate synthetase 1, mitochondrial	AAGCTACCA [C/A]CATTACATCA	M	C	A	T	N
G4659u1	WIAF-14143	HT1183	1830	Catenin, alpha	GTGCCAAGCT [T/C]CCTCAACCGT	S	T	C	V	V

G466u1	WIAF-13164	U00958	2403	SREBF1, sterol regulatory element binding transcription factor 1	AGCAGTGGCC [G/A] CCAGCCTGTC	M	G	A	R	H
G4662u1	WIAF-13710	HT2142	2183	CTNBN1, catenin (cadherin-associated protein), beta-1 (88kD)	TTTGTCTCG [A/C] ATGCTGAGG	S	A	C	R	R
G467a1	WIAF-13304	X72861	827	ADRB3, adrenergic, beta-3-, receptor	GGCCATCGCC [T/C] GGACTCCGAG	M	T	C	H	R
G467a2	WIAF-13305	X72861	832	ADRB3, adrenergic, beta-3-, receptor	TGCGCTGGAC [T/A] CCGAGACTCC	S	T	A	T	T
G467a3	WIAF-13306	X72861	870	ADRB3, adrenergic, beta-3-, receptor	TTGCTGACTT [C/T] GCTGCGCGCA	M	C	T	S	L
G467a4	WIAF-13307	X72861	1761	ADRB3, adrenergic, beta-3-, receptor	TGCGCGCGCG [C/T] CGGCGCGGCC	M	C	T	A	V
G467a5	WIAF-13308	X72861	1899	ADRB3, adrenergic, beta-3-, receptor	TCTGTGTGATC [A/C] GAACCTGTGG	-	A	C	-	-
G4671u1	WIAF-13956	HT1925	161	NDUFB7, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7	TGGTGGCCAC [A/G] CAGCAGGAGA	S	A	G	T	T
G4673u1	WIAF-13889	HT0191	1349	CDC25A, cell division cycle 25A	TCTGGGGCCA [G/C] CCCCAGAG	M	G	C	S	T
G4674u1	WIAF-13821	HT1393	261	CDC25B, cell division cycle 25B	ACGACCTCG [C/T] GGGCTGGCA	S	C	T	A	A
G4674u2	WIAF-13822	HT1393	1297	CDC25B, cell division cycle 25B	GATGTGGCC [C/T] TATTGACGG	S	C	T	L	L
G4674u3	WIAF-13823	HT1393	1083	CDC25B, cell division cycle 25B	ATAAGCGGAG [G/A] CGAGCGTGA	S	G	A	R	R
G4674u4	WIAF-13827	HT1393	1446	CDC25B, cell division cycle 25B	AGAGCCCCAT [C/T] GCGCCCTGTA	S	C	T	I	I
G468a1	WIAF-13309	L37019	192	ASIP, agouti (mouse)-signaling protein	AAATCAAAAC [C/A] GATCGGCAGA	M	C	A	P	Q
G4691u1	WIAF-13753	HT97602	179	CKMBR9, chemokine (C-C motif) receptor 9	TATAGCCTGA [T/A] TTTTGTGTTG	M	T	A	I	N
G4691u2	WIAF-13754	HT97602	134	CKMBR9, chemokine (C-C motif) receptor 9	AAGGATGCAG [T/C] GGTGTCTTT	M	T	C	V	A
G4691u3	WIAF-13755	HT97602	193	CKMBR9, chemokine (C-C motif) receptor 9	TGTGTGGGCG [C/T] TCAGCGGGAA	M	C	T	L	P

G4691u4	WIAP-13756	HT97602	770	CMKBR9, chemokine (C-C motif) receptor 9	AAATAGCTG [C/T] AGCCTTGGTG	M	C	T	A	V
G4691u5	WIAP-13759	HT97602	1130	CMKBR9, chemokine (C-C motif) receptor 9	TCTGAGAACT [A/C] CCTAACAAG	M	A	C	Y	S
G4691u6	WIAP-13796	HT97602	482	CMKBR9, chemokine (C-C motif) receptor 9	AGGCTGAGGA [C/A] CCGGGCCAAG	M	C	A	T	N
G4691u7	WIAP-13797	HT97602	259	CMKBR9, chemokine (C-C motif) receptor 9	GATGGTTGAG [A/G] TCTATCTGCT	M	A	G	I	V
G4691u8	WIAP-13798	HT97602	434	CMKBR9, chemokine (C-C motif) receptor 9	ATGAGGCTGG [A/G] CAGGTACCTG	M	A	G	D	G
G4691u9	WIAP-13799	HT97602	755	CMKBR9, chemokine (C-C motif) receptor 9	CAGGGCCGG [C/T] TTTAAAAATA	M	C	T	A	V
G4699u1	WIAP-14040	HT4277	1426	BAAT, bile acid Coenzyme A: amino acid N-acyltransferase (glycine N-choyltransferase)	TTCCAGATGT [G/T] ACCAGTCAC	S	G	T	V	V
G4726u1	WIAP-14128	HT48614	1606	AOC3, amine oxidase, copper containing 3 (vascular adhesion protein 1)	TCCACCCGAG [T/C] GGGGCCATAG	S	T	C	S	S
G4726u2	WIAP-14129	HT48614	2342	AOC3, amine oxidase, copper containing 3 (vascular adhesion protein 1)	TTCTTAACAC [A/G] GTGACTGTGG	S	A	G	T	T
G4726u3	WIAP-14141	HT48614	659	AOC3, amine oxidase, copper containing 3 (vascular adhesion protein 1)	CCTGCCCTAT [C/T] ACCGACGCC	M	C	T	H	Y
G4744u1	WIAP-13683	HT2599	564	CTH, cystathionase (cystathionine gamma-lyase)	ATATTGTCCA [T/C] AAGCATGGAG	S	T	C	H	H
G4748u1	WIAP-14144	HT1061	242	CYBA, cytochrome b-245, alpha polypeptide	GGGACAGAAG [C/T] ACATGACCGC	M	C	T	H	Y
G4748u2	WIAP-14145	HT1061	265	CYBA, cytochrome b-245, alpha polypeptide	TGGTCAAGCT [G/C] TTCGGGCCCT	S	G	C	L	L
G4750u1	WIAP-14116	HT48417	156	CYB5, cytochrome b-5	TGAAGTACTA [C/T] ACCCTAGAGG	S	C	T	Y	Y
G4751u1	WIAP-13770	HT1285	495	UQCRC2, ubiquinol-cytochrome c reductase core protein II	AGATTTCCTG [C/A] GTTGGGAAGT	M	C	A	R	S

G4788u1	WIAF-13931	HT28249	1864	DSC3, desmocollin 3	CTGTGATCG [T/C] GATGAACCTG	S	T	C	P	P
G4788u2	WIAF-13933	HT28249	2000	DSC3, desmocollin 3	TGGATTTCAA [G/T] BATATACCAT	N	G	T	E	*
G4788u3	WIAF-13945	HT28249	2524	DSC3, desmocollin 3	ACACTTACTC [G/A] GAGTGGCACA	S	G	A	S	S
G479u1	WIAF-12567	U36310	894	GPD2, glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	GOGAAAGTGC [A/G] TGTGAGCGGC	M	A	G	H	R
G479u2	WIAF-12574	U36310	1657	GPD2, glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	CTGGCAAAAG [G/T] TGGCCTATTG	M	G	T	R	S
G479u3	WIAF-12575	U36310	1131	GPD2, glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	GTTATTTTCT [T/C] CTTACCCCTGG	M	T	C	F	S
G480u1	WIAF-12175	HT336	250	GRB2, growth factor receptor-bound protein 2	AATGAAACCA [C/A] ATCCGTGGTT	M	C	A	H	N
G4819u1	WIAF-13985	HT97576	1804	EYAL1, eyes absent (Drosophila) homolog 1	CCCTGCACCA [T/C] GCCTTGGAAC	S	T	C	H	H
G482u1	WIAF-12181	J04501	1186	GYS1, glycogen synthase 1 (muscle)	CTGACGTCTT [T/C] CTGGAGGCAT	S	T	C	F	F
G482u2	WIAF-12195	J04501	1406	GYS1, glycogen synthase 1 (muscle)	CCTTCCCGAC [A/G] TGAACAAGAT	M	A	G	M	V
G4827u1	WIAF-14177	HT97477	68	elongation	CGAGCTGGCC [A/G] TGATGGTGAT	M	A	G	H	R
G483a1	WIAF-12113	HT4341	1850	GSY2	TTACCAGCAT [G/T] CCAGCACCT	M	G	T	A	S
G483u2	WIAF-12148	HT4341	1130	GSY2	GTTTTTCATT [A/C] TGCCTGCCAA	M	A	C	M	L
G483u3	WIAF-12149	HT4341	880	GSY2	GCTTGAATGT [T/G] AAGAAATTTT	S	T	G	V	V
G483u4	WIAF-12150	HT4341	1115	GSY2	CATCACAGTG [G/A] TGGTGTTTTT	M	G	A	V	M
G483u5	WIAF-12155	HT4341	1230	GSY2	GAAAAGTTTG [G/A] AAAAAAACTC	M	G	A	G	E
G483u6	WIAF-12159	HT4341	2033	GSY2	TGAGAGATAC [G/A] ATGAGGAAGA	M	G	A	D	N
G483u7	WIAF-12160	HT4341	1836	GSY2	TACTTAGGCA [G/C] ATATTACCAG	M	G	C	R	T
G483u8	WIAF-12161	HT4341	1678	GSY2	CTTAGGGTAT [T/C] TACATCGTTG	S	T	C	I	I
G483u9	WIAF-12177	HT4341	790	GSY2	CGGCTCAGT [G/C] TTCACACGG	S	G	C	V	V
G483u10	WIAF-12188	HT4341	1728	GSY2	TGCAATCAGC [T/C] GACTAAGTTT	M	T	C	L	P
G484u1	WIAF-12151	HT5111	487	GSY3	CATCAAGTGA [A/G] TTGGCAATGG	M	A	G	I	V
G484u2	WIAF-12187	HT5111	1141	GSY3	AACCGGGA [C/T] AATCCGAGA	N	C	T	Q	*
G489u1	WIAF-12152	HT2607	1181	IRS1, insulin receptor substrate 1	AAGAAGTGGC [G/A] GCACAAGTCG	M	G	A	R	Q
G489u2	WIAF-12184	HT2607	1031	IRS1, insulin receptor substrate 1	ATGGCGAGCC [C/T] TCCGGAGAGC	M	C	T	P	L
G492a1	WIAF-13345	L08603	307	MC4R, melanocortin 4 receptor	AGNAACCAT [A/G] TCATCACCCCT	M	A	G	I	V

G493u1	WIAF-12154	X67594			346	MC1R, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)	CGCGCTGGTG [G/T] TGCCCAACCAT	M	G	T	V	L
G493u2	WIAF-12167	X67594			646	MC1R, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)	GACCTGCCG [C/T] GGCGCGGCA	M	C	T	R	M
G493u3	WIAF-12170	X67594			1110	MC1R, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)	AGGTGCTGAC [A/G] TGCTCTGGT	S	A	G	T	T
G493u4	WIAF-12186	X67594			442	MC1R, melanocortin 1 receptor (alpha melanocyte stimulating hormone receptor)	CGGAGCAAC [G/T] TGCTGAGAC	M	G	T	V	L
G498u1	WIAF-11809	J04127			1305	CYP19, cytochrome P450, subfamily XIX (aromatization of androgens)	CTTATAGGTA [C/T] TTTGAGCCAT	S	C	T	Y	Y
G498u2	WIAF-11810	J04127			1377	CYP19, cytochrome P450, subfamily XIX (aromatization of androgens)	TGAAAGCCAT [C/T] CTCGTTACAC	S	C	T	I	I
G498u3	WIAF-11811	J04127			1406	CYP19, cytochrome P450, subfamily XIX (aromatization of androgens)	CGATTCCACG [T/C] GAAGACATTG	M	T	C	V	A
G498u4	WIAF-11838	J04127			1055	CYP19, cytochrome P450, subfamily XIX (aromatization of androgens)	ATTGGTGAGA [G/A] AGACATAAAG	M	G	A	R	K
G498u5	WIAF-11800	J04127			1001	CYP19, cytochrome P450, subfamily XIX (aromatization of androgens)	ATTGCAAGC [A/G] CCTAATGTT	M	A	G	H	R
G499u1	WIAF-11785	HT1439			2142	ESR1, estrogen receptor 1	TCCCTGCCAC [A/G] GTCTGAGAGC	S	A	G	T	T
G499u2	WIAF-11801	HT1439			443	ESR1, estrogen receptor 1	CCCTGAACC [G/A] TCCGAGCTC	M	G	A	R	H
G500u1	WIAF-11803	X99101			793	ESR1, estrogen receptor 1	CATGATCAG [T/C] GGCCCAAGAA	M	T	C	W	R

G500u2	WIAF-11816	X99101	489	ESR1, estrogen receptor 1	GGAAGTGTGA [C/T] GAAGTGGGAA	S	C	T	Y	Y
G500u3	WIAF-11817	X99101	474	ESR1, estrogen receptor 1	AGGCTGCGG [A/G] CTTGGAAGT	S	A	G	R	R
G505u1	WIAF-11824	HT1113	1063	PRLR, prolactin receptor	GCTTGAAGG [G/A] CTATAGCATG	M	G	A	G	D
G505u2	WIAF-11827	HT1113	2083	PRLR, prolactin receptor	GCAACATCAA [G/A] CAAGTGCAGG	M	G	A	S	N
G505u3	WIAF-11787	HT1113	582	PRLR, prolactin receptor	GAGGACATAC [A/G] TCATGATGTT	M	A	G	I	V
G505u4	WIAF-11802	HT1113	792	PRLR, prolactin receptor	CCTGTATGAA [A/C] TTCGATTAAA	M	A	C	I	L
G509u1	WIAF-11789	M32313	378	SRD5A1, steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)	CACTGTGGG [A/G] TGTACAATGG	S	A	G	A	A
G510a1	WIAF-13348	U17280	582	STAR, steroidogenic acute regulatory protein	CCAATGTCAA [G/A] GAGATCAAGG	S	G	A	K	K
G52u1	WIAF-10224	HT0488	1139	Inhibin, beta B	CCAACATGAT [T/C] GTGGAGGAGT	S	T	C	I	I
G520u1	WIAF-13507	D31770	517	ACVR2, activin A receptor, type II	CTTATTTTCC [G/A] GAGATGGAAG	S	G	A	P	P
G520u2	WIAF-13532	D31770	1177	ACVR2, activin A receptor, type II	CAGCTTGCAT [T/G] GCTGACTTTG	M	T	G	I	M
G520u3	WIAF-13533	D31770	1189	ACVR2, activin A receptor, type II	CTGACTTTGG [G/C] TTGGCCTTAA	S	G	C	G	G
G520u4	WIAF-13534	D31770	1024	ACVR2, activin A receptor, type II	TCTCTTGGAA [T/C] GAACTGTGTC	S	T	C	N	N
G523u1	WIAF-12155	HT4996	538	OXTR, oxytocin receptor	TGAGCGGAA [C/T] GCGTGTGTGC	S	C	T	N	N
G523u2	WIAF-12180	HT4996	1057	OXTR, oxytocin receptor	TCTGGCAGAA [C/T] TTGCGGCTCA	S	C	T	N	N
G524a1	WIAF-13349	L05144	190	PK1, phosphoenolpyruvate carboxykinase 1 (soluble)	TGGACAGCCT [G/A] CCCCAGGCAG	S	G	A	L	L
G528u1	WIAF-11831	V00572	988	PK1, phosphoglycerate kinase 1	AAGCCACTGT [G/C] GCTTCTGGCA	S	G	C	V	V
G53u1	WIAF-10307	HT0508	723	DNA repair protein XRCC1	CCAGCGACCC [G/A] GCAGGACCTA	S	G	A	P	P
G53u2	WIAF-10308	HT0508	746	DNA repair protein XRCC1	TATGCAGCTG [C/T] TACCCCTCCAG	M	C	T	A	V
G53u3	WIAF-10309	HT0508	1884	DNA repair protein XRCC1	GGGATCCACG [C/T] TTTGAGGAGG	S	C	T	S	S
G53u4	WIAF-10362	HT0508	425	DNA repair protein XRCC1	AACCCCAACC [G/A] CGTTGCGCATG	M	G	A	R	H
G534a1	WIAF-13310	U28281	1284	SCTR, secretin receptor	GCTTCTCTAA [T/C] GGGGAGGTGC	S	T	C	N	N
G534a2	WIAF-13311	U28281	1404	SCTR, secretin receptor	AGCAGAGCCA [G/A] GGCACCTGCA	S	G	A	Q	Q
G535u1	WIAF-12157	HT5001	1158	SHC1	ATGCTCTTGG [G/C] GTGCTCTCCAC	S	G	C	R	R
G535u2	WIAF-12196	HT5001	774	SHC1	ATGAGGAGGA [G/A] GAAGAGCCAC	S	G	A	E	E



G536u1	WIAF-13923	M20747			SLC2A4, solute carrier family 2 (facilitated glucose transporter), member 4	535			GCCTGGCAA[C/T]GCTGCTGCT	S	C	T	N	N
G538u1	WIAF-11812	M55531			SLC2A5, solute carrier family 2 (facilitated glucose transporter), member 5	438			GCAGCAGAGT[C/T]GCCACATCAT	S	C	T	V	V
G538u2	WIAF-11813	M55531			SLC2A5, solute carrier family 2 (facilitated glucose transporter), member 5	124			GACGCTTGTC[C/T]TTGCCCTGGC	M	C	T	L	F
G538u3	WIAF-11791	M55531			SLC2A5, solute carrier family 2 (facilitated glucose transporter), member 5	816			ACAGGGAGGT[G/A]GCCGAGATCC	S	G	A	V	V
G539u1	WIAF-12158	K03195			Human (HepG2) glucose transporter gene mRNA, complete cds.	224			TCATGCTGGC[T/C]GTGGGAGAG	S	T	C	A	A
G539u2	WIAF-12191	K03195			Human (HepG2) glucose transporter gene mRNA, complete cds.	1244			CCATCGCGCT[A/G]GCACGTGCTGG	S	A	G	L	L
G540a1	WIAF-12114	HT960			WIAF-12114	1100	SOS1		AGTGAAGATC[A/C]AGAAGACAAG	M	A	C	Q	P
G540u2	WIAF-12165	HT960			WIAF-12165	933	SOS1		ATGATCGTTT[C/T]CTTAGTCAGT	S	C	T	F	F
G540u3	WIAF-12178	HT960			WIAF-12178	399	SOS1		TACTAGCAGT[C/T]TTAGAATACA	S	C	T	V	V
G540u4	WIAF-12193	HT960			WIAF-12193	195	SOS1		CTCAGCCCG[A/C]AGTCTTCAG	S	A	C	R	R
G540u5	WIAF-12197	HT960			WIAF-12197	1329	SOS1		GTTGTAATGA[A/G]TTTATAATGG	S	A	G	E	B
G540u6	WIAF-12198	HT960			WIAF-12198	1339	SOS1		ATTATAATG[G/A]AAGAACTCT	M	G	A	E	K
G543a1	WIAF-13312	J00306			WIAF-13312	1373	SST, somatostatin		AAGCAGGAAC[T/C]GGCAAGTAC	M	T	C	L	P
G543a2	WIAF-13313	J00306			WIAF-13313	1603	SST, somatostatin		AGTATTGTCC[A/G]TATCAGACCT	-	A	G	-	-
G544u1	WIAF-12174	HT27489			SUR, sulfonylurea receptor (hyperinsulinemia)	982			CCATTGACAT[G/C]GCCACGGAAA	M	G	C	M	I
G546u1	WIAF-13618	HT225			TKT, transketolase (Wernicke- Korsakoff syndrome)	426			GCTACATTGC[C/T]GAGCAGAAC	S	C	T	A	A
G551u1	WIAF-11709	HT1118			TNFRSF1B, tumor necrosis factor receptor superfamily, member 1B	257			GCTGCAGCAA[A/G]TGCTCGCGG	S	A	G	K	K

G555lu2	WIAF-11710	HT1118	449	TNFRSF1B, tumor necrosis factor receptor superfamily, member 1B	TCTGCACCTG [C/T]AGGCCCGGCT	S	C	T	C	C
G555lu3	WIAF-11719	HT1118	648	TNFRSF1B, tumor necrosis factor receptor superfamily, member 1B	GATCTGTAAC [G/A]TGGTGGCCAT	M	G	A	V	M
G555lu4	WIAF-11673	HT1118	676	TNFRSF1B, tumor necrosis factor receptor superfamily, member 1B	AATGCAAGCA [T/G]GGATGCAGTC	M	T	G	M	R
G555lu5	WIAF-11720	HT1118	808	TNFRSF1B, tumor necrosis factor receptor superfamily, member 1B	CCAAGCAGCT [C/T]CTTCTGCTC	M	C	T	S	F
G552u1	WIAF-12229	HT5108	384	TRAP3	GCCGCTGCC [G/A]CTCATGCTGA	S	G	A	P	P
G555u1	WIAF-12211	U94592	478	UCP2, uncoupling protein 2 (mitochondrial, proton carrier)	CGCGTTACAG [T/C]CAGGCCCCAG	M	T	C	V	A
G556u1	WIAF-11804	AF001787	480	UCP2, uncoupling protein 2 (mitochondrial, proton carrier)	TGGGCGCTCA [T/C]GACTCCGTC	S	T	C	Y	Y
G556u2	WIAF-11805	AF001787	563	UCP2, uncoupling protein 2 (mitochondrial, proton carrier)	TGCACCCACAG [G/A]AGCCATGGCG	M	G	A	G	E
G556u3	WIAF-11823	AF001787	1113	UCP2, uncoupling protein 2 (mitochondrial, proton carrier)	TACGGGAATC [A/G]CGTTTTGAA	S	A	G	S	S
G556u4	WIAF-11782	AF001787	386	UCP2, uncoupling protein 2 (mitochondrial, proton carrier)	ATCTTGACCA [T/C]GGTGGGACT	M	T	C	M	T
G561a1	WIAF-12111	HT1176	2430	IDB, insulin-degrading enzyme	ACTGTGGCAT [C/A]GAGATATACT	S	C	A	I	I
G561u2	WIAF-12222	HT1176	3099	IDB, insulin-degrading enzyme	ATATTAACTT [C/G]ATGGCTGCCAA	M	C	G	P	L
G562u1	WIAF-12223	HT27503	680	tumor necrosis factor receptor type 1 associated protein	CCTGTAGTGA [A/C]TCGGCCGCTG	M	A	C	N	T
G562u2	WIAF-12224	HT27503	900	tumor necrosis factor receptor type 1 associated protein	CGCTGCAGCG [C/A]CTGGTGAGG	S	C	A	R	R

G573u1	WIAF-12199	HT28094	469 SSTR1, somatostatin receptor 1	GGACCGCTAC [G/C] TGGCCGTGGT	M	G	C	V	L
G573u2	WIAF-12208	HT28094	480 SSTR1, somatostatin receptor 1	TGGCCGTGGT [G/A] CATCCCATCA	S	G	A	V	V
G573u3	WIAF-12209	HT28094	879 SSTR1, somatostatin receptor 1	TGCAGCTGGT [T/C] AACGTGTTTG	S	T	C	V	V
G574u1	WIAF-11822	HT4058	1054 SSTR5, somatostatin receptor 5	GCACGGAGC [C/T] GCGTCCAGAC	M	C	T	P	L
G575u1	WIAF-12200	HT28095	99 SSTR3, somatostatin receptor 3	ACGTGTCGGC [G/A] GGCCCAAGCC	S	G	A	A	A
G575u2	WIAF-12217	HT28095	453 SSTR3, somatostatin receptor 3	CCACCCGCTC [G/A] GCCCGCTGGC	S	G	A	S	S
G585u1	WIAF-12204	HT1022	1133 PYGL, phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)	AGCTGAATGA [T/C] ACTCACCTTC	S	T	C	D	D
G585u2	WIAF-12205	HT1022	1988 PYGL, phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)	AGCTGATCAC [T/C] TCAGTGGCAG	S	T	C	T	T
G585u3	WIAF-12225	HT1022	1883 PYGL, phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)	TGTACAACCG [C/T] ATTAAGAAG	S	C	T	R	R
G585u4	WIAF-12236	HT1022	2037 PYGL, phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)	AAGCAAGTTG [A/G] AAGTCATCTT	M	A	G	K	E
G585u5	WIAF-12231	HT1022	1387 PYGL, phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)	GATGTGGACC [C/G] TCTGAGAAGG	M	C	G	P	R
G586a1	WIAF-12112	HT1878	2410 PFKM, phosphofructokinase, muscle	CCGGGGAAGC [T/G] GCCGTCTAAA	S	T	G	A	A
G586u2	WIAF-12206	HT1878	375 PFKM, phosphofructokinase, muscle	GGACGACTCC [G/A] AGCTGCCTAC	M	G	A	R	Q

-167-

G586u3	WIAF-12207	HT1878		322 PFKM, phosphofructokinase, muscle	TGGAGGCAC [G/A] GTGATTGGAA	S	G	A	T	T
G586u4	WIAF-12227	HT1878		334 PFKM, phosphofructokinase, muscle	TGATTGGAAG [T/C] GCCCGGTGCA	S	T	C	S	S
G586u5	WIAF-12228	HT1878		408 PFKM, phosphofructokinase, muscle	CGTGGATCA [C/G] CAATCTCTGT	M	C	G	T	S
G586u6	WIAF-12235	HT1878		717 PFKM, phosphofructokinase, muscle	CACCTGTGCAT [A/G] CCTGGCCCTT	M	A	G	Y	C
G587u1	WIAF-12615	HT3847		366 phosphofructokinase, liver	ATGGCAGCCT [T/C] ACAGGTGCCA	S	T	C	L	L
G589u1	WIAF-12210	L39211		CPT1A, carnitine 1327 palmitoyltransferase I, liver	CAGCGTTCTT [C/T] GTGACGTTAG	S	C	T	P	P
G589u2	WIAF-12215	L39211		CPT1A, carnitine 2080 palmitoyltransferase I, liver	AATATCTCGC [T/C] GTGAGTCCC	S	T	C	A	A
G589u3	WIAF-12216	L39211		CPT1A, carnitine 679 palmitoyltransferase I, liver	ACTTCAAACG [G/T] ATGACAGCAC	S	G	T	R	R
G589u4	WIAF-12218	L39211		CPT1A, carnitine 1844 palmitoyltransferase I, liver	CCTCACATAC [G/C] AGGCCTCCAT	M	G	C	E	Q
G592u1	WIAF-11814	X96586		NSMAF, neutral sphingomyelinase (N-SMase) activation associated 1089 factor	TCCGGGATCT [C/T] AGTAAGCCAG	S	C	T	L	L
G592u2	WIAF-11815	X96586		NSMAF, neutral sphingomyelinase (N-SMase) activation associated 2020 factor	AAGTATATCA [T/G] TTTCAAATAT	M	T	G	F	V
G592u3	WIAF-11834	X96586		NSMAF, neutral sphingomyelinase (N-SMase) activation associated 1673 factor	GTAGCCATGC [T/C] TACGCAATC	M	T	C	L	P

G592u4	WIAF-11784	X96586	NSMAF, neutral sphingomyelinase (N-SMase) activation associated factor	1899	CACGAGCACT [A/G] TAAATCCAC	M	A	G	Y	C
G592u5	WIAF-11798	X96586	NSMAF, neutral sphingomyelinase (N-SMase) activation associated factor	1677	CCATGCTTAC [G/A] CAAATCTTG	S	G	A	T	T
G592u6	WIAF-11799	X96586	NSMAF, neutral sphingomyelinase (N-SMase) activation associated factor	2429	TGCCATTGAG [G/C] GATTGTATGT	M	G	C	G	A
G592a7	WIAF-13156	X96586	NSMAF, neutral sphingomyelinase (N-SMase) activation associated factor	2205	ATTCTGCATC [G/A] TGGGACTCTA	S	G	A	S	S
G594u1	WIAF-10065	HT3921	annexin V, alt. transcript 2	1153	TTGTGAAATC [T/A] ATTGGAAGTA	S	T	A	S	S
G594u2	WIAF-10098	HT3921	annexin V, alt. transcript 2	567	CGAAGTAATG [C/T] TCAGGGCCAG	M	C	T	A	V
G594u3	WIAF-10099	HT3921	annexin V, alt. transcript 2	774	ATTGCTTCAA [G/C] GACACCTGAA	M	G	C	R	T
G594a4	WIAF-10505	HT3921	annexin V, alt. transcript 2	424	GAGTAGTGGC [C/T] ATGGCACAGG	-	C	T	-	-
G594a5	WIAF-13123	HT3921	annexin V, alt. transcript 2	571	GTAATGCTCA [G/C] CGCCAGGAAA	M	G	C	Q	H
G595u1	WIAF-12203	HT27983	NR1P1, nuclear receptor interacting protein 1	1008	TGCAAGATTA [C/T] AGGCTGTTGC	N	C	T	Q	*
G595u2	WIAF-12220	HT27983	NR1P1, nuclear receptor interacting protein 1	785	CCCTCAGTCA [T/C] GATTCTTTAA	S	T	C	H	H
G595u3	WIAF-12232	HT27983	NR1P1, nuclear receptor interacting protein 1	1231	GTTGGCAGTT [A/T] CCAGCTCCCA	M	A	T	Y	F
G595u4	WIAF-12261	HT27983	NR1P1, nuclear receptor interacting protein 1	2048	GCAGTACTCA [G/A] TCTGAAAGC	S	G	A	Q	Q
G595u5	WIAF-12274	HT27983	NR1P1, nuclear receptor interacting protein 1	2376	TCCTGAACCA [G/T] GGCTTCTGG	M	G	T	G	W
G595u6	WIAF-12275	HT27983	NR1P1, nuclear receptor interacting protein 1	3498	ACTATATTAC [A/G] TGCTTCADAAA	M	A	G	M	V

G595u7	WIAP-12276	HT27983	3671	NR1p1, nuclear receptor interacting protein 1	ACAATAGCCA[T/C]ATGGGAATA	S	T	C	H	H
G595u8	WIAP-12294	HT27983	2020	NR1p1, nuclear receptor interacting protein 1	ATCAATGGA[A/G]TTCCCAACA	M	A	G	N	S
G595u9	WIAP-12295	HT27983	3140	NR1p1, nuclear receptor interacting protein 1	ATTGTCCC[G/A]CACAGAATA	S	G	A	P	P
G596u1	WIAP-10144	HT3537	3299	PC, pyruvate carboxylase	TGGGTCCAT[C/T]TTGGTCAAGG	S	C	T	I	I
G596u2	WIAP-10158	HT3537	2662	PC, pyruvate carboxylase	ACCACTGC[A/C]CTCCAGGCC	M	A	C	H	P
G596u3	WIAP-10159	HT3537	2156	PC, pyruvate carboxylase	CCATCTCATA[C/A]ACGGGACG	N	C	A	Y	*
G598a1	WIAP-12118	HT48666	5585	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	GGACCTATG[C/T]TGATAACTG	M	C	T	A	V
G598u2	WIAP-12236	HT48666	4456	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	CCTGTTAATA[T/C]TAGGAGTAG	S	T	C	L	L
G598u3	WIAP-12237	HT48666	6356	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	GGTAATGAAG[G/T]CAGGTGTGT	M	G	T	G	V
G598u4	WIAP-12240	HT48666	12219	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	GTACCTTTGT[C/T]ATCCAGGCCA	S	C	T	V	V
G598u5	WIAP-12241	HT48666	12480	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	CCAGGCAGAT[C/G]GAGGCCTTAC	M	C	G	I	M
G598u6	WIAP-12244	HT48666	12975	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	GAGTATCAT[T/A]GAAGATGTGG	S	T	A	I	I

-170-

G598u7	WIAP-12245	HT48666	1424	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	TCCAATAATC [A/T] GTCACCTTTA	M	A	T	Q	L
G598u8	WIAP-12250	HT48666	5854	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	TTCAAAAGCA [A/T] TTCATCAAA	M	A	T	I	P
G598u9	WIAP-12251	HT48666	6754	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	TATTCAGCTC [G/A] TCCGTATCCT	M	G	A	V	I
G598u10	WIAP-12252	HT48666	7635	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	ATCTTTACCT [C/T] GGTGCTATGA	S	C	T	L	L
G598u11	WIAP-12254	HT48666	9189	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	GTGGAAATCC [A/G] TACTACCTGT	S	A	G	P	P
G598u12	WIAP-12255	HT48666	10119	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	TTGTGGCATT [G/C] CTAGCAGACA	M	G	C	L	F
G598u13	WIAP-12257	HT48666	11109	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	ATCCATCTAT [T/C] GTAAATGGCA	S	T	C	I	I

-171-

G598u14	WIAF-12258	HT48666	13513	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	CTATGGACCT [C/T]AGATRACTGT	N	C	T	Q	*
G598u15	WIAF-12259	HT48666	13697	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	ACCATCACAG [A/G]GATGTGCCAG	M	A	G	E	G
G598u16	WIAF-12265	HT48666	1098	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	CCCTTTACGA [G/A]GCACGATTAT	S	G	A	E	E
G598u17	WIAF-12272	HT48666	6079	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	TATGTGGGAG [A/G]CACCCATTGC	M	A	G	T	A
G598u18	WIAF-12273	HT48666	9551	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	AAGAGTCTCT [C/T]TGGGAGAATA	M	C	T	S	F
G598u19	WIAF-12277	HT48666	666	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	GTCTTTGCAA [C/T]GATGTCATTTC	S	C	T	N	N
G598u20	WIAF-12278	HT48666	882	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	GCTCATTTGCG [A/G]TATCTTCTTTC	S	A	G	R	R



G598u21	WIAF-12279	HT48666	893	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	TATCTTCTTG [A/T]ATGATAGAA	M	A	T	E	V
G598u22	WIAF-12280	HT48666	13276	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	AGAAATCAGC [A/G]TTCACACGGT	M	A	G	I	V
G598u23	WIAF-12283	HT48666	6519	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	CCTGTGTGTT [A/T]GACATGGAG	M	A	T	L	F
G598u24	WIAF-12284	HT48666	8386	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	GGGTTCTCT [C/T]TTCGGCAGAT	M	C	T	L	F
G598u25	WIAF-12286	HT48666	10266	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	CAGCTCAGCA [A/T]CTCGTGGCA	M	A	T	Q	H
G598u26	WIAF-12287	HT48666	10099	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	CTTTGTTGTA [A/G]CACAGGCCCT	M	A	G	T	A
G598u27	WIAF-12289	HT48666	11835	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	AGAACTGTCT [G/C]CCTGACCCCTG	S	G	C	L	L

G598u28	WIAF-12290	HT48666	12689	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	TAAACCACA [C/T] TTTGGCAGTG	M	C	T	T	I
G598u29	WIAF-12291	HT48666	14655	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	ACGTGGACAA [C/T] GCCGAGGGCT	S	C	T	N	N
G598u30	WIAF-12296	HT48666	393	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	ATTCCCAATT [T/C] GCCGGGGCAC	S	T	C	F	P
G598u31	WIAF-12297	HT48666	479	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	GGCAAGGTGA [A/G] GCAGACGACG	M	A	G	K	R
G598u32	WIAF-12298	HT48666	1197	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	ATGCTCCCAT [T/C] GTCTCCGAAA	S	T	C	I	I
G598u33	WIAF-12300	HT48666	3595	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	TCCAGAGGAA [C/T] AGGACACTGC	N	C	T	Q	*
G598u34	WIAF-12301	HT48666	3661	HERC1, hect (homologous to the E6 AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1	CACCTCTCAA [T/C] TGGATAAATG	S	T	C	L	L
G601u1	WIAF-12246	HT27734	106	PRKMS, protein kinase, mitogen-activated, kinase 5 (MAP kinase 5)	TGGAGAACCA [G/A] GTCTGTGTAA	S	G	A	Q	Q

G601u2	WIAF-12247	HT27734		PRKMS, protein kinase, mitogen-activated, kinase 5 (MAP kinase 5)	351	GTAANTGAC[A/G]GTTAATAGAG	M		A	G	Q	R
G601u3	WIAF-12292	HT27734		PRKMS, protein kinase, mitogen-activated, kinase 5 (MAP kinase 5)	617	AGCATATCAT[G/C]TCCGAGTGG	M		G	C	V	L
G603u1	WIAF-12248	HT4291		mitogen-activated protein (MAP) kinase p38	1336	AGTCATCAGC[T/C]TTGTGCCACC	M		T	C	F	L
G603u2	WIAF-12281	HT4291		mitogen-activated protein (MAP) kinase p38	1230	CTCAGTACCA[C/T]GATCCTGATG	S		C	T	H	H
G610u1	WIAF-12249	HT48690		protein kinase, mitogen-activated, p38Beta (MAP kinase p38Beta)	1012	CCGAGCCATA[T/C]GATGAGAGCG	S		T	C	Y	Y
G610u2	WIAF-12263	HT48690		protein kinase, mitogen-activated, p38Beta (MAP kinase p38Beta)	799	AAATCTCCTC[G/A]GAACACGCC	S		G	A	S	S
G610u3	WIAF-12264	HT48690		protein kinase, mitogen-activated, p38Beta (MAP kinase p38Beta)	848	GCCCCAGAAG[G/A]ACCTGAGCAG	M		G	A	D	N
G610u4	WIAF-12282	HT48690		protein kinase, mitogen-activated, p38Beta (MAP kinase p38Beta)	439	TCCTGGTTTA[C/T]CAGCTGCTGC	S		C	T	Y	Y
G612u1	WIAF-12344	HT1436		RAF1, v-raf-1 murine leukemia viral oncogene homolog 1	1513	TTTGCATGCA[A/G]AGAACATCAT	M		A	G	K	B
G614u1	WIAF-12267	HT321		BRAF, v-raf murine sarcoma viral oncogene homolog B1	603	GACAGTCTAA[A/G]GAAAGCACTG	M		A	G	K	R
G614u2	WIAF-12268	HT321		BRAF, v-raf murine sarcoma viral oncogene homolog B1	2282	CCAAACAGAG[G/A]ATTTTAGTCT	M		G	A	D	N
G614u3	WIAF-12299	HT321		BRAF, v-raf murine sarcoma viral oncogene homolog B1	973	AGGAAGAGGC[G/A]TCCTTAGCAG	S		G	A	A	A
G616u1	WIAF-12253	HT48746		TRAF-interacting protein (I-TRAF)	498	AAGAAGACAA[G/T]AGGTTTCTTC	N		G	T	E	*
G616u2	WIAF-12269	HT48746		TRAF-interacting protein (I-TRAF)	1338	GCATATACCT[C/G]GAGTATGTGA	M		C	G	R	G

-175-

G616u3	WIAP-12285	HT48746	377	TRAF-interacting protein (I-TRAF)	ATAACAATTA [T/C] GGCTGTGTCC	S	T	C	Y	Y
G616u4	WIAP-12288	HT48746	1032	TRAF-interacting protein (I-TRAF)	TGAAATTCAG [G/A] GAATTGACCC	M	G	A	G	R
G617u1	WIAP-12256	HT1614	52	PPP1CA, protein phosphatase 1, catalytic subunit, alpha isoform	GAAGCTCAAC [C/T] TGGACTCGAT	S	C	T	L	L
G617u2	WIAP-12270	HT1614	792	PPP1CA, protein phosphatase 1, catalytic subunit, alpha isoform	AAGACGGCTA [C/T] GAGTTCTTTG	S	C	T	Y	Y
G618u1	WIAP-12238	HT27508	1598	protein phosphatase, 2A B56-alpha subunit	CATTGAACCA [A/C] CACAGTTCAA	M	A	C	T	P
G618u2	WIAP-12271	HT27508	1135	protein phosphatase, 2A B56-alpha subunit	ATCAGAAATT [C/T] GTACACACGC	S	C	T	F	F
G62u1	WIAP-10369	HT0855	214	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	AGGAGTACCT [G/C] TCCTTTGTTT	S	G	C	L	L
G62u2	WIAP-10370	HT0855	926	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	AAAACGTGCT [T/C] TTGAAAGGAA	M	T	C	F	L
G62u3	WIAP-10428	HT0855	2904	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	AGCACGGACA [C/T] GCAGGCCCGG	M	C	T	T	M
G62u4	WIAP-10430	HT0855	3368	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	TGACCCTCAC [A/G] TGAGTAGTAA	M	A	G	M	V
G62u5	WIAP-10451	HT0855	1376	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	TTCTGGGGAA [G/A] AAGCTGAAGC	M	G	A	E	K
G62u6	WIAP-10452	HT0855	3716	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	TAAGCATTGC [A/G] GAGACGCCAA	M	A	G	R	G

-176-

G62u7	WIAF-10453	HT0855		3957	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	CCCTGAAAGC [A/C] CTGAGGCTCT	S	A	C	A	A
G62u8	WIAF-10454	HT0855		4016	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	TGGTGTTCCTCC [A/G] CCTGGACTGG	M	A	G	T	A
G62u9	WIAF-10455	HT0855		3979	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	TGAGGCTCTC [T/C] CGTCAGCGGT	S	T	C	S	S
G62u10	WIAF-10456	HT0855		3729	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	GACGCCAAGT [T/G] TGAAGGAAT	M	T	G	F	C
G62u11	WIAF-10476	HT0855		1275	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	TCTGGAGATG [G/A] TACTGACTAT	M	G	A	G	D
G62u12	WIAF-10477	HT0855		2017	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	TGATCTTGGA [C/T] GAAAGACACA	S	C	T	D	D
G62u13	WIAF-10479	HT0855		3265	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	CTACATATC [T/C] CTAATGATG	S	T	C	S	S
G62u14	WIAF-10481	HT0855		4317	ERCC6, excision repair cross-complementing rodent repair deficiency, complementation group 6	GGGCACCTGC [A/G] GGAAGCTTCT	M	A	G	Q	R
G620a1	WIAF-12116	HT1943		1256	PPP2CB, protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform	TATCATGGAA [T/A] TAGATGACAC	M	T	A	L	I



-178-

G630u8	WIAF-12352	HT5086	703	protein phosphatase 2A, 130 kDa regulatory subunit	CAAAGATGCA [G/A] ATCTGAATCT	M	G	A	D	N
G630u9	WIAF-12353	HT5086	1069	protein phosphatase 2A, 130 kDa regulatory subunit	ACCTTTGTCT [C/T] ATAGAAATCT	M	C	T	H	Y
G634u1	WIAF-11825	X04434	2283	IGF1R, insulin-like growth factor 1 receptor	TGCAAGTGGC [C/T] AACACCACCA	S	C	T	A	A
G634u2	WIAF-11826	X04434	2279	IGF1R, insulin-like growth factor 1 receptor	GTCTATGCAAG [T/C] GGCCACACC	M	T	C	V	A
G634u3	WIAF-11781	X04434	1731	IGF1R, insulin-like growth factor 1 receptor	ACAAGGACGT [G/A] GAGCCCGGCA	S	G	A	V	V
G634a4	WIAF-13106	X04434	948	IGF1R, insulin-like growth factor 1 receptor	TCCACGACGG [C/A] GAGTGCATGC	S	C	A	G	G
G634a5	WIAF-13107	X04434	1089	IGF1R, insulin-like growth factor 1 receptor	CTTCTGCTCA [G/C] ATGCTCCAAG	M	G	C	Q	H
G634a6	WIAF-13108	X04434	2539	IGF1R, insulin-like growth factor 1 receptor	AGAAGGAGCA [G/A] ATGACATTCC	M	G	A	D	N
G634a7	WIAF-13109	X04434	2606	IGF1R, insulin-like growth factor 1 receptor	AAGTGGCCGG [A/C] ACCTGAGAAT	M	A	C	E	A
G634a8	WIAF-13111	X04434	1543	IGF1R, insulin-like growth factor 1 receptor	CTCCACCACC [A/T] CGTGAAGAA	M	A	T	T	S
G634a9	WIAF-13112	X04434	1549	IGF1R, insulin-like growth factor 1 receptor	CACCACGTCG [A/G] AGAATCCAT	M	A	G	K	B
G634a10	WIAF-13113	X04434	1596	IGF1R, insulin-like growth factor 1 receptor	CCCCTGACTA [C/T] AGGGATCTCA	S	C	T	Y	Y
G645u1	WIAF-12332	HT5191	1127	retinoic acid-binding protein II	TCTGCAGACT [C/T] TTCAGGAGAG	M	C	T	L	F
G645u2	WIAF-12333	HT5191	1048	retinoic acid-binding protein II	AAGCATTAGA [G/A] GCCTTACAGA	S	G	A	E	E
G646u1	WIAF-12303	X81479	1204	EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	CAATATCCA [T/C] GTGGACTAAA	M	T	C	M	T
G646u2	WIAF-12304	X81479	1919	EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	TTCTGCTGTG [T/G] CGCTCCATCC	M	T	G	C	W

G646u3	WIAP-12316	X81479		EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	590	CTGCCACAG [G/T] CATGCAACTT	M	G	T	E	D
G646u4	WIAP-12317	X81479		EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	799	GCACCAAGCA [G/A] TGGACAGTTG	M	G	A	S	N
G646u5	WIAP-12318	X81479		EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	558	TGAAGACGTG [A/G] ATGAATGTGC	M	A	G	N	D
G646u6	WIAP-12334	X81479		EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	207	TTACTATTGC [A/G] CTTCGAAACA	M	A	G	T	A
G646u7	WIAP-12335	X81479		EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	458	TCACCAGCAG [G/C] GTCTGCCCTG	M	G	C	R	S
G646u8	WIAP-12336	X81479		EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	1308	CTCAGCAAT [G/A] TCACTCCGGC	M	G	A	V	I
G646u9	WIAP-12337	X81479		EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	1285	ACACTGGCAT [C/T] TTTTGGAA	M	C	T	S	F
G646u10	WIAP-12338	X81479		EMR1, egf-like module containing, mucin-like, hormone receptor-like sequence 1	2026	GACACAAAG [C/T] GGGCTGGCGC	M	C	T	T	M
G647u1	WIAP-12339	HT5190		RARA, retinoic acid receptor, alpha	174	TGCCTCCCTA [C/T] GCCTTCTTCT	S	C	T	Y	Y
G648a1	WIAP-13332	HT0070		469 retinoic acid receptor, beta	469	AACGTGAGCC [A/G] GGAGCAGCCT	-	A	G	-	-
G648a2	WIAP-13333	HT0070		532 retinoic acid receptor, beta	532	ATTGTTTTRA [A/G] GGTGAGAAAT	-	A	G	-	-



G650u1	WIAP-12323	X52773	862 RXRA, retinoid X receptor, alpha	CTCGCGAAG [G/A] ACCCTGTAC	M	G	A	D	N
G650u2	WIAP-12341	X52773	102 RXRA, retinoid X receptor, alpha	TCCTGCGCT [C/T] GATTTCTCA	S	C	T	L	L
G650u3	WIAP-12348	X52773	673 RXRA, retinoid X receptor, alpha	GGCATGGG [A/G] TGAAGGGGA	M	A	G	M	V
G650u4	WIAP-12349	X52773	902 RXRA, retinoid X receptor, alpha	GACAAACAG [T/C] TTTCACCTG	M	T	C	L	P
G653a1	WIAP-13326	HT1458	RARB, retinoic acid receptor, beta	AGGAGAAAG [T/C] CTCAAAGCAT	S	T	C	A	A
G655a1	WIAP-13327	J05252	PCSK2, proprotein convertase subtilisin/kexin type 2	CCTTCAGCA [C/T] GGGAGGAAA	S	C	T	N	N
G655a2	WIAP-13334	J05252	PCSK2, proprotein convertase subtilisin/kexin type 2	CCTATCCTTA [C/A] CCTCGGTACA	N	C	A	Y	*
G655a3	WIAP-13335	J05252	PCSK2, proprotein convertase subtilisin/kexin type 2	TTTCTGCTG [C/T] GCCAACAACA	S	C	T	A	A
G658u1	WIAP-11856	J02943	CBG, corticosteroid binding globulin	TCTATGACT [T/C] GGAGATGTG	S	T	C	L	L
G658u2	WIAP-13407	J02943	CBG, corticosteroid binding globulin	CCTTCATGAC [T/G] CAGAGCTCC	M	T	G	S	A
G658u3	WIAP-13408	J02943	CBG, corticosteroid binding globulin	TTCATGACT [A/G] GAGTCCCT	S	A	G	S	S
G658u4	WIAP-13409	J02943	CBG, corticosteroid binding globulin	TCACCCAGGA [C/T] GCCCAGCTGA	S	C	T	D	D
G663u1	WIAP-13400	HT3157	1202 TPO, thyroid peroxidase	GGCCAGGCG [G/A] CCTCGGCT	S	G	A	A	A
G663u2	WIAP-13401	HT3157	1282 TPO, thyroid peroxidase	GGCCGGCCA [G/C] CGAGTCCCC	M	G	C	S	T
G668a1	WIAP-13350	U53506	DIO2, deiodinase, iodothyronine, type II	TCGATGCCTA [C/A] AAACAGGTGA	N	C	A	Y	*
G668a2	WIAP-13351	U53506	DIO2, deiodinase, iodothyronine, type II	TGCCTACAAA [C/A] AGGTGAAATT	M	C	A	Q	K
G668a3	WIAP-13352	U53506	DIO2, deiodinase, iodothyronine, type II	TGCTCCACT [A/G] CAGAGGAGG	M	A	G	T	A
G673a1	WIAP-13328	M57464	Human ret proto-oncogene mRNA for tyrosine kinase.	CGAGCTGGG [G/A] AGCCCCGGG	M	G	A	E	K
G673a2	WIAP-13336	M57464	Human ret proto-oncogene mRNA for tyrosine kinase.	GGCTGCCGA [T/A] TTGCCAGAT	M	T	A	F	I

-181-

G673a3	WIAF-13337	M57464	Human ret proto-oncogene mRNA for tyrosine kinase.	1227	ACTGCCAGGC [G/A] TTCAGTGGCA	S	G	A	A	A
G673a4	WIAF-13338	M57464	Human ret proto-oncogene mRNA for tyrosine kinase.	2118	TTGGAAAAAC [T/A] CTAGGAGAAG	S	T	A	T	T
G673a5	WIAF-13339	M57464	Human ret proto-oncogene mRNA for tyrosine kinase.	2238	CGAGTGAAGCT [T/G] CGAGACCTGC	S	T	G	L	L
G678a1	WIAF-13353	D49492	GDF10, growth differentiation factor 10	1439	TCGGCTGGAA [T/A] GAATGGATAA	M	T	A	N	K
G68u1	WIAF-10434	HT1115	ERCC3, excision repair cross-complementing rodent repair deficiency, complementation group B 3 (xeroderma pigmentosum group B complementing)	1214	CTGTGGAGCA [G/A] TGGAAAGCCC	S	G	A	Q	Q
G68u2	WIAF-10435	HT1115	ERCC3, excision repair cross-complementing rodent repair deficiency, complementation group B 3 (xeroderma pigmentosum group B complementing)	1155	TGTGACTGCT [G/C] CATGCACCTGT	M	G	C	A	P
G68u3	WIAF-10436	HT1115	ERCC3, excision repair cross-complementing rodent repair deficiency, complementation group B 3 (xeroderma pigmentosum group B complementing)	1327	AGCACCCTACT [C/T] CATGCTGGGC	M	C	T	S	F
G68u4	WIAF-10461	HT1115	ERCC3, excision repair cross-complementing rodent repair deficiency, complementation group B 3 (xeroderma pigmentosum group B complementing)	926	AGGAATGAT [T/C] GAGGAACCTCC	S	T	C	I	I
G68u5	WIAF-10464	HT1115	ERCC3, excision repair cross-complementing rodent repair deficiency, complementation group B 3 (xeroderma pigmentosum group B complementing)	1430	AAGTGCACAC [C/T] ATACCAGCCA	S	C	T	T	T

G684a1	WIAF-13359	X51801			BMP7, bone morphogenetic protein 7 (osteogenic protein 1)	GTTTATCAGG [T/G] GCTCCAGGAG	M	T	G	V	G
G684a2	WIAF-13360	X51801			BMP7, bone morphogenetic protein 7 (osteogenic protein 1)	AGGTGCTCCA [G/A] GAGCATTGG	S	G	A	Q	Q
G684a3	WIAF-13361	X51801			BMP7, bone morphogenetic protein 7 (osteogenic protein 1)	GGCTGGCTGG [T/G] GTTTGACATC	M	T	G	V	G
G684a4	WIAF-13362	X51801			BMP7, bone morphogenetic protein 7 (osteogenic protein 1)	GGCTGTCAGC [T/G] CTCGGTGGAG	M	T	G	L	R
G684a5	WIAF-13363	X51801			BMP7, bone morphogenetic protein 7 (osteogenic protein 1)	ATCTACRAGG [A/G] CTACATCCGG	M	A	G	D	G
G684a6	WIAF-13834	X51801			BMP7, bone morphogenetic protein 7 (osteogenic protein 1)	GCCACTAGCT [C/T] CTCGAGAAT	-	C	T	-	-
G685a1	WIAF-13329	D89675			BMP1B, bone morphogenetic protein receptor, type IB	GTTCCTTTA [T/G] GATTATCTGA	N	T	G	Y	*
G685a2	WIAF-13330	D89675			BMP1B, bone morphogenetic protein receptor, type IB	GCTAAATCAA [T/C] GCTGAAGTTA	M	T	C	M	T
G685a3	WIAF-13331	D89675			BMP1B, bone morphogenetic protein receptor, type IB	TATCAGACAG [T/G] GTTGATGAGG	M	T	G	V	G
G685a4	WIAF-13340	D89675			BMP1B, bone morphogenetic protein receptor, type IB	TCCTTATCAT [G/A] ACCTAGTGCC	M	G	A	D	N
G685a5	WIAF-13341	D89675			BMP1B, bone morphogenetic protein receptor, type IB	GTTACGCCCC [T/G] CATTCCAAA	M	T	G	S	A
G685a6	WIAF-13342	D89675			BMP1B, bone morphogenetic protein receptor, type IB	TGTTGGACGA [G/A] AGCTTGAACA	S	G	A	B	E
G686u1	WIAF-13816	Z48923			BMP2, bone morphogenetic protein receptor, type II (serine/threonine kinase)	AAATTTGGCA [G/A] CAAGCACAAA	M	G	A	S	N

G586u2	WIAF-13817	248923		2749	BMPP2, bone morphogenetic protein receptor, type II (serine/threonine kinase)	TGGAGTTGCC[A/T]AGATGAATAC	N	A	T	K	*
G687a1	WIAF-13343	HT1455		626	CALB1, calbindin 1, (28kD)	ATGATCAGGA [C/T]GGCAATGGAT	S	C	T	D	D
G596u1	WIAF-11839	HT27700		1075	calcium-sensing receptor	GGGACAAAT [G/C]CAGCTGATGA	M	G	C	A	P
G596u2	WIAF-11840	HT27700		1551	calcium-sensing receptor	TACCTGTGGA [C/T]ACCTTTCTGA	S	C	T	D	D
G596u3	WIAF-11841	HT27700		1688	calcium-sensing receptor	TTACGGATAT [C/T]CTACAATGTG	M	C	T	S	F
G596u4	WIAF-11842	HT27700		1698	calcium-sensing receptor	CCTACAATGT [G/T]TACTTAGCAG	S	G	T	V	V
G596u5	WIAF-11858	HT27700		1767	calcium-sensing receptor	GGAGAGGGCT [C/T]TTCACCAATG	S	C	T	L	L
G596u6	WIAF-11859	HT27700		1689	calcium-sensing receptor	TACGGATATC [C/T]TACAATGTGT	S	C	T	S	S
G596u7	WIAF-11860	HT27700		2541	calcium-sensing receptor	TCGTGCTCTG [C/T]ATCTCATGCA	S	C	T	C	C
G596u8	WIAF-11861	HT27700		2581	calcium-sensing receptor	TGCTCTCTG [G/A]TGTTGAGGC	M	G	A	V	M
G596u9	WIAF-11863	HT27700		3159	calcium-sensing receptor	TCTCCCGCAA [G/C]CGGTCCAGCA	M	G	C	K	N
G596u10	WIAF-11872	HT27700		562	calcium-sensing receptor	TCCTATTTCAT [T/A]TTGGAGTAGC	M	T	A	F	I
G596u11	WIAF-11878	HT27700		2941	calcium-sensing receptor	CATTCCAGCC [T/G]ATGCCAGCAC	M	T	G	Y	D
G596u12	WIAF-13386	HT27700		1145	calcium-sensing receptor	AGGATATCT [G/A]CATCGACTTC	M	G	A	C	Y
G596u13	WIAF-13395	HT27700		670	calcium-sensing receptor	GATATTTGCC [A/G]TAGAGGAGAT	M	A	G	I	V
G596u14	WIAF-13396	HT27700		2243	calcium-sensing receptor	TTCTGGFCCA [A/G]TGAGAACAC	M	A	G	N	S
G596u15	WIAF-13397	HT27700		2742	calcium-sensing receptor	AGCTGGAGGA [T/C]GAGATCATCT	S	T	C	D	D
G598u1	WIAF-13547	X61598		393	CBP1, collagen-binding protein 1	TCAGCAACTC [G/C]ACGGCGGCCA	S	G	C	S	S
G598u2	WIAF-13549	X61598		628	CBP1, collagen-binding protein 1	CGGCGCCCTG [C/T]TAGTCAACGC	S	C	T	L	L
G598u3	WIAF-13550	X61598		1230	CBP1, collagen-binding protein 1	GCGCTCCCT [G/A]CTATTTCATTG	S	G	A	L	L
G701u1	WIAF-12382	HT27657		706	CGRP type I receptor	AACGATGTG [C/A]AGCAGGAACT	M	C	A	A	E
G701u2	WIAF-12391	HT27657		841	CGRP type I receptor	TGGACAATT [A/T]TACCCAGTGT	M	A	T	Y	F
G704u1	WIAF-14046	X60382		1396	COL10A1, collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	AGGCATTCCA [G/A]GATTCCCTGG	M	G	A	G	R
G704u2	WIAF-14070	X60382		1648	COL10A1, collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	TGCCAACCCAG [G/C]GGGTAAACGG	M	G	C	G	R

G704u3	WIAP-14071	X60382	1824	COL10A1, collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	CATACCACGT [G/C] CATGTGAAG	S	G	C	V	V
G704u4	WIAP-14072	X60382	1582	COL10A1, collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	AGTCATGCCT [G/C] AGGGTTTTAT	M	G	C	E	Q
G705a1	WIAP-13228	J04177	686	COL11A1, collagen, type XI, alpha	AGAGAGAAAC [T/A] GTGACAATGA	S	T	A	T	T
G705a2	WIAP-13229	J04177	698	COL11A1, collagen, type XI, alpha	TGACAATGAT [T/A] GTTGATTGTA	S	T	A	I	I
G705a3	WIAP-13230	J04177	888	COL11A1, collagen, type XI, alpha	TAGTCCAGAC [T/A] GTGACTCTTC	M	T	A	C	S
G705a4	WIAP-13231	J04177	894	COL11A1, collagen, type XI, alpha	AGACTGTGAC [T/A] CTTTCAGCAC	M	T	A	S	T
G705a5	WIAP-13232	J04177	651	COL11A1, collagen, type XI, alpha	TGACGGGAAG [T/A] GGCATCGGT	M	T	A	M	R
G705a6	WIAP-13233	J04177	661	COL11A1, collagen, type XI, alpha	TGSCATCGGG [T/A] AGCAATCAGC	M	T	A	V	E
G705a7	WIAP-13234	J04177	1597	COL11A1, collagen, type XI, alpha	CGTCTTGGCT [T/C] ACCAGGGGCT	M	T	C	L	S
G705a8	WIAP-13235	J04177	2745	COL11A1, collagen, type XI, alpha	TGGGTTTCCA [G/A] GTGCCAATGG	M	G	A	G	S
G705a9	WIAP-13236	J04177	4385	COL11A1, collagen, type XI, alpha	GTCCAGGAAG [T/A] CTTGGGGCA	S	T	A	G	G
G705a10	WIAP-13237	J04177	4576	COL11A1, collagen, type XI, alpha	GAAAGGTG [A/T] CGAGGGCTC	M	A	T	D	V
G705a11	WIAP-13238	J04177	4306	COL11A1, collagen, type XI, alpha	GCTAAGGGGG [A/C] AGCAGGTGCA	M	A	C	E	A
G705a12	WIAP-13239	J04177	4837	COL11A1, collagen, type XI, alpha	AGACATACTG [A/G] AGGCATGCAA	M	A	G	E	G
G705a13	WIAP-13240	J04177	4931	COL11A1, collagen, type XI, alpha	AACAAGACAT [C/T] GAGCATATGA	S	C	T	I	I
G705a14	WIAP-13346	J04177	299	COL11A1, collagen, type XI, alpha	AAGCACTAGA [T/G] TTTCACAATT	M	T	G	D	E
G705a15	WIAP-13347	J04177	2225	COL11A1, collagen, type XI, alpha	GGGAGCCTGG [G/C] CCTCCAGGTC	S	G	C	G	G

G705u16	WIAF-13679	J04177	COL11A1, collagen, type XI, alpha 1	5493	COL11A1, collagen, type XI, alpha 1	AATGATCAA [G/A] TACCTATTGT	M	G	A	V	I
G705u17	WIAF-13700	J04177	COL11A1, collagen, type XI, alpha 1	3484	COL11A1, collagen, type XI, alpha 1	GGAGTTCAAG [G/A] TCCTGTTGGT	M	G	A	G	D
G705u18	WIAF-13709	J04177	COL11A1, collagen, type XI, alpha 1	5392	COL11A1, collagen, type XI, alpha 1	GAGATGTCT [A/T] TGACAATAAT	M	A	T	Y	F
G707u1	WIAF-13363	U32169	COL11A2, collagen, type XI, alpha 2	4996	COL11A2, collagen, type XI, alpha 2	TCCCTGAGA [C/T] TCCGTGGGCG	M	C	T	L	F
G707u2	WIAF-13374	U32169	COL11A2, collagen, type XI, alpha 2	3580	COL11A2, collagen, type XI, alpha 2	CAATGGCGCT [G/A] ATGGCCCA	M	G	A	D	N
G707u3	WIAF-13385	U32169	COL11A2, collagen, type XI, alpha 2	2059	COL11A2, collagen, type XI, alpha 2	GCCTGGCTCA [G/A] ACGGACCCCG	M	G	A	D	N
G708a1	WIAF-13354	U73778	COL12A1, collagen, type XII, alpha 1	1885	COL12A1, collagen, type XII, alpha 1	GCCTCTCTCTC [C/T] TGCAGAGACC	M	C	T	P	L
G708a2	WIAF-13355	U73778	COL12A1, collagen, type XII, alpha 1	3630	COL12A1, collagen, type XII, alpha 1	TGTTGGACAA [G/A] AAATGACAAAC	M	G	A	E	K
G708a3	WIAF-13356	U73778	COL12A1, collagen, type XII, alpha 1	3905	COL12A1, collagen, type XII, alpha 1	GCTTGTGCA [A/T] GCTGTGGCAA	M	A	T	Q	H
G708a4	WIAF-13357	U73778	COL12A1, collagen, type XII, alpha 1	7051	COL12A1, collagen, type XII, alpha 1	ATTCCACCAG [C/A] CCGGATGTA	M	C	A	A	D
G708a5	WIAF-13358	U73778	COL12A1, collagen, type XII, alpha 1	8036	COL12A1, collagen, type XII, alpha 1	RAGACTAAA [G/A] ACATTATTTT	S	G	A	K	K
G708a6	WIAF-13364	U73778	COL12A1, collagen, type XII, alpha 1	1461	COL12A1, collagen, type XII, alpha 1	TGGCTCCTAT [A/T] GCATTGGGAT	M	A	T	S	C
G708a7	WIAF-13365	U73778	COL12A1, collagen, type XII, alpha 1	2344	COL12A1, collagen, type XII, alpha 1	ATTACTTGGG [C/T] TCAAGCTCCA	M	C	T	T	I
G708a8	WIAF-13366	U73778	COL12A1, collagen, type XII, alpha 1	5207	COL12A1, collagen, type XII, alpha 1	CAGATAAGAT [G/A] GAGACCATCT	M	G	A	M	I
G708a9	WIAF-13367	U73778	COL12A1, collagen, type XII, alpha 1	6592	COL12A1, collagen, type XII, alpha 1	GAACCATGG [A/T] AGCCTTTGTT	M	A	T	E	V
G708a10	WIAF-13368	U73778	COL12A1, collagen, type XII, alpha 1	7434	COL12A1, collagen, type XII, alpha 1	CCAGGATGAG [G/A] TCAAGAAGGC	M	G	A	V	I
G708a11	WIAF-13369	U73778	COL12A1, collagen, type XII, alpha 1	9108	COL12A1, collagen, type XII, alpha 1	ACCTCGGGG [C/G] TGCCTGGGCC	M	C	G	L	V
G708a12	WIAF-13370	U73778	COL12A1, collagen, type XII, alpha 1	9111	COL12A1, collagen, type XII, alpha 1	TCGGGGGCTG [C/T] CTGGGCCCCC	M	C	T	P	S
G708a13	WIAF-13371	U73778	COL12A1, collagen, type XII, alpha 1	9196	COL12A1, collagen, type XII, alpha 1	CCCCCTGGCC [G/A] TCCTGGAAAC	M	G	A	R	H

G708u14	WIAP-13972	U73778	COL12A1, collagen, type XII, alpha 1	3044	CAGTATTTCG [C/A]ACTTACAGCA	S	C	A	A	A
G708u15	WIAP-13977	U73778	COL12A1, collagen, type XII, alpha 1	5853	TGTGACTGTA [G/C]TTCCGTTTA	M	G	C	V	L
G710u1	WIAP-13371	D38163	COL19A1, collagen, type XIX, alpha 1	3082	AGGAAACAAG [G/T]GCTCCATGG	M	G	T	G	C
G710u2	WIAP-13388	D38163	COL19A1, collagen, type XIX, alpha 1	2089	TCCAGGGACT [C/T]CAGGGAATGA	M	C	T	P	S
G711u1	WIAP-13360	L25286	COL15A1, collagen, type XV, alpha 1	1449	TGTGGGTCCA [A/G]GCAGTGAAGA	M	A	G	S	G
G711u2	WIAP-13372	L25286	COL15A1, collagen, type XV, alpha 1	4001	ATATTCCAAT [A/G]TACTCCTTTG	M	A	G	I	M
G711u3	WIAP-13373	L25286	COL15A1, collagen, type XV, alpha 1	3867	CCATTGTCAA [G/T]ATCTGTCCAC	M	G	T	D	Y
G711a4	WIAP-13372	L25286	COL15A1, collagen, type XV, alpha 1	395	CCAGCAGCAC [C/T]CGTGTGGCG	S	C	T	T	T
G711a5	WIAP-13373	L25286	COL15A1, collagen, type XV, alpha 1	3101	AAGGCGACCA [G/A]GGAGCCCAGG	S	G	A	Q	Q
G712u1	WIAP-13619	M92642	COL16A1, collagen, type XVI, alpha 1	3608	GGCGACCAAG [G/A]ATTTCAGGC	M	G	A	G	E
G712u2	WIAP-13620	M92642	COL16A1, collagen, type XVI, alpha 1	4944	CCATGAAAAC [C/T]ATGAAGGGGC	S	C	T	T	T
G712u3	WIAP-13621	M92642	COL16A1, collagen, type XVI, alpha 1	4707	CCAAAGGTGA [A/C]AAAGGGGACA	M	A	C	E	D
G712u4	WIAP-13654	M92642	COL16A1, collagen, type XVI, alpha 1	421	GCCCAGGCGA [C/A]GAGTATTCCC	S	C	A	R	R
G712u5	WIAP-13655	M92642	COL16A1, collagen, type XVI, alpha 1	444	GGGGTCTCCC [G/A]GAGGAGTTTG	S	G	A	P	P
G712u6	WIAP-13656	M92642	COL16A1, collagen, type XVI, alpha 1	338	CTCATGNAGA [A/C]GTCTGCCATC	M	A	C	K	T
G712u7	WIAP-13862	M92642	COL16A1, collagen, type XVI, alpha 1	3227	CCTGGTCTCT [C/T]GGGATTGCCA	M	C	T	P	L
G712u8	WIAP-13863	M92642	COL16A1, collagen, type XVI, alpha 1	3199	TCCTGGCTGT [G/T]TTGGAGGCC	M	G	T	V	F
G712u9	WIAP-13878	M92642	COL16A1, collagen, type XVI, alpha 1	318	ACCTCATCCA [C/T]GCAGCTCAGCC	S	C	T	H	H
G712u10	WIAP-13882	M92642	COL16A1, collagen, type XVI, alpha 1	1346	ACAGGCGAGA [A/G]GGGCCAGAAA	M	A	G	K	R

-187-

G712u11	WIAF-13883	M92642	COL16A1, collagen, type XVI, alpha 1	1309	GTGAGGAGCT [C/T] TGGGACCTCTC	S	C	T	L	L
G715a1	WIAF-13344	Z74615	COL1A1, collagen, type I, alpha 1	3504	TCCTGGTGAA [C/G] AAGTCCCTC	M	C	G	Q	E
G717u1	WIAF-12639	Z74616	COL1A2, collagen, type I, alpha 2	3988	ATGAGGAGAC [T/C] GGCACCTCTGA	S	T	C	T	T
G720u1	WIAF-12367	X14420	COL3A1, collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)	3494	GGTGCAATCG [G/A] CAGTCCAGGA	M	G	A	G	D
G720u2	WIAF-12383	X14420	COL3A1, collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)	3035	GGTGTCAAGG [G/A] TGAAGTGGG	M	G	A	G	D
G720a3	WIAF-13374	X14420	COL3A1, collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)	214	TCTTGGTCAG [T/C] CCTATGGGA	M	T	C	S	P
G720a4	WIAF-13375	X14420	COL3A1, collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)	1953	CTGGACCTCA [A/G] GGACCCCTCAG	S	A	G	Q	Q
G720a5	WIAF-13376	X14420	COL3A1, collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)	2194	TAGAGGTGGA [G/A] CTGGTCCCCC	M	G	A	A	T
G720a6	WIAF-13377	X14420	COL3A1, collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)	3731	GGGATTGGAG [G/A] TGA AAAAGCT	M	G	A	G	D
G722u1	WIAF-14132	HT3162	COL4A2, collagen, type IV, alpha 2	140	GAGATTGGCG [C/T] GACTGGTGAT	M	C	T	A	V
G724a1	WIAF-12120	X81053	COL4A4, collagen, type IV, alpha 4	3892	CTCGTGGAAA [G/A] AAAGTCCCC	S	G	A	K	K
G724a2	WIAF-12121	X81053	COL4A4, collagen, type IV, alpha 4	4187	GAAAGGACCA [A/G] TGGGATTCCC	M	A	G	M	V
G724a3	WIAF-12122	X81053	COL4A4, collagen, type IV, alpha 4	3802	ATGATGTGGG [G/A] CCACCTGGTC	S	G	A	G	G



G724a4	WIAP-12123	X81053	1838 <sub>4</sub>	COL4A4, collagen, type IV, alpha <sub>4</sub>	ACCAGAAAG [C/A] ATGGTGCCTC	M	C	A	H	N
G724u5	WIAP-12364	X81053	376 <sub>4</sub>	COL4A4, collagen, type IV, alpha <sub>4</sub>	CTGTTTGCCA [C/T] TGTGTTCTCG	S	C	T	H	H
G724u6	WIAP-12365	X81053	2018 <sub>4</sub>	COL4A4, collagen, type IV, alpha <sub>4</sub>	TCCAGGGGAT [C/G] ATGAAGATGC	M	C	G	H	D
G724u7	WIAP-12366	X81053	4756 <sub>4</sub>	COL4A4, collagen, type IV, alpha <sub>4</sub>	GCCTTCCCTT [A/G] TTTAGCAGCC	S	A	G	V	V
G724u8	WIAP-12377	X81053	3595 <sub>4</sub>	COL4A4, collagen, type IV, alpha <sub>4</sub>	CTGGACCAAC [A/G] GGGTGCCCG	S	A	G	P	P
G724u9	WIAP-12378	X81053	3516 <sub>4</sub>	COL4A4, collagen, type IV, alpha <sub>4</sub>	GGAGCATCCG [G/C] AGAGCAGGGC	M	G	C	G	A
G724u10	WIAP-12379	X81053	4288 <sub>4</sub>	COL4A4, collagen, type IV, alpha <sub>4</sub>	CTGGTCTTCC [A/G] GGTCCACAG	S	A	G	P	P
G724u11	WIAP-12380	X81053	5140 <sub>4</sub>	COL4A4, collagen, type IV, alpha <sub>4</sub>	GCCACTTTT [C/A] GCAATAAGT	M	C	A	F	L
G724u12	WIAP-12387	X81053	207 <sub>4</sub>	COL4A4, collagen, type IV, alpha <sub>4</sub>	GACTTGCCCTG [C/T] GATGTGGTCT	-	C	T	-	-
G727u1	WIAP-12362	D90279	5135	COL5A1, collagen, type V, alpha <sub>1</sub>	TTCAAGGTTT [A/T] CTGCAACTTC	M	A	T	Y	P
G727u2	WIAP-12369	D90279	4686	COL5A1, collagen, type V, alpha <sub>1</sub>	AAACAGGGTAT [C/T] ACTGTGCTTT	S	C	T	I	I
G727u3	WIAP-12370	D90279	4608	COL5A1, collagen, type V, alpha <sub>1</sub>	TGGGTCTCTC [G/C] GGTGAACAGG	S	G	C	P	P
G727a4	WIAP-13300	D90279	2034	COL5A1, collagen, type V, alpha <sub>1</sub>	ACGGCTGGC [T/A] GGGTTGCCAG	S	T	A	A	A
G727a5	WIAP-13301	D90279	2073	COL5A1, collagen, type V, alpha <sub>1</sub>	GTGACCTGG [T/C] CCTTCGGCC	S	T	C	G	G
G727a6	WIAP-13302	D90279	3763	COL5A1, collagen, type V, alpha <sub>1</sub>	CGGGCAGAAA [G/A] GTGATGAAGG	M	G	A	G	S
G729u1	WIAP-11844	L02870	2345	COL7A1, collagen, type VII, alpha <sub>1</sub> (epidermolysis bullosa, dystrophic, dominant and recessive)	ATGGACTGGA [G/A] CCAGATACCTG	S	G	A	E	E

G729u2	WIAP-11845	L02870		3083	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	TATCCTGGGG[G/A]CCACTCAGAG	S	G	A	R	R
G729u3	WIAP-11846	L02870		3031	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	GACTCGGTGA[C/T]TTTGGCCTGG	M	C	T	T	I
G729u4	WIAP-11851	L02870		1289	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	CGGACTATGA[G/T]GTGACGGTGA	M	G	T	E	D
G729u5	WIAP-11852	L02870		1032	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	CCAAGTGAAGT[G/T]TGATTGCCCT	M	G	T	V	L
G729u6	WIAP-11853	L02870		1897	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	CGCCGGGAGC[C/T]GGAAACTCCA	M	C	T	P	L
G729u7	WIAP-11854	L02870		1827	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	GCTTAGCTAC[A/T]CTGTGCGGGT	M	A	T	T	S
G729u8	WIAP-11855	L02870		1893	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	TGTCCCGCGG[G/A]AGCCGGAAC	M	G	A	B	K

G729u9	WIAF-11864	L02870	2142	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	GGGCCCTGCT [G/A] CAGTCATCGT	M	G	A	A	T
G729u10	WIAF-11865	L02870	2353	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	GAGCCAGATA [C/T] TGAGTATACG	M	C	T	T	I
G729u11	WIAF-11866	L02870	2221	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	TCATCTGTCA [C/T] CATTACCTGG	M	C	T	T	I
G729u12	WIAF-11869	L02870	6585	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	ACCAGGAGAG [C/T] GTGGTATGGC	M	C	T	R	C
G729u13	WIAF-11870	L02870	8169	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	GGGTGACCGA [G/T] GCTTTGACGG	M	G	T	G	C
G729u14	WIAF-11877	L02870	438	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	CCCCATCCGT [G/A] AGCTTAGCTA	M	G	A	E	K
G729u15	WIAF-11882	L02870	3481	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	AGGATCCGTG [A/T] CATGCCCTAC	M	A	T	D	V

G729u16	WIAP-11883	L02870	5654	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	ACGAGRACC [T/C] GGGGACCTG	S	T	C	P	P
G729u17	WIAP-11884	L02870	7124	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	TGCCAGGGCC [G/C] CGAGGCGAGA	S	G	C	P	P
G729u18	WIAP-11885	L02870	7757	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	GCTTGGATGG [T/C] GACAAAGGAC	S	T	C	G	G
G729u19	WIAP-13389	L02870	1615	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	ACGTCGTTT [C/T] CACTGGACCA	M	C	T	P	L
G729u20	WIAP-13390	L02870	2930	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	TCCTAGGGCC [G/A] GCTGGAGAAG	S	G	A	P	P
G729u21	WIAP-13399	L02870	5145	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	CCAGGAGAT [C/T] CTGGAGAGGA	M	C	T	P	S
G729u22	WIAP-13411	L02870	3472	COL7A1, collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive)	ATCTTGCANA [G/A] GATCCGTGAC	M	G	A	R	K
G730a1	WIAP-13303	X57527	305	COL8A1, collagen, type VIII, alpha 1	ATGGCAAGG [A/G] AGCGTTCCC	M	A	G	E	G
G732u1	WIAP-12616	M95610	936	COL9A2, collagen, type IX, alpha 2	CAGCGGGAC [A/G] GCCCGAAGT	S	A	G	T	T

G732u2	WIAP-12617	M95610	696	COL9A2, collagen, type IX, alpha 2	AAGGAGAGA [C/T] GGCCCTCAT	S	C	T	D	D
G732u3	WIAP-12619	M95610	1288	COL9A2, collagen, type IX, alpha 2	AAGTGGGTGA [C/T] CCAGGGGTGG	M	C	T	P	S
G732u4	WIAP-12620	M95610	962	COL9A2, collagen, type IX, alpha 2	CCACCAGGC [C/G] TAGCGGTGT	M	C	G	P	R
G737u1	WIAP-13394	M13436	?	INHBA, inhibin, beta A (activin A, activin AB alpha polypeptide)	TGCTCCCTG [G/T]	?	G	T		
G738a1	WIAP-13383	M58549	183	MGP, matrix Gla protein	ATGAGAGCT [A/G] AAGTCCAAGA	M	A	G	K	E
G738a2	WIAP-13384	M58549	330	MGP, matrix Gla protein	GGCCGAGGG [A/G] CCAATGAGA	M	A	G	T	A
G739u1	WIAP-11867	U94332	862	TNFRSF11B, tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	TGCTGAAGTT [A/G] TGGAAACATC	S	A	G	L	L
G739u2	WIAP-11874	U94332	1244	TNFRSF11B, tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	GTATCAGAAG [T/C] TATTTTAGA	S	T	C	L	L
G743u1	WIAP-13402	HT847	1669	PTHr1, parathyroid hormone receptor 1	CCCTGGAGAC [C/A] CTCGAGACCA	S	C	A	T	T
G747u1	WIAP-12414	J03040	123	SPARC, secreted protein, acidic, cysteine-rich (osteonectin)	CTCAGCAAGA [A/G] GCCTGCCTG	S	A	G	E	B
G748u1	WIAP-12628	HT0157	117	VDR, vitamin D (1,25-dihydroxyvitamin D3) receptor	CCTTCAGGGA [T/C] GAGGGCAATG	M	T	C	M	T
G748u2	WIAP-12629	HT0157	1171	VDR, vitamin D (1,25-dihydroxyvitamin D3) receptor	CCGGCTGAT [T/C] GAGGCCATCC	S	T	C	I	I
G748u3	WIAP-12640	HT0157	172	VDR, vitamin D (1,25-dihydroxyvitamin D3) receptor	TTGACCGGAA [C/T] GTGCCCGGA	S	C	T	N	N
G749u1	WIAP-11862	HT3734	679	osteopontin, alt. transcript 1	ATCACCTCAC [A/T] CATGAAAGC	M	A	T	H	L
G749u2	WIAP-11875	HT3734	386	osteopontin, alt. transcript 1	AAGATGATGA [A/G] GACCATGTGG	S	A	G	D	D
G749u3	WIAP-11876	HT3734	419	osteopontin, alt. transcript 1	CCATTGACTC [G/A] AAGCACTCTG	S	G	A	S	S

G749a4	WIAF-12084	HT3734		171	osteopontin, alt. transcript 1	TAAACAGGCT[G/A]ATTCTGGAAG	M	G	A	D	N
G749u5	WIAF-13387	HT3734		738	osteopontin, alt. transcript 1	CCAGGACCTG[A/C]ACGGGCTTC	M	A	C	N	K
G749u6	WIAF-13388	HT3734		716	osteopontin, alt. transcript 1	CATACAAGGC[C/A]ATCCCGTTG	S	C	A	A	A
G751u1	WIAF-12631	HT5036		410	ADM, adrenomedullin	GACAGCACTC[G/G]GGATGCCGCC	M	C	G	P	R
G752u1	WIAF-11843	HT1782		1405	CHGA, chromogranin A (parathyroid secretory protein 1)	CGGCCATTGA[A/G]GCAGAGCTGG	S	A	G	E	E
G752u2	WIAF-11873	HT1782		1187	CHGA, chromogranin A (parathyroid secretory protein 1)	GGACAACCGG[G/A]ACAGTTCAT	M	G	A	D	N
G754a1	WIAF-13382	K02043		663	NPPA, natriuretic peptide precursor A	GTACAATGCC[G/A]TGTCACAGC	M	G	A	V	M
G756u1	WIAF-12395	HT3508		2086	SCNN1A, sodium channel, nonvoltage-gated 1 alpha	CAGTTCTTCC[A/G]CCTGTCTCT	M	A	G	T	A
G757u1	WIAF-12420	HT28563		797	SCNN1B, sodium channel, nonvoltage-gated 1, beta (Liddle syndrome)	CCTGCAGGCC[A/C]CCAACTCTT	M	A	C	T	P
G757u2	WIAF-12421	HT28563		1006	SCNN1B, sodium channel, nonvoltage-gated 1, beta (Liddle syndrome)	GAACTGAATT[C/T]GGCCTGAAGT	S	C	T	F	F
G757u3	WIAF-12430	HT28563		1768	SCNN1B, sodium channel, nonvoltage-gated 1, beta (Liddle syndrome)	TCATCGACTT[T/C]GTGTGGATCA	S	T	C	F	F
G757u4	WIAF-12494	HT28563		662	SCNN1B, sodium channel, nonvoltage-gated 1, beta (Liddle syndrome)	AAGCAGCTCA[G/C]CATCAGARAA	M	G	C	A	P
G757u5	WIAF-12506	HT28563		1091	SCNN1B, sodium channel, nonvoltage-gated 1, beta (Liddle syndrome)	GATGCTTCAC[G/C]AGCAGAGGTC	M	G	C	E	Q
G757u6	WIAF-12507	HT28563		1452	SCNN1B, sodium channel, nonvoltage-gated 1, beta (Liddle syndrome)	ACCTGCATTG[G/T]CATGTGCAAG	M	G	T	G	V
G758u1	WIAF-12621	HT27856		415	SCNN1D, sodium channel, nonvoltage-gated 1, delta	CGGGAACCCA[C/T]GTGCGCCGAG	M	C	T	R	C
G758u2	WIAF-12632	HT27856		325	SCNN1D, sodium channel, nonvoltage-gated 1, delta	CCTCTTTGAG[C/T]GTCACGTGGCA	M	C	T	R	C

G758u3	WIAF-12634	HT27856	879	SCNN1D, sodium channel, nonvoltage-gated 1, delta	ATGGCGTCTG [G/A] ACAGCTCAGC	N	G	A	W	*
G758u4	WIAF-12635	HT27856	1138	SCNN1D, sodium channel, nonvoltage-gated 1, delta	CGTGGAGGTG [G/C] AGCTGCTACA	M	G	C	E	Q
G762u1	WIAF-12622	HT27531	1850	NPR3, natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C)	TAGGAGCTGG [C/T] TTGCTAATGG	S	C	T	G	G
G762u2	WIAF-12623	HT27531	1926	NPR3, natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C)	AGAAGAAAGT [A/G] ACCTTGGAAA	M	A	G	N	D
G762u3	WIAF-12624	HT27531	1791	NPR3, natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C)	CAATCATCA [G/T] GTGGCCTAGA	M	G	T	G	C
G762u4	WIAF-12636	HT27531	1963	NPR3, natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C)	GAAGATTCCA [T/C] CAGATCCCAT	M	T	C	I	T
G763u1	WIAF-12659	HT3183	1633	NPR2, natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B)	CTGGGCCCTT [C/T] CCTGATGAAC	M	C	T	S	F
G763u2	WIAF-12678	HT3183	668	NPR2, natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B)	TGCCATCACT [T/C] CTGCTGTTGG	S	T	C	L	L
G763u3	WIAF-12684	HT3183	2354	NPR2, natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B)	TGTTTGAAC [C/T] AAACATATGA	S	C	T	L	L

-195-

G764u1	WIAF-12698	HT1221		NPRI, natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor 3021 A)	CCCCGTACT [G/T] TCTCTTGGG	M	G	T	C	F
G764u2	WIAF-12708	HT1221		NPRI, natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor 588 A)	GAGGCAAG [C/T] GCTCATGCTC	M	C	T	A	V
G764u3	WIAF-12709	HT1221		NPRI, natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor 1897 A)	GTCCCGTGG [G/A] AGCCTGCAGG	S	G	A	G	G
G765u1	WIAF-10012	HT2456		DCPI, dipeptidyl carboxypeptidase 1 (angiotensin I converting enzyme) 604	GCTGGCACA [A/G] GCTGGGGCA	S	A	G	N	N
G765u2	WIAF-10014	HT2456		DCPI, dipeptidyl carboxypeptidase 1 (angiotensin I converting enzyme) 2350	TGATGCCAC [A/G] TCCCGGAAT	S	A	G	T	T
G765u3	WIAF-10025	HT2456		DCPI, dipeptidyl carboxypeptidase 1 (angiotensin I converting enzyme) 1688	CCCACTGCAC [C/A] AGTGTACAT	M	C	A	Q	K
G765u4	WIAF-10027	HT2456		DCPI, dipeptidyl carboxypeptidase 1 (angiotensin I converting enzyme) 3220	TCCCTTCAG [C/T] TACCTGTCG	S	C	T	S	S
G765u5	WIAF-10028	HT2456		DCPI, dipeptidyl carboxypeptidase 1 (angiotensin I converting enzyme) 3409	TCAGTACTT [T/C] GTCAGCTTCA	S	T	C	P	F
G765u6	WIAF-10040	HT2456		DCPI, dipeptidyl carboxypeptidase 1 (angiotensin I converting enzyme) 775	AGCCCTCTA [C/T] CTGAACCTCC	S	C	T	Y	Y



G772u1	WIAP-12626	HT2121	1064	AVPR2, arginine vasopressin receptor 2 (nephrogenic diabetes insipidus)	TCAGCAGCAG [C/T] GTGTCCTCAG	S	C	T	S	S
G772u2	WIAP-12627	HT2121	998	AVPR2, arginine vasopressin receptor 2 (nephrogenic diabetes insipidus)	CCTTGTGCT [A/G] CTCATGTGTC	S	A	G	L	L
G773u1	WIAP-12644	HT2141	163	SLC6A6, solute carrier family 6 (neurotransmitter transporter, taurine), member 6	CTAGCAAGAT [C/T] GACTTTGTGC	S	C	T	I	I
G773u2	WIAP-12645	HT2141	445	SLC6A6, solute carrier family 6 (neurotransmitter transporter, taurine), member 6	TGCTCATCCT [G/C] GCTGGGCCA	S	G	C	L	L
G773u3	WIAP-12665	HT2141	289	SLC6A6, solute carrier family 6 (neurotransmitter transporter, taurine), member 6	TGTTGGGAG [C/T] GGCCTGCCTG	S	C	T	S	S
G773u4	WIAP-12666	HT2141	382	SLC6A6, solute carrier family 6 (neurotransmitter transporter, taurine), member 6	CCTTGTCTC [T/C] GGTATCGGCT	S	T	C	S	S
G776u1	WIAP-11857	U66088	1457	SLC5A5, solute carrier family 5 (sodium iodide symporter), member 5	TAGAAGCCT [C/T] ATCAACCTC	S	C	T	L	L
G776u2	WIAP-11871	U66088	2039	SLC5A5, solute carrier family 5 (sodium iodide symporter), member 5	GATTGTGTG [G/C] TGGGACCTCG	M	G	C	W	C
G776u3	WIAP-13398	U66088	1379	SLC5A5, solute carrier family 5 (sodium iodide symporter), member 5	GGCTTTTCT [G/A] GCTGTGCTT	S	G	A	L	L
G777u1	WIAP-12646	HT27843	4348	SMRT	ATACAATATC [A/G] GCCAGCCTGG	M	A	G	S	G
G777u2	WIAP-12654	HT27843	2031	SMRT	CTGAGCTGGG [T/C] AGCCGCGGC	S	T	C	G	G
G777u3	WIAP-12655	HT27843	2052	SMRT	AGAGCCCT [G/A] ACCTATGAGG	S	G	A	L	L
G777u4	WIAP-12675	HT27843	2205	SMRT	CTCGTAGAT [C/T] GCCAAGTCCC	S	C	T	I	I
G778u1	WIAP-14093	HT1449	8212	TG, thyroglobulin	ATCTGCTCTC [T/C] GAAGACATCT	M	T	C	L	P
G778u2	WIAP-14111	HT1449	6033	TG, thyroglobulin	ATGTGAACGA [C/T] GTGCGATGC	M	C	T	R	W

G778u3	WIAP-14112	HT1449	6894	TG, thyroglobulin	GTATCTCAAT [G/T] TGTTCACTCC	M	G	T	V	L
G778u4	WIAP-14125	HT1449	2375	TG, thyroglobulin	ATGGCCTCC [T/C] AGCAGGTCT	S	T	C	P	P
G778u5	WIAP-14136	HT1449	1931	TG, thyroglobulin	AGGATGTCCA [A/G] TGCTTTTCCG	S	A	G	Q	Q
G783u1	WIAP-12649	X97674	4008	H.sapiens mRNA for transcriptional intermediary factor 2.	CTAGTGGTAT [G/C] CCAGCAACTA	M	G	C	M	I
G783u2	WIAP-12658	X97674	2556	H.sapiens mRNA for transcriptional intermediary factor 2.	GCCTGGCAGT [G/A] AGCTGGACAA	M	G	A	E	K
G783u3	WIAP-12671	X97674	3828	H.sapiens mRNA for transcriptional intermediary factor 2.	CTCTGAGGCC [T/C] GGACTACCAA	S	T	C	P	P
G785u1	WIAP-13385	HT1291	386	TTR, transthyretin (prealbumin, amyloidosis type I)	CCACGACTC [C/T] GGCCCCCGCC	S	C	T	S	S
G787u1	WIAP-12652	HT27477	458	TRIP15: thyroid receptor interacting protein 15	GAAATTTATA [T/C] TTAGAACGAG	S	T	C	Y	Y
G792u1	WIAP-12661	HT27476	265	thyroid receptor interactor 14	CAGCTGGAAC [G/A] TGAAGAGGCC	M	G	A	V	M
G793u1	WIAP-12643	HT5152	458	thyroid receptor interactor 8	GGAGCTTTT [C/G] AAGAATGTT	N	C	G	S	*
G794u1	WIAP-12664	HT5136	1110	PSMC5, proteasome (prosome, macropain) 26S subunit, ATPase, 5	GGGTGTGCAC [G/A] GAAGCTGGCA	S	G	A	T	T
G797u1	WIAP-11847	HT3919	140	glutamate receptor 3, flip isoform	CTCAGGAGG [A/G] TTCCCAACA	S	A	G	G	G
G797u2	WIAP-11848	HT3919	759	glutamate receptor 3, flip isoform	GTTTGTGATC [C/T] TAGGGAACA	S	C	T	L	L
G797u3	WIAP-11849	HT3919	1253	glutamate receptor 3, flip isoform	GCTACTGGAA [C/T] GAGTATGAA	S	C	T	N	N
G797u4	WIAP-11850	HT3919	1770	glutamate receptor 3, flip isoform	TCTTTTCCTA [G/A] TCAGCAGGTT	M	G	A	V	I
G797u5	WIAP-13404	HT3919	2711	glutamate receptor 3, flip isoform	GCTACAACGT [G/A] TATGGAACAG	S	G	A	V	V
G797u6	WIAP-13405	HT3919	2376	glutamate receptor 3, flip isoform	CTCAGCATTA [G/A] GNACGCCTGT	M	G	A	G	R
G798u1	WIAP-11868	X77748	2655	GRM3, glutamate receptor, metabotropic 3	TCCAGACGAC [A/G] ACCATGTGCA	S	A	G	T	T

G798u2	WIAP-11879	X77748	GRM3, glutamate receptor, metabotropic 3	2771	CACAGACTGC[A/G]CCTCAACAGG	M	A	G	H	R
G798a3	WIAP-12085	X77748	GRM3, glutamate receptor, metabotropic 3	2699	GTGTCCTTGG[G/C]CTGTTTCTTT	M	G	C	G	A
G798a4	WIAP-12086	X77748	GRM3, glutamate receptor, metabotropic 3	2738	ATCCTGTTTC[A/G]ACCCAGAAG	M	A	G	Q	R
G798a5	WIAP-12087	X77748	GRM3, glutamate receptor, metabotropic 3	2072	ACACCTTTGG[T/C]CAAAGCATCG	M	T	C	V	A
G798a6	WIAP-12088	X77748	GRM3, glutamate receptor, metabotropic 3	2235	CCCTGCTGAC[C/T]AAGCAAACT	S	C	T	T	T
G798u7	WIAP-13391	X77748	GRM3, glutamate receptor, metabotropic 3	1131	GCGCCAATGC[C/T]TCCTTCACCT	S	C	T	A	A
G799u1	WIAP-11880	M81883	GAD1, glutamate decarboxylase 1 (brain, 67kD)	2000	CAACAATGC[C/T]TGGAACTGGC	S	C	T	L	L
G799u2	WIAP-11881	M81883	GAD1, glutamate decarboxylase 1 (brain, 67kD)	1822	AGGTATATCT[C/T]CAAGGATGCA	S	C	T	L	L
G799u3	WIAP-13392	M81883	GAD1, glutamate decarboxylase 1 (brain, 67kD)	661	GGCTGGCCCA[T/C]GGATGCACCA	S	T	C	H	H
G799u4	WIAP-13393	M81883	GAD1, glutamate decarboxylase 1 (brain, 67kD)	556	AGCTGATGSC[G/A]TCTTCGACCC	S	G	A	A	A
G799u5	WIAP-13410	M81883	GAD1, glutamate decarboxylase 1 (brain, 67kD)	1229	CCTCATGGAA[C/T]AAATAACACT	N	C	T	Q	*
G801u1	WIAP-13403	D49394	HTR3, 5-hydroxytryptamine (serotonin) receptor 3	1596	TTTACTCTGCT[A/G]GCGGTGCTGG	S	A	G	L	L
G803a1	WIAP-13118	U66406	EFNB3, ephrin-B3	1446	CTGGGCTTGG[G/A]GGGTGGAGGT	M	G	A	G	E
G804u1	WIAP-11887	Z26653	LAMA2, laminin, alpha 2 (merosin, congenital muscular dystrophy)	7237	TCACCTGATGG[G/T]CACATAAAAG	S	G	T	G	G
G804u2	WIAP-11901	Z26653	LAMA2, laminin, alpha 2 (merosin, congenital muscular dystrophy)	9351	GCAAGCCACT[G/C]GAGGTTAATT	M	G	C	W	S
G804u3	WIAP-11924	Z26653	LAMA2, laminin, alpha 2 (merosin, congenital muscular dystrophy)	8740	ACACTACCCG[A/G]AGAATTGGTC	S	A	G	R	R

G804u4	WIAP-11943	Z26653	8577	LAMA2, laminin, alpha 2 (merosin, congenital muscular dystrophy)	ACCAAAATCA [A/G] TGATGGCCAG	M	A	G	N	S
G804a5	WIAP-12089	Z26653	3372	LAMA2, laminin, alpha 2 (merosin, congenital muscular dystrophy)	CTCTGTGACT [G/A] CTTCCTCCCT	M	G	A	C	Y
G804a6	WIAP-13227	Z26653	7047	LAMA2, laminin, alpha 2 (merosin, congenital muscular dystrophy)	GTCAGTCCTC [A/G] GGTGGAAGAT	M	A	G	Q	R
G804u7	WIAP-13437	Z26653	6791	LAMA2, laminin, alpha 2 (merosin, congenital muscular dystrophy)	TGTGAGAGCC [C/T] TGGATGACC	S	C	T	L	L
G805u1	WIAP-13416	U14755	799	LHX1, LIM homeobox protein 1	AAGTAACAGC [A/G] GTGTGGCAA	M	A	G	S	G
G805u2	WIAP-13417	U14755	743	LHX1, LIM homeobox protein 1	GGCGAGGAAC [T/C] CTACATCATC	M	T	C	L	P
G805u3	WIAP-13428	U14755	639	LHX1, LIM homeobox protein 1	GGCGTCAGGG [C/A] ATCTCCCTTA	S	C	A	G	G
G806u1	WIAP-11886	AF026547	2656	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	TTGGAGTTCC [A/G] GCCATGTCTA	S	A	G	P	P
G806u2	WIAP-11895	AF026547	529	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	TGACCTTCGC [T/C] GAGGCCCAGG	S	T	C	A	A
G806u3	WIAP-11896	AF026547	477	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	GAGGTGACAG [G/A] TGTGTGTTTC	M	G	A	G	D
G806u4	WIAP-11917	AF026547	89	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	ACAGGATATC [A/G] CCGATGCCAG	M	A	G	T	A
G806u5	WIAP-11918	AF026547	213	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	AGCGCAGCCC [G/C] AGATGCCCCT	M	G	C	R	P
G806u6	WIAP-11929	AF026547	769	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	GCTTTGCCCG [G/A] GAGCTGGGG	S	G	A	R	R
G806u7	WIAP-11931	AF026547	3148	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	ACATTGATGA [C/T] TGCCTCTGCA	S	C	T	D	D

G806u8	WIAP-11949	AF026547		209	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	GCCACGCGCA [G/A] CCGGAGATGC	M	G	A	A	T
G806a9	WIAP-13114	AF026547		3430	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	ATGAAAACAC [G/A] TGGATCGGCC	S	G	A	T	T
G806u10	WIAP-13420	AF026547		2113	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	CCAGGGCAGA [C/G] TTCAGAGAAA	M	C	G	D	E
G806u11	WIAP-13431	AF026547		94	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	ATATCACCGA [T/G] GCCAGCGAAA	M	T	G	D	E
G806u12	WIAP-13432	AF026547		275	CSPG3, chondroitin sulfate proteoglycan 3 (neurocan)	ACAGGACTTG [C/T] CCATCCTGGT	M	C	T	P	S
G808a1	WIAP-13117	Y13276		177	TLX, tailless homolog (Drosophila)	GCATGAGCAA [G/A] CCAGCCGGAT	S	G	a	K	K
G810u1	WIAP-11890	X98248		990	Sort1, sortilin 1	ATAAGGATAC [C/A] ACAAGAAGGA	S	C	A	T	T
G810u2	WIAP-11891	X98248		1093	Sort1, sortilin 1	GGCAGCAAT [G/T] ATGACATGGT	M	G	T	D	Y
G810u3	WIAP-11907	X98248		1683	Sort1, sortilin 1	CAGACGAGG [T/G] CAATGCTGGC	S	T	G	G	G
G810u4	WIAP-11908	X98248		1433	Sort1, sortilin 1	ATCTCCAGA [A/C] ACTGAATGTT	M	A	C	K	T
G810u5	WIAP-11909	X98248		1354	Sort1, sortilin 1	GAAGCCTGAA [N/G] ACAGTGAATG	M	A	G	N	D
G810u6	WIAP-11910	X98248		2180	Sort1, sortilin 1	TACCGGAAA [T/A] TCCAGGGGAC	M	T	A	I	N
G810u7	WIAP-11911	X98248		2264	Sort1, sortilin 1	AACTTTTGA [G/A] TCCGGAAAA	M	G	A	S	N
G810u8	WIAP-11925	X98248		1993	Sort1, sortilin 1	TCAGACTAT [G/A] TTGTGACCAA	M	G	A	V	I
G810u9	WIAP-11939	X98248		1351	Sort1, sortilin 1	GAGGAAGCCT [G/C] AAACAGTGA	M	G	C	E	Q
G810u10	WIAP-11940	X98248		2232	Sort1, sortilin 1	AAGTAAAAGA [C/T] TTGAAAAGA	S	C	T	D	D
G810a11	WIAP-13115	X98248		1769	Sort1, sortilin 1	TCATGAATA [T/A] GAGCATTTGG	M	T	A	I	N
G810a12	WIAP-13116	X98248		1757	Sort1, sortilin 1	CCTGGAGCTA [G/A] GTCCATGAAT	M	G	A	R	K
G811u1	WIAP-11893	HT3676		900	synapsin I, alt. transcript 1	TGACCAAGAC [G/A] TATGCCACTG	S	G	A	T	T
G811u2	WIAP-11894	HT3676		758	synapsin I, alt. transcript 1	ACCTTCTACC [C/T] CAATCAGAAA	M	C	T	P	L
G811u3	WIAP-11927	HT3676		996	synapsin I, alt. transcript 1	CGTCAGTGTG [A/T] GGGAACTGGA	S	A	T	S	S
G811u4	WIAP-11928	HT3676		1054	synapsin I, alt. transcript 1	CATGCTCTGAC [A/G] GATCAGAGCT	M	A	G	R	G
G811u5	WIAP-13418	HT3676		249	synapsin I, alt. transcript 1	TGTCCAACGC [G/A] GTCAGCAGAA	S	G	A	A	A

G811u6	WIAF-113419	HT3676	432 synapsin I, alt. transcript 1	TTAAGTAGA [G/A] CAGGCCGAAT	S	G	A	E	E
G812u1	WIAF-11898	HT4564	163 STX1A, syntaxin 1A (brain)	CCAACCCGA [T/C] GAGAAGACGA	S	T	C	D	D
G812u2	WIAF-11942	HT4564	604 STX1A, syntaxin 1A (brain)	TACAGACAT [G/T] TTCATGGACA	M	G	T	M	I
G813u1	WIAF-11934	U72508	939 Human B7 mRNA, complete cds.	TATGACAGAG [G/A] ACAGAGGATG	M	G	A	G	E
G813u2	WIAF-11948	U72508	619 Human B7 mRNA, complete cds.	GCATCCACAT [G/C] GTGACAGGTC	M	G	C	M	I
G816u1	WIAF-11897	HT4230	151 HTR2B, 5-hydroxytryptamine (serotonin) receptor 2B	CTAACTGGTC [T/G] GGATTACAGA	S	T	G	S	S
G816u2	WIAF-11930	HT4230	189 HTR2B, 5-hydroxytryptamine (serotonin) receptor 2B	GAAATGAAC [A/G] GATTGTTGAG	M	A	G	Q	R
G818u1	WIAF-11902	HT2694	753 TPH, tryptophan hydroxylase (tryptophan 5-monoxygenase)	GAGTTTTTCA [C/T] TGCACCTCAAT	S	C	T	H	H
G818u2	WIAF-11903	HT2694	775 TPH, tryptophan hydroxylase (tryptophan 5-monoxygenase)	TGTGACACAC [A/G] GTTCAGATCC	M	A	G	S	G
G818u3	WIAF-11904	HT2694	1211 TPH, tryptophan hydroxylase (tryptophan 5-monoxygenase)	TATAATCCAT [A/C] TACACGGAGT	M	A	C	Y	S
G818u4	WIAF-11905	HT2694	1081 TPH, tryptophan hydroxylase (tryptophan 5-monoxygenase)	GATTACCTGC [A/C] AACAGGAATG	M	A	C	K	Q
G818u5	WIAF-11933	HT2694	795 TPH, tryptophan hydroxylase (tryptophan 5-monoxygenase)	CCTTCTATAC [C/T] CCAGAGCCAG	S	C	T	T	T
G818u6	WIAF-11935	HT2694	1239 TPH, tryptophan hydroxylase (tryptophan 5-monoxygenase)	TCCTGAAGA [C/T] ACCAAGAGCA	S	C	T	D	D
G822u1	WIAF-11906	HT0207	936 ASMT, acetylserotonin N-methyltransferase	CAGACGGAAA [G/T] TGCTCACACC	M	G	T	K	N
G822u2	WIAF-11919	HT0207	637 ASMT, acetylserotonin N-methyltransferase	TGGTGGGACA [C/T] GGATTAAGCT	M	C	T	R	W

G822u3	WIAP-11936	HT0207	ASMT, acetylserotonin N-methyltransferase	318	GAAAAGCTTT[C/T]TATCGAAACA	S	C	T	P	F
G822u4	WIAP-11937	HT0207	ASMT, acetylserotonin N-methyltransferase	116	AATGACTACG[C/T]CAACGGCTTC	M	C	T	A	V
G822u5	WIAP-11938	HT0207	ASMT, acetylserotonin N-methyltransferase	930	ACTGGGCAGA[C/T]GGAAAGTGCT	S	C	T	D	D
G822u6	WIAP-11937	HT0207	ASMT, acetylserotonin N-methyltransferase	120	ACTAGGCCAA[C/A]GGCTTCATGG	M	C	A	N	K
G825u1	WIAP-11888	HT4974	ADAR, adenosine deaminase, RNA-specific	236	GCTCAGATAC[C/T]AGCAGCCTGG	N	C	T	Q	*
G825u2	WIAP-11900	HT4974	ADAR, adenosine deaminase, RNA-specific	3076	TCTTTGACAA[A/G]TCTCTGCAGCG	S	A	G	K	K
G825u3	WIAP-11912	HT4974	ADAR, adenosine deaminase, RNA-specific	2537	CTTGATTGGG[G/C]AGAACGAGNA	M	G	C	E	Q
G825u4	WIAP-11941	HT4974	ADAR, adenosine deaminase, RNA-specific	3558	GATGGCTATG[A/G]CCTGGAGATC	M	A	G	D	G
G825a5	WIAP-12090	HT4974	ADAR, adenosine deaminase, RNA-specific	1305	CCTGAGACCA[A/G]AAGAAACGCA	M	A	G	K	R
G825u6	WIAP-13426	HT4974	ADAR, adenosine deaminase, RNA-specific	3683	CCGCAGGGAT[C/T]TACTGAGACT	S	C	T	L	L
G826u1	WIAP-12554	X99383	ADAR1, adenosine deaminase, RNA-specific, B1 (homolog of rat RED1)	2109	AGATTACCAA[A/G]CCCAACGTGT	S	A	G	K	K
G826u2	WIAP-12566	X99383	ADAR1, adenosine deaminase, RNA-specific, B1 (homolog of rat RED1)	1698	TGTCCTGCAG[T/G]GACAAGATTG	M	T	G	S	R
G829u1	WIAP-13735	U49262	DVL3, dishevelled 3 (homologous to Drosophila dsh)	1404	GGGTTGGAGG[T/C]CCGTGACTGC	M	T	C	V	A
G83u1	WIAP-10449	HT1576	DNMT1, DNA (cytosine-5-) methyltransferase 1	1338	ATGATGACCC[G/A]TCTCTTGAAG	S	G	A	P	P
G83u2	WIAP-10450	HT1576	DNMT1, DNA (cytosine-5-) methyltransferase 1	1871	AAGCTGGTCT[A/G]CCAGATCTTC	M	A	G	Y	C
G83u3	WIAP-10468	HT1576	DNMT1, DNA (cytosine-5-) methyltransferase 1	928	AAATCCACAG[A/G]TTTCTGTATGA	M	A	G	I	V
G83u4	WIAP-10469	HT1576	DNMT1, DNA (cytosine-5-) methyltransferase 1	1562	AAATCCGACT[C/T]GACCTATGAG	M	C	T	S	L
G83u5	WIAP-10471	HT1576	DNMT1, DNA (cytosine-5-) methyltransferase 1	2424	GGGCCACGTC[G/A]GACCTCTGG	S	G	A	S	S

-203-

G83u6	WIAF-10473	HT1576	3790	DNMT1, DNA (cytosine-5)-methyltransferase 1	GTTCTTCTC [C/T] TGCAGAATGT	S	C	T	L	L
G83u7	WIAF-10486	HT1576	1561	DNMT1, DNA (cytosine-5)-methyltransferase 1	AGGACCTGAT [C/A] AACCAAGATCG	S	C	A	I	I
G832u1	WIAF-12577	LI3387	1129	PAFAH1B1, platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit (45KD)	AGACATTGAC [A/T] GGACACAGAG	S	A	T	T	T
G835u1	WIAF-12555	U38276	1311	SEMA3P, sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3F	CCTCTGGCTC [C/A] GTGTTCCGAG	S	C	A	S	S
G835u2	WIAF-12556	U38276	1229	SEMA3F, sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3F	ACTCACTTTG [A/T] TGAGCTCCAG	M	A	T	D	V
G835u3	WIAF-12557	U38276	1473	SEMA3F, sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3F	GAACCTTCAC [G/A] CCATCTATGA	S	G	A	T	T
G835a4	WIAF-13138	U38276	1726	SEMA3F, sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3F	TGACCAGGAG [A/T] TGGAGGAGCT	M	A	T	M	L
G836u1	WIAF-12592	U28369	1056	SEMA3B, sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3B	AACGACGTGG [G/A] CGGCCACCGC	M	G	A	G	D
G836u2	WIAF-12609	U28369	1479	SEMA3B, sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3B	GTCCTGCCCA [C/T] TGGGGGCGC	M	C	T	T	I
G838u1	WIAF-12590	U72671	1107	ICAM5, intercellular adhesion molecule 5, telencephalin	CGCAGCTGGG [A/G] CCCAAGCTCT	M	A	G	T	A
G838u2	WIAF-12591	U72671	966	ICAM5, intercellular adhesion molecule 5, telencephalin	CAGGCAGCTG [A/G] TCTGCAACGT	M	A	G	I	V



G840a1	WIAP-12109	HT961	2232	SOS1, son of sevenless (Drosophila) homolog 1	CTCAGGCAAA [T/C] GGAGTAAGCC	S	T	C	N	N
G840a2	WIAP-12110	HT961	2404	SOS1, son of sevenless (Drosophila) homolog 1	ACCGTCTGAA [C/G] TTGTAGGAG	M	C	G	L	V
G840u3	WIAP-12213	HT961	3813	SOS1, son of sevenless (Drosophila) homolog 1	CAAGGTACC [G/A] CGTCATGCT	S	G	A	P	P
G841u1	WIAP-12153	HT97420	1372	SMOH, smoothened (Drosophila) homolog	TTTGGCTTC [C/G] TGGCCTTTGG	M	C	G	L	V
G841u2	WIAP-12179	HT97420	858	SMOH, smoothened (Drosophila) homolog	CCAGTTCAT [G/T] GATGGTGCC	M	G	T	M	I
G841u3	WIAP-12185	HT97420	1164	SMOH, smoothened (Drosophila) homolog	CTGTGACTGG [C/G] ATTGTTTGG	S	C	G	G	G
G847u1	WIAP-12588	L41939	2019	EPHB2, EPHB2	GGTCTGCAGT [G/T] GCCACCTGAA	M	G	T	G	C
G847u2	WIAP-12596	L41939	1806	EPHB2, EPHB2	GTGTAACAGA [A/C] GACGGGGTT	S	A	C	R	R
G847u3	WIAP-12613	L41939	2885	EPHB2, EPHB2	AGCCATCAA [G/C] ATGGGCGAGT	M	G	C	K	N
G848u1	WIAP-12685	L40636	2484	EPHB1, EPHB1	GTCAACAGTA [A/G] CTTGGTGTGC	M	A	G	N	S
G848u2	WIAP-12690	L40636	2020	EPHB1, EPHB1	CCTTCACTTA [T/C] GAGGATCCCA	S	T	C	Y	Y
G849u1	WIAP-11920	D83492	1544	EPHB6, EPHB6	ACCTGTGTGG [C/T] TCATGCAGAG	M	C	T	A	V
G849u2	WIAP-11921	D83492	3301	EPHB6, EPHB6	CTTGGGATA [C/T] TCATGTGGGA	M	C	T	L	F
G849u3	WIAP-13412	D83492	1139	EPHB6, EPHB6	GAGACCTTCA [C/T] CCTTCTACTAC	M	C	T	T	I
G849u4	WIAP-13413	D83492	1895	EPHB6, EPHB6	TTTGGGTGC [A/C] AGGCTCAGCA	M	A	C	Q	P
G849u5	WIAP-13414	D83492	2338	EPHB6, EPHB6	CTATGACCAG [G/A] CAGAGACGA	M	G	A	A	T
G849u6	WIAP-13415	D83492	2367	EPHB6, EPHB6	GGGCTTTGG [C/G] CTTCTCTCTG	M	C	G	A	G
G849u7	WIAP-13422	D83492	2860	EPHB6, EPHB6	GGCCATCCAG [G/A] CCTGTGGGC	M	G	A	A	T
G849u8	WIAP-13423	D83492	2782	EPHB6, EPHB6	GGAGGTCAAT [G/C] GGACAGGCTC	M	G	C	G	R
G849u9	WIAP-13424	D83492	3038	EPHB6, EPHB6	TTCTCAGGC [A/G] GCGGAGGGC	M	A	G	Q	R
G849u10	WIAP-13425	D83492	3637	EPHB6, EPHB6	AGCCATTGGA [C/T] TGGAGTGCTA	S	C	T	L	L
G856u1	WIAP-12625	D45906	1323	LIMK2, LIM domain kinase 2	AGCTGAACCT [G/C] CTGACAGAGT	S	G	C	L	L
G858u1	WIAP-12630	U65019	864	MADH2, MAD (mothers against decapentaplegic, Drosophila) homolog 2	TTTGGTGTTC [G/A] ATAGCATATT	S	G	A	S	S
G86u1	WIAP-10437	HT1701	263	RAD51, RAD51 (S. cerevisiae) homolog (E. coli RecA homolog)	TGAAGCAAT [G/C] CAGATACTTC	M	G	C	A	P
G86u2	WIAP-10465	HT1701	861	RAD51, RAD51 (S. cerevisiae) homolog (E. coli RecA homolog)	GCATCAGCCA [T/C] GATGGTAGAA	M	T	C	M	T

G86u3	WIAP-10466	HT1701	924	RAD51, RAD51 (S. cerevisiae) homolog (E. coli RecA homolog)	TACAGAACAG [A/G]CTACTCGGT	M	A	G	D	G
G86a1	WIAP-13139	X82324	183	POU3F4, POU domain, class 3, transcription factor 4	CAGCAATGG [C/T]ATCCCTCGG	M	C	E	H	Y
G86u1	WIAP-12637	HT0101	2576	glutamate receptor (GB:M64752)	AAATCCCCTA [G/A]TGAATCCAAG	M	G	A	S	N
G86u2	WIAP-12638	HT0101	1131	glutamate receptor (GB:M64752)	TAACAGGAAA [C/T]GTGCAGTTTA	S	C	T	N	N
G86u1	WIAP-13406	HT33620	3627/2C	GRIN2C, glutamate receptor, ionotropic, N-methyl D-aspartate	AGATCAGCAG [G/T]GTAGCCCGTG	M	G	T	R	S
G870u1	WIAP-11889	HT4468	714	SLC1A1, solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	CAGAGAGTC [C/G]TTCACAGCTG	S	C	G	S	S
G870u2	WIAP-11913	HT4468	314	SLC1A1, solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	CTAGAGAAAT [T/A]CTACTTTGCT	M	T	A	F	Y
G870u3	WIAP-11914	HT4468	579	SLC1A1, solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	AAGTCAGTAC [G/A]GTGGATGCCA	S	G	A	T	T
G870u4	WIAP-11922	HT4468	706	SLC1A1, solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	GAACATGACA [G/A]AAGATCCTT	M	G	A	E	K

G870u5	WIAF-11923	HT4468		SLCIA1, solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1	978		GGAAGATCAT [A/G] GAAGTTGAAG	M	A	G	I	M
G871u1	WIAF-11892	HT3187		SLCIA3, solute carrier family 1 (glial high affinity glutamate transporter), member 3	1004		TTCTCTTAAC [G/C] AAGCCATCAT	M	G	C	E	Q
G871u2	WIAF-11915	HT3187		SLCIA3, solute carrier family 1 (glial high affinity glutamate transporter), member 3	1154		TGTTGGCTTA [C/T] TCATTCAAGC	M	C	T	L	F
G871u3	WIAF-11926	HT3187		SLCIA3, solute carrier family 1 (glial high affinity glutamate transporter), member 3	1412		GGCTGCCATT [T/G] TCATTGCTCA	M	T	G	F	V
G871u4	WIAF-11944	HT3187		SLCIA3, solute carrier family 1 (glial high affinity glutamate transporter), member 3	1217		AAACCCCTGG [G/A] TTTTATTGG	M	G	A	V	I
G872u1	WIAF-13433	HT4077		SLCIA2, solute carrier family 1 (glial high affinity glutamate transporter), member 2	1271		CTGTTGGAGC [A/C] ACCATTAAACA	S	A	C	A	A
G879u1	WIAF-11899	HT28317		GRM2, glutamate receptor, metabotropic 2	1273		GACTTTGTCG [T/C] CRAAGTCAAG	M	T	C	L	P
G879u2	WIAF-11932	HT28317		GRM2, glutamate receptor, metabotropic 2	2349		CTTCTATGTC [A/G] CCTCCAGTGA	M	A	G	T	A
G879u3	WIAF-13421	HT28317		GRM2, glutamate receptor, metabotropic 2	2186		ATGCAAGTAT [G/T] TTGGGGCTGCG	M	G	T	M	I
G879u4	WIAF-13429	HT28317		GRM2, glutamate receptor, metabotropic 2	2567		CCCAGTTTGT [C/T] CCCACTGTTT	S	C	T	V	V
G879u5	WIAF-13436	HT28317		GRM2, glutamate receptor, metabotropic 2	2046		ACAGGTGGCC [A/G] TCTGGCTGGC	M	A	G	I	V
G879u6	WIAF-13438	HT28317		GRM2, glutamate receptor, metabotropic 2	2425		GTGCTTGGCT [G/T] CCTCTTTGGG	M	G	T	C	F

G879u7	WIAF-13439	HT28317	GRM2, glutamate receptor, metabotropic 2	2463	CCTCTTCCAG [C/T] CGCAGAAGAA	M	C	T	P	S
G880u1	WIAF-12164	HT33719	GRM4, glutamate receptor, metabotropic 4	2117	AGCCGACCT [T/G] GGCACCTGCT	S	T	G	L	L
G880u2	WIAF-12176	HT33719	GRM4, glutamate receptor, metabotropic 4	2427	GGACCTGTCG [C/T] TCATCTGCCT	M	C	T	L	F
G880u3	WIAF-12192	HT33719	GRM4, glutamate receptor, metabotropic 4	2372	ACCAGCGGAC [A/G] CTCGACCCCC	S	A	G	T	T
G883a1	WIAF-13140	HT48863	GRM7, glutamate receptor, metabotropic 7	1408	ATCGCAAATG [C/A] ACAGGACAGG	N	C	a	C	*
G883a2	WIAF-13141	HT48863	GRM7, glutamate receptor, metabotropic 7	2027	TCCTGTCTTC [C/T] TGGCAATGTT	S	C	t	L	L
G883a3	WIAF-13147	HT48863	GRM7, glutamate receptor, metabotropic 7	1813	TGTGCACACT [A/G] CCATGTAAGC	S	A	g	L	L
G883a4	WIAF-13148	HT48863	GRM7, glutamate receptor, metabotropic 7	1536	TGTGCTGACT [A/T] CCGGGGTGTC	M	A	t	Y	F
G883a5	WIAF-13149	HT48863	GRM7, glutamate receptor, metabotropic 7	2473	AAGCCAGAGG [G/A] GTTCTCAAGT	S	G	a	G	G
G883a6	WIAF-13150	HT48863	GRM7, glutamate receptor, metabotropic 7	2434	TCATGACTA [C/T] GATGAACACA	S	C	t	Y	Y
G884u1	WIAF-11916	U95025	GRM8, glutamate receptor, metabotropic 8	1052	CGAACTCTTG [C/A] CAATAATCGA	M	C	A	A	D
G884u2	WIAF-11945	U95025	GRM8, glutamate receptor, metabotropic 8	2016	AAACAAACCG [T/C] ATCCACCGAA	S	T	C	R	R
G884u3	WIAF-11946	U95025	GRM8, glutamate receptor, metabotropic 8	1952	GAGGGCTTCA [G/A] GACGCGAACT	M	G	A	G	R
G884u4	WIAF-11947	U95025	GRM8, glutamate receptor, metabotropic 8	2078	ATTAGTCCAG [C/G] ATCTCAGCTG	M	C	G	A	G
G884u5	WIAF-13430	U95025	GRM8, glutamate receptor, metabotropic 8	1897	TTTTCTCTGT [T/G] ATTCAATCAC	M	T	G	Y	D
G884u6	WIAF-13435	U95025	GRM8, glutamate receptor, metabotropic 8	2364	TTACCATGTA [T/C] ACCACCTGCA	S	T	C	Y	Y
G885u1	WIAF-13434	AF002700	GFRA2, GDNF family receptor alpha	1363	AACTCAGGCC [C/A] CACGACAGCC	M	C	A	P	H
G886a1	WIAF-13142	U95847	GFRA1, GDNF family receptor alpha	497	CAAGTCGCTC [T/a] ACAACTGCCG	M	T	a	Y	N
G886a2	WIAF-13143	U95847	GFRA1, GDNF family receptor alpha	1385	GTCGTAGAAT [G/a] AAATTCACC	M	G	a	S	K

G886a3	WIAF-11151	U95847	7811	GFRA1, GDNF family receptor alpha	CGGTGTCCAA [T/C] GATGTCGCA	S	T	C	N	N
G892u1	WIAF-11956	U12140	798	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	TGGCAATCC [A/G] TTACATGCT	S	A	G	P	P
G892u2	WIAF-11957	U12140	834	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	GGATCAAGAC [T/A] CTCCAAGAG	S	T	A	T	T
G892u3	WIAF-11958	U12140	956	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	GCAATCTGG [C/T] CGCACCTAAC	M	C	T	A	V
G892u4	WIAF-11960	U12140	1738	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	CTCCAAGTTT [G/A] GCATGAAGG	M	G	A	G	S
G892u5	WIAF-11962	U12140	2486	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	GTCGGTGGCC [A/G] CACATGCTG	M	A	G	H	R
G892u6	WIAF-11965	U12140	1106	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	TCCTTAAGGA [T/C] AACTAACATT	M	T	C	I	T
G892u7	WIAF-11966	U12140	2085	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	AGGATGCCAG [T/C] GACAAATGCAC	S	T	C	S	S
G892u8	WIAF-11967	U12140	2230	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	GGACCTCAAC [A/C] AGTTCCTCAG	M	A	C	K	Q
G892u9	WIAF-11968	U12140	2223	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	AGCATGGGGA [C/T] CTCACCAAGT	S	C	T	D	D
G892u10	WIAF-11992	U12140	1602	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	GTAATGAAAT [C/T] CCTTCCACAG	S	C	T	I	I
G892u11	WIAF-11998	U12140	1354	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	TACTAAATA [C/T] ATGTTACCAA	M	C	T	H	Y
G892u12	WIAF-11999	U12140	1944	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	CATTGTTCAT [G/C] CACATCAAGC	M	G	C	Q	H

G892u13	WIAF-12000	U12140	2103	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	CACGCAAGGA [C/T] TTCCACCGTG	S	C	T	D	D
G892u14	WIAF-12001	U12140	1860	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	CTGTCAATTAT [T/C] GGAATGACCA	S	T	C	I	I
G892a15	WIAF-13144	U12140	1868	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	ATTGGAATGA [C/G] CAAGATCCCT	M	C	G	T	S
G892a16	WIAF-13145	U12140	1903	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	CCAGTACTTT [G/T] GCATCACCAA	M	G	T	G	C
G892a17	WIAF-13146	U12140	1965	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	GACATAACAT [T/G] GTTCTGAAAA	M	T	G	I	M
G892u18	WIAF-13442	U12140	958	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	AAATCTGGCC [G/T] CACCTAACCT	M	G	T	A	S
G892u19	WIAF-13446	U12140	2502	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	TGCTGCCCAT [T/C] CGTGGAGTC	S	T	C	I	I
G892u20	WIAF-13447	U12140	2317	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	GATGCTGCAT [A/T] TAGCCCAGCA	M	A	T	I	L
G892u21	WIAF-13448	U12140	2364	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	CGTCCCAGCA [C/A] TTGCTGCACC	M	C	A	H	Q
G892u22	WIAF-13449	U12140	2507	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	CCCATTCGCT [G/A] GATGCTCTCCA	N	G	A	W	*
G892u23	WIAF-13471	U12140	2389	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	TTTGCCACCA [A/C] GGAATCTGCT	S	A	C	R	R
G892u24	WIAF-13472	U12140	2416	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	GGAGAACTTG [C/T] TGGTGAATAAT	S	C	T	L	L
G892u25	WIAF-13474	U12140	359	NTRK2, neurotrophic tyrosine kinase, receptor, type 2	GGGATGTCCT [C/T] CTGGATAAGG	M	C	T	S	F

G992u26	WIAF-13479	U12140		NTRK2, neurotrophic tyrosine kinase, receptor, type 2	1044	TGTAATTGGGA [T/C] GTTGTRACC	S	T	C	D	D
G9u1	WIAF-10222	J03826		FDXR, ferredoxin reductase	1130	GGTATAAGAG [C/T] CCCCCGTGG	S	C	T	S	S
G9u2	WIAF-10258	J03826		FDXR, ferredoxin reductase	388	CCGGAGCTGC [A/G] GGAGGCGCTAC	M	A	G	Q	R
G900u1	WIAF-11970	HT3470		STX4A, syntaxin 4A (placental)	497	TGCAATTCAA [T/C] GCAGTCCGAA	M	T	C	M	T
G901u1	WIAF-11969	HT27792		STX3A, syntaxin 3A	758	TGCACACAGT [G/A] GACCACGTGG	S	G	A	V	V
G901u2	WIAF-11971	HT27792		STX3A, syntaxin 3A	317	ACGTCCGGAA [C/A] AAATGAAGA	M	C	A	N	K
G901u3	WIAF-12002	HT27792		STX3A, syntaxin 3A	611	AGCAAGCCCT [C/T] AGTGAGATTG	S	C	T	L	L
G901u4	WIAF-12003	HT27792		STX3A, syntaxin 3A	909	GCTGAATTAA [G/A] AGTGGCGCTAA	-	G	A	-	-
G901u5	WIAF-12004	HT27792		STX3A, syntaxin 3A	163	ATTGAGGAAA [C/T] TCGGCTTAA	M	C	T	T	I
G901a6	WIAF-13152	HT27792		STX3A, syntaxin 3A	82	CAGCTGACAC [A/G] GGATGATGAT	M	A	G	Q	R
G901u7	WIAF-13453	HT27792		STX3A, syntaxin 3A	828	CCGGAAGAAA [T/C] TGATAATTAT	S	T	C	L	L
G901u8	WIAF-13455	HT27792		STX3A, syntaxin 3A	226	TACAGTATCA [T/C] TCTCTCTGCA	M	T	C	I	T
G902u1	WIAF-13454	HT27744		STX5A, syntaxin 5A	848	ACTTCCAGTC [T/A] GTCACCTCCA	S	T	A	S	S
G902u2	WIAF-13456	HT27744		STX5A, syntaxin 5A	338	ATTTCGTGAG [A/G] GCCAAGGGCA	S	A	G	R	R
G905u1	WIAF-12202	HT27789		CREBL1, cAMP responsive element binding protein-like 1	487	TCCAGATCAA [C/T] GTTATCCCCA	S	C	T	N	N
G905u2	WIAF-12219	HT27789		CREBL1, cAMP responsive element binding protein-like 1	151	ATTCTGGCCT [A/T] GATGAAGTGG	S	A	T	L	L
G905u3	WIAF-12230	HT27789		CREBL1, cAMP responsive element binding protein-like 1	649	AGTCCCTGTC [C/G] CCTTCAGGAT	S	C	G	S	S
G906u1	WIAF-12214	HT4372		N-ethylmaleimide-sensitive factor	2127	AAGGGAAGAA [G/A] GTCTGGATAG	S	G	A	K	K
G906u2	WIAF-12221	HT4372		N-ethylmaleimide-sensitive factor	514	GGGAGAGCCT [G/A] CGACAGGGAA	M	G	A	A	T
G908u1	WIAF-12201	HT3665		RAB5A, member RAS oncogene family	98	GCCCAATATAC [T/G] GGAAATAAAA	S	T	G	T	T

G91u1	WIAF-10438	HT1848		496	ERCC1, excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)	TCTGGCCAA [C/T] GTGCCCTGG	S	C	T	N	N
G91u2	WIAF-10439	HT1848		367	ERCC1, excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)	CTGGGCCAC [G/A] TGCCCCACAG	S	G	A	T	T
G914a1	WIAF-13210	HT3672		252	synaptobrevin 1	GCAGTCTGC [C/A] AAGCTAAAGA	S	C	A	A	A
G915a1	WIAF-12115	D63506		1390	Homo sapiens mRNA for unc-18homologue, complete cds.	TTACCTTGGT [G/A] TTCCCATTTGT	M	Q	A	V	I
G915u2	WIAF-12293	D63506		685	Homo sapiens mRNA for unc-18homologue, complete cds.	ACAGCTTGT [G/A] AAAAAAGCT	M	Q	A	E	K
G916a1	WIAF-13209	HT28523		308	Huntingtin associated protein 1-like protein	GAGCAGTTT [C/T] GGAGGCCAGC	M	C	T	S	L
G916a2	WIAF-13211	HT28523		762	Huntingtin associated protein 1-like protein	CGGAGGAGTT [G/C] TGCCCCAGG	M	G	C	L	F
G916a3	WIAF-13212	HT28523		560	Huntingtin associated protein 1-like protein	GAGCTCAGAA [C/T] GTCTCTAAGG	M	C	T	T	M
G917u1	WIAF-11972	U79734		1075	HIP1, huntingtin interacting protein 1	AGAGCCAGCG [G/A] GTTGTGCTGC	S	G	A	R	R
G917u2	WIAF-11973	U79734		1005	HIP1, huntingtin interacting protein 1	GACCCTTAA [T/C] TGAGCGACTA	M	T	C	I	T
G917u3	WIAF-11977	U79734		1539	HIP1, huntingtin interacting protein 1	CTGCAAGGCA [G/A] CCTGGAAACT	M	G	A	S	N
G917u4	WIAF-12005	U79734		817	HIP1, huntingtin interacting protein 1	TGGTGGTGAT [C/T] CCTGCAGAGG	S	C	T	I	I
G917u5	WIAF-12006	U79734		1906	HIP1, huntingtin interacting protein 1	GCTGGAGCCA [G/C] TATCTGGCCT	M	G	C	Q	H
G917a6	WIAF-13157	U79734		993	HIP1, huntingtin interacting protein 1	AAGGATGAGA [A/G] GGACCACTTA	M	A	G	K	R
G919u1	WIAF-11974	D30742		707	CAMK4, calcium/calmodulin-dependent protein kinase IV	ACTGGCGACC [T/C] GAATTTCTTA	S	T	C	P	P



G919u2	WIAF-11991	D30742	1139	CAMK4, calcium/calmodulin-dependent protein kinase IV	AGAGCCACAA [G/A] GCTAGCCGAG	S	G	A	K	K
G919u3	WIAF-12007	D30742	834	CAMK4, calcium/calmodulin-dependent protein kinase IV	CATGTTCCAGG [A/T] GAATTCGAA	N	A	T	R	*
G919u4	WIAF-13443	D30742	1088	CAMK4, calcium/calmodulin-dependent protein kinase IV	TGGCTCTTTC [C/G] CGCTGGGAA	S	C	G	S	B
G920u1	WIAF-11979	X78520	1952	CLCN3, chloride channel 3	ATGACATTCC [T/C] GATCGTCCAG	S	T	C	P	P
G920u2	WIAF-11980	X78520	1819	CLCN3, chloride channel 3	ATAGCCTTCC [C/T] TAATCCATAC	M	C	T	P	L
G920u3	WIAF-11981	X78520	2094	CLCN3, chloride channel 3	CATTGGAGCG [A/G] TCGAGGAAG	M	A	G	I	V
G920u4	WIAF-11983	X78520	2822	CLCN3, chloride channel 3	ATATTTTCCG [A/G] AAGCTGGAC	S	A	G	R	R
G920u5	WIAF-11984	X78520	2745	CLCN3, chloride channel 3	GCCATTGAAG [C/T] TTCGAAGCAT	M	C	T	L	F
G920u6	WIAF-11987	X78520	2499	CLCN3, chloride channel 3	TCCCTTAGCT [G/T] TCCTGACACA	M	G	T	V	F
G920u7	WIAF-12008	X78520	1251	CLCN3, chloride channel 3	CATCATCAGA [G/A] GTTACTTGGG	M	G	A	G	S
G920u8	WIAF-12011	X78520	888	CLCN3, chloride channel 3	AGTAGTAACR [C/T] TAACAGGATT	S	C	T	L	L
G920u9	WIAF-13459	X78520	2804	CLCN3, chloride channel 3	CAATGGAGAT [T/C] GTGGTGGATA	S	T	C	I	I
G921u1	WIAF-11954	J02908	931	CLU, clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J)	GAGAGTTTGA [C/T] CAGGAATAC	M	C	T	T	I
G921u2	WIAF-11955	J02908	880	CLU, clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J)	CCCTCCCAAG [C/T] TAAGCTGGG	M	C	T	A	V
G921u3	WIAF-11990	J02908	1051	CLU, clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J)	CTCAGCAAG [G/C] CGAAGACCAG	M	G	C	G	A

-213-

G921u4	WIAP-13469	J02908		CLU, clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J)	986	TCAACACCTC [C/T] TCCTTGCTGG	S	C	T	S	S
G923u1	WIAP-11993	M19650		Human 2',3'-cyclic nucleotide 3'-phosphodiesterase mRNA, complete cds.	1059	GAGCTAAGCC [G/A] GGGCAAGCTC	M	G	A	R	Q
G923u2	WIAP-11994	M19650		Human 2',3'-cyclic nucleotide 3'-phosphodiesterase mRNA, complete cds.	1062	CTAAGCCGGG [G/T] CAAGCTCTAT	M	G	T	G	V
G923u3	WIAP-13445	M19650		Human 2',3'-cyclic nucleotide 3'-phosphodiesterase mRNA, complete cds.	1141	TCCTCACGGG [G/A] TACTACGGGA	S	G	A	G	G
G925u1	WIAP-11953	L11315		666 CAK, cell adhesion kinase	666	GGGTATGAG [T/C] GTCTGTCTGC	S	T	C	S	S
G925u2	WIAP-11959	L11315		2562 CAK, cell adhesion kinase	2562	TGCTGCCCAT [C/T] CGCTGGATGG	S	C	T	I	I
G925u3	WIAP-11996	L11315		2049 CAK, cell adhesion kinase	2049	AAGATCTGGT [T/C] AGTCTTGATT	S	T	C	V	V
G925u4	WIAP-13440	L11315		1601 CAK, cell adhesion kinase	1601	TACCAGGAG [C/T] CGGGCTCGT	M	C	T	P	L
G925u5	WIAP-13441	L11315		1629 CAK, cell adhesion kinase	1629	CGCCCACTC [C/T] GCTCCTGTG	S	C	T	S	S
G925u6	WIAP-13451	L11315		2262 CAK, cell adhesion kinase	2262	TGGAGAACGG [C/T] GACCTCAACC	S	C	T	G	G
G926u1	WIAP-11961	AF018956		577 NRP1, neuropilin 1	577	TGAAGCTTT [G/T] ACCTGGAGCC	M	G	T	D	Y
G926u2	WIAP-11963	AF018956		1683 NRP1, neuropilin 1	1683	CCACGGATT [C/G] ATCAGGATCT	M	C	G	F	L
G926u3	WIAP-11975	AF018956		2176 NRP1, neuropilin 1	2176	GACCTTCTGG [T/C] ATCAGATGTC	M	T	C	Y	H
G926u4	WIAP-11976	AF018956		2092 NRP1, neuropilin 1	2092	TTCCCAAGCT [G/T] AGGAAATCA	M	G	T	D	Y
G926u5	WIAP-13158	AF018956		747 NRP1, neuropilin 1	747	TTTTTACAC [C/T] GACAGCGGA	S	C	T	T	T
G926u6	WIAP-13159	AF018956		996 NRP1, neuropilin 1	996	ACTGGGCTT [T/C] CTGCGCTTGG	S	T	C	L	L
G926u7	WIAP-13444	AF018956		644 NRP1, neuropilin 1	644	GAATCTGGG [A/C] TGGATTCCCT	M	A	C	D	A
G926u8	WIAP-13450	AF018956		1738 NRP1, neuropilin 1	1738	CAGAATGGAG [C/G] TGCTGGGCTG	M	C	G	L	V
G926u9	WIAP-13452	AF018956		537 NRP1, neuropilin 1	537	TTGTCCTTGG [G/A] CCAAGATGT	S	G	A	A	A
G926u10	WIAP-13457	AF018956		2197 NRP1, neuropilin 1	2197	TGGTCCAC [G/A] TCGGCACACT	M	G	A	V	I
G927u1	WIAP-11978	AF022860		870 NRP2, neuropilin 2	870	GGATTGCTAA [T/C] GAACAGATCA	S	T	C	N	N
G927u2	WIAP-11982	AF022860		1674 NRP2, neuropilin 2	1674	ATGACACCCC [T/G] GACATCCGNA	S	T	G	P	P
G927u3	WIAP-11985	AF022860		1250 NRP2, neuropilin 2	1250	TGGCACTCAG [G/A] TATGCCCTC	M	G	A	G	D
G927u4	WIAP-11986	AF022860		1071 NRP2, neuropilin 2	1071	ATGGCTACTA [C/T] GTCNAATCCT	S	C	T	Y	Y

-214-

G927u5	WIAP-12009	AF022860	726	NRP2, neuropilin 2	GTTTCATCGAC [G/A]GGGATCCTCT	S	G	A	T	T
G927u6	WIAP-12010	AF022860	2522	NRP2, neuropilin 2	GCAACCTCAG [G/T]GTCTGGGCC	M	G	T	G	V
G927u7	WIAP-12012	AF022860	123	NRP2, neuropilin 2	GCTATATCAG [C/T]TCTCCGGTT	S	C	T	T	T
G927a8	WIAP-13160	AF022860	2427	NRP2, neuropilin 2	CTTTTGCAGT [G/T]GACATCCGAG	S	G	T	V	V
G927a9	WIAP-13161	AF022860	2430	NRP2, neuropilin 2	TTGCAGTGA [C/G]ATCCGAGAA	M	C	G	D	E
G927a10	WIAP-13162	AF022860	2463	NRP2, neuropilin 2	AAGGATATGA [A/G]GATGAAATTG	S	A	G	B	E
G927a11	WIAP-13163	AF022860	2473	NRP2, neuropilin 2	AGATGAAATT [G/T]ATGATGAATA	M	G	T	D	Y
G927u12	WIAP-13480	AF022860	724	NRP2, neuropilin 2	TCGTTTCATCG [A/T]CGGGATCCT	M	A	T	T	S
G927u13	WIAP-13481	AF022860	767	NRP2, neuropilin 2	ATGGCGGTGG [C/T]CAAGATGGC	M	C	T	A	V
G930a1	WIAP-13164	HT2608	609	GABRA2, gamma-aminobutyric acid (GABA) A receptor, alpha 2	ACAATGGGAA [G/A]AAATCAGTAG	S	G	a	K	K
G931a1	WIAP-13153	HT2609	1111	GABRA3, gamma-aminobutyric acid (GABA) A receptor, alpha 3	ACTGGTTCAT [A/G]GCCGTCTGTT	M	A	g	I	M
G931a2	WIAP-13165	HT2609	1448	GABRA3, gamma-aminobutyric acid (GABA) A receptor, alpha 3	TGTCAGCAAG [G/A]TTGACAAAAT	M	G	A	V	I
G932a1	WIAP-13154	HT27773	1077	GABRA4, gamma-aminobutyric acid (GABA) A receptor, alpha 4	CAAAAGAAAG [A/G]CATCAAGGCC	M	A	G	T	A
G932a2	WIAP-13155	HT27773	1189	GABRA4, gamma-aminobutyric acid (GABA) A receptor, alpha 4	AGAACAATG [C/A]TTGGTTCAC	M	C	A	A	D
G936u1	WIAP-12308	HT3432	1027	GABRB2, gamma-aminobutyric acid (GABA) A receptor, beta 2	AATTACGATG [C/T]TTCAGCTGCA	M	C	T	A	V
G936u2	WIAP-12327	HT3432	362	GABRB2, gamma-aminobutyric acid (GABA) A receptor, beta 2	AAGGCTATGA [C/T]ATTGCTCTGA	S	C	T	D	D
G936u3	WIAP-12328	HT3432	571	GABRB2, gamma-aminobutyric acid (GABA) A receptor, beta 2	CTCTGGGTGC [C/T]TGATACCTAT	M	C	T	P	L
G939u1	WIAP-12330	HT2236	1219	GABRR2, gamma-aminobutyric acid (GABA) receptor, rho 2	CTGGATGGAA [G/C]CTACAGTGAG	M	G	C	S	T
G939u2	WIAP-12355	HT2236	1003	GABRR2, gamma-aminobutyric acid (GABA) receptor, rho 2	ACCACCATCA [T/C]CAGGGCGTG	M	T	C	I	T

G939u3	WIAF-12356	HT2236	1041	GABRR2, gamma-aminobutyric acid (GABA) receptor, rho 2	CGTCTCTAC[G/A]TCAGGCCGT	M	G	A	V	I
G950u1	WIAF-13622	U64871	785	Human putative G protein-coupled receptor (GPR19) gene, complete cds.	GTCTGTCTCC[A/C]GTTCCACT	M	A	C	Q	P
G950u2	WIAF-13624	U64871	443	Human putative G protein-coupled receptor (GPR19) gene, complete cds.	GATAACAGCA[A/C]GCCACATTG	M	A	C	K	T
G950u3	WIAF-13625	U64871	818	Human putative G protein-coupled receptor (GPR19) gene, complete cds.	CTGGGTAGTG[C/T]AACGTGCAAG	M	C	T	A	V
G955a1	WIAF-13166	HT3860	5110	calcium channel, voltage-gated, alpha 1 subunit, L type, alt. transcript 1	CTGGCTCTTT[T/C]ACCGTGGAGA	S	T	C	P	F
G955a2	WIAF-13167	HT3860	3842	calcium channel, voltage-gated, alpha 1 subunit, L type, alt. transcript 1	CTACCCCAAC[C/a]CAGAAACTAC	M	C	a	P	T
G955a3	WIAF-13168	HT3860	5624	calcium channel, voltage-gated, alpha 1 subunit, L type, alt. transcript 1	GTGTGCCCA[G/a]AGTCCGAGCC	M	G	a	E	K
G955a4	WIAF-13169	HT3860	5703	calcium channel, voltage-gated, alpha 1 subunit, L type, alt. transcript 1	ATCAGCTTCT[A/G]CATGCTCTGT	M	A	G	Y	C
G955a5	WIAF-13170	HT3860	5809	calcium channel, voltage-gated, alpha 1 subunit, L type, alt. transcript 1	ACCACCTGGA[T/C]GAGTTTAAA	S	T	C	D	D
G955a6	WIAF-13171	HT3860	6616	calcium channel, voltage-gated, alpha 1 subunit, L type, alt. transcript 1	CCGGCTCCAA[C/t]GCCAACATCA	S	C	t	N	N
G956u1	WIAF-14187	HT2199	1334	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	CTTCATAG[C/T]CCTTTTGTA	M	C	T	A	V
G956u2	WIAF-14188	HT2199	1452	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	AAGAGGACCC[A/T]GCTCCATGTG	S	A	T	P	P
G956u3	WIAF-14189	HT2199	1614	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	GCTGGACAGA[C/T]GTGCTCTACT	S	C	T	D	D

G956u4	WIAF-14190	HT2199		2540	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	GGCAAGTTTA [A/T] TTTTGATGAA	M	A	T	N	I
G956u5	WIAF-14191	HT2199		3210	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	TGCTGAGCAG [T/C] GCTGCCCTGG	S	T	C	S	S
G956u6	WIAF-14192	HT2199		3326	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	TTGAAGATGA [C/T] AACTTTTGGGA	M	C	T	T	I
G956u7	WIAF-14193	HT2199		3274	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	ACTGGGTTAC [T/C] TTGACTATGC	M	T	C	F	L
G956u8	WIAF-14194	HT2199		5127	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	TGCCCTCTCAA [C/T] AGTGACGGGA	S	C	T	N	N
G956u9	WIAF-14195	HT2199		5173	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	TGCTTTGGTT [C/T] GAACGGCTCT	N	C	T	R	*
G956u10	WIAF-14200	HT2199		1437	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	CAGATATCGT [A/G] GCTGAAGAGG	S	A	G	V	V
G956u11	WIAF-14201	HT2199		2567	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	ACCAAGCGGA [G/T] CACCTTTGAC	M	G	T	S	I
G956u12	WIAF-14202	HT2199		4464	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	TCACCTTTT [C/T] CGTCTTTTCC	S	C	T	F	F
G956u13	WIAF-14215	HT2199		6927	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	GCTACAGCGA [C/T] GAAGAGCCAG	S	C	T	D	D
G956u14	WIAF-14216	HT2199		6858	calcium channel, voltage-gated, alpha 1D subunit, DHP-sensitive	CCCGAGCCAA [C/T] GGGGATGTGG	S	C	T	N	N
G957u1	WIAF-12306	HT4229		915	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript 2	TACATCGAGC [G/A] TGCTTCATGA	M	G	A	P	R
G957u2	WIAF-12309	HT4229		3555	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript 2	GCCACTACAT [C/T] GTGAACCTGC	S	C	T	I	I

G957u3	WIAP-12310	HT4229			4116	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript	ATGTAGATCA [C/T] GAGAAAAACA	S	C	T	H	H
G957u4	WIAP-12313	HT4229			5181	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript	AGAACGAGAA [T/C] GAACGCTGG	S	T	C	N	N
G957u5	WIAP-12314	HT4229			5971	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript	TATGGACCCC [G/A] CCGATGACGG	S	G	A	T	T
G957u6	WIAP-12315	HT4229			5985	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript	ATGACGGACA [G/T] TTCCAAGAAC	M	G	T	Q	H
G957u7	WIAP-12329	HT4229			3100	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript	GCTGGCAGGA [G/A] GCCTTGATGA	M	G	A	G	S
G957u8	WIAP-12331	HT4229			6492	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript	CCCTCCTTTC [C/T] TACAGCTCCC	M	C	T	T	R
G957u9	WIAP-12354	HT4229			3839	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript	AACGCTTTGG [G/C] AACCAACAAA	M	G	C	G	A
G957u10	WIAP-12357	HT4229			4753	calcium channel, voltage-gated, alpha 1E subunit, alt. transcript	TGACTTCATC [A/G] CCGTGATTGG	M	A	G	T	A
G960u1	WIAP-12305	HT3336			1246	CACNB3, calcium channel, voltage-dependent, beta 3 subunit	TTGATGCCCT [C/T] TGATGAGGCC	M	C	T	S	F
G960u2	WIAP-12340	HT3336			1288	CACNB3, calcium channel, voltage-dependent, beta 3 subunit	TGGACAGGAT [C/T] TTCACAGCGT	M	C	T	S	F
G960u3	WIAP-12345	HT3336			641	CACNB3, calcium channel, voltage-dependent, beta 3 subunit	AGGCTCTCTT [C/T] GACTTCTCTCA	S	C	T	F	F
G960u4	WIAP-12346	HT3336			576	CACNB3, calcium channel, voltage-dependent, beta 3 subunit	CATCGGCGCT [G/A] TGGTGCTGGT	M	G	A	V	M
G961u1	WIAP-12322	U95019			2037	CACNB2, calcium channel, voltage-dependent, beta 2 subunit	ACTCTGCCTA [C/T] GTAGAGCCAA	S	C	T	Y	Y

-218-

G961u2	WIAF-12347	U95019	2007	CACNB2, calcium channel, voltage-dependent, beta 2 subunit	CATTGACTC [G/A] GAAACCCAGG	S	G	A	S	S
G962u1	WIAF-12344	U95020	1423	CACNB4, calcium channel, voltage-dependent, beta 4 subunit	CCAATTGAAA [G/A] ACGRAGTCTA	M	G	A	R	K
G962u2	WIAF-12342	U95020	167	CACNB4, calcium channel, voltage-dependent, beta 4 subunit	GGAGCAGGTT [G/T] AAAAGATCCG	M	G	T	L	F
G962u3	WIAF-12350	U95020	1571	CACNB4, calcium channel, voltage-dependent, beta 4 subunit	ACACTTACAA [A/G] CCCCATAGGA	S	A	G	K	K
G965u1	WIAF-12312	U40583	1276	CHRNA7, cholinergic receptor, nicotinic, alpha polypeptide 7	TCCTGCACGG [T/C] GGGCAACCCC	S	T	C	G	G
G968a1	WIAF-12119	HT27592	1008	CHRNA1, cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)	ACACACACCA [C/T] CGCTCACCCA	S	C	T	H	H
G968u2	WIAF-12368	HT27592	1136	CHRNA1, cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)	AAGATTTTAA [C/T] AGAAGACATT	M	C	T	T	I
G973a1	WIAF-13172	HT48774	800	CHRNA2, cholinergic receptor, nicotinic, alpha polypeptide 2 (neuron)	ACACTTCAGA [C/C] GTGGTGATTG	S	C	t	D	D
G973a2	WIAF-13173	HT48774	927	CHRNA2, cholinergic receptor, nicotinic, alpha polypeptide 2 (neuron)	CTGGAACCCC [G/A] CTGATTTTGG	M	G	a	A	T
G977u1	WIAF-13949	Y08419	366	CHRNA5, cholinergic receptor, nicotinic, alpha polypeptide 5	AAGTTATACG [T/C] GTTCCTTCAG	S	T	C	R	R
G978a1	WIAF-13179	Y08417	1331	CHRNA3, cholinergic receptor, nicotinic, beta polypeptide 3	CCATTAGATA [C/A] ATTTCGAGAC	N	C	a	Y	*
G983a1	WIAF-13214	HT0374	236	NPY, neuropeptide Y	GATACTACTC [G/A] GCGCTGCGAC	S	G	A	S	S
G983a2	WIAF-13215	HT0374	290	NPY, neuropeptide Y	GAJAACGATC [C/T] AGCCACAGAGA	S	C	T	S	S
G983a3	WIAF-13216	HT0374	111	NPY, neuropeptide Y	CGGACTGGGG [C/T] TGTCGGGACT	S	C	T	L	L
G987a1	WIAF-13174	HT27830	159	PPYR1, pancreatic polypeptide receptor 1	TGGTCTTCAT [C/T] GTCACCTTCCT	S	C	T	I	I

G987a2	WIAF-13175	HT27830	PPYR1, pancreatic polypeptide receptor 1	222	PPYR1, pancreatic polypeptide	TGATGTGTGT [G/A] ACTGTGAGGC	S	G	A	V	V
G987a3	WIAF-13176	HT27830	PPYR1, pancreatic polypeptide receptor 1	322	PPYR1, pancreatic polypeptide	GCGCTGACC [G/T] CGCTCTACAC	M	G	T	A	S
G987a4	WIAF-13177	HT27830	PPYR1, pancreatic polypeptide receptor 1	1074	PPYR1, pancreatic polypeptide	TGAGGAGTCTC [G/A] GAGCATCTGC	S	G	A	S	S
G987a5	WIAF-13178	HT27830	PPYR1, pancreatic polypeptide receptor 1	975	PPYR1, pancreatic polypeptide	CCTCCACCTG [C/T] GTCACCCAT	S	C	T	C	C
G987a6	WIAF-13180	HT27830	PPYR1, pancreatic polypeptide receptor 1	615	PPYR1, pancreatic polypeptide	AGTTCTGTGG [A/G] GATPAGGTGG	S	A	G	A	A
G987a7	WIAF-13181	HT27830	PPYR1, pancreatic polypeptide receptor 1	718	PPYR1, pancreatic polypeptide	GGCTTCATC [C/T] TGCTCTGTTA	S	C	T	L	L
G987a8	WIAF-13182	HT27830	PPYR1, pancreatic polypeptide receptor 1	745	PPYR1, pancreatic polypeptide	CATCTACCGG [C/T] GCCTGCAGAG	M	C	T	R	C
G987a9	WIAF-13183	HT27830	PPYR1, pancreatic polypeptide receptor 1	842	PPYR1, pancreatic polypeptide	GTGATGTGTG [T/A] GGCTTTGCC	M	T	A	V	E
G987a10	WIAF-13184	HT27830	PPYR1, pancreatic polypeptide receptor 1	852	PPYR1, pancreatic polypeptide	TGGCCTTTGC [C/T] GTGCTCTGGC	S	C	T	A	A
G987a11	WIAF-13185	HT27830	PPYR1, pancreatic polypeptide receptor 1	889	PPYR1, pancreatic polypeptide	CAACAGCTG [G/A] AGAGCTGGCA	M	G	a	B	K
G987a12	WIAF-13186	HT27830	PPYR1, pancreatic polypeptide receptor 1	924	PPYR1, pancreatic polypeptide	CCATCTGCCA [C/T] GGGACCTCA	S	C	T	H	H
G989u1	WIAF-13573	D86519	NPY6R, neuropeptide Y receptor Y6	891	NPY6R, neuropeptide Y receptor Y6	TGACTCATGC [C/T] TACTGGGCA	S	C	T	A	A
G989u2	WIAF-13588	D86519	NPY6R, neuropeptide Y receptor Y6	465	NPY6R, neuropeptide Y receptor Y6	ACCACCCAGC [A/G] TCTAATACAA	S	A	G	A	A
G989u3	WIAF-13591	D86519	NPY6R, neuropeptide Y receptor Y6	980	NPY6R, neuropeptide Y receptor Y6	GAGCCCTTCC [G/A] CAACCTCTCT	M	G	A	R	H
G991u1	WIAF-12390	HT97376	Notch2	336	Notch2	AAGGTACTTG [C/T] GTTCAGAAA	S	C	T	C	C
G993u1	WIAF-12359	U95299	NOTCH4, Notch (Drosophila) homolog 4	1343	NOTCH4, Notch (Drosophila) homolog 4	TCCACACTCT [G/T] CCTGTGTGAG	M	G	T	C	F
G993u2	WIAF-12361	U95299	NOTCH4, Notch (Drosophila) homolog 4	2020	NOTCH4, Notch (Drosophila) homolog 4	TAAGGACCAG [A/G] AGACAGGCC	M	A	G	K	E
G993u3	WIAF-12384	U95299	NOTCH4, Notch (Drosophila) homolog 4	5775	NOTCH4, Notch (Drosophila) homolog 4	GGGCTATTTC [G/T] CATTTGCCGA	S	G	T	S	S
G996a1	WIAF-13213	HT3329	OPRM1, opioid receptor, mu 1	356	OPRM1, opioid receptor, mu 1	CTTAGATGGC [A/G] ACCTGTCCGA	M	A	G	N	D
LPLa4	WIAF-13314	HT1320	LPL, lipoprotein lipase	443	LPL, lipoprotein lipase	ATGATGAGA [G/T] TTGGGTGCCA	M	G	T	S	I
LPLa5	WIAF-13315	HT1320	LPL, lipoprotein lipase	579	LPL, lipoprotein lipase	GACAGGATGT [G/A] GCCCGGTTTA	S	G	A	V	V



LPLa6	WIAF-13316	HT1320	609	LPL, lipoprotein lipase	TCGAGGAGGA [G/A] TTTAACTACC	S	G	A	E	S
LPLa7	WIAF-13317	HT1320	1338	LPL, lipoprotein lipase	CAATAAGAC [C/A] TACTCCTTCC	S	C	A	T	T
LPLa8	WIAF-13318	HT1320	1117	LPL, lipoprotein lipase	CAATCTGGGC [T/G] ATGAGATCAA	M	T	G	Y	D
LPLa9	WIAF-13319	HT1320	715	LPL, lipoprotein lipase	CAGAATTACT [G/A] GCCTCGATCC	M	G	A	G	S
LPLa10	WIAF-13320	HT1320	834	LPL, lipoprotein lipase	CTGCTCGAAG [C/A] ATTGGATCC	M	C	A	S	R
LPLa11	WIAF-13321	HT1320	951	LPL, lipoprotein lipase	GACTTGGAGA [T/A] GTGACCAGC	M	T	A	D	E
LPLa12	WIAF-13322	HT1320	1595	LPL, lipoprotein lipase	AATAAGAGT [C/G] AGGCTGAAAC	N	C	G	S	*
LPLa13	WIAF-13323	HT1320	1597	LPL, lipoprotein lipase	TAGAAGTCA [G/A] GCTGAAACTG	M	G	A	G	S
LPLa14	WIAF-13324	HT1320	1606	LPL, lipoprotein lipase	AGGCTGAAC [T/C] GGGCGAATCT	-	T	C	-	-
LPLa15	WIAF-13325	HT1320	1611	LPL, lipoprotein lipase	GAAACTGGGC [G/A] AATCTACAGA	-	G	A	-	-

-221-

(This page has been intentionally left blank.)

-222-

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

-223-

## CLAIMS

## WE CLAIM:

1. A method of diagnosing or aiding in the diagnosis of a vascular disease in an individual comprising
  - 5 a) obtaining a nucleic acid sample from the individual; and
  - b) determining the nucleotide present at nucleotide position 2210 of the thrombospondin-1 gene,  
wherein presence of a G at nucleotide position 2210 is indicative of increased likelihood of a vascular disease in the individual as compared with an  
10 individual having an A at nucleotide position 2210.
2. The method of Claim 1, wherein the thrombospondin-1 gene has the nucleotide sequence of SEQ ID NO: 1.
3. The method of Claim 1, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, myocardial  
15 infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
4. The method of Claim 3, wherein the vascular disease is myocardial infarction.
5. The method of Claim 3, wherein the vascular disease is coronary heart disease.
6. A method of diagnosing or aiding in the diagnosis of a vascular disease in an  
20 individual comprising
  - a) obtaining a nucleic acid sample from the individual; and
  - b) determining the nucleotide present at nucleotide position 2210 of the thrombospondin-1 gene,

-224-

wherein presence of an A at nucleotide position 2210 is indicative of decreased likelihood of a vascular disease in the individual as compared with an individual having a G at nucleotide position 2210.

- 5 7. The method according to Claim 6, wherein the thrombospondin-1 gene has the nucleotide sequence of SEQ ID NO: 1.
8. The method according to Claim 6, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, myocardial infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
- 10 9. The method according to Claim 8, wherein the vascular disease is myocardial infarction.
10. The method according to Claim 8, wherein the vascular disease is coronary heart disease.
11. A method for predicting the likelihood that an individual will have a vascular  
15 disease, comprising the steps of:
  - a) obtaining a DNA sample from an individual to be assessed; and
  - b) determining the nucleotide present at nucleotide position 2210 of the thrombospondin-1 gene,  
20 wherein presence of a G at nucleotide position 2210 is indicative of increased likelihood of a vascular disease in the individual as compared with an individual having an A at nucleotide position 2210.
12. The method according to Claim 11, wherein the thrombospondin-1 gene has the nucleotide sequence of SEQ ID NO: 1.
13. The method according to Claim 11, wherein the individual is an individual at  
25 risk for development of a vascular disease.

-225-

14. The method according to Claim 11, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, myocardial infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
- 5 15. The method according to Claim 14, wherein the vascular disease is myocardial infarction.
16. The method according to Claim 14, wherein the vascular disease is coronary heart disease.
- 10 17. A nucleic acid molecule comprising all or a portion of the nucleic acid sequence of SEQ ID NO: 1 wherein said nucleic acid molecule is at least 10 nucleotides in length and wherein the nucleic acid sequence comprises a polymorphic site at nucleotide position 2210 of SEQ ID NO: 1.
- 15 18. The nucleic acid molecule according to Claim 17, wherein the nucleotide at the polymorphic site is different from a nucleotide at the polymorphic site in a corresponding reference allele.
19. An allele-specific oligonucleotide that hybridizes to the nucleic acid molecule of Claim 17.
- 20 20. A peptide of SEQ ID NO: 2 which is at least ten contiguous amino acids, wherein the peptide comprises the serine at amino acid position 700 of SEQ ID NO: 2.
21. A method of diagnosing or aiding in the diagnosis of a vascular disease in an individual comprising
  - a) obtaining a biological sample comprising thrombospondin-1 protein or relevant portion thereof from the individual; and

-226-

- b) determining the amino acid present at amino acid position 700 of the thrombospondin-1 protein,  
wherein presence of an asparagine at amino acid position 700 is indicative of increased likelihood of a vascular disease in the individual as compared with  
5 an individual having a serine at amino acid position 700.
22. The method of Claim 21, wherein the thrombospondin-1 protein has the amino acid sequence of SEQ ID NO: 2.
23. The method of Claim 22, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, myocardial  
10 infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
24. The method of Claim 23, wherein the vascular disease is myocardial infarction.
25. The method of Claim 23, wherein the vascular disease is coronary heart  
15 disease.
26. A method of diagnosing or aiding in the diagnosis of a vascular disease in an individual comprising
- a) obtaining a biological sample comprising thrombospondin-1 protein or relevant portion thereof from the individual; and
- 20 b) determining the amino acid present at amino acid position 700 of the thrombospondin-1 protein,  
wherein presence of a serine at amino acid position 700 is indicative of reduced likelihood of a vascular disease in the individual as compared with an individual having an asparagine at amino acid position 700.
- 25 27. The method according to Claim 26, wherein the thrombospondin-1 protein has the amino acid sequence of SEQ ID NO: 2.

-227-

28. The method according to Claim 26, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, myocardial infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
- 5 29. The method of Claim 28, wherein the vascular disease is myocardial infarction.
30. The method of Claim 28, wherein the vascular disease is coronary heart disease.
- 10 31. A method of diagnosing or aiding in the diagnosis of a vascular disease in an individual comprising
- a) obtaining a nucleic acid sample from the individual; and
  - b) determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene,
- 15 wherein presence of a C at nucleotide position 1186 is indicative of increased likelihood of a vascular disease in the individual as compared with an individual having an G at nucleotide position 1186.
32. The method of Claim 31, wherein the thrombospondin-4 gene has the nucleotide sequence of SEQ ID NO: 3.
- 20 33. The method of Claim 31, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, myocardial infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
34. The method of Claim 33, wherein the vascular disease is myocardial infarction.



-228-

35. The method of Claim 33, wherein the vascular disease is coronary heart disease.
36. A method of diagnosing or aiding in the diagnosis of a vascular disease in an individual comprising
- 5     a)     obtaining a nucleic acid sample from the individual; and
- b)     determining the nucleotide present at nucleotide position 1186 of the thrombospondin-4 gene,
- wherein presence of a G at nucleotide position 1186 is indicative of decreased likelihood of a vascular disease in the individual as compared with an
- 10    individual having a C at nucleotide position 1186.
37. The method according to Claim 36, wherein the thrombospondin-4 gene has the nucleotide sequence of SEQ ID NO: 3.
38. The method according to Claim 36, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease,
- 15    myocardial infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
39. The method according to Claim 38, wherein the vascular disease is myocardial infarction.
40. The method according to Claim 38, wherein the vascular disease is coronary
- 20    heart disease.
41. A method for predicting the likelihood that an individual will have a vascular disease, comprising the steps of:
- a)     obtaining a DNA sample from an individual to be assessed; and
- b)     determining the nucleotide present at nucleotide position 1186 of the
- 25    thrombospondin-4 gene,

-229-

wherein presence of a C at nucleotide position 1186 is indicative of increased likelihood of a vascular disease in the individual as compared with an individual having a G at nucleotide position 1186.

- 5 42. The method according to Claim 41, wherein the thrombospondin-4 gene has the nucleotide sequence of SEQ ID NO: 3.
43. The method according to Claim 41, wherein the individual is an individual at risk for development of a vascular disease.
- 10 44. The method according to Claim 41, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, myocardial infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
45. The method according to Claim 44, wherein the vascular disease is myocardial infarction.
- 15 46. The method according to Claim 44, wherein the vascular disease is coronary heart disease.
47. A nucleic acid molecule comprising all or a portion of the nucleic acid sequence of SEQ ID NO: 3 wherein said nucleic acid molecule is at least 10 nucleotides in length and wherein the nucleic acid sequence comprises a polymorphic site at nucleotide position 1186 of SEQ ID NO: 3.
- 20 48. The nucleic acid molecule according to Claim 47, wherein the nucleotide at the polymorphic site is different from a nucleotide at the polymorphic site in a corresponding reference allele.
49. An allele-specific oligonucleotide that hybridizes to the nucleic acid molecule of Claim 47.

-230-

50. A peptide of SEQ ID NO: 4 which is at least ten contiguous amino acids, wherein the peptide comprises the proline at amino acid position 387 of SEQ ID NO: 4.
51. A method of diagnosing or aiding in the diagnosis of a vascular disease in an individual comprising
- 5 a) obtaining a biological sample comprising thrombospondin-4 protein or relevant portion thereof from the individual; and
- b) determining the amino acid present at amino acid position 387 of the thrombospondin-4 protein,
- 10 wherein presence of an alanine at amino acid position 387 is indicative of increased likelihood of a vascular disease in the individual as compared with an individual having a proline at amino acid position 387.
52. The method of Claim 51, wherein the thrombospondin-4 protein has the amino acid sequence of SEQ ID NO: 4.
- 15 53. The method of Claim 52, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, myocardial infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
54. The method of Claim 53, wherein the vascular disease is myocardial infarction.
- 20 55. The method of Claim 53, wherein the vascular disease is coronary heart disease.
56. A method of diagnosing or aiding in the diagnosis of a vascular disease in an individual comprising

-231-

- a) obtaining a biological sample comprising thrombospondin-4 protein or relevant portion thereof from the individual; and
  - b) determining the amino acid present at amino acid position 387 of the thrombospondin-4 protein,
- 5 wherein presence of a proline at amino acid position 387 is indicative of reduced likelihood of a vascular disease in the individual as compared with an individual having an alanine at amino acid position 387.
57. The method according to Claim 56, wherein the thrombospondin-4 protein has the amino acid sequence of SEQ ID NO: 4.
- 10 58. The method according to Claim 56, wherein the vascular disease is selected from the group consisting of atherosclerosis, coronary heart disease, myocardial infarction, stroke, peripheral vascular diseases, venous thromboembolism and pulmonary embolism.
- 15 59. The method of Claim 58, wherein the vascular disease is myocardial infarction.
60. The method of Claim 58, wherein the vascular disease is coronary heart disease.
- 20 61. A nucleic acid molecule selected from the group consisting of the genes listed in the Table, wherein said nucleic acid molecule is at least 10 nucleotides in length and comprises a polymorphic site identified in the Table, wherein a nucleotide at the polymorphic site is different from a nucleotide at the polymorphic site in a corresponding reference allele.
- 25 62. A nucleic acid molecule according to Claim 61, wherein said nucleic acid molecule is at least 15 nucleotides in length.

-232-

63. A nucleic acid molecule according to Claim 61, wherein said nucleic acid molecule is at least 20 nucleotides in length.
64. A nucleic acid molecule according to Claim 61, wherein the nucleotide at the polymorphic site is the variant nucleotide for the gene listed in the Table.
- 5 65. An allele-specific oligonucleotide that hybridizes to a portion of a gene selected from the group consisting of the genes listed in the Table, wherein said portion is at least 10 nucleotides in length and comprises a polymorphic site identified in the Table, wherein a nucleotide at the polymorphic site is different from a nucleotide at the polymorphic site in a corresponding  
10 reference allele.
66. An allele-specific oligonucleotide according to Claim 65 that is a probe.
67. An allele-specific oligonucleotide according to Claim 65, wherein a central position of the probe aligns with the polymorphic site of the portion.
68. An allele-specific oligonucleotide according to Claim 65 that is a primer.
- 15 69. An allele-specific oligonucleotide according to Claim 68, wherein the 3' end of the primer aligns with the polymorphic site of the portion.
70. An isolated gene product encoded by a nucleic acid molecule according to Claim 61.
71. A method of analyzing a nucleic acid sample, comprising obtaining the  
20 nucleic acid sample from an individual; and determining a base occupying any one of the polymorphic sites shown in the Table.
72. A method according to Claim 71, wherein the nucleic acid sample is obtained from a plurality of individuals, and a base occupying one of the polymorphic

-233-

positions is determined in each of the individuals, and wherein the method further comprising testing each individual for the presence of a disease phenotype, and correlating the presence of the disease phenotype with the base.

1/8

## HT1220 Report

---

### RECORD INFORMATION

Gene ID:	1220
Sequence ID:	1220
Protein ID:	1220
Sequence name:	thrombospondin 1, alt. transcript 1
Genome:	nucleus
Taxon:	Homo sapiens
Locus:	1220
Common Name:	thrombospondin 1
Role ID:	40

Coding sequence length:	3513 nt
Transcript sequence length:	5722 nt
Expression data:	<u>481987</u>

---

### ACCESSION DATA

HT1220 is derived from accessions(s):

SP:P07996 (THROMBOSPONDIN 1 PRECURSOR.)  
GB:X04665 (Human mRNA for thrombospondin)  
GB:X14787 (Human mRNA for thrombospondin)  
GB:U12471 (thrombospondin-p50 {Homo sapiens})  
GB:M99425 (Human thrombospondin mRNA, 3' end.)  
PIR:G01478 (thrombospondin-p50 - human (fragment))  
GB:U12471 (Human thrombospondin-1 gene, partial cds.)  
GB:J04835 (Human thrombospondin gene, exons 1, 2 and 3.)  
GB:M25631 (Homo sapiens (clone lambda-TS-33) thrombospondin (THBS) mRNA, 5' end.)

---

### ALTERNATIVE SPLICE INFORMATION

Alternative splice forms for this gene:

HT3987 thrombospondin 1, alt. transcript 2

---

### MAPPING DATA

GDB accession(s) for this gene:

GDB ID:	Symbol
-----	

Figure 1A

gdb:120438 THBS1

2/8

**cDNA FEATURES**

Feature	End 5	End 3
coding_seq	112	3624
3'UT	3625	5722
spjunc_h	1235	1236

**SEQUENCE****nucleotide:**

ggacgcacaggcattccccgcgcccctccagccctcgccgcccctcgccaccgctcccggc  
 cgccgcgctccggtacacacaggatccctgctggggaccaacagctccaccatggggctg  
 gcctggggactaggcgtcctgttccctgatgcatgtgtgtggaccaaccgcattccagag  
 tctggcgagacaacagcgtgtttgacatcttgaactcaccggggcgcccgcaagggg  
 tctgggcgcccactgggtgaaggfcccgcaccctccagcccagcttccgcatcgaggat  
 gccaacctgatccccctgtgcctgatgacaagtccaagacctgggtggatgctgtgcgg  
 gcagaaaagggtttcctccttctggcatccctgaggcagatgaagaagaccggggcacg  
 ctgctggccctggagcggaaagaccactctggccaggtcttcagcgtgggtgtccaatggc  
 aaggcgggcaccctggacctcagcctgaccgtccaaggaaagcagcacgtgggtgtctgtg  
 gaagaagctctcctggcaaccggccagtggaagagcatcaccctgtttgtgcaggaagac  
 agggcccaagctgtacatcgactgtgaaaagatggagaatgctgagttggacgtcccatc  
 caaagcgtcttcaccagagacctggccagcatcgccagactccgcatcgcaaaggggggc  
 gtcaatgacaatttcagggggtgctgcagaatgtgaggtttgtctttggaaccacacca  
 gaagacatcctcaggaacaaaggctgctccagctctaccagtgtcctcctcacccttgac  
 aacaacgtgggtgaatgggtccagccctgccatccgcactaactacattggccacaagaca  
 aaggacttgcaagccatctgcggcatctcctgtgatgagctgtccagcatgggtcctggaa  
 ctcaggggcctgcgaccattgtgaccacgctgcaggacagcatccgcaaagtgactgaa  
 gagaacaaagagttggccaatgagctgaggcggcctcccctatgctatcacaacggagt  
 cagtacagaaataacgaggaatggactgttgatagctgcactgagtgctactgtcagaac  
 tcagttaccatctgcaaaaagggtgtcctgccccatcatgccctgttccaatgccacagtt  
 cctgatggagaatgctgtcctcgctgttgcccagcgactctgcggacgatggctgggtct  
 ccattggtccgagtggaacctcctgttctacgagctgtggcaatggaattcagcagcgcggc  
 cgctcctgcgatagcctcaacaaccgatgtgagggtcctcggtccagacacggacctgc  
 cacattcaggagtgtagcaaaagatttaaaccaggatgggtggctggagccactgggtccccg  
 tggatcatctgttctgtgacatgtgggtgatgggtgtgatcacaaggatccggctctgcaac  
 tctcccagccccagatgaatgggaaaccctgtgaaggcgaagcggggagaccaaagcc  
 tgcaagaaagacgcctgccccatcaatggaggctggggctccttgggtaccatgggacatc  
 tgttctgtcacctgtggaggaggggtacagaaacgtagtcgtctctgcaacaaccccgca  
 cccagtttggaggcaaggactgcgttgggtgatgtaacagaaaaccagatctgcaacaag  
 caggactgtccaattgatggatgcctgtccaatccctgcttggccggcgtgaagtgtact  
 agctaccctgatggcagctggaaatgtggtgcttgtccccctgggttacagtggaaatggc  
 atccagtgcacagatgttgatgagtgcaagaagtgccctgatgcctgcttcaaccacaat  
 ggagagcaccgggtgtgagaacacggaccccggtacaactgcctgcctgccccccacgc  
 ttaccggctcacagcccttcggccagggtgtcgaacatgccacggccaacaaacaggtg  
 tgcaagccccgtaaccctgcacggatgggacccacgactgcaacaagaacgccaagtgc  
 aactacctggggccactatagcgaccccatgtaccgctgcgagtgcaagcctggctacgct  
 ggcaatggcatcatctgcggggaggacacagacctggatggctggcccaatgagaacctg  
 gtgtgcgtggccaatgcgacttaccactgcaaaaaggataattgccccaaccttcccaac  
 tcagggcaggaagactatgacaaggatggaattgggtgatgcctgtgatgatgacgatgac  
 aatgataaaattccagatgacagggacaactgtccattccattacaaccacagctcagtat  
 gactatgacagagatgatgtgggagaccgctgtgacaactgtccctacaaccacaacca

Figure 1B



3/8

gatcaggcagacacagacaacaatggggaaggagacgctgtgctgcagacattgatgga  
gacgggtatcctcaatgaacgggacaactgccagtagctctacaattgtggaccagagagac  
actgatatggatgggggttgagatcagtgtagacaattgcccccttggaacacaatccggat  
cagctggactctgactcagaccgcatggagatacctgtgacaacaatcaggatattgat  
gaagatggccaccagaacaatctggacaactgtccctatgtgccaatgccaaccaggct  
gacctgacaaagatggcaaggagatgctgtgaccacgatgatgacaacgatggcatt  
cctgatgacaaggacaactgcagactcgtgccaatcccagaccagaaggactctgacggc  
gatgggtcgagggtgatgcctgcaaagatgattttgaccatgacagtgtgccagacatcgat  
gacatctgtcctgagaatgttgacatcagtgagaccgatttccgccgattccagatgatt  
cctctggaccccaaggagacatcccaaatgaccctaactgggtgtacgccatcagggt  
aaagaactcgtccagactgtcaactgtgatcctggactcgtgtagggttatgatgagttt  
aatgctgtggacttcagtggcaccttcttcatcaacaccgaaaggagcagtgactatgct  
ggatttgtctttggctaccagtcagcagccgcttttatgttgtgatgtggaagcaagtc  
accagtcctactgggacaccaaccccacgagggtcagggaatactcgggcctttctgtg  
aaagtgtgaaactccaccacagggtcctggcgagcacctgcggaacgcccctgtggcacaca  
ggaaacacccctggccagggtgcgcaccctgtggcatgacccctcgtcacataggctggaa  
gatttcaccgcctacagatggcgctcagccacaggccaaagacgggtttcattagagtg  
gtgatgtatgaagggaagaaaatcatggctgactcaggaccatctatgataaaacctat  
gctgggtgtagactagggtgtttgtcttctctcaagaaatgggtgttcttctctgacctg  
aaatacgaatgtagagatccctaatacatcaaatgttgattgaaagactgatcataaacc  
aatgctgggtattgcaccttctggaactatgggcttgagaaaaccccaggatcacttctc  
cttggcttctcttctttctgtgcttgcatcagtgtagctcctagaacgtgcgacctgcc  
tcaagaaaatgcagttttcaaaaacagactcatcagcattcagcctccaatgaataagac  
atcttccaagcatataaacaattgctttgggttccctttgaaaaagcatctactgtctt  
agtgggaagggtgccattccactctgcttggtcacagagcagggtgctattgtgagggc  
catctctgagcagtgtagctcaaaagcattttcaggcatgtcagagaaggaggagactcact  
agaattagcaaaacaaaccacccctgacatcctcctcaggaacacggggagcagaggcca  
aagcactaaggggagggcgcatacccgagacgattgtatgaagaaaatatggaggaaactg  
ttacatgttcggtaactaagtcattttcaggggattgaaagactattgctggatttcataga  
tgctgactggcggttagctgattaaacccatgtaaataggcacttaaatagaagcaggaaag  
ggagacaaagatggcttctggacttctcctctgatccccacccttactcatcaccttgc  
agtggccagaattagggaatcagaatcaaaccagtgtaaaggcagtgctggctgccattgc  
ctggtcacattgaaattgggtggcttcatcttagatgtagcttgtgcagatgtagcaggaa  
aataggaaaacctaccatctcagtgagcaccagctgcctcccaaggaggggcagccgtg  
cttatatttttatgggttacaatggcacaaaattattatcaacctaaactaaaacattcctt  
ttctctttttccgtaattactaggtagttttctaatctctcttttggaaagtatgattt  
ttttaagtcctttacgatgtaaaatatttatttttactttattctggaagatctggctga  
aggattattcatggaacaggaagaagcgtaaagactatccatgtcatctttgttgagagt  
cttcgtgactgtaagattgtaaatacagattatttattaaactctgttctgcctggaaatt  
taggcttcatacggaaagtgtttgagagcaagtagttgacatttatcagcaaatctcttg  
caagaacagcacaaaggaaaatcagtcctaataagctgctctgccccttggtcagagtgg  
atgttatgggattcctttttctctgttttatcttttcaagtggaaattagttgggtatcc  
atttgcaaatgttttaaatgcaagaaagccatgaggtcttcaatactgttttacccca  
tccccttgatcatatttccagggaagaaagcatatacacttttttcttcttattttcc  
aaaagagaaaaaaatgacaaaagggtgaaacttacatacaaatattacctcatttgttgtg  
tgactgagtaagaatttttggatcaagcggaaagagtttaagtgcttaacaaacttaaa  
gctactgtagtacctaaaagtcagtggtgtacatagcataaaaactctgcagagaagta  
ttcccaataaggaaatagcattgaaatgttaatacaatttctgaaagtattgtttttt  
tctatcatctggtataaccattgcttttattttataaattatttctcattgccattggaa  
tagaatattcagattgtgtagatatgctattttaaataattttatcaggaaatactgcctgt  
agagttagttatttctatttttatataatgtttgcacactgaattgaagaattgttgggtt  
tttctttttttgtttttttttttttttttttttttgttttgacctccattttta  
ctatttgccaataccttttctaggaatgtgctttttttgtacacatttttatccattt  
tacatttcaaagcagtgtaagttgtatattactgtttcttatgtacaaggaacaacaata  
aatcatatggaaatttatattt

protein:

MGLAWGLGVFLMHVCGTNRIPESGGDNSVFDIFELTGAARKGSGRRLVKGPDPSSPAFR

Figure 1C

4/8

IEDANLIPPVPDDKFQDLVDAVRAEKGFLLLASLRQMKTGTLALLERKDHSGQVFSVV  
 SNGKAGTLDLSLTVQKQHVVSVEEALLATGQWKSITLHVQEDRAQLYIDCEKMEAEED  
 VPIQSVFTRDLASLARLRIAKGGVNDNFQGVQLQNVRFVFGTTPEDILRNKGCSSSTSVLL  
 TLDNNVVGSSPAIRTNYIGHKTKDLQAICGISCEDELSSMVLELRGLRTIVTTLQDSIRK  
 VTEENKELANELRRPPLCYHNGVQYRNNEEWTVDSCTECHCQNSVTICKVSCPIMPSCN  
 ATVPDGECCPRCWPSPDSADDGWSWPSEWTSCSTSCGNGIQQRGRSCDSLNNRCEGSSVQT  
 RTCHIQCEDKRFKQDGGWSEWSPWSSCSVTGCGDVITRIRLNCNSPSPQMNGKPCGEARE  
 TKACKKDACPINGGWGPSPWDICSVTCGGGVQKRSRLCNPAPQFGGKDCVGDVTENQI  
 CNKQDCPIDGCLSNPCFAGVKCTSYPDGSWKCGACPPGYSGNGIQCTDVDECKEVPDACF  
 NHNGEHCENTDPGYNCLPCPPRFTGSQPFQGVGHATANKQVCKPRNPCTDGTDCNKN  
 AKCNYLGHYSDPMYRCECKPGYAGNGIICGEDTDLGWPENLVCVANATYHCKKDNCPN  
 LPNSGQEDYDKDIGDACDDDDNDKIIPDDRDNCPFHYNPAQYDYDRDDVGDRCNCPYN  
 HNPQADTDNNGEGDACAADIDGDGILNERDNCQYVYNVDQRTDMDGVGDQCDNCPLEH  
 NPDQLDSDSRIGDTCDNNQDIDEDGHQNNLDNCPYVPNANQADHDKDGKGDACDHDNDN  
 DGIPDDKDNCRCLVPNPDQKSDGDGRGDACKDDFDHDSVDDIDDCPENVDISETDFRRF  
 QMIPLDPKGTSQNDPNWVVRHQGKELVQTVNCDPGLAVGYDEFNAVDFSGTFFINTERDD  
 DYAGFVFGYQSSSRFYVMWVKVTSYWDINPTAQGYSGLSVKVNSTTGPGHEHLRNAL  
 WHTGNTPGQVRTLWHDPRHIGWKDFTAYRWRLSHRPTGFIIRVVMYEGKKIMADSGPIYD  
 KTYAGGRLGLFVFSQEMVFFSDLKYECRDP



Figure 1D

5/8



## HT2143 Report

### RECORD INFORMATION

Gene ID: 2081  
 Sequence ID: 2143  
 Protein ID: 2125  
 Sequence name: thrombospondin 4  
 Genome: nucleus  
 Taxon: Homo sapiens  
 Locus: 2081  
 Common Name: thrombospondin 4  
 Role ID: 40

Coding sequence length: 2886 nt  
 Transcript sequence length: 3074 nt  
 Expression data: THC168897

### ACCESSION DATA

HT2143 is derived from accessions(s):

SP:P35443 (THROMBOSPONDIN 4 PRECURSOR.)  
GB:Z19585 (thrombospondin-4 {Homo sapiens})  
GB:Z19585 (H.sapiens mRNA for thrombospondin-4)  
PIR:A55710 (thrombospondin 4 precursor - human)

### cDNA FEATURES

Feature	End 5	End 3
coding_seq	29	2913
3'UT	2914	3074

### SEQUENCE

nucleotide:

```

gaattccggggagcaggaagagccaacatgctggccccgcgaggccgcccctcctctg
ctgcacctgggtcctgcagcgggtggctagcggcaggcgcaccccccagggtcttc
gaccttctcccatcttccagtcagaggctaaacccaggcgcctctgctgccagtcctgaca
gaccccgccctgaatgatctctatgtgatttccaccttcaagctgcagactaaaagtcca
gccaccatcttcgggtctttactcttcaactgacaacagtaaatattttgaatttactgtg
atgggacgcttaagcaaagccatcctccgttacctgaagaacgatgggaagggtgcatttg
  
```

Figure 2A

6/8

gaattccggggagcaggaagagccaacatgctggcccccgcgaggagccgctcctctg  
 ctgcacctgggtcctgcagcgggtggctagcggcaggcgccaggccacccccagggtcttt  
 gaccttctcccatcttccagtcagaggctaaccaggcgctctgctgccagtcctgaca  
 gacccccccctgaatgatctctatgtgatttccaccttcaagctgcagactaaaagttca  
 gccaccatcttcgggtctttactcttcaactgacaacagtaaatattttgaatttactgtg  
 atgggaagcgttaagcaaaagccatcctccgttacctgaagaacgatgggaaggtgcatttg  
 gtggttttcaacaacctgcagctggcagacggaaggcgccacaggatcctcctgagggtg  
 agcaatttgagcagaggggcggtccctagagctctacctggactgcatccagggtggat  
 tccgttcacaatctccccagggtcttctgctggccctcccagaaacctgagaccattgaa  
 ttgaggactttccagaggaagccacaggacttcttggaagagctgaagctgggtgggtgaga  
 ggctcactgttccagggtggccagcctgcaagactgcttctgagcagagtgagccactg  
 gctgccacaggcacaggggactttaaccggcagttcttggggtcaaatgacacaattaaac  
 caactcctgggagaggtgaaggaccttctgagacagcaggttaaggaaacatcatttttg  
 cgaaacaccatagctgaatgccaggcttgcgggtcctctcaagtttcagtctccgacccca  
 agcacgggtgggtcgccccgggtccccctgcaccgccaacacgcccacctcgctcgggtgtgac  
 tccaacccatgtttccagggtgtccaatgtaccgacagtagagatgggttccagtgtggg  
 ccctgccccgagggtacacaggaaacgggatcacctgtattgatgttgatgagtgcaaa  
 taccatccctgctaccggggcggtgcactgcataaatttgtctcctgggttcagatgtgac  
 gcctgcccagtggttccacagggcccatgggtgcagggtgttgggatcagttttgccaag  
 tcaaaacagcaggtctgcactgacattgatgagtgctgaaatggagcgtgcgttcccaac  
 tcgactcgtcgttaatactttgggatcttaccgctgttgggcttgaagccgggtatact  
 ggtgatcagataaggggatgcaaaagtggaaagaaactgcagaaacccagagctgaaccct  
 tgcagtgtgaatgccagtgcatgaagagaggcagggggatgtgacatgtgtgtgtgga  
 gtcggttgggttgagatggctatatctgtggaaaggatgtggacatcgacagttacccc  
 gacgaagaactgccatgctctgccaggaactgtaaaaaggacaactgcaaatatgtgcca  
 aattctggccaagaagatgcagacagagatggcattggcgacgcttgtgacgaggatgct  
 gacggagatgggatcctgaatgagcagataaactgtgtcctgattcataatgtggacca  
 aggaacagcgataaagatatcttggggatgcctgtgataactgcctgagtgctttaa  
 aacgaccagaaagacaccgatggggatggaagaggagatgcctgtgatgatgacatggat  
 ggagatggaataaaaaacattctggacaactgccccaaatttcccaatcgtgaccaacgg  
 gacaaggatgggtgatgggtgtgggggatgcctgtgacagttgtcctgatgtcagcaaccct  
 aaccagtctgatgtggataatgatctgggttggggactcctgtgacaccaatcaggacagt  
 gatggagatgggcaccaggacagcacagacaactgccccaccgtcattaacagtgccag  
 ctggacaccgataaggatgggaattgggtgacgagtgatgatgatgacaatgatggt  
 atcccagacctgggtgccccctggaccagacaactgcccggctgggtccccaaccagcccag  
 gaggatagcaacagcgacggagtgaggagacatctgtgagtgctgactttgaccaggaccag  
 gtcacatcgatcggtacgctctgcccagagaacgcagaggtcacctgaccgacttcagg  
 gcttaccagaccgtgggctggatcctgaaggggatgcccagatcgatcccaactgggtg  
 gtcctgaaccagggtcagagattgtacagaccatgaacagtgatcctggcctggcagtg  
 ggggtacacagcttttaaggagttgacttcgaaggaccttccatgtgaataccagaca  
 gatgatgactatgcaggctttatctttggctaccaagatagctccagcttctacgtggtc  
 atgtggaagcagacggagcagacatatgggaagccacccattccgagcagttgcagaa  
 cctggcattcagctcaaggctgtgaagtctaagacaggtccaggggagcatctccggaac  
 tccctgtggcacacgggggacaccagtgaaccaggtcaggctgctgtggaaggactccagg  
 aatgtgggtggaaggacaaggtgtcctaccgctgggtcctacagcacaggccccagggtg  
 ggctacatcagggtacgattttatgaaggctctgagttgggtggctgactctggcgtcacc  
 atagacaccacaatgcgtggaggccgacttggcggttttctgcttctcctcaagaaaacatc  
 atctggtccaacctcaagtatcgctgcaatgacaccatccctgaggacttccaagagttt  
 caaaccagaaatttcgaccgcttcgataattaaaccaaggaagcaatctgtaactgcttt  
 tcggaacactaaaaccatatatattttaacttcaattttcttttagcttttaccacccaa  
 atatatcaaaacgttttatgtgaatgtggcaataaaggagaagagatcatttttaaaaaa  
 aaaaaaaaaaaaaa

**protein:**

MLAPRGAIVLLHLVLQRLAAGAQAATPQVFDLLPSSSQRLNPGALLPVLTPALNDLYV  
 ISTFKLQTKSSATIFGLYSSTDNSKYFEFTVMGRLSKAILRYLKNDGKVHLVVFNNLQLA  
 DGRHRILLRLSNLQRGAGSLELYLDCIQVDSVHNLPRAFAGPSQKPEITELRTFQRKPQ

Figure 2B

7/8

ACDSCP DVSNFNQSDVDNDLVGDS CDTNQSDG DGHQDST DNCPTVINS AQLD TDKDGIG  
 DECDDDDNDGIPDLVPPGPDNCRLVPNPAQEDSN SDGVGDICESDFDQDQVIDRIDVCP  
 ENAEVTLTDFRAYQTVGLDPEGDAQIDPNWVVLNQGM EIVQTMNSDPGLAVGYTAFNGVD  
 FEGTFHVNTQTDDDYAGFIFGYQDSSSFYVVMWKQTEQTYWQATPFRAVAEPGIQLKAVK  
 SKTGPG EHLRNSLWHTGDTSDQVRL LWKDSRNVGW KDKVSYRWFLQHRPQVG YIRVRFYE  
 GSELVADSGVTIDTTMRGGRLGVFCFSQENI IWSNLKYRCNDTIPEDFQEFQTQNFDRFD  
 N



Figure 2C

Poly ID	Sequence ID	Position	Gene Description	Flanking Seq	Mutation Type	Ref NT	Alt NT	Ref AA	Alt AA
G334u4	HT:HT1220_mRNA	2110	THBS1, thrombosp- ondin 1	TGGATGGCTGGCCCA[A/G]TGA GAACCTGGTGTG	Missense	A	G	N	S
G355u2	HT:HT2143_mRNA	1186	THBS4, thrombosp- ondin 4	GAGTGTCGAAATGGA[G/C]CGT GCGTCCCCAACT	Missense	G	C	A	P

Figure 3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number  
**WO 01/018250 A3**

(51) International Patent Classification: **C12Q 1/68,**  
C07K 14/47, 14/78

(US). **BOLK, Stacey**; 202 Baker Street #1, West Roxbury, MA 02132 (US). **DALEY, George, Q.**; 50 Young Road, Weston, MA 02193 (US). **MCCARTHY, Jeanette, J.**; 3625 Dupont Street, San Diego, CA 92106 (US).

(21) International Application Number: PCT/US00/24503

(22) International Filing Date:  
7 September 2000 (07.09.2000)

(74) Agent: **TREANNIE, Lisa, M.**; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Road, P.O. Box 9133, Concord, MA 01742-9133 (US).

(25) Filing Language: English

(81) Designated States (national): AU, CA, JP, MX.

(26) Publication Language: English

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(30) Priority Data:  
60/153,357 10 September 1999 (10.09.1999) US  
60/220,947 26 July 2000 (26.07.2000) US  
60/225,724 16 August 2000 (16.08.2000) US

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicants: **WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH** [US/US]; Nine Cambridge Center, Cambridge, MA 02142 (US). **MILLENNIUM PHARMACEUTICALS, INC.** [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).

(88) Date of publication of the international search report:  
25 July 2002

(72) Inventors: **LANDER, Eric, S.**; 151 Bishop Allen Drive, Cambridge, MA 02139 (US). **GARGILL, Michele**; 1 Warwick Park #3, Cambridge, MA 02140 (US). **IRELAND, James, S.**; 1 Warwick Park #3, Cambridge, MA 02140

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 01/018250 A3**

(54) Title: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES

(57) Abstract: The invention provides nucleic acid segments of the human genome, particularly nucleic acid segments from a gene, including polymorphic sites. Allele-specific primers and probes hybridizing to regions flanking or containing these sites are also provided. The nucleic acids, primers and probes are used in applications such as phenotype correlations, forensics, paternity testing, medicine and genetic analysis. A role for the thrombospondin gene(s) in vascular disease is also disclosed. Use of single nucleotide polymorphisms in the thrombospondin gene(s) for diagnosis, prediction of clinical course and treatment response, development of therapeutics and development of cell-culture-based and animal models for research and treatment are disclosed.

## INTERNATIONAL SEARCH REPORT

Inter: Application No  
PCT/US 00/24503

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12Q1/68 C07K14/47 C07K14/78

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, SEQUENCE SEARCH, BIOSIS, EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 750 502 A (KLAR AVIHU ET AL) 12 May 1998 (1998-05-12) SEQ ID NO:20	1-30
A	--- POLYMERPOULOS M H ET AL: "DINUCLEOTIDE REPEAT POLYMORPHISM AT THE HUMAN THROMBOSPONDIN GENE THBS1" NUCLEIC ACIDS RESEARCH, vol. 18, no. 24, 1990, page 7467 XP002188932 ISSN: 0305-1048 abstract --- -/--	1-30

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 February 2002

Date of mailing of the international search report

15. 05. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

van Klompenburg, W



## INTERNATIONAL SEARCH REPORT

Inter  
Application No  
PCT/US 00/24503

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WANG D G ET AL: "Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 280, 1998, pages 1077-1082, XP002089398 ISSN: 0036-8075 the whole document</p> <p>---</p>	1-30
A	<p>FAN J ET AL: "Genetic mapping: Finding and analyzing single-nucleotide polymorphisms with high-density DNA arrays" AMERICAN JOURNAL OF HUMAN GENETICS, UNIVERSITY OF CHICAGO PRESS, CHICAGO,, US, vol. 61, no. 4, SUPPL, 1 October 1997 (1997-10-01), page 1601 XP002089397 ISSN: 0002-9297 abstract</p> <p>-----</p>	1-30

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/24503

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-30

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1, claims 1-30

A method for predicting or diagnosing a vascular disease comprising; determining the nucleotide present at position 2210 of the thrombospondin 1 gene (SEQ ID NO:1). A nucleic acid molecule, a peptide (SEQ ID NO:2). A method for predicting or diagnosing a vascular disease comprising; determining the amino acid at position 700 of thrombospondin-1.

Invention 2, claims 31-60

A method for predicting or diagnosing a vascular disease comprising; determining the nucleotide present at position 2210 of the thrombospondin-4 gene (SEQ ID NO:3). A nucleic acid molecule, a peptide (SEQ ID NO:4). A method for predicting or diagnosing a vascular disease comprising; determining the amino acid at position 700 of thrombospondin-4.

Inventions 3 - 2547, claims 61-72

A nucleic acid molecule, an isolated gene product. A method of analyzing a nucleic acid sample. Every invention is characterised by each individual sequence of table 1 (corresponding to SEQ ID NO: 7-2551).

# INTERNATIONAL SEARCH REPORT

Inte I Application No  
PCT/US 00/24503

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5750502 A	12-05-1998	US 5279966 A	18-01-1994
		AU 713198 B2	25-11-1999
		AU 1269897 A	15-05-1997
		AU 677185 B2	17-04-1997
		AU 3945593 A	08-11-1993
		CA 2133443 A1	14-10-1993
		EP 0670895 A1	13-09-1995
		JP 7508402 T	21-09-1995
		WO 9320196 A1	14-10-1993
		ZA 9302362 A	15-06-1994
-----			